Phase I Cancer Clinical Trials





Phase I Cancer Clinical Trials

A Practical Guide

S E C O N D E D I T I O N n

E D I T E D B Y

E L I Z A B E T H A . E I S E N H A U E R

CHRIS TWELVES

MARC BUYSE

1





1



Oxford University Press is a department of the University of

Oxford. It furthers the University’s objective of excellence in research,

scholarship, and education by publishing worldwide.

Oxford New York

Auckland Cape Town Dar es Salaam Hong Kong Karachi

Kuala

Lumpur Madrid Melbourne Mexico

City Nairobi

New

Delhi Shanghai Taipei Toronto

With offices in

Argentina Austria Brazil Chile Czech

Republic France Greece

Guatemala Hungary Italy Japan Poland Portugal Singapore

South

Korea Switzerland Thailand Turkey Ukraine Vietnam

Oxford is a registered trademark of Oxford University Press

in the UK and certain other countries.

Published in the United States of America by

Oxford University Press

198 Madison Avenue, New York, NY 10016

© Oxford University Press 2015

All rights reserved. No part of this publication may be reproduced, stored in

a retrieval system, or transmitted, in any form or by any means, without the prior

permission in writing of Oxford University Press, or as expressly permitted by law,

by license, or under terms agreed with the appropriate reproduction rights organization.

Inquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above.

You must not circulate this work in any other form

and you must impose this same condition on any acquirer.

Library of Congress Cataloging-in-Publication Data

Phase I cancer clinical trials : a practical guide / edited by Elizabeth A. Eisenhauer, Chris Twelves, Marc Buyse.—Second edition.

p. ; cm.

Preceded by Phase I cancer clinical trials : a practical guide / Elizabeth A. Eisenhauer, Christopher Twelves, Marc Buyse. 1st ed. 2006.

Includes bibliographical references and index.

ISBN 978–0–19–935901–1 (alk. paper)

I. Eisenhauer, Elizabeth A., editor. II. Twelves, Chris, editor. III. Buyse, Marc E., editor.

IV. Eisenhauer, Elizabeth A. Phase I cancer clinical trials.

[DNLM: 1. Neoplasms—therapy. 2. Clinical Trials, Phase I as Topic—methods. QZ 266]

RC267

616.99′400724—dc23

2014034346

This material is not intended to be, and should not be considered, a substitute for medical or other professional advice.

Treatment for the conditions described in this material is highly dependent on the individual circumstances. And, while this material is designed to offer accurate information with respect to the subject matter covered and to be current as of the time it was written, research and knowledge about medical and health issues is constantly evolving and dose schedules for medications are being revised continually, with new side effects recognized and accounted for regularly. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulation.

The publisher and the authors make no representations or warranties to readers, express or implied, as to the accuracy or completeness of this material. Without limiting the foregoing, the publisher and the authors make no representations or warranties as to the accuracy or efficacy of the drug dosages mentioned in the material. The authors and the publisher do not accept, and expressly disclaim, any responsibility for any liability, loss, or risk that may be claimed or incurred as a consequence of the use and/or application of any of the contents of this material.

9 8 7 6 5 4 3 2 1

Printed in the United States of America

on acid-free paper





CONTENTS

Preface vi

Contributors ix

1. Introduction 1

Elizabeth A. Eisenhauer

2. Preclinical Data and Requirements 9

Sophie Postel-Vinay, Jean-Charles Soria, and

Elizabeth A. Eisenhauer

3. Phase 0 Clinical Trials 44

Shivaani Kummar and James H. Doroshow

4. Basics of Phase I Design: First-in-Human Studies 57

Donna M. Graham, Aaron R. Hansen, Elizabeth A. Eisenhauer,

and Lillian L. Siu

5. Ethical Issues in First-in-Human Phase I Cancer Trials 91

Elizabeth A. Eisenhauer

6. Phase I Trials in Special Populations and Circumstances 104

Rajiv Kumar, Chris Twelves, and Udai Banerji

7. Phase I Trials of Immunotherapeutics 149

Christy Ralph, Emma King, Chris Twelves,

and Christian Ottensmeier

8. Statistical Designs for First-in-Man Phase I Cancer Trials 170

Xavier Paoletti and Marc Buyse

9. Writing the Protocol 200

Penelope A. Bradbury and Elizabeth A. Eisenhauer

10. Practical Aspects of Pharmacokinetics and Pharmacodynamics 227

Chris Twelves, Maria Jove, and Paul Loadman

v i C O N T E N TS

11. Process, Pitfalls, and Logistics of Phase I Trials 273

Elizabeth A. Eisenhauer, Chris Twelves, Hayley Farmer, and Philip Ross

12. Reporting and Interpreting Results 308

Lesleigh S. Abbott, Elizabeth A. Eisenhauer, and Lesley K. Seymour

Appendix: Useful Web Resources 339

Index 343





PREFACE

This is an exciting time in cancer research, with the number and type of potential

new cancer agents increasing exponentially. Phase I trials are a critical first step

in the study of novel cancer therapeutic approaches in humans. Their primary

goals are to identify the recommended dose, schedule and pharmacologic and

pharmacodynamics behavior of new agents or new combinations of agents and

to describe the adverse effects of treatment.

In cancer therapeutics, such studies have particular challenges. In general,

because of the nature of the effects of treatment, most such studies are con-

ducted in patients with advanced malignancy, rather than in healthy volunteers.

Further, the endpoints of these trials are usually measures adverse effects rather

than molecular target or anti-tumor effects. In addition to the goals noted above,

increasingly phase I trials are seen as a key step in identifying the effects of new

drugs, often targeted to affect a specific aberrant protein or pathway, on the

markers of that effect—through tissue biopsies, circulating measures or imaging

evaluations. Furthermore, as new agents in cancer are expected to have maximal

effects in biologically defined subgroups of patients, phase I trials provide the

opportunity to begin to evaluate the new drug’s impact in patients selected based

on such putative biomarkers. These factors render the design, conduct, analysis

and ethical aspects of phase I cancer trials unique and this book addresses all of

these in depth.

The publication of the second edition of this book has updated many topics to

reflect changes in the decade since the first edition and also includes sections and

chapters dealing with new and evolving areas of importance including phase 0 trials,

phase I evaluation of immunological therapies, biomarker driven trial design, phase I trials in pediatric populations and including those with hematological malignancies.

Phase I Cancer Clinical Trials: A Practical Guide is a unique resource for a comprehensive understanding of the design and methods for trials of the first studies

v i i i P R E FA C E

of new therapeutic cancer agents in human subjects. This new edition provides

updated and expanded information from a wide array of international experts

that will ensure it is useful to oncology trainees, as well as those in more senior

positions, and workers in related clinical specialities such as research nurses,

pharmacists and data mangers who are vital to the effective delivery of phase

I trials as well as statisticians and translational laboratory scientists whose

specialist input is increasingly important in early clinical trials.

Elizabeth Eisenhauer, MD, FRCPC

Chris Twelves, B Med Sci, MD, FRCP

Marc Buyse, ScD

September 2014





CONTRIBUTORS

Lesleigh S. Abbott, MD

James H. Doroshow, MD

Division of Hematology/Oncology

Center for Cancer Research

Department of Pediatrics

Division of Cancer Treatment and

Children’s Hospital of Eastern Ontario

Diagnosis

Assistant Professor

National Cancer Institute

University of Ottawa

Bethesda, Maryland

Ottawa, Ontario, Canada

Elizabeth A. Eisenhauer,

Udai Banerji, MBBS, MD, DNB,

MD, FRCPC

MRCP, PhD, FRCP

Head, Department of Oncology

The Institute of Cancer Research

Queen’s University

The Royal Marsden Hospital

Medical Director, Oncology Program

Sutton, United Kingdom

Kingston General Hospital

Penelope A. Bradbury, MBBCh,

Cancer Centre of Southeastern

FRACP, MD

Ontario

Associate Professor

Kingston, Ontario, Canada

Department of Medicine

Hayley Farmer, BSc (Hons), PhD

University of Toronto

Cancer Research UK Centre for Drug

Medical Oncologist

Development

Princess Margaret Cancer Centre

London, United Kingdom

Toronto, Ontario, Canada

Donna M. Graham, MBBCh

Marc Buyse, ScD

Department of Medicine

Founder and Chairman

University of Toronto

International Drug Development

Division of Medical Oncology and

Institute

Hematology

Louvain-la-Neuve, Belgium

Princess Margaret Cancer Centre

Associate Professor of Biostatistics

Toronto, Ontario, Canada

Universiteit Hasselt

Diepenbeek, Belgium

x C O N T R I B U TO R S

Aaron R. Hansen, MBBS

Christian Ottensmeier, MD, PhD

Department of Medicine

Cancer Sciences Division

University of Toronto

Department of Medical Oncology

Division of Medical Oncology and

University of Southampton

Hematology

Southampton University Hospitals

Princess Margaret Cancer Centre

Southampton, United Kingdom

Toronto, Ontario, Canada

Xavier Paoletti, PhD

Maria Jove, MD

Biostatistics

Clinical Research Fellow

INSERM U900

Leeds Institute of Cancer and

Institut Curie

Pathology

Paris, France

St. James’s Institute of Oncology

Sophie Postel-Vinay, MD

Leeds, United Kingdom

Clinical Fellow

Emma King, BMSc (Hons),

Institut Gustave Roussy

MBChB, PhD, FRSC-ORLHNS

Villejuif, France

CRUK Senior Lecturer Head and

Christy Ralph, MD

Neck Surgery

Associate Professor

University of Southampton

Leeds Institute of Cancer and

Southampton, United Kingdom

Pathology

Rajiv Kumar, MD

St. James’s Institute of Oncology

The Institute of Cancer Research

Leeds, United Kingdom

The Royal Marsden Hospital

Philip Ross, BSc (Hons), MSc

Sutton, United Kingdom

Cancer Research UK Centre for Drug

Shivaani Kummar, MD

Development

Division of Cancer Treatment and

London, United Kingdom

Diagnosis

Lesley K. Seymour, MD, PhD

National Cancer Institute

NCIC Clinical Trials Group

Bethesda, Maryland

Professor of Oncology

Paul Loadman, BSc (Hons), PhD

Queen’s University

Professor in Pharmacokinetics and

Kingston General Hospital

Drug Metabolism

Kingston, Ontario, Canada

School of Life Sciences

Lillian L. Siu, MD, FRCPC

Institute of Cancer Therapeutics

Professor of Medicine

University of Bradford

University of Toronto

Bradford, United Kingdom

Drug Development Program

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

C O N T R I B U TO R S

x i

Jean-Charles Soria, MD, PhD

Chris Twelves, BMedSci, MD,

Chief of Service, Institut de

FRCP

Cancérologie

Professor of Clinical Pharmacology

Director of the SIRIC Socrates Project

and Oncology

Professor of Medicine

Head, Section of Clinical Cancer

Institut Gustave Roussy

Research Groups

Villejuif, France

Leeds Institute of Cancer and

Pathology

St. James’s Institute of Oncology

Leeds, United Kingdom





1

Introduction

E L I Z A B E T H A . E I S E N H A U E R ■



1.1 DRUG DEVELOPMENT IN CANCER



The development of new agents for cancer therapy is an orderly and systematic

process. Beginning with a preclinical body of data that includes evidence for effi-

cacy, toxicology, and mechanism of action, the classical clinical development of

a new agent proceeds through three steps or “phases.” These steps have as their

major goals: (a) establishment of a recommended dose and schedule; (b) dis-

covery of whether the drug shows any preliminary evidence of activity in spe-

cific tumor types (or subtypes); and, finally, (c) determination of whether the

new agent alone, or in combination, has a meaningful impact on survival or other

measures of efficacy in cancer patients. In all phases of investigation, compilation

of drug safety and other data also takes place. Table 1.1 outlines these steps and

highlights the types of questions, trial design, and endpoints that are typically

associated with each in cancer drug development.



1.1.1 Historical perspective—Cytotoxic

chemotherapy development

Historically, this phased process of clinical development dates to the dawn of

the era of cytotoxic chemotherapy in the 1960s. As summarized in an historical

review by Chabner and Roberts [1] , early research into the relationship between

dose and cell kill by Schabel and Skipper [2,3] provided the foundation for the

strategy of giving the highest tolerable dose in clinical studies, and in fact laid the foundations for research in high-dose chemotherapy with stem cell support that

occupied a great deal of clinical research activity in the 1980s and 1990s. Thus,

Table 1.1. Cancer Trial Goals, Designs, and Endpoints

Phase Goal

Question(s)

Design

Usual outcome

Issues for targeted agents

measure(s)

(primary endpoint)

I

Determine

What is maximum dose that

Non-randomized

Toxic effects using

Is dosing to toxicity appropriate

recommended

can be safely administered?

Dose escalation

standard criteria

or necessary?

dose for fur-

What is pharmacokinetic

Can direct measures of target

ther evaluation

behavior?

effect be utilized to determine dose?

Can seamless transition to

phase II be undertaken?

Should the population be

restricted by molecular genotype?

II

Determine if

What is the response rate

Non-randomized

Objective response

Is phase II necessary? Can there be

sufficient evi-

of the drug in a defined

(some phase

seamless transition from phase II to III

dence of bio-

population?

II trials may be

through randomized designs? If

logical effect to

Does it surpass a preset

randomized)

tumor regression is not anticipated,

continue drug

minimum?

Multistage

what endpoints are appropriate for

development

enrollment

non-randomized trials screening

to allow early

for efficacy? Should population be

stopping

restricted to those expressing target?

How should biomarker for efficacy be

defined and identified?

III

Determine

Does the treatment

Randomized

Survival

How should population be enriched for

relative effi-

incorporating the new drug

Early stopping

Relapse-free survival

expression of relevant biomarker or

cacy of new

produce improved survival

rules for extreme Quality of life

target?

versus standard

or freedom from relapse?

differences

measures

How to combine/sequence with other

treatment

Is the new treatment superior

al owed

agents?

in terms of quality of life?

Introduction 3

phase I trials employing dose escalation to achieve levels of the “maximum toler-

ated dose” of the cancer agent became the norm [4,5], not only because of the

preclinical science, but also because the toxic effects that limited dose, usually

myelosuppression, provided evidence of the biological effects that were desired

of the new agent on the tumor.

Following completion of phase I trials, phase II evaluation, designed to screen

new drugs for signals of antitumor activity meriting further investigation, uti-

lized tumor regression, defined by objective standard measures, as the primary

endpoint [6,7].

Finally, phase III trials in which the new agent was evaluated (alone or incorpo-

rated into combination) in comparison with standard treatment, provided a mecha-

nism for unbiased assessment of the impact of the new drug in randomized designs

that utilized clinically meaningful endpoints of relapse-free or overall survival.



1.1.2 Drug development of molecular targeted therapeutics

Some decades later, although many new cytotoxic drugs and other agents iden-

tified by empirical screening and other means have continued to enter clinical

trials, the landscape of new anticancer agents has changed. Therapeutic agents

entering the clinic that are rationally designed or selected to affect specific intracellular and extracellular targets thought to be relevant to malignant transforma-

tion are commonplace. In this new era of “molecular targeted therapy,” questions

have been posed about the appropriateness of applying the same clinical devel-

opment paradigm and utilizing the same endpoints as are employed for cytotoxic

drugs. Agents that are targeted to molecular aberrations in cellular and extracel-

lular pathways or to immune modulatory targets may be devoid of traditional

toxic effects, may not cause tumor regression, and may have effects only in molec-

ularly defined subpopulations. Although it is generally agreed that phase III trials

utilizing clinical endpoints are the final vital step in the development of newer

agents, special attention needs to be paid to how the early clinical evaluation of

such novel agents should most rationally proceed. Some of the questions that

face targeted therapies are highlighted in the final column of Table 1.1.



1.2 SPECIAL ROLE OF FIRST-IN-HUMAN PHASE I

TRIALS: FINDING THE DOSE AND SCHEDULE

Regardless of the debate about the endpoints and design of trials testing dif-

ferent types of cancer agents, it remains the case that phase I first-in-human

cancer trials are a critical first step in cancer drug development [8] . They are

4

P H A S E I C A N C E R C l I N I C A l T R I A l S

small-sample-size, generally non-randomized, dose-escalation studies that

define the recommended dose for subsequent study of a new drug in each sched-

ule tested; they also provide the opportunity for important early observations

about the drug’s safety, pharmacokinetic behavior, and preliminary evidence of

antitumor activity in humans. The recommended dose is based on observations

of toxic effects, pharmacokinetic outcomes, or other measures of drug effects, as

this book will describe. A wealth of preclinical information is utilized to inform

phase I trial starting dose and design. Furthermore, statistical and other research

have been undertaken to address issues of safety, ethics, and efficiency in the trial conduct and dose-escalation methodologies.

As the subsequent development path for a drug is heavily dependent on the

information garnered from phase I trials, it is critically important to assure that

the design, conduct, and analysis of these trials are rigorous. Rushing to finish

phase I trials, inclusion of patients very different from those who will be treated

in later studies, or taking a poorly justified decision at the end of phase I (e.g.,

choosing a schedule based only on convenience rather than one supported by

other data) may paradoxically increase the overall time of subsequent drug development or jeopardize the drug’s future altogether. The history of gemcitabine

provides an example of this.

When the phase I trials of gemcitabine were originally conducted, it was rec-

ognized early on that schedule played a very prominent role in the dose of drug

that could be delivered and in its toxic effects: the daily×5 schedule was fraught

with significant flu-like effects, and only relatively small doses could be admin-

istered [9] . When the dose was given as a 30-minute infusion for three of four

weeks, more drug could be delivered per cycle, and myelosuppression, particu-

larly thrombocytopenia, was dose-limiting. The latter schedule was thus selected

for further development and the recommended phase II dose was 790 mg/m2

(rounded to 800 mg/m2 in initial phase II trials) [10]. However, as is often the

case in phase I trials, heavily pretreated patients made up the population enrolled,

and dose escalation was very conservative, resulting in a large number of patients’

being treated at low doses without any toxicity, and very few patients were treated

near the recommended dose. When gemcitabine began its phase II evaluation

at the recommended dose, little in the way of toxic effects was seen, and doses

were first escalated to 1000 mg/m2, then to 1250 mg/m2 [11–14]. In the end,

the phase I trial was repeated in non–small cell lung cancer patients who were

treatment-naïve: a dose of 2200 mg/m2 was recommended [15], although many

continued to use single-agent doses in the range of 1000 mg/m2 (the dose that

was in fact approved for use in pancreatic carcinoma in the United States in 1996).

It is possible that if phase I trials were undertaken today with gemcitabine, the

same issues could arise; citing these experiences is not intended to fault the decisions taken at the time, which were carefully considered. However, this historical

Introduction 5

example serves to highlight how important it is that the phase I trials that deter-

mine the dose for future studies be designed to include appropriate numbers and

types of subjects in order to limit the risk of making inaccurate recommenda-

tions. Otherwise, considerable time and effort will need to be invested when the

drug is undergoing phase II investigation to refine dosing, leading to potential

delays in the overall drug development process.



1.3 DIFFERENCES BETWEEN CANCER

AND OTHER THERAPEUTIC AREAS

Unlike most other therapeutic areas, studies of cancer therapeutics usually are

conducted first in patients with the disease rather than in normal healthy volunteers. The major reason for this is that anticancer agents often cause substantial

toxic effects, or may need to be given in doses producing such effects, which are

thought to be inappropriate for healthy subjects. Furthermore, the pharmaco-

logical behavior of drugs may differ between patients and healthy subjects. Thus,

cancer drugs are first studied in cancer patients to assure that knowledge of dos-

ing and pharmacology is acquired in the population in which the drugs will be

used. An important exception to this has been the rise in interest in so-called

phase 0 trials, which may enroll healthy volunteers (or cancer patients) to evalu-

ate microdoses of new drugs to address specific questions for which answers in

human subjects are necessary before full phase I investigation can begin.

The study of cancer patients in a phase I setting poses unique ethical issues.

Patients who have disease for which no active therapy remains who are offered

participation in phase I trials may view this as an opportunity to help future

patients, but more often they are hopeful that this treatment may prove effective

in control ing their disease. While this may indeed be possible, it is not the goal

of the phase I trial to establish efficacy, but rather dosing and safety information.

This and other ethical issues associated with phase I trials in an advanced-disease

population oblige investigators, institutions, and sponsors to address these

through appropriate review of the study protocol and development of a process

of trial conduct and consent that is rigorous, balanced, and in compliance with

internationally accepted standards.



1.4 WHAT THIS BOOK WILL DO

This updated second edition will describe the process of phase I development

for cancer agents, from the preclinical information required before a new agent

is given to humans for the first time, through to generation of the final phase

6

P H A S E I C A N C E R C l I N I C A l T R I A l S

I study report. The book’s main focus is on first-in-human trials, although some

sections address combination phase I trials and other special circumstances or

populations. Agents that have direct effects on cancer and its tissue environment

are emphasized, but special sections on immunological agents highlight key dif-

ferentiating features of these agents in early clinical and in preclinical investiga-

tion. Regulatory, ethical, and practical issues are covered. Chapter 2 describes the

non-human (preclinical) data that should be in place before human testing may

begin. Chapter 3, new in this edition, highlights the rising role of phase 0 trials in cancer drug development. Chapters 4 through 6 offer theoretical considerations

in phase I trial design, ethics and conduct, including issues surrounding special

populations. Chapter 7, also new in this edition, describes the special consider-

ations for phase I studies of immunotherapeutics. Chapter 8 provides a broad

overview of statistical phase I designs, while chapters 9 through 12 give practical

information and examples covering protocol development, trial conduct, phar-

macokinetic (PK) and pharmacodynamic (PD) assay development, and how to

report the final study in its published form. Finally, the Appendix offers useful

resources for the clinician or investigator interested in studying new therapies or

combinations of agents in a first-in-human assessment.



1.5 PHASE I TERMS AND NORMS

ADOPTED FOR THIS BOOK

As is described in Chapter 4, some terms used in the phase I literature may have

more than one definition. The term “maximum tolerated dose” (MTD) is high-

lighted as the most important example. There are variations in the definition of

MTD, which frequently have led to confusion. In Europe, MTD is typically the

dose level at which a pre-specified allowable number of patients with dose limit-

ing toxicity (DlT) is exceeded (i.e., is above the recommended dose), whereas in the United States the MTD is typically meant to be the dose level at which the

incidence of DlT is at or below the acceptable threshold (i.e., may be equivalent to the dose recommended for further evaluation).

To avoid this confusion, it has been suggested that the dose at which escala-

tion ceases because of the observation of a critical number of DlT events be

referred to as the “maximum administered dose (MAD),” rather than the MTD.

In this book, MAD will be used for clarity—except when citing publications.

Another advantage of using MAD instead of MTD is that dose escalation may

cease before dose-limiting toxicity is observed. In particular, this may be the

case when biological agents that are not expected to induce toxicity are tested

in phase I; in such cases, the term MTD may be misleading and suggest that

Introduction 7

dose escalation was stopped for toxicity, while the term MAD means exactly

what it states—the highest dose administered (whether for toxicity reasons or

others).

The other term that will be used consistently in this book is “recommended

phase II dose” (RP2D). In some settings the term “maximum tolerated dose”

has been used to describe the highest dose tolerable recommended for further

evaluation. It is felt however, that much greater clarity and precision is con-

veyed when this is described by RP2D, and this will be the approach adopted

in this book.



REFERENCES

1. Chabner BA, Roberts RG Jr. Timeline: Chemotherapy and the war on cancer. Nat

Rev Cancer. 2005;5:65–72.

2. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anti-

cancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukaemia. Cancer Chemother Rep. 1964;35:1–111.

3. Skipper HE, Griswold DP. Frank Schabel. 1918–1983. Cancer Res. 1984;44:871–872.

4. Carter SK. Clinical trials in cancer chemotherapy. Cancer. 1977;40 (Suppl. 1): 544–547.

5. EORTC New Drug Development Committee. EORTC Guidelines for phase I trials

with single agents in adults. Eur J Cancer Clin Oncol. 1985;21:1005–1007.

6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214.

7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the

response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst.

2000;92:205–216.

8. Critical role of phase I clinical trials in cancer treatment. J Clin Oncol.

1997;15:853–859.

9. O’Rourke TJ, Brown TD, Havlin K, et al. Phase I clinical trial of gemcitabine given as intravenous bolus on 5 consecutive days. Eur J Cancer. 1994;30A:417–418.

10. Abbruzzese Jl, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498.

11. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated small cell lung cancer (SClC). A study of the National Cancer

Institute of Canada Clinical Trials Group. Ann Oncol. 1994;5:283–285.

12. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell

carcinoma. A phase II study of the National Cancer Institute of Canada Clinical

Trials Group. Ann Oncol. 1993;4:331–332.

13. Anderson H, lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study.

J Clin Oncol. 1994;12:1821–1826.

8

P H A S E I C A N C E R C l I N I C A l T R I A l S

14. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (lY

188011) in patients with advanced squamous cell carcinoma of the head and neck.

EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:543–547.

15. Fosel a FV, lippman SM, Shin DM, et al. Maximum-tolerated dose defined for

single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naïve

patients with advanced non–small cell lung cancer. J Clin Oncol. 1997;15:310–316.





2

Preclinical Data and

Requirements

S O P H I E P O S T E L - V I N A Y , J E A N - C H A R L E S S O R I A ,

A N D E L I Z A B E T H A . E I S E N H A U E R ■



2.1 INTRODUCTION

This chapter is intended to guide investigators through some basic principles

of preclinical evaluation. It is not expected that it will provide recipes for the

conduct of preclinical studies or offer instructions for assembling the docu-

mentation necessary to have a new drug submission made to government

authorities. Rather, this chapter will offer investigators advice regarding the

critical evaluation of preclinical studies on new agents that they may be asked

to consider studying in a phase 0 or phase I trial. The following questions will

be addressed:

• What scientific and other data are needed before studying a new agent

in cancer patients?

• What aspects of preclinical evaluation are subject to government

regulation?

In particular, this section is geared to examining the data needed before the

first human trials of a new agent may take place, although the preclinical studies

described are also of importance to later combination phase I studies, as they

may facilitate decisions about drug combinations and study design.

1 0

P H A S E I C A N C E R C l I N I C A l T R I A l S



2.2 GENERAL COMMENTS

Before considering the study of any new anticancer therapy in humans, the body

of preclinical (also referred to as “non-clinical”) data must provide substantial

evidence to support the initiation of clinical studies. The issues that should be

addressed are: the biological plausibility of the agent’s activity in cancer; the expectation of benefit for patients; a reasonable expectation of safety; and sufficient information on which to base a starting dose [1] . More recently, Workman and colleagues introduced the concept of the pharmacological audit trail (PhAT),

which includes an integrated approach of in vitro, in vivo, and human data going from bench to bedside and from bedside to bench, in order to ultimately improve

the drug development process [2,3].



2.3 THE AGENT: ITS TARGET AND CHEMISTRY

The reward of decades of research aimed at understanding the biological basis of

cancer is an ever-increasing list of molecular changes believed to be responsible

for instigating or maintaining the malignant behavior of tumors. The starting

point for review of a “package” of information for a new therapeutic begins with

the question: What is its target?

For most new agents, the target is known (or believed to be known) largely

because the drug in question has been designed to affect a particular molecular target. However, drugs discovered through empirical screening of natural products

are also brought into clinical trials. Although the decision to evaluate empirically

discovered agents in the clinic may be based on their efficacy in animal models,

considerable effort goes into defining the molecular targets of these drugs before

first-in-human studies commence.

Assuming that most new agents have a putative target, and thus a mechanism

of action, defined in preclinical experiments, an important question to consider

as part of the evaluation of a phase I study proposal is how important the drug’s target is likely to be for cancer therapy. Most investigator brochures and protocols contain relevant background information on the drug target to assist in mak-

ing a judgement, but it is wise to supplement these overviews with additional

readings. Evidence of the validity of a target for cancer therapy comes from a

variety of experimental sources:

a. the association of its expression with prognosis or its impact on a signal-

ing pathway of documented relevance in cancer;

b. the consequences of its amplification or inhibition in laboratory test

systems;

c. its relevance in carcinogenesis experiments;

Preclinical Data and Requirements 11

d. the frequency or pattern of its expression in a variety of tumor

types; and

e. the efficacy of agents already in the clinic affecting the same target.

The sum of such information provides the “validation” that the target of a new

agent is relevant in cancer biology and, by extension, that drugs affecting valid

targets are interesting to study.

Beyond target validation, the identification of the drug target creates a burden

to show, in preclinical experiments, that the drug has the desired effect on its

target. For agents designed to inhibit the action of a specific protein, such as a

kinase, this should include demonstration of protein inhibition in vitro and in vivo, and also documentation that antitumor effects are accompanied by (and, by inference, due to) inhibition of the target kinase.

Another key aspect of compound review relates to its chemistry; i.e., the knowledge of the general chemical class and structure of the agent: small molecule,

antibody, anti-sense oligodeoxynucleotides (ODN), novel structure, natural

product, analogue of a normal cell component, etc. The nature of the agent, its

target and chemistry, provide the plausibility that the drug may be effective in treating cancer.



2.4 PRECLINICAL EFFICACY DATA

(NON-CLINICAL PHARMACOLOGY)



If the previous section discussed, in general terms, the requirement for plausi-

bility that the new drug could have an impact in cancer, this section deals with another important topic: the expectation of benefit. Although it is not reasonable to expect a new drug to show substantial antitumor effects in phase I trials where

the goal is to identify its recommended dose, there should be a reasonable expec-

tation, based on preclinical data, that the drug will have efficacy in later clinical development, based on the results of in vitro and in vivo efficacy experiments.

There is little prescribed by regulatory agencies regarding the laboratory

models that are to be used to address efficacy. The International Conference of

Harmonization (ICH) guideline, General Considerations for Clinical Trials, mentions only that non-clinical pharmacological studies should include “mechanism

of action, dose–response relationships, and studies of the potential clinical routes

of administration” [4] . The Committee for Medicinal Products for Human Use

(CHMP) of the European Medicines Agency (EMA) suggests a variety of in vitro

and in vivo studies to consider in the preclinical testing of an anticancer agent (Table 2.1), although the recommendations are very general [5].

United States Food and Drug Administration (FDA) regulations are listed in

Title 21 of the Code of Federal Regulations in section 312.23(a)8. No particular

1 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

Table 2.1. Suggested Preclinical Studies of Antitumor Activity:

from the CPMP (CHMP) Note for Guidance

Nature of

Detailed description

Comment in guideline

study

In vitro

Drug activity: In appropriately

Cell line panels that are well

selected cell panel, Identify

characterized, such as the US

IC for each line to develop

National Cancer Institute cell

50

drug-specific activity profile. If

line panel, may be used.

drug has specific target, activity

can be determined in cell lines

expressing different target levels

Mechanisms of resistance: In par-

e.g., overexpression of

allel with above studies, develop

P-glycoprotein, multidrug

profile with respect to possible

resistance protein, changes in

mechanism of resistance

topoisomerase I or II, as appro-

priate to mechanism

Exposure time and cel -cycle

dependency

Disease-specific activity

Further profile may be obtained

using fresh human tumor samples

In vivo

Tumor-bearing animals: Route of Both xenograft or allograft mod-

administration and dosing regi-

els are possible

men (schedule)—should mimic

planned human testing. Efficacy

criteria can include: tumor

growth measures, survival time,

and degree of remission or cure

species tests are mandated, but the record-keeping and reporting requirements

are summarized in the regulations and described in an FDA Guidance doc-

ument, “Content and format of Investigational New Drug Applications

(INDs) for phase 1 studies of drugs including wel -characterized, therapeutic,

biotechnology-derived products” [6] .

The absence of required minimal preclinical efficacy standards means it is

left to the judgement of those developing the agent, potential clinical investiga-

tors, and review committees (including those in government review agencies) to

judge whether a given agent has demonstrated sufficient preclinical efficacy to

justify human clinical trials. The studies described in the following section there-

fore represent, in our view, an ideal (not a mandatory) list of preclinical efficacy

studies. Any individual drug must be assessed on the basis of the totality of preclinical information available supporting its human testing: efficacy models are

but one aspect of that data set.

Preclinical Data and Requirements 13

Table 2.2, which summarizes published in vitro and in vivo data on ZD6474, a compound with vascular endothelial growth factor receptor 2 (VEGFR–2)

inhibiting activity, will be referenced throughout the next sections as an example

of the output in a variety of preclinical efficacy studies [7] .



2.4.1 Evidence of target effect

Agents that are developed specifically to affect a molecular system or target

should be evaluated with respect to that effect in preclinical development. As

many drugs affect aberrant proteins and enzyme systems found in malignan-

cies and are intended to inhibit gain of function behavior, the usual assessment

begins with determination of the concentration of drug needed to inhibit its tar-

get. Results are expressed in terms of the IC (i.e., the inhibitory concentration

50

of the drug needed to inhibit 50% of enzyme activity). This evaluation should

include not only the putative drug target, but also other molecules in the same

class or family, in order to determine the spectrum of inhibition and the relative

potency of the drug. Table 2.2 provides the data obtained for a small-molecule

inhibitor of VEGFR–2, ZD6474. As can be seen in this example, the agent not

only inhibits the target tyrosine kinase enzyme, but also other kinases with vary-

ing degrees of potency.

The degree to which high levels of specificity are desirable depends on the

drug and its intended target, and also the prevailing views of the time. It was

argued a decade ago that highly specific inhibitors were ideal; the views have

now shifted with the successes seen with several small molecules such as BAY

43–9006 (sorafenib), which has multiple targets relevant to malignancy [8] .

Moreover, the anticancer activity of a targeted agent does not always directly

result from the inhibition of the enzyme catalytic activity, as illustrated by the

different mechanisms of action of poly(ADP-ribose) polymerase (PARP) inhibi-

tors, and their various ability to act as PARP poisons [9,10]. Target inhibition

should also be assessed in cellular and in in vivo systems (see below). Generally, for kinase inhibitors, demonstration that the drug changes phosphorylation or

changes measures of downstream signaling are the types of assays used. Other

approaches include assessment of the agent’s ability to inhibit the consequences

of signaling stimulation (e.g., see the vascular endothelial growth factor stimu-

lated human umbilical vein endothelial cell [HUVEC] experiment in Table 2.2).

When dealing with agents such as ODNs, target inhibition is assessed by mea-

suring levels of target protein or mRNA before and after treatment in controlled

conditions.

Extremely useful experiments are those that show target inhibition in

implanted tumors and relate the degree of inhibition to the dose administered,

Table 2.2. Example of Preclinical in Vitro and in Vivo Mechanistic and Efficacy Data: ZD6474

Assay

Assay type

Goal (s)

Results

Interpretation

Kinase

In vitro

To determine the IC of

IC ( μM):

ZD6474 inhibits kinase activity of

50

50

inhibition

Non-cellular

ZD6474 in inhibiting target

VEGFR2: 0.04 PDGFR

VEGFR2 (KDR) in submicromolar

enzyme activity: VEGF

1.1 Flt-4: 0.11 MEK>10

concentrations. It is relatively specific but

receptor-2 tyrosine kinase.

Flt-1: 1.6 CDK2>10 EGFR

also has micromolar inhibitory activity on

To assess selectivity against

0.5 AKT>100

EGFR, PDGFR, FlT-4, and FlT-1

other kinases (on-target effect)

HUVEC

In vitro Cellular

To determine if ZD6474 can

IC (μM): 0.06

ZD6474 inhibits VEGF stimulated endo-

50

inhibition

Non-cancer cell

inhibit the in vitro growth of

thelial cell growth in submicromolar con-

line

VEGF-stimulated endothelial

centrations as assessed by [3H]thymidine

cell line HUVEC

incorporation

Tumor cell

In vitro Cellular

To determine if ZD6474 can

IC (μM): 2.7–13.5

ZD6474 inhibits in vitro tumor cell growth

50

growth

Cancer cell

inhibit the in vitro growth of a

in micromolar concentrations as mea-

lines

variety of human and murine

sured by [3H]thymidine incorporation

cancer cell lines

Concentrations required to inhibit in vitro

cell growth are 45- to 225-fold greater

than those required to inhibit HUVEC

growth

Inhibition

In vivo

To determine if ZD6474 can

2.5 mg/kg i.v. produces a 63%

Oral ZD6474 caused a partial reversal of

of VEGF

Non-tumor-

affect VEGF-stimulated hypo-

inhibition of VEGF-induced

VEGF-induced hypotension in vivo; it also

Signaling

bearing rat

tension and VEGF-dependent

hypotension 50 mg/kg p.o.

produced a dose-dependent hypertrophy

responses

model

growth plate morphology in

× 14 days: 57% increase

of the growth plate in young rats. Both

in vivo

a rat model compared with

growth plate 100 mg/kg p.o.

observations support an in vivo effect on

control

× 14 days: 75% increase

VEGF signaling

growth plate

Intradermal

In vivo

To determine the effect of

ZD6474 administered daily

Oral ZD6474 cased inhibition of

tumor

Tumor-bearing

ZD6474 on tumor vasculariza-

× 5 days: 50 mg/kg: 63%

tumor-induced new vessel formation in an

angiogenesis

animal

tion in an intradermal model

inhibition of new tumor

intradermal murine tumor model

compared with control

blood vessels

100 mg/kg: 79% inhibition of

new tumor blood vessels

Tumor

In vivo

To determine the effect of

At 12.5 mg/kg/day p.o.

Dose-dependent growth inhibition

growth

Tumor-bearing

daily oral chronic administra-

× 3 weeks: 5/7 xenografts

Maximal effects seen at 75 or 100 mg p.o.

inhibition

animal

tion of ZD6474 on in vivo

had significant growth delay

daily in most models

tumor growth in a variety of

At 25 mg/kg/day p.o. × 3

subcutaneous human xeno-

weeks: 7/7 xenografts had

graft models compared with

significant growth delay

control. Tumors grown to 0.1

(46–89% growth inhibition)

–0.47 cm3 before treatment

At 100 mg/kg/day p.o. × 3

weeks: 7/7 xenografts had

significant growth delay

(79–100% inhibition)

Tumor

In vivo

As above, except in established

At 100 mg/kg/day

ZD6474 has activity in wel -established

growth

Tumor-bearing

xenografts (0.65–1.4 cm3

p.o.: ZD6474 caused regres-

tumors

inhibition

animal

before treatment)

sion of established PC-3

xenografts and growth delay

of Calu-6 xenografts

Abbreviations: AKT, protein kinase B; EGFR, epidermal growth factor receptor.; CDK2, cyclin-dependent kinase 2; FlT, fms-related tyrosine kinase; KDR, kinase insert domain receptor; MEK, mitogen activated protein kinase; PDGFR, platelet derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor

Data adapted from Wedge SR et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645–4655.

1 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

the measured antitumor effects, and plasma levels of drug. This type of experi-

ment neatly links four critical parameters for phase I trial design: (a) the dose; (b) the plasma level; (c) the maximal efficacy; and (d) the degree of target inhibition. Unfortunately, experiments evaluating all of these elements are not often performed, although they would facilitate intel igent phase I trial conduct and design.



2.4.2 Single-agent in vitro studies

In vitro assessment is the usual starting point for the efficacy evaluation of a potential new cancer agent. In vitro cellular assays may examine mechanistic questions, for example as in Table 2.2, where the VEGF-receptor targeted drug ZD6474

was tested for growth inhibition of human umbilical vein endothelial cel s, an

endothelial cell line whose growth is dependent on VEGF signaling. Other in

vitro assays have been developed to evaluate antitumor effects in malignant cell lines or fresh tumor samples.

Antitumor in vitro assays include several types, such as antiproliferative or viability assays [11]. Most new cancer agents that are likely to be effective in clinical testing should have demonstrated antiproliferative and/or cytotoxic effects in a

number of in vitro assay systems. Exceptions to this are agents that have mechanisms of action that require engagement of a secondary biological system (e.g.,

biological response modifiers, angiogenesis inhibitors) or those whose activity

derives solely from modulating the activity of other cancer drugs (e.g., chemo-

therapy resistance modulators). Under these circumstances, appropriate in vivo

(for biologically activated agents) or combination in vitro studies (in the case of modulating agents) are needed.



2.4.3 Single-agent in vivo efficacy studies



Much has been written about the value of in vivo tumor model systems as a

method of predicting clinical activity. In short, there is no single system gener-

ally agreed to have reliable, positive predictive value in human tumors. Some

have even argued that in vivo data are unnecessary before proceeding into clinical trials in humans. Despite this, all anticancer agents in use today had preclini-

cal in vivo efficacy testing. While positive in vivo results cannot guarantee clinical success, they offer additional favorable evidence that the agent can reasonably be expected to provide benefit. Furthermore, in vivo studies afford opportunities to assess the relative impact of route and schedule of administration on antitumor

effects as well as on pharmacodynamic (PD) effects of the agent on its molecu-

lar target.

Preclinical Data and Requirements 17



2.4.3.1 Choice Of Model System

The choice and number of in vivo models used in preclinical studies is somewhat arbitrary, but it must be biology-driven as often as possible (e.g., for a targeted

therapy active in BRCA2-/- cell lines, BRCA2-/- mice or BRCA2-/- xenograft models should be used for in vivo experiments) [12–14]. A sampling of the types of in vivo models available and the major variables associated with tumor model studies are shown in Table 2.3.

Although xenograft models have been modestly more successful than allograft

models in predicting the activity of agents in the clinic, the results have not been

striking [15,16]. In a review of preclinical efficacy experiments of 31 cytotoxic

cancer agents, Voskoglou-Nomikos et al. [15] showed that activity of a com-

pound in a panel of ovarian xenografts was significantly correlated with activity

of that same agent in phase II trials in solid tumors (in general) as well as in

ovarian malignancies (in particular). Johnson et al. [16] concluded that, while

no specific relationship between activity in xenografts of a particular histologi-

cal type and clinical activity in that tumor type could be found, activity in more

than one-third of xenograft models was correlated with positive results in at least

some phase II clinical trials. In both these reviews, results from cytotoxic drugs

were compiled, and xenograft studies generally used subcutaneous or intraperi-

toneal tumor cell implantation. Approaches to developing more predictive mod-

els have included the use of orthotopic transplantation (tumor implantation in

the relevant organ) [17], the use of models of naturally occurring tumors [18],

and the integration of pharmacology with in vivo models to enhance their positive predictive value [19]. Furthermore, with the advent of molecular targeted

agents, there has been interest in using models driven by specific molecular aber-

rations as are found in transgenic models (spontaneous tumor development

in genetically predisposed rodents) [18], or at the very least, in using models

whose genetic abnormalities are carefully catalogued [12–14]. None of these

approaches, while intellectually appealing, has generated sufficiently large data

sets on multiple agents to ascertain their positive predictive value. Transgenic

and orthotopic approaches are relatively labor-intensive and require special

expertise in the research laboratory, so their widespread use will depend upon

their demonstrated utility in predicting accurately success and failure in clinical

development (Table 2.4) [20].

An assay that has been developed to help select compounds for xenograft stud-

ies is the hollow-fiber assay. Cultured cell lines are flushed into hollow fibers that are subsequently implanted in the subcutaneous and intraperitoneal cavities of

nude mice. Following four days of intraperitoneal drug administration, the fibers

are removed and cell viability determined using a colorimetric assay. Compounds

are identified as active with the use of a detailed scoring system. Activity in the

hollow fiber assay correlates well with subsequent xenograft activity [16] so it

Table 2.3. In Vivo Murine Model Variables

Parameter

Variables

Murine host

Immune-competent mouse

Immune-deficient mouse (nude mouse

or SCID mouse)

Transgenic mouse (Genetically Engineered cancer

Model: GEM)

Type of tumor

Allograft cell line

Human xenograft cell line

Spontaneous (e.g., in transgenic mouse)

Tumor profile

Characterized with respect to key targets

Not characterized

Tumor location

Subcutaneous

Intraperitoneal

Orthotopic

Subrenal capsule

Hollow fiber

Drug route of administration

Oral

Intravenous

Intraperitoneal

Intratumoral

Drug schedule

Continuous (daily)

Single dose

Intermittent (e.g., days 1, 5, 9)

Repeat dose (e.g., days 1–5)

Drug dose

Single or multiple dose levels

Include MTD for each schedule or other doses

Timing of drug administration

At same time as tumor implantation

After implanted tumor is established/palpable

After implanted tumor has micrometastases

After implanted tumor has macrometastases

After resection of implanted tumor (“adjuvant”)

Measures of efficacy

Tumor regression

Tumor growth delay (%T/C)

Tumor weight

Markers of necrosis (pathological tumor analysis)

Animal survival

Animal cures (or proportion long-term survival)

Preclinical Data and Requirements 19

Table 2.4. Models Most Commonly Used in Preclinical Studies, and

Their Main Advantages and Drawbacks

Model

Advantages

Drawbacks

SC xenografts

Growth of tumor easily

Poor transplant take

monitored using calipers

rate for patient-derived

Relevant for PK and PD

xenografts

assessment

Time-consuming

Expensive

Animal ethical issues

SC model does not

metastasize

Orthotopic xenograft

Metastasis to similar sites as

Technically challenging

models

human equivalent

Time-consuming

Allow to study the process

Requirement of specific

of local invasion and spread

imaging assessments

Genetically

Intact immune system

Cost

Engineered cancer

More precisely mimics

Patent and

Models (GEM)

human situation

technical issues

Ability to breed animals

Reprinted from Goodwin R et al. Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer. 2012;48(2):170–178, with permission from Elsevier.

offers a rapid “pre-screen” to select agents for full testing in xenograft models,

thus reducing the overall resource burden in preclinical testing. This technique

also has the advantage of permitting molecular analysis of treated tumors to

investigate preliminary PD endpoints.

Generally speaking, activity in multiple tumor models or panels of models

is more predictive of clinical activity than activity in only a single model [16].

Further prospective and retrospective work is needed to determine the utility of

various in vivo efficacy models in predicting the clinical activity of non-cytotoxic, molecular targeted therapy.



2.4.3.2 Choice of Design and Endpoints

Controversy also exists regarding the design of in vivo experiments. Tumor cel s can be injected subcutaneously, intraperitoneally, or orthotopically (in the organ

of origin). Treatment may begin immediately (same day as tumor cell adminis-

tration), after establishment of primary tumor growth to a minimum size, after

metastatic disease appears, or after surgical excision of an established primary (a

quasi-adjuvant design) (Table 2.3). Most studies evaluate several doses of drug

in comparison with vehicle controls and generally utilize only one schedule of

2 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

administration. Clearly, the outcome of the experiment using the same cell line

and the same investigational treatment can be dramatically influenced by these

variables. For example, Kerbel showed that different outcomes of various treat-

ment approaches were seen in a MDA-MB 231 breast xenograft model in severe

combined-immunodeficient (SCID) mice, depending on whether the mice had

micro- or macrometastatic disease [21].

A further important consideration in interpreting the results of in vivo experiments relates to measures of efficacy. Tumor growth delay (expressed often as

the treated over control tumor volume ratio [% T/C], or the tumor volume

growth inhibition ratio [% GI]), tumor regression, survival, and cures are all

reported as outcomes. The observation of dose-dependent efficacy is consid-

ered ideal. Furthermore, there are varying thresholds applied to these measures to claim activity: 40% T/C is a cutoff often applied to define activity, but there

has been little work to determine, based on subsequent clinical efficacy, what the threshold for activity in animal tumor models ought to be. As some targeted

therapies’ antitumor effect can result in intratumor necrosis without reduction

in tumor volume, assessing the tumors’ weight as well as performing a pathologi-

cal analysis is key after mice culling. In these cases, solely assessing the tumor

volume would miss an anticancer effect. Also, very sophisticated imaging tech-

niques (including MRI, metabolic imaging, and dynamic imaging) have been

developed for mice bearing xenografts either from cel s labeled with a biolu-

minescent tracer, or unlabeled cel s [22,23]; such techniques may also provide

complementary data on antitumor activity as well as in vivo PD properties of the investigational agent.

As well as exploration of a variety of doses to establish a dose–effect relation-

ship, in vivo experiments offer the opportunity to evaluate a variety of routes and schedules of administration to guide clinical development. Often a single xenograft or allograft model is selected to define the schedule that has maximal effi-

cacy, and thereafter this schedule is evaluated in a wider array of models. In vitro work may suggest that certain schedules are more likely to be efficacious, but

it is important to confirm this hypothesis and optimize the schedule in animal

studies.

A final note of caution: the cell lines used in preclinical models differ

in several respects from “normal” human tumors, but one of considerable

importance is that they are very rapidly growing. The ability to grow this

quickly to palpable size means these tumor lines must be extremely efficient

at inducing angiogenesis (and, by inference, particularly sensitive to agents

that might interfere with new vessel formation). This behavior is at variance

with most human tumors where doubling in size usually requires months,

not days, of growth.

Preclinical Data and Requirements 21



2.4.3.3 Effects on Target And Their

Relation to In Vivo Activity

For agents designed to affect a particular molecular target, in vitro assays as described above can determine if the molecular interaction is happening, but

that, of course, is not the same as knowing if that interaction is happening in vivo, or if it is responsible for the observed antitumor effects. In reviewing a dossier

on a new drug that is supposed to exert its anticancer effects by inhibition of a

specific target, it is therefore useful to see if there is evidence provided that, in animal studies, the agent’s level of activity is related to the putative mechanism

of action of the drug. A variety of assays can be conducted to study this. Which

ones are appropriate depends on the nature of the investigational agent and its

target, as follows:

• For antibodies and small molecular inhibitors of signaling or other

enzymes: Assess downstream measures of effect in the pathways affected

by the agent in normal or tumor tissue in animal models. To be con-

vincing, there should be a parallel relationship observed between the

degree of antitumor effect and the quantitative effects on downstream

measures: the greater the antitumor effect seen, the lower the levels of

downstream measures.

• For ODNs: Measures of mRNA and protein should fall in response to

higher doses of drug, and those changes should have an inverse relation-

ship to the degree of antitumor effect.

Assessment of these effects as part of the in vivo efficacy assessment of a new drug can also provide support for the use of similar measures in the clinical trial(s) of

the agent: often, as will be described in Chapter 4, there is an interest in demon-

strating that the drug is having its desired molecular effect in human tissues as

wel . Assays developed to study this as part of animal testing can play an addi-

tional role by becoming a means to evaluate similar endpoints in the clinic.

It should be noted that not all agents have a known target when the decision

is taken to place them in clinical development. Under these circumstances, pre-

clinical data showing a target–antitumor effect relationship are not possible.



2.4.3.4 Comparative Data With Other Agents

As noted earlier, some new agents are designed to be new and improved varia-

tions of active cancer drugs. Some are true analogues (e.g., platinum compound

series or anthracycline series), while others may be new chemical entities having

the same target (e.g., a small molecule versus an antibody affecting the same cel-

lular receptor). In either case, the preclinical evaluation should include a number

2 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

of studies that pit the new agent against the parent or prototype to address ques-

tions of efficacy and toxicology. With respect to efficacy, key questions include

potency, impact on schedule, range of activity across a spectrum of tumor types,

as well as activity in models resistant to the parent. Potency alone is not par-

ticularly interesting, except when it facilitates greater ease of delivery (fewer or smaller volume infusions, smaller tablets) or is associated with a different therapeutic index (i.e., increased activity, but not at the cost of a parallel increase in toxicity). In terms of schedule impact, here one seeks to find a drug that may

need less frequent administration due to its chemistry. When it comes to efficacy,

the new agent will be most interesting if it appears to be active across a broader

spectrum of tumor types, including those with de novo or acquired resistance, so experimental models set up to address these questions are the most pertinent. In

designing comparative studies, it is important to administer all agents using their

optimal dose and schedule to adequately interpret results. Finally, most laborato-

ries involved in drug discovery also evaluate new agents against the “best” drugs

available (whether analogues or not) for treating particular xenografts in order to

provide a benchmark for interpretation of in vivo results.



2.4.3.5 Combination Efficacy Data

For most anticancer agents there is no requirement to undertake combination

in vivo studies before beginning phase I first-in-man trials, unless both agents are investigational. The Methodology for the Development of Innovative Cancer

Therapies task force reported its recommendations on the optimal preclinical

package that should precede clinical combination studies [24]. Key amongst

these was the recommendation that combinations should first and foremost be

based on a strong understanding of the underlying biology and mechanism of the

drugs to be combined, and not simply empirically based on single agent activity.

Furthermore, in vivo studies should be performed as often as possible, notably to demonstrate the expected synergy or additivity, and in multiple different models.

In particular, preclinical pharmacokinetics should be performed to investigate

which minimal dose of each agent is required to reach the expected effect, and

also explore different schedules of administration. Moreover, pharmacodynam-

ics should be performed when an interaction is anticipated. All this may indeed

provide important insight into subsequent development steps, and, thus, may

have an impact on phase I design and avoid starting the phase I protocol at an

inappropriate dose or schedule.

An obvious exception to this argument is found with agents developed

expressly to enhance the efficacy of other active drugs. Resistance-modulating

agents, for example, should be studied in combination both in vitro and in vivo with the relevant drugs in appropriate models to show they produce the desired

effects on sensitization.

Preclinical Data and Requirements 23



2.4.3.6 Summary of In Vivo Efficacy Studies

There is no standard panel of in vivo efficacy testing that will perfectly predict clinical efficacy. The following bullet points represent a synthesis of the studies that contribute positively to the decision to take an agent into phase I trials

because of expectation of benefit, and linkage of that benefit to drug effects.

• Multiple xenograft models: Xenografts have greater predictive value than

allografts, and activity in multiple models is a reasonable indicator of

clinical activity. The independent value of orthotopic and transgenic

models is uncertain, but activity in those models clearly adds weight

to the body of evidence that the drug may be active in humans. Studies

in models that have been characterized regarding their molecular

genetic changes may be particularly informative for targeted therapies.

Moreover, when available, xenograft models of cell lines isogenic for the

alteration of interest (i.e., the alteration supposed to be targeted by the

drug) should be used in priority, as compared to non-isogenic models,

as they provide a much better proof-of-principle.

• Models that establish the tumor prior to treatment: It seems intuitively

reasonable that agents active in models that more closely resemble the

clinical situation, whether overt metastases or adjuvant-like, are of high-

est interest to evaluate.

• Models that use intravenous or oral administration of drug. Experiments in which drug is administered into a cavity or locally are not investigating a

scenario likely to apply in humans so are not a good basis from which to

infer efficacy.

• Confirmation of target inhibition: When the drug target is known,

establishing its alteration in concert with dose/plasma level and in turn

with efficacy outcomes is useful. These data provide further evidence

that the putative mechanism of action is true and offers assistance in

designing phase I PD studies. Research methods developed and stan-

dardized to study this in the animal model setting may be used in the

clinic as wel .

Table 2.2 shows a number of in vivo models that were studied in the evaluation of the example agent, ZD6474.

It is important to acknowledge that, given the large number of new targets

and drugs being discovered as a result of the technological advances enabling

discovery science, and given the rising cost of clinical development, there is an

increasing urgency to utilize non-clinical studies to select active compounds

with greater precision [25]. For cancer, this means work in the development of

better preclinical models and also in identifying useful surrogates for activity in

2 4

P H A S E I C A N C E R C l I N I C A l T R I A l S

both animal and human studies from which accurate predictions of efficacy can

be made.



2.4.3.7 Special Considerations for In Vivo

Evaluation of Immune Therapies

Over the last few years, several new immune-based therapeutics have been evalu-

ated in the clinic. Notable amongst these are anti-CTlA4 (e.g., ipilimumab and

tremelimumab) [26] as well as anti-PD1/PDl1 (e.g., lambrolizumab, nivolumab)

therapies [27], which have demonstrated antitumor activity in diseases such

as melanoma, renal cell carcinoma, and non–small cell lung cancer [28]. like

other classes of cancer therapy, immune-based therapies require a thorough pre-

clinical evaluation, but there have been challenges in simply utilizing the same

model systems with these agents. Indeed, the anticancer effect of such therapies

is dependent on the host immune system response, which is of course disabled

in the immune-deficient animal models used for most in vivo studies, rendering these inadequate for the preclinical evaluation of immune-based therapies. These

challenges to efficacy and safety evaluation have largely been addressed through

the creation of novel “humanized” animal models.

The NOD/SCID/Il-2Rγnul or NSG mice, are homozygous for targeted muta-

tions at the Il-2 receptor γ chain locus [29], and have severely impaired B-, T-,

and NK-cell function. Due to the profound immune impairment, these mice can

tolerate both the prolonged engraftment of human hematopoietic, peripheral

blood mononuclear, and tumor cel s better than earlier immunodeficient mice

strains. As such, they allow the study of both the antitumor effect and the human

immune response to immune-based therapies in a murine model. Moreover,

subcutaneous or orthotopic implantation of non-disrupted pieces of human

tumors in NSG mice, leads to the generation of xenografts in which the tissue

architecture—including stromal components, fibroblasts, leukocytes, and tumor

cel s—are preserved [30,31]. Genetically engineered mouse (GEM) models

represent another approach for studying immunotherapies, although the het-

erogeneity of GEM tumor model phenotypes requires greater numbers of ani-

mals, so their cost can be limiting. Moreover, some of these models are based on

the tissue-specific expression of a strong oncogene driver, which accelerates the

tumor growth, thereby bypassing the early antitumor immune response [32,33].

With respect to the safety evaluation of immune-based therapies, mice express-

ing the appropriate human leukocyte antigen (HlA) type or human antigen

sequences have been generated to predict the safety of novel antigen-based can-

cer immunotherapies. For immune therapies for which no adequate preclinical

model is available to assess toxicity, in vitro assays have been developed to identify the minimum anticipated biological effect level (MABEl) [34]. However, these

Preclinical Data and Requirements 25

tools are currently insufficient, and further investigation of better approaches

to safety assessment is badly needed, since some of these agents have produced

both unexpected and unpredicted toxicity in human studies [33,35,36].



2.5 PRECLINICAL TOXICOLOGY



As important as assessing the potential for benefit is the determination of a

reasonable expectation of safety, based on toxicological data. The International Conference on Harmonization has developed guidelines for the non-clinical

safety (toxicity) assessment of new agents prior to their study in humans. The

following sections of this chapter are based on the content of several pertinent

ICH guidelines (M3, S4A, S6, and S7A) and also refer to interpretive comments,

when appropriate, from various regulatory agencies (Table 2.4). In all cases, it is

anticipated that toxicology studies be carried out using good laboratory practice

(GlP) standards or GlP-like quality [37–39].



2.5.1 Single-dose toxicity studies

Using the formulation to be studied in humans, single-dose studies should be

conducted in two mammalian species. Dose-escalation designs are used to estab-

lish the maximal dose compatible with survival (maximum tolerated dose [MTD], or lD10, lethal dose in 10% of animals). The CHMP in Europe has stated in its

Note for Guidance on Preclinical Evaluation of Anticancer Medicinal Products that mice and rats can be the two species evaluated, unless the agent is of a class in

which rodents are known to be poor predictors of human toxicity (e.g., antifo-

lates), in which case a non-rodent should be the second species. The US FDA

guidance document “PT 1” (not specifically for cancer drugs) recommends eval-

uation of a rodent and a non-rodent species [40].

Animals should be treated in dose groups of six to ten, including both males

and females, and observations should continue for two weeks after dosing. Both

the no-observed adverse effect level (NOAEl) and the MTD should be deter-

mined. The nature and extent of adverse effects are to be documented, as well

as their time of onset, reversibility, and duration. Pharmacokinetic (PK) studies

that accompany the toxicity evaluation will contribute to understanding of the

relationships between exposure and specific organ effects. For biological prod-

ucts (e.g., antibodies) or other agents with species specificity (e.g., anti-sense

ODNs), care must be taken to include at least one species in which the test agent

is pharmacologically active (Table 2.5).

Table 2.5. Required Toxicology Testing Prior to Phase i Trials of Anticancer Agents

Type of

Requirements

Comments

toxicology

Single dose

Two mammalian species: rodent

Some jurisdictions will accept

and non-rodent

two rodent species under

Clinical formulation

some circumstances

Several doses studied

For species-specific com-

Determine MTD and organ

pounds such as monoclonal

effects

antibodies and ODNs,

testing may need to be in a

non-rodent that shares the

same target, or may need to

be conducted in the rodent

with the rodent-equivalent

homologue of the agent

Repeat dose

Two mammalian species: rodent

Some jurisdictions will accept

and non-rodent

two rodent models in some

Formulation, dose, and sched-

circumstances.

ule as is planned for the

For phase 1 trials, some juris-

clinical study

dictions require only 2–4

Several dose levels; animals of

weeks or 1–2 cycles of repeat

both sexes at each level

dose testing

Duration of treatment: same as

See note regarding

planned treatment duration

species-specific compounds

in clinic

above

Determine highest doses that can

be safely administered, organ

effects, severity, and reversibility

Chronic

Two mammalian species: rodent

Some variety in required dura-

toxicity

and non-rodent

tion of non-rodent testing

(for clinical

Formulation, dose, and sched-

in some situations in certain

treatment

ule as is planned for the

countries

planned

clinical study

to be

Duration of treatment:

>6 months)

rodents: 6 months;

non-rodents: 9 months

Determine chronic or late effects

of treatment and their severity,

reversibility

( continued)

Preclinical Data and Requirements 27

Table 2.5 (Continued)

Safety phar-

Evaluation for specific major

Not required prior to phase 1

macology

organ effects

trials, unless drug is of class

Test system depends on organ

with known effects on major

system of concern or interest

organs, target is likely to be

Basic battery includes cardiovas-

relevant to a major organ, or

cular, respiratory, CNS studies

findings of standard toxicol-

ogy point to the need

Genotoxicity

In vitro tests for mutations and

Generally not required prior

chromosomal damage from the

to initiation of phase 1 trials

experimental agent

local toxicity Assessment of local tolerance

Generally performed as part

using routes relevant to method

of other toxicity studies

of administration

Based on ICH guidelines S4, S4A, M3, S6, and S7A.



2.5.2 Repeat-dose and chronic toxicity studies

The general approach for repeat-dose toxicity studies is that they should be

conducted in a rodent and a non-rodent species using the formulation intended for clinical use, the schedule proposed for study in humans, and be of the same duration as the proposed clinical trial. For chronic administration, ICH guidelines stipulate that the duration of rodent testing be six months, and non-rodent

be nine months [41]. However, guidance documents from specific jurisdictions

provide some modifications and exceptions to the above for phase I trials and/or

for trials in life-threatening illness.

The European CHMP guidance on anticancer products [5] states that two

rodent species may be evaluated, unless the product has a novel mechanism of

action: in which case rodent and non-rodent testing are required. Furthermore,

it is specified that the equivalent of only two to four weeks or one to two cycles

of treatment need be evaluated in toxicology studies prior to beginning phase

I cancer trials (Table 2.6). For phase II and III trials, six-month toxicology stud-

ies in rodents and non-rodents are required. The requirement for use of rodent

and non-rodent species for novel compounds has been challenged by Cancer

Research UK. A review of their database of preclinical and clinical studies showed

that all but one of 39 agents (an antifolate) had a safe starting dose predicted

using only rodent toxicology [42].

The FDA guidance on this subject [43] stipulates that six-month or 12-month

(rather than nine-month) studies may be indicated for “drugs intended for indi-

cations for life-threatening disease for which substantial long-term clinical data

2 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

Table 2.6. Examples of Treatment Schedules for Anticancer Agents to

Support Initial Clinical Trials

Clinical schedule

Examples of nonclinical treatment

schedules

Once every 3–4 weeks

Single dose

Daily for 5 days, every 3 weeks

Daily for 5 days

Daily for 5–7 days, alternating weeks

Daily for 5–7 days, alternating weeks

(2-dose cycles)

Once a week for 3 weeks, a week off

Once a week for 3 weeks

Two or three times a week

Two or three times a week for 4 weeks

Daily

Daily for 4 weeks

Weekly

Once a week for 4–5 doses

Reproduced from ICH Guideline S9; http://www.ich.org.

are available, such as cancer chemotherapy in advanced disease.” Although the

specific duration of toxicity studies required to commence phase I cancer trials

is not specified, generally, repeat-dose studies representing one to three cycles of

treatment have been sufficient.

As for acute-dose (single-dose) toxicity studies, repeat and chronic dosing

studies require multiple animals per group of each sex. Follow-up includes clini-

cal observations, blood and other laboratory tests, and assessment of the nature,

timing, and reversibility of any toxic effects. Observations from the repeat-dose

or chronic-dose studies may lead to specific supplemental toxicity studies to eval-

uate particular organ effects in greater detail.



2.5.3 Special toxicology: safety pharmacology studies

In addition to the standard toxicology requirements detailed above, specific

safety studies to investigate adverse pharmacological effects on major organ sys-

tems may be required in certain circumstances: (a) when the experimental agent

is a member of a class known to cause renal, cardiac, neurological, or pulmonary

damage; (b) when in vitro or other data demonstrate it affects receptors or proteins of critical importance in a major organ; or (c) when results of concern from

standard toxicology studies mandate further investigation. Details of the stud-

ies required are found in the ICH Guideline S7A: Safety Pharmacology Studies

for Human Pharmaceuticals [44]. For agents that have the potential to prolong

the QT interval, a special guideline (S7B) has been developed for recommended

non-clinical electrophysiological studies [45].

Preclinical Data and Requirements 29



2.5.4 Toxicology for drug combinations

Phase I trials that combine two or more agents are not generally preceded by

combination toxicology studies. Usually, all the drugs will have undergone prior

human evaluation to establish recommended single-agent dosing; therefore the

combination trial will use this information to set safe starting doses. There are

three exceptions to this approach: (1) when both agents are investigational;

(2) when the experimental drug is designed to modulate the action of other

agents, in which case preclinical toxicology (and PK evaluation) of the planned

clinical combination is needed; and (3) when the agents to be combined share

significant organ toxicities [24].



2.5.5 Selecting the starting dose

One of the critical objectives of preclinical evaluation is to amass the data necessary to determine a safe starting dose for phase I trials. The calculation of the starting dose (see Chapter 4) is based on toxicology results obtained using the same formulation, route, and schedule planned for clinical trials. Usually the murine lD10

(or MTD) is converted from mg/kg to mg/m2 using conversion factors, and the

human starting dose is 1/10th the mouse lD10 equivalent, unless the non-rodent

species shows that this dose is excessively toxic. Under these circumstances, 1/3

to 1/6 the lowest toxic-dose equivalent in the more sensitive species becomes the

starting dose for human trials. Other factors playing a role in determining the starting dose include clinical toxicity data from analogues of the experimental agent,

data from in vitro studies comparing sensitivity of human and non-human cell lines, and drug protein-binding characteristics in human and rodent plasma.



2.6 ANIMAL PHARMACOKINETICS

Information on drug distribution, absorption, and metabolism obtained from

animal studies provide helpful data that can inform clinical development.

Relationships between plasma drug levels and both toxicity and efficacy out-

comes in animal models provide important linkage information that may con-

tribute to phase I escalation decisions (e.g., pharmacologically guided dose

escalation [46]) or to determination of recommended doses (Chapters 4 and 8).

Knowledge of the major organs involved in excretion and/or metabolism, such

as liver, kidney, or a specific cytochrome P450, will appropriately inform decisions

about patient inclusion and exclusion criteria, including co-medications’ restric-

tions. Studies on protein binding may be important if plasma drug levels or some

3 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

measure of drug exposure will contribute to dose recommendations. Finally, PK

data should, whenever possible, be correlated with changes in measures of target

effect in normal and tumor tissue in animal studies (PK–PD studies). These experi-

ments can provide important information to link dose, exposure, and target inhibi-

tion and thus may contribute to rational dose selection in human clinical trials.



2.7 CORRELATIVE ASSAYS: PRECLINICAL ASSAY

DEVELOPMENT FOR USE IN HUMAN TRIALS

It is increasingly common that early clinical studies of targeted agents will include some measure of effect on the putative target, whether as an endpoint for dose

escalation or as a simple proof of principle that the agent is affecting the target as designed. All too often, the assays for such studies are first undertaken as part of

the clinical trial itself. Ideally, the preclinical data set for such drugs should include development of an assay that can reproducibly and sensitively measure the key

changes in the patient tissue(s). Assay development ought to include measures

in tumors or tissue resected from treated animals so that relationships between

changes in target over time, as measured by the intended clinical assay, can be cor-

related with dose, PK, and antitumor effects. This type of study is not commonly

undertaken prior to clinical development, because of its complexity and cost, but

it could certainly prove useful in early trial design and may save time and money

in the clinic by providing key information in advance of first-in-human exposure.

Excised tumor tissue from patients, removed for diagnosis or treatment, is another

source of material in which assay methods can be developed and tested.



2.8 CHEMISTRY, FORMULATION, AND

MANUFACTURING QUALITY

Before any new pharmaceutical product is given to humans, it must meet

government-defined quality control standards for its manufacturing and purity.

“Good manufacturing practice” is a set of minimum standards for pharmaceuti-

cal manufacture that detail the equipment, processes, documentation, and qual-

ity control procedures that are to be followed.

Intravenous drugs may present challenges for formulation. Excipients to aid

in solubilizing or emulsifying the parent drug may be required (e.g., cremo-

phor El), as may substances that stabilize the drug. The importance of this is

that these added agents may carry their own risk of toxicity and have special

intravenous administration requirements. Cremophor El is a case in point: it

is a non-ionic surfactant derived from castor oil used to solubilize intravenous

Preclinical Data and Requirements 31

paclitaxel formulations, but it has its own toxic effects [47,48] and pharmacologi-

cal effects ( p-glycoprotein modulation) [49], which may contribute to the toxicity produced by paclitaxel and other drugs given concurrently. Furthermore, it

cannot be given in standard polyvinyl chloride intravenous tubing, as it can leach

plasticizer from the tube. Thus knowledge of the specifics of the drug formula-

tion can reveal additional issues for investigators to consider in the design and

interpretation of first-in-human studies.

Biological agents and those derived from biotechnology are subject to special

guidelines with respect to purity, manufacture, and potency testing. Depending

on the source of the agent, special testing for viral contamination may be required,

for example. At the ICH website (http://www.ich.org) there are numerous specific guidance documents available on the quality and preclinical safety evalu-

ation for these types of products. Individual countries may have additional

regulations that apply in addition to those listed.



2.9 INVESTIGATOR’S BROCHURE

The “investigator’s brochure” (also called the clinical brochure or the investiga-

tor drug brochure) is a summary document of the preclinical (and, if relevant,

clinical) data available on the experimental drug. It includes information on the

physical, chemical, and pharmaceutical properties of the new drug; and sum-

mary data on preclinical studies (efficacy, toxicology, PK, and more) and on any

clinical studies that have been conducted. For phase I first-in-human trials, the

latter section will be incomplete, of course, but as clinical data emerge, the inves-

tigator’s brochure is updated, often on an annual basis. This document thus pro-

vides an excellent overview of the evidence to support the initiation of human

clinical trials with a new agent. Table 2.7 provides a list of the table of contents

to be included in an investigator’s brochure, as defined by ICH. A summary of

the preclinical evaluations required for a targeted agent is displayed in Table 2.8.

Four essential aspects of a novel anticancer drug should be addressed in the

investigator’s brochure: the biological plausibility, the expectation of benefit for patients, a reasonable expectation of safety, and sufficient information on which to base a starting dose.



2.10 SPECIFIC REQUIREMENTS FOR PHASE 0 STUDIES



In contrast to phase I trials, the main aim of a “phase 0” trial is not assessment

of toxicity, but evaluation of the pharmacodynamic and/or pharmacokinetic

properties of the selected investigational agent. This can lead to a lower burden

Table 2.7. Investigator’s Brochure: Content

Major headings

Details/content

Title page

Table of contents

Summary

Brief summary of 1–2 pages highlighting significant

physical, chemical, pharmaceutical, pharmacological,

toxicological, PK, and clinical information

Introduction

Summary of chemical name, active ingredients, phar-

macological class of drug, rationale for performing

research, and likely indications. Include at the end a

summary of the approach to the clinical evaluation

Physical, chemical, phar-

maceutical properties

and formulation

Non-clinical studies

Pharmacology: includes efficacy models, receptor bind-

ing, or other mechanistic studies

Other studies: in vitro and in vivo studies that support

mechanism, establish IC , biomarker development

50

(i.e., assays that may be used in clinical trials to estab-

lish proof of principle for drug’s mechanism), PK and

product metabolism: disposition, metabolism, and

excretion in animal models. If oral, should include bio-

availability studies. Relationship of PK to efficacy and

toxicological findings

Toxicology: At least two species (rodent and

non-rodent). Single dose, and, if multiple or repeat

doses will be given in clinic, those schedules must be

assessed as wel . Genotoxicity and reproductive toxi-

cology (may be waived for initial human trials of an

anticancer agent in patients). Include species tested,

number and sex of animals in each group, dose units,

route of administration, dosing interval, duration

of dosing, duration of post-exposure follow-up and

results. Results should include: nature, frequency and

severity of toxic (or pharmacological) effects, time to

onset, duration, and reversibility. Finally a summary

regarding dose-response.

Effects in humans

For phase I first-in-human studies, this section will usually

(if available)

be empty. If normal volunteer data are available, or if the

drug was previously studied in a non-malignant condition,

data should be summarized according to the following

sections. For phase I combination trials, the information

for the following sections will be available from studies in

cancer patients

( continued)

Preclinical Data and Requirements 33

Table 2.7. (Continued)

PK and product metabolism in humans

Safety and efficacy: description of outcomes of phase

I, II, and III studies, including recommended dose/

schedule. In addition, a table summarizing overall

safety experience

Marketing experience

Summary of data

Guidance for the investigator

References

Publications

Reports

Investigator brochure content adapted from ICH Good Clinical Practice Guideline (E6)

found at http://www.ich.org.

of preclinical data required to begin human study, compared to that required for

phase I trials. Phase 0 trials generally are undertaken with agents for which: (a)

the modulation of the target is associated with antitumor effect; (b) analytically

validated PD (or PK) assays are available to accurately measure that target modu-

lation on a limited number of samples; (c) a wide therapeutic window is antici-

pated, and the target can be modulated at nontoxic doses, after a single-dose or

a very short exposure; and (d) the success of the subsequent clinical develop-

ment relies on the evaluation of that PD/PK biomarker [50–58]. Thus there still

remains a considerable amount of preclinical data required prior to starting a

phase 0 trial.



2.10.1 Preclinical knowledge of the molecule and efficacy data

Comprehensive preclinical knowledge of the molecule should be obtained prior

to starting the phase 0 trial. This includes the biochemical knowledge of the mol-

ecule and accurate determination of the IC in cel -free assays, the knowledge of

50

the IC in vitro (tumor cel s assays), as well as the assessment of the area under 50

the curve (AUC), the minimum drug exposure required to affect the target, the

C above the threshold required for efficacy, the optimal administration sched-

max

ule, and a validated biomarker assay in vivo [51,59]. Preclinical imaging should also ideally be developed at this stage, Appropriate animal models, to conduct

drug-effect studies in xenografts and provide specimens for the design and build-

ing of the assay, are therefore key [14,17,59–61].



2.10.2 Standard operating procedures (SOPs)

The development of standard operating procedures before initiating the phase 0 trial

is crucial: these SOPs should be translatable to clinical practice (“clinical readiness”)

Table 2.8. Summary of Preclinical Evaluation: Example for a Targeted Agent Element

Assay

Study goals

Results/comments

Target effect

In vitro:

Determine IC

Agents active at nanogram levels are more likely

50

non-cellular

Comparison with other agents of similar structure

to achieve those levels in vivo than those that are

systems

or targeted intent Comparison with other targets in

active at microgram levels

the same molecular family

Non-specific compounds may still be of interest if

other effects are on relevant targets

In vitro: cellular

Determine IC for effect on target protein

Compare IC for cellular and non-cellular effects,

50

50

systems

Determine maximal suppression possible, concen-

for effects on target and on growth inhibition

tration needed to achieve it, and time course for

If IC is substantially dissimilar between target

50

recovery

inhibition and growth inhibition, other mecha-

Determine IC for growth inhibition in a few cell

nisms may be involved

50

lines

In vivo:

Determine dose and /or plasma concentration

Proof of principle in animals that the agent can

animal models

effects on measures of target effect in normal and/

affect the target

or tumor tissue (PK–PD studies)

Seek correlation between: dose-target

effect–antitumor effect or PK parameter-target

effect–antitumor effect (PK–PD efficacy)

Refine assays for use in clinic

Efficacy

In vitro

Determine growth inhibitory concentrations across

Pattern of sensitivity may assist in confirming

a range of malignant cell lines

mechanism of action, similarity (or not) to other

Assess activities in sensitive/resistant paired

agents, clues to sensitive tumor types

cell lines

Activity based on concentration and level of target

Assess activity by level of target expression

expression assists in confirming mechanism

(if possible)

In vivo

Assess activity in a range of xenograft models having,

look for agents with activity (dose-related) across

if possible, range of target expression levels

a range of xenografts

Use models with established tumors, including some

Ovarian xenografts of particular interest

with large tumors or metastatic disease Compare

Seek evidence of in vivo target inhibition and its

doses and schedules if formulation allows

magnitude and duration in reference to maximal

Orthotopic models may be explored

antitumor effects and plasma drug levels

Assess target level over time in tumor; add PK

How does the agent compare with other

assessment to this experiment

active drugs?

If appropriate, determine efficacy in combination

look for evidence that schedule or route may play

with other agents

a role in efficacy

Active and vehicle control groups

Toxicology

Single dose

Using clinical formulation, determine MTD in

Exceptions to requirement for non-rodent allowed

rodent and non-rodent species

in some jurisdictions

6–10 animals per dose. Include both sexes. Observe

Determine MTD (lD10), clinical signs, nature of

14 days after dosing

organ and other toxicity

Repeat dose/

Using clinical formulation, study rodent and

Determine nature, severity, reversibility of toxicity

chronic

non-rodents in schedule planned for clinical

Determine MTD in mg/kg for rodent species in

evaluation at several dose levels and in both sexes

schedule planned for clinical study

Duration of treatment should be similar to planned

Determine relationship between PK parameters

human exposure

and toxic effects

For planned chronic (long-term) treatment, rodent

Determine if need for special safety pharmacology

study is 6 months and non-rodent 9 months

studies

Animal PK

Assess PK with toxicology or separate study

Basic PK parameters

Consider adding PK to some efficacy models

Organs/enzyme systems involved in excretion and

(see above)

metabolism

Metabolism and excretion

3 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

and should simulate clinical procedures to allow the use of the early-developed

assay at later clinical stages [62]. The effects of tissue or biological fluid handling on the expression and assessment of the biomarker of interest should also be evaluated before initiating the phase 0 trial [59,63], and an IRB (Institutional Review

Board)–approved protocol should be set up to obtain specimens from healthy vol-

unteers as well as cancer patients to evaluate and optimize the assay.



2.10.3 Pharmacodynamics

The requirements for a successful pharmacodynamic assay are its accuracy,

analytical performance, reproducibility (intra-assay reproducibility as well

as transferability to other laboratories), sensitivity, and adequate dynamic

range for measurements from samples exposed and not exposed to the drug.

Importantly, this pharmacodynamics assay also needs to be therapeutically

relevant in preclinical studies [16,64]. Ideally, a dynamic endpoint, associ-

ating the measurement of two variables (e.g., one related to the activity of

the enzyme of interest and one evaluating its degradation), should be cho-

sen [51]. Furthermore, the material on which the assay should be performed,

its handling procedure, as well as the amount of material needed to allow an

accurate analysis should be determined.



2.10.4 Pharmacokinetics

As certain circulating levels of the agent above a predetermined threshold are

required to reach target modulation, a comprehensive evaluation of the preclini-

cal pharmacokinetics of the drug is required prior to choosing a starting dose

and schedule (single or multiple dose), which should also take into account the

planned administration schedule of the agent [51,59].



2.10.5 Toxicity data

Toxicology data required to start a phase 0 trial are less than for a phase I trial,

which allows an earlier initiation of the former trial [58]. However, minimal

safety and toxicity data must be established in preclinical models in parallel to

efficacy data and drug-concentration measurements in order to establish the

appropriate starting dose. This dose must be within the therapeutic window

that associates the modulation of the target with an absence of (or minimal)

toxicity [57].

Preclinical Data and Requirements 37



2.10.6 Design and statistics

Considering the extensive amount of data generated on a very limited number of

patients, innovative statistical designs, based on a biological primary endpoint,

are needed for phase 0 trials [65].



2.10.7 Ethical considerations

Several ethical particularities should be taken into account prior to enrol ing a

patient in a phase 0 trial, considering the absence of potential therapeutic benefit

from the trial [66,67].



2.10.8 Phase 0 preclinical evaluation:

Example ABT888 [59,68]

The first-in-human clinical pharmacodynamics phase 0 trial of the poly

(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib; Abbott), was

completed by the National Cancer Institute in 2008. Prior to starting the trial,

the value of the pharmacodynamics assay, the biopsy procedures, and the perfor-

mance of the study design were evaluated in xenograft tumor models. Multiple

later-phase trials are now evaluating this drug (veliparib) in several tumor types.

As an illustration, the preclinical requirements for this specific trial are summa-

rized in Table 2.9.



2.10.9 Phase 0—Summary

Although some investigators are skeptical about the added value of phase 0 trials

in having an impact on the overall timeline of drug development, phase 0 tri-

als could soon play a more important role as preclinical animal models improve,

col aboration between scientists and clinicians increases, and personalized medi-

cine requiring patient selection based on reliable biomarkers becomes more

common. The combination of validated PD or PK assays with clinically relevant

SOPs for tissue collection and handling, together with the improvement of ani-

mal models, may lead to greater clarity about the circumstances where phase 0

trials may play a key role. (More on phase 0 trials is found in Chapter 3.) The key

message for this chapter is that such studies do require a considerable amount of

preclinical information, so the net effect of these trials on shortening the timeline to the clinic may be minimal. Thus their conduct should be driven by specific

questions for which phase 0 trials provide the most appropriate design.

3 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

Table 2.9. Example of Preclinical Data Collected Prior to Starting the

Abt-888 Phase 0 Trial

Preclinical requirement

Method used

Result

Quantification of PAR (prod-

ElISA

Analytical performance

uct of PARP1/2 activity)

(enzyme-linked

Accuracy

immunosorbent

Reproducibility

assay)

Dynamic range

Sensitivity

Therapeutic relevance

Cross-validation between

Abbott and NCI

laboratories

Sample collection and

Fine-needle biopsy

SOP designed to

handling

Xenografts collec-

stabilize PAR

tion (SOP)

Optimum quantity of material

Protein extraction

1–10 μg/wel

to be analyzed

from tumors

(SOPs)

Variability in untreated samples

Intertumor and intratumor

ElISA

Random variability

variability of PAR levels in

xenografts

Variability in PAR levels

ElISA

Random variability but

between biopsy samples and

trend to higher PAR

tumor xenografts

levels in biopsy samples,

probably due to better

preservation of the PAR

antigen

Variability over time of PAR

ElISA

Random variability

levels for a given xenograft

Pharmacodynamic effect in samples from mice treated with ABT-888

PD response in excised

ElISA

Dose-dependent suppres-

xenografts

sion of PAR activity

PD response in biopsy samples

ElISA

Dose-dependent suppres-

sion of PAR activity



2.11 SUMMARY

There is a large body of preclinical data required before a new agent can be inves-

tigated in its first human trials. While much of the data generated is in response

to government regulations and guideline requirements, other aspects, particu-

larly tests of efficacy and target inhibition, are not. Using the example of a novel

Preclinical Data and Requirements 39

targeted agent, Table 2.8 summarizes the elements of a preclinical data set that

require careful review by the investigator before undertaking a phase I trial. The

table describes the ideal list of information that should be available prior to initiation of human studies. Important in this list are not only standard toxicology and

efficacy assays, but also data that provide linkages between dose or PK measures,

target effect, and outcomes (whether efficacy or toxicity). These data will greatly

assist in early clinical trial design.



REFERENCES

1. Hirschfeld S. Clinical drug trials in children. In: Yaffe S, Aranda Y, eds. Neonatal and Pediatric Pharmacology. 3rd ed. Philadelphia: lippincott, Wil iams & Wilkins; 2004:69–91.

2. Workman P. How much gets there and what does it do? The need for better phar-

macokinetic and pharmacodynamic endpoints in contemporary drug discovery and

development. Curr Pharm Des. 2003;9(11):891–902.

3. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;10(7):514–523.

4. IHC Harmonised Tripartite Guidelines: General Considerations for Clinical Trials (E8).

1997: quotation from p. 4.

5. IHC Guideline S9 on nonclinical evaluation for anticancer pharmaceuticals. EMA, ed. 2010.

6. Content and Format of Investigational New Drug Applications (INDs) for Phase 1

Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. FDA, ed. 1995.

7. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Cancer Res. 2002;62(16):4645–4655.

8. Wilhelm SM, Carter C, Tang l, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases

involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.

9. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP

inhibitors. Cancer Res. 2012;72(21):5588–5599.

10. Pettitt SJ, Rehman Fl, Bajrami I, et al. A genetic screen using the PiggyBac transpo-son in haploid cel s identifies Parp1 as a mediator of olaparib toxicity. PLoS One.

2013;8(4):e61520.

11. Zaharevitz DW, Holbeck Sl, Bowerman C, Svetlik PA. COMPARE: a web acces-

sible tool for investigating mechanisms of cell growth inhibition. J Mol Graph Model.

2002;20(4):297–303.

12. Damia G, Broggini M. Improving the selectivity of cancer treatments by interfering with cell response pathways. Eur J Cancer. 2004;40(17):2550–2559.

13. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005;11(3):971–981.

4 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

14. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer.

2007;7(9):645–658.

15. Voskoglou-Nomikos T, Pater Jl, Seymour l. Clinical predictive value of the in

vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9(11):4227–4239.

16. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer.

2001;84(10):1424–1431.

17. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 2004;40(6):852–857.

18. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use

in preclinical cancer drug development. Eur J Cancer. 2004;40(6):858–880.

19. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in

preclinical and clinical drug development. Eur J Cancer. 2004;40(6):837–844.

20. Goodwin R, Giaccone G, Calvert H, lobbezoo M, Eisenhauer EA. Targeted agents:

how to select the winners in preclinical and early clinical studies? Eur J Cancer.

2012;48(2):170–178.

21. Kerbel RS. Human tumor xenografts as predictive preclinical models for antican-

cer drug activity in humans: better than commonly perceived—but they can be

improved. Cancer Biol Ther. 2003;2(4 Suppl 1):S134–S139.

22. O'Neill K, lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imag-

ing: a critical tool in pre-clinical oncology research. J Pathol. 2010;220(3):317–327.

23. lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol. 2005; 205(2):194–205.

24. Seymour lK, Calvert AH, lobbezoo MW, Eisenhauer EA, Giaccone G. Design

and conduct of early clinical studies of two or more targeted anticancer therapies:

recommendations from the Task Force on Methodology for the Development of

Innovative Cancer Therapies. Eur J Cancer. 2013;49(8):1808–1814.

25. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. www.fda.gov; http://www.fda.gov/downloads/ScienceResearch/

SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/

UCM113411.pdf; last accessed October 2014.

26. lipson EJ, Drake CG. Ipilimumab: an anti-CTlA-4 antibody for metastatic mela-

noma. Clin Cancer Res. 2011;17(22):6958–6962.

27. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab

(anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.

28. Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 recep-

tor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer.

2013;49(14):2968–2971.

29. Shultz lD, Ishikawa F, Greiner Dl. Humanized mice in translational biomedical

research. Nat Rev Immunol. 2007;7(2):118–130.

30. Simpson-Abelson MR, Sonnenberg GF, Takita H, et al. long-term engraftment and

expansion of tumor-derived memory T cel s following the implantation of non-

disrupted pieces of human lung tumor into NOD-scid Il2Rgamma(null) mice. J

Immunol. 2008;180(10):7009–7018.

Preclinical Data and Requirements 41

31. Bankert RB, Balu-Iyer SV, Odunsi K, et al. Humanized mouse model of ovarian can-

cer recapitulates patient solid tumor progression, ascites formation, and metastasis.

PLoS One. 2011;6(9):e24420.

32. Stauffer JK, Scarzello AJ, Andersen JB, et al. Coactivation of AKT and beta-

catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res.

2011;71(7):2718–2207.

33. Fox BA, Schendel DJ, Butterfield lH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9(1):214.

34. Römer PS, Berr S, Avota E, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist

TGN1412. Blood. 2011;118(26):6772–6782.

35. Morgan RA, Yang JC, Kitano M, Dudley ME, laurencot CM, Rosenberg SA. Case

report of a serious adverse event following the administration of T cel s transduced

with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851.

36. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cel s: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666–668.

37. www.fda.gov; http://www.fda.gov/downloads/drugs/guidancecomplianceregula-

toryinformation/guidances/ucm074957.pdf; last accessed October 2014.

38. htt p://ec.europa .eu/enter pr i se/sector s/chemical s/doc uments/

specific-chemicals/laboratory-practice/index_en.html. Available at www.ec.europa.

eu; last accessed October 2014.

39. htt p://ec.europa .eu/enter pr i se/sector s/chemical s/doc uments/

specific-chemicals/laboratory-practice/index_en.html. Available at www.ec.europa.

eu; last accessed October 2014.

40. Published in the US Federal Register August 26, 1996 (61 FR 43934).

41. ICH Harmonised Tripartite Guideline: Duration of Chronic Toxicity Testing in Animals (Rodent and Non-Rodent Toxicity Testing) (S4A) (2 September 1998); available at

www.ich.org; last accessed October 2014.

42. Newell DR, Silvester J, McDowell C, Burtles SS. The Cancer Research UK experi-

ence of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer. 2004;40(6):899–906.

43. US Federal Register (FR 99-16189). 1999;62(122).

44. ICH Harmonised Tripartite Guideline: Safety Pharmacology Studies for Human

Pharmaceuticals (S7A); available at www.ich.org http://www.ich.org/products/

guidelines/safety/safety-single/article/safety-pharmacology-studies-for-hu

man-pharmaceuticals.html; last accessed October 2014.

45. ICH Harmonised Tripartite Guideline: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human

Pharmaceuticals (S7B): available at www.ich.org http://www.ich.org/prod-

ucts/guidelines/safety/safety-single/article/the-non-clinical-evaluation-of-

the-potential-for-delayed-ventricular-repolarization-qt-interval-pro.html; last accessed October 2014.

4 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

46. Col ins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase

I clinical trials based upon preclinical drug development. J Natl Cancer Inst.

1990;82(16):1321–1326.

47. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15): 1004–1014.

48. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol.

J Clin Oncol. 1990;8(7): 1263–1268.

49. Webster l, linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D.

Measurement of cremophor El following taxol: plasma levels sufficient to reverse

drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst.

1993;85(20):1685–1690.

50. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf; .available at

http://www.fda.gov; last accessed October 2014.

51. Kummar S, Kinders R, Rubinstein l, et al. Compressing drug development time-

lines in oncology using phase ‘0’ trials. Nat Rev Cancer. 2007;7(2):131–139.

52. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory

Information/Guidances/ucm078933.pdf.; available at http://www.fda.gov; last accessed October 2014.

53. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug devel-

opment in relation to Phase 0 trials. Br J Cancer. 2007;97(5):577–581.

54. Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in

oncology. Clin Cancer Res. 2007;13(14):4033–4034.

55. Jacobson-Kram D, Mil s G. leveraging exploratory investigational new drug studies to accelerate drug development. Clin Cancer Res. 2008;14(12):3670–3674.



56. Doroshow JH, Parchment RE. Oncologic phase 0 trials incorporat-

ing clinical pharmacodynamics: from concept to patient. Clin Cancer Res.

2008;14(12):3658–3663.

57. Murgo AJ, Kummar S, Rubinstein l, et al. Designing phase 0 cancer clinical trials.

Clin Cancer Res. 2008;14(12):3675–3682.

58. Kummar S, Doroshow JH, Tomaszewski JE, et al. Phase 0 clinical trials: recommen-

dations from the Task Force on Methodology for the Development of Innovative

Cancer Therapies. Eur J Cancer. 2009;45(5):741–746.

59. Kinders RJ, Hol ingshead M, Khin S, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in

tumor biopsies of mouse xenografts. Clin Cancer Res. 2008;14(21):6877–6885.

60. Damia G, D’Incalci M. Contemporary pre-clinical development of anticancer

agents—what are the optimal preclinical models? Eur J Cancer. 2009;45(16):

2760–2781.

61. Kel and lR. Of mice and men: values and liabilities of the athymic nude mouse

model in anticancer drug development. Eur J Cancer. 2004;40(6):827–836.

62. Parchment RE, Kinders RJ, Hol ingshead M, Dancey JE, Tomaszewski JE, Doroshow

JH. Technical criteria of “clinical readiness” to qualify validated pharmacodynamic

(PD) assays for clinical trial use. J Clin Oncol. 2007;Suppl(Abst 14068).

Preclinical Data and Requirements 43

63. Baker AF, Dragovich T, Ihle NT, Wil iams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res.

2005;11(12):4338–4340.

64. Workman P, Aboagye EO, Chung Yl, et al. Minimally invasive pharmacokinetic and

pharmacodynamic technologies in hypothesis-testing clinical trials of innovative

therapies. J Natl Cancer Inst. 2006;98(9):580–598.

65. Rubinstein lV, Steinberg SM, Kummar S, et al. The statistics of phase 0 trials. Stat Med. 2010;29(10): 1072–1076.

66. Hill TP. Phase 0 trials: are they ethically challenged? Clin Cancer Res. 2007;13(3): 783–784.

67. Abdoler E, Taylor H, Wendler D. The ethics of phase 0 oncology trials. Clin Cancer Res. 2008;14(12):3692–3697.

68. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J

Clin Oncol. 2009;27(16):2705–2711.





3

Phase 0 Clinical Trials

S H I V A A N I K U M M A R A N D J A M E S H . D O R O S H O W ■



3.1 INTRODUCTION

High failure rates and increasing complexity of early-phase clinical trials in oncol-

ogy continue to present challenges for the development of effective anticancer

therapies. Drug development in oncology is resource-intensive, with develop-

ment costs estimated in the hundreds of mil ions of dol ars for each drug that

becomes part of the standard therapeutic armamentarium. The whole process

of drug development from drug synthesis through marketing approval takes, on

average, 16 years [1,2]. Despite continuing efforts to improve this process, the

failure rate of novel agents remains high. Only 13% of agents entering clinical

development are eventually approved for standard use; however, 75% undergo

both phase I and II trials before the decision is made to end their clinical devel-

opment [3] . This has resulted in the need to rethink the drug-development

paradigm by trying to identify promising agents earlier and to expedite their

development, while de-prioritizing potential “failures.” Phase 0 trials were pro-

posed as one strategy to address such considerations.

Phase 0 trials are first-in-human studies that are conducted prior to traditional

dose-finding phase I trials. Phase 0 trials are conducted under the US Food and

Drug Administration’s (FDA) exploratory investigational new drug (IND) guid-

ance and involve only a few patients (usually 10–12) who are exposed to a limited

number (fewer than 7 days) of low doses of an investigational drug, either microdo-

ses (defined as less than 1/100th of the pharmacologically active dose as determined

in animal models) or sub-therapeutic but pharmacologically active doses [4] . The

limited exposure to low doses of study agent provides a margin of safety that requires less extensive preclinical toxicology evaluation than traditional phase I trials (which

Phase 0 Clinical Trials 45

are designed to establish safety and define toxicities) prior to trial initiation [5–7].

Phase 0 trials provide a platform to assess the pharmacokinetic (PK) and pharma-

codynamic (PD) properties of an agent in humans very early in the drug evaluation

process. Data generated from such trials can inform the subsequent development of

the agent, providing a rational basis for “go” and “no-go” clinical decisions. Similar guidance was issued by the European Medicine Agency regarding exploratory clinical trials conducted early in phase 1 [8,9].



3.2 WHEN TO CONDUCT A PHASE 0 TRIAL?

The objectives of phase 0 trials include:

1. determining whether the mechanism of action defined in preclinical

models can be demonstrated in humans;

2. evaluating PK–PD relationships;

3. refining a qualified PD assay in human tissues;

4. optimizing the sequence and schedule of drug combinations;

5. selecting a lead agent from analogs based on human PK/PD data; and

6. examining agent biodistribution, binding, and target effects in humans,

using highly sensitive imaging technologies.

Depending on clinical objectives, the decision to proceed with a phase 0 rather

than a phase I trial will depend on a number of factors. Trials conducted to assess

the PK profile of an agent in humans require development of qualified assays capa-

ble of measuring the agent and any selected metabolites prior to the initiation of the study. Assay attributes such as accuracy, sensitivity, and robustness should be carefully defined prior to use on clinical trial samples. Depending on whether a micro-dose

study is planned or pharmacologically active doses are administered, the type of assay and facilities needed for analyses may vary. Preclinical testing to determine the starting dose and to predict exposures would aid in designing the sampling schedule for PK

assessments following one or several doses of study agent. Phase 0 studies conducted

to evaluate PK endpoints, such as bioavailability, can also be performed in healthy volunteers. Such studies have the potential to expedite the initial evaluation of the study drug in healthy volunteers, allowing ‘go’ and ‘no-go’ decisions to be made based on PK

characteristics of the agent. Although drug effect on target in surrogate tissues can be assessed in health volunteer studies, follow-up trials in patients would be required to establish the PD in the tissue of interest and define the PK-PD relationship.

Phase 0 trials with PD endpoints present a further challenge because they neces-

sitate the development of validated assays to measure target modulation in human

samples and access to paired tissue samples, such as tumor biopsies, collected both

4 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

prior to and at a defined time point following drug administration. Agents selected

for evaluation in PD-driven phase 0 trials should meet certain criteria, such as:

1. the study agent is potent and has a wide therapeutic index in preclinical

models so that target or biomarker modulation is anticipated at non-

toxic doses and over short durations of exposure;

2. validated assays to measure target modulation and/or its consequences

must be available;

3. a drug effect of sufficient magnitude to be reliably measured in small

sample sets should be anticipated; and

4. the observation of target modulation (or lack thereof) will be used to

determine the future development of that agent.

Therefore, not all novel agents need to undergo phase 0 testing prior to under-

going traditional phase I evaluation. The commitment to conduct a phase 0 trial

should be based on strong preclinical data with clear decision points affecting the

future development of the agent (see Figure 3.1).



3.3 TYPES OF PHASE 0 TRIALS



3.3.1 Single-agent trials

Administration of limited doses of a single agent with tumor and blood/surro-

gate tissue sampling for PK and PD could provide essential information regard-

ing target modulation and PK–PD relationships in humans. Because few patients

will receive a limited number of drug doses, novel statistical designs are needed

to interpret the data and draw valid conclusions [10] . Doses can be escalated in

subsequent patient(s) to evaluate dose response as long as all of the doses are rela-

tively low and nontoxic. Target drug exposures that are probably associated with

drug effects can be defined prospectively based on PK/PD data generated in pre-

clinical models. Post-dose tumor biopsy collections that are performed to demon-

strate target modulation can be initiated and appropriately timed once adequate

drug exposures and PK profiles are achieved. This requires real-time analysis of

samples with effective communication between multidisciplinary teams of clinical

and laboratory research staff. This teamwork allows decisions to be made quickly

about dosing and the need for and timing of tumor biopsies. Preliminary data on

surrogate tissues and the relationship of this information to effects observed in

tumor samples can be obtained and guide the need for obtaining tumor biopsies

in definitive trials. The first PD-driven phase 0 trial of the single agent ABT-888,

an oral inhibitor of poly (ADP) ribose polymerase (PARP), was conducted at the

Phase 0 Clinical Trials 47

New

molecular

entity

Therapeutic

index

Wide

Narrow

PD endpoint

studies

Phase 0

Phase 0

Traditional

PK study

microdose

Phase I

(pharmacol.

study

study

active)

Analytically validated

No PD assay

PD assay

• Expedite future

development of agent

• Eliminate drug/select

PD-driven

from analogs

Phase 0 trial

−

+

• Eliminate drug

Phase I/II study

or Phase I

combination study

Figure 3.1 Phase 0/Phase I decision chart for clinical evaluation of a new molecular entity. The decision to proceed with a phase I or phase 0 study design depends on the characteristics of the agent as well as on development objectives.

Reproduced with permission from Kummar S, Doroshow JH, Tomaszewski JE, Calvert

AH, lobbezoo M, Giaccone G. Phase 0 clinical trials: recommendations from the task

force on methodology for the development of innovative cancer therapies. Eur J Cancer.

2009;45(5):741–746.

US National Cancer Institute (NCI) in thirteen patients with advanced malignan-

cies, of whom nine underwent paired tumor biopsies. This study demonstrated

that target modulation could be achieved in tumor biopsies at clinically achiev-

able concentrations of ABT-888 [11]. Data from this trial informed the dose

and schedule of phase I combination trials of ABT-888 with DNA-damaging

agents [12,13]. The NCI also conducted a first-in-human phase 0 trial with oral

5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR), a prodrug of iododeoxyuridine

(IdUrd) that is a halogenated nucleoside with radiosensitizing properties. This

study was conducted to establish that oral administration provided adequate sys-

temic exposures to IdUrd and its metabolites for use as a feasible alternative to

continuous intravenous IdUrd infusions. Detailed PK analysis was performed to

assess drug exposures in a total of ten patients enrolled on five dose levels (single doses of 150–2,400 mg); blood samples were collected from patients before and

4 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

at multiple time-points (5 minutes to 24 hours) after IPdR administration [14].

There were no drug-related adverse events in this study, and clinical trials of IPdR

in combination with radiotherapy are now being planned.



3.3.2 Sequencing of agents in designing drug combinations

Designing drug combination trials that optimize efficacy while minimizing the

risk of toxicities remains a challenge. Phase 0 trials provide the opportunity to

evaluate more than one schedule and sequence by using PK and PD assessments

to determine the study design for more definitive trials. However, given the com-

plexities of dosing two agents at sub-therapeutic nontoxic doses, whether phase

0 trials with sub-therapeutic doses could optimize the administration schedule of

combination drugs has yet to be explored.



3.3.3 Selecting a lead candidate from analogs

During initial drug discovery efforts to select compounds specific for a given target, multiple structurally related analogs of a given class are generated. Following initial preclinical development, the decision regarding lead agent selection for further clinical development is made based on the in vitro and in vivo data generated. However, it has long been established that preclinical models are not necessarily predictive of efficacy and/or toxicity in humans [15–17]. Phase 0 trials offer a practical approach for the selection of a lead molecule, in that multiple analogs can be administered at nontoxic doses to a limited number of patients to compare their respective PK and

PD properties. Several phase 0 trials are known to have been conducted by industry

to inform selection of the lead candidate for traditional phase I studies [18].



3.3.4 Phase 0 imaging trials

There is increasing interest in evaluating the presence of receptors or targets in

metastatic lesions using imaging modalities such as positron emission tomog-

raphy (PET) and single-photon-emission computed tomography (SPECT).

These modalities provide a noninvasive platform for whole body imaging to

assess the presence of a molecular target in metastatic lesions and to evaluate

target modulation following drug administration. Such early trials could pro-

vide data to inform patient selection in definitive studies. Another area of inter-

est is to label agents with a radiotracer to study uptake and kinetics through

imaging. Multiple phase 0 trials are currently evaluating this approach, such

as the phase 0 trial of F-18-5-fluoro-2′-deoxycytidine with tetrahydrouridine

Phase 0 Clinical Trials 49

(NCT01479348), and PET imaging of an investigational heat shock pro-

tein 90 inhibitor I-124-PU-H71, to measure biodistribution (NCT01269593).

Imaging studies need not be limited to small molecules: the FDA Guidance

allows microdoses of 1/100 of the dose shown to cause a pharmacological

effect up to a maximum of 100 μg or 30 nM for protein products [19,20].

Proof-of-concept phase 0 trials with biologics have been demonstrated in a

study evaluating the pharmacokinetics, biodistribution, and specific tumor

targeting of 124-I-anti-tenascin-C antibody F16SIP in 4 patients with head

and neck cancer who were scheduled for surgery [21]. Other trials are also

underway, including a study of 111-In-trastuzumab to examine biodistribu-

tion and correlate HER2/Neu expression in patients with breast cancer with

uptake of the drug using gamma camera imaging (NCT01445054). However,

radiopharmaceuticals need to be specific and have favorable PK profiles to

provide optimal tumor to background ratios. This may require initial evalu-

ation of more than one compound against a target to determine the optimal

radiopharmaceutical for clinical development. Given the complexity and

resource-intense nature of imaging trials, this could present a major hurdle in

the development of radiopharmaceuticals. Phase 0 imaging trials using micro-

doses of the radiopharmaceutical in a few patients allow more than one agent

to be tested, more effectively utilizing resources and expediting development.



3.4 ETHICAL CONSIDERATIONS



The non-therapeutic nature of phase 0 trials, the potential need for serial invasive

tumor biopsies [22], the possibility of delaying subsequent therapy for partici-

pants, and their potential exclusion from participation in future clinical trials are among the ethical issues that continue to be raised during discussion of phase 0

trials. These questions need to be considered when planning a phase 0, or indeed

any other, clinical trial, and they should be clearly addressed in presentations to

clinical study oversight committees to minimize potential delays. All such con-

siderations should be clearly stated in the informed consent form and carefully

explained to potential participants, who are likely to be more familiar with “tra-

ditional” clinical trials and have expectations of the possibility of therapeutic

benefit. Having a simple checkbox in the consent asking potential participants

to acknowledge and verbalize that they understand the lack of therapeutic intent

can help emphasize this point, providing an opportunity for clinicians obtaining

informed consent to discuss this aspect of the trial with patients.

Prior to requiring tumor biopsies in a phase 0 trial or, for that matter, in any

clinical trial, assays should be validated and performed consistently with the data

reported in a timely manner [22]. Specific attention must be paid during the

design of phase 0 trials to optimize the timing of sample collection with respect

5 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

to drug administration. Requiring shorter drug washout periods (e.g., requiring a

two-week washout from prior therapy rather than the more standard four weeks),

and a short duration of study participation (e.g., one to two weeks) will minimize

delay in a patient’s participation in a subsequent trial or therapy. Awareness of these issues when designing phase I and II trials is also essential; for example, allowing

participants on phase 0 trials to enroll in subsequent trials after shorter washout

periods (e.g., two weeks from receiving agent in a phase 0 trial). In addition, phase I and II trials should not, simply because of standard “template” language, exclude

patients from participation who previously received a study agent administered

with non-therapeutic intent, such as during a phase 0 trial. Once tissue has been

collected, there must be assays and sample-handling procedures in place to ensure

that sample analysis yields scientifically valid data that will contribute to study

objectives. There is a further obligation to publish data expeditiously to inform the development of the specific agent and other agents of that class [23].



3.4.1 Assay development

Depending on the objectives of a phase 0 trial, assays to measure drug levels and

target modulation may need to be developed and qualified prior to the initiation

of the first-in-humans trial. Such assays should be applied in preclinical models to

measure drug concentrations and/or demonstrate the effect of the drug on the tar-

get, and the observed drug effect should be associated with demonstrated antitu-

mor activity. Because drug effect on target is dynamic, questions such as degree and

duration of modulation, tumor heterogeneity [24], and recovery kinetics should

be evaluated in preclinical models, with the objective of quantifying the biological

consequences of target inhibition that are associated with the observed antitumor

effects. Assays should be developed that are accurate, reliable, and have sufficient

dynamic range to provide quantifiable data for assessment of drug-dose effects

[7] . Standard operating procedures (SOPs) for sample handling, processing, and

storage should also be developed and integrated into clinical protocols to allow

cross-sample comparisons. These efforts are resource-intense and require a mul-

tidisciplinary group, but are critical for achieving accurate and actionable results.1



3.5 GO AND NO-GO DECISIONS

In view of the limited number of doses and low drug levels achieved in phase 0 trials, such studies do not provide definitive conclusions regarding the safety or efficacy

of a new anticancer agent. However, data from phase 0 trials can form the basis for

1. http://dctd.cancer.gov/ResearchResources/ResearchResources-biomarkers.htm

Phase 0 Clinical Trials 51

go/no-go decisions very early in the clinical development of an agent. A phase 0 trial conducted by investigators at the University of Pittsburgh School of Medicine tested

intratumoral injection of a STAT3 decoy oligonucleotide against a vehicle-treated

control group in 30 patients undergoing surgery for squamous cell carcinoma of the

head and neck. Analysis of pre- and post-treatment biopsies showed evidence of

STAT3 target-gene suppression without a change in total or phosphorylated STAT3

levels, supporting the proposed mechanism of action and informing continuing

studies to stabilize the decoy oligonucleotide for systemic administration [25].

Demonstrating modulation of a PD target in a phase 0 trial, therefore, provides

confirmation of proof-of-mechanism and can also generate PK data to assess

PK–PD relationships that form the basis for starting doses, dose escalation, and

schedules to be evaluated in subsequent trials. If no modulation of the target is

observed despite achieving desired PK exposures, then a “no-go” decision for the

specific agent should be considered. For a PD-driven phase 0 trial, this decision

requires that the preclinical data used to support the phase 0 trial were robust,

and that the PD interaction was either associated with antitumor activity in pre-

clinical models, or demonstrated proof-of-mechanism for further development

[7] . The PD outcome evaluated in such trials could include assessment of the

downstream consequences of target modulation in addition to the direct PD

effect, providing confidence in the observed results (Figure 3.2). The ability to

de-prioritize agents early in the clinical development process allows resources

to be reallocated to expedite the development of other promising compounds.



3.6 TOXICOLOGY AND DRUG-MANUFACTURING

CONSIDERATIONS

The purpose of toxicology studies remains the protection of human subjects

for both traditional and exploratory INDs [26]. Both IND applications require

Decision Based on

Preclinical Evaluation

Results of PK/PD

Outcome of Phase 0 Trial

• Achieve desired plasma levels

PK

PD

• Develop analytically validated PD

+

+

GO

assay to detect target modulation

• Achieve target modulation at the

desired plasma levels

−

−

NO GO

• Demonstrate that antitumor

activity is associated with target

+

−

GO/NO GO

modulation

Figure 3.2 Go/no-go clinical development decisions based on PK and PD assessments in phase 0 trials.

Reproduced with permission from Kummar S, Doroshow JH, Tomaszewski JE, Calvert

AH, lobbezoo M, Giaccone G. Phase 0 clinical trials: Recommendations from the task

force on methodology for the development of innovative cancer therapies. Eur J Cancer.

2009;45(5):741–746.

5 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

toxicology studies in two mammalian species to calculate a safe clinical starting

dose and to provide safety information for the dose and schedule being evaluated

in the first-in-humans trial. Because study-drug exposures are limited in phase

0 trials, toxicology studies can assess the safety of administering only a limited

number of low doses prior to the initiation of the trial, allowing human trials to be initiated earlier in the process of drug development, with plans for a full toxicology evaluation if initial phase 0 data are promising. An FDA guidance document

released in conjunction with the exploratory IND guidance on complying with

current good manufacturing practice (CGMP) regulations [27] described an

incremental (i.e., “laboratory” scale) rather than full-scale approach to the manu-

facture of investigational drugs for early-phase clinical trials, using the appropri-

ate quality control procedures for manufacturing, labeling, and documentation.



3.7 CONCLUSIONS

The shift from traditional cytotoxic chemotherapies to molecularly targeted agents

(MTA) for the treatment of cancer requires the identification and understanding

of the role of the therapeutic target in normal and cancer cel s, and the conse-

quences of its modulation, as well as ways to quantify the effect of the MTA on its

target. The traditional drug-development paradigm for cytotoxic chemotherapies

was based on the inherent assumption that the investigational agent under study

had a dose–toxicity relationship, and that efficacy was associated with toxicity.

This formed the basis for defining the maximum tolerated dose in first-in-humans

trials; however, because the dose–response relationship for MTAs differs from

standard cytotoxic agents, defining the “optimal biologic dose” may be a more rel-

evant endpoint for early-phase trials with MTAs. This requires developing, quali-

fying, and integrating validated assays into early-phase trials to be able to quantify target modulation and its consequences. Validation of assays is resource-intense

and requires a multidisciplinary team. In the traditional drug-development para-

digm, these resources are allotted later in the process, usually around the time of

conducting phase II trials. Phase 0 studies require reallocation of such resources

and the time it takes to develop them to a point earlier in the process, with the

emphasis on developing criteria for prioritizing and de-prioritizing agents prior to

the initiation of the first-in-humans trial. This requires both programmatic deci-

sions and a wil ingness to accept the outcome of the results of the phase 0 study. It is certainly plausible that the insertion of phase 0 trials into the development path of an individual drug may result in no savings of time or resource, which makes

it important to ensure that phase 0 trials are undertaken when the information

gathered will truly inform drug-development decisions.

Phase 0 Clinical Trials 53

Even though the potential utility of phase 0 trials has been debated and acknowl-

edged, the wider adoption of phase 0 trials is hampered by lack of resources,

incomplete understanding of the therapeutic target of multikinase inhibitors,

reluctance to de-prioritize agents, potential concerns about false-negative results

due to the small sample sizes employed, and the concern that conducting phase 0

trials could delay initiation of subsequent phase I trials (Table 3.1). The increasing number of phase 0 trials being conducted and the use of data generated from such

Table 3.1. Differences Between Phase 0 and Standard

Phase I Trial Designs

Phase I trials

Phase 0 trials

Basis for

Results from full standard

Results from limited preclinical

starting

IND-directed preclinical

toxicology studies to support

dose

toxicology studies

Exploratory IND

Preclinical

Not consistently done before

Target/biomarker analytical

biomarker

initiating the trial

assays are validated in pre-

studies

clinical models before initiating

phase 0 clinical trial

Primary

Establish dose-limiting toxicities

Establish a dose range that

endpoint

and maximum tolerated dose

modulates (or images)

target, for use in subsequent

developmental trials

Establish the pharmacokinetic

(PK) properties of the agent(s)

Population

Patients with advanced incur-

Patients with advanced incur-

able malignancy, after failure of

able malignancy, after failure of

standard therapy

standard therapy, or indolent

disease (e.g., chronic lympho-

cytic leukemia) not requiring

immediate treatment

OR

For PK questions, the popula-

tion may be healthy volunteers

Washout

Usually a minimum of 4 weeks

May be 2 weeks or less

period

before

and after

entry

Total

Usually >20

10–15

number of

patients

( continued)

5 4

P H A S E I C A N C E R C l I N I C A l T R I A l S

Table 3.1 (Continued)

Phase I trials

Phase 0 trials

Dose

Guided primarily by toxicity

Intended to achieve desired

escalation

drug exposure and/or target

modulation without significant

toxicity

Duration of Repeated dosing with multiple

limited dosing (e.g., 1–7 days);

dosing

cycles until disease progression

one cycle only

or unacceptable toxicity

Evaluation

Tumor response routinely evalu-

None

for thera-

ated periodically to prevent con-

peutic

tinued dosing with no potential

benefit

for clinical benefit

Biomarker

Not consistently done because

PD markers are integrated in the

assays

most phase I trials do not

trial to establish mechanism of

emphasize PD markers

action and target/biomarker

analytic assay validation in

patient tissue samples

Tumor

Almost always optional

At least one pre-drug and one

biopsies

post-drug administration

tumor biopsy required to

evaluate drug effect on target

PK/PD

Samples are usually batched and

Real time

analysis

analyzed at a later time point,

generally after completion of

the trial

Reproduced with permission from Murgo AJ, Kummar S, Rubinstein l, et al. Designing

phase 0 cancer clinical trials. Clin Cancer Res. 2008;14(12):3675–3682.

trials to inform further clinical development will be needed to establish the place

of phase 0 trials in the drug-development paradigm. Data should address questions

such as:

1. Does conduct of phase 0 trials compress drug-development timelines?

2. Do the agents prioritized based on data from phase 0 trials have a higher

likelihood of being approved for standard use?

3. Are agents de-prioritized based on phase 0 results, and how does that

affect the incidence of “failures” later on in the development process?

4. What is the economic impact of conducting phase 0 trials?

5. How does the development of validated assays early in the

drug-development process affect the progress of that specific agent and/

or class of agents?

Phase 0 Clinical Trials 55

The NCI has made the SOPs for its validated assays developed within its PD

program available for researchers worldwide, facilitating their use in clinical trials.2

In summary, phase 0 trials provide a platform to obtain human data early in

the drug-development process, allowing a more rational basis for further deci-

sions regarding the clinical development of an agent. The eventual acceptance of

the use of such trials will depend on a number of factors and data from current

trials establishing their utility.



REFERENCES

1. DiMasi JA. Risks in new drug development: approval success rates for investiga-

tional drugs. Clin Pharmacol Ther. 2001;69(5):297–307.

2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of

drug development costs. J Health Econ. 2003;22(2):151–185.

3. DiMasi JA, Reichert JM, Feldman l, Malins A. Clinical approval success rates for

investigational cancer drugs. Clin Pharmacol Ther. 2013;94(3):329–335.

4. US Food and Drug Administration. Guidance for industry: exploratory IND

studies. 2006; available at http://www.fda.gov/downloads/Drugs/Guidance

ComplianceRegulatoryInformation/Guidances/ucm078933.pdf. Accessed Sept.

24, 2013.

5. Kinders RJ, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007;7(6):325–334.

6. Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, lobbezoo M,

Giaccone G. Phase 0 clinical trials: recommendations from the Task Force on

Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer.

2009;45(5):741–746.

7. Kummar S, Kinders R, Rubinstein l, et al. Compressing drug development time-

lines in oncology using phase ‘0’ trials. Nat Rev Cancer. 2007;7(2):131–139.

8. European Medicines Agency. Concept paper on the development of a CHMP

guideline on the non-clinical requirements to support early phase I clinical trials

with pharmaceutical compounds. 2006; http://www.ema.europa.eu/docs/en_GB/

document_library/Scientific_guideline/2009/10/WC500003979.pdf. Accessed 18 Dec, 2013.

9. European Medicines Agency. ICH guideline M3(R2) on non-clinical safety stud-

ies for the conduct of human clinical trials and marketing authorisation for phar-

maceuticals. 2009; http://www.ema.europa.eu/docs/en_GB/document_library/

Scientific_guideline/2009/09/WC500002720.pdf. Accessed 18 Dec, 2013.

10. Rubinstein lV, Steinberg SM, Kummar S, et al. The statistics of phase 0 trials. Stat Med. 2010;29(10):1072–1076.

11. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

J Clin Oncol. 2009;27(16):2705–2711.

2. http://dctd.cancer.gov/ResearchResources/ResearchResources-biomarkers.htm

5 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

12. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726–1734.

13. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer

Res. 2011;71(17):5626–5634.

14. Kummar S, Anderson l, Hill K, et al. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2′-deoxyribose in patients with advanced malignancies. Clin Cancer

Res. 2013;19(7):1852–1857.

15. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg Toxicol Pharmacol. 2000;32(1):56–67.

16. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer.

2001;84(10):1424–1431.

17. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotech. 2012;30(7):648–657.

18. Robinson WT. Innovative early development regulatory approaches: expIND,

expCTA, microdosing. Clin Pharmacol Ther. 2007;83(2):358–360.

19. Wagner CC, langer O. Approaches using molecular imaging technology—use of

PET in clinical microdose studies. Adv Drug Del Rev. 2011;63(7):539–546.

20. Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug

development in relation to Phase 0 trials. Br J Cancer. 2007;97(5):577–581.

21. Heuveling DA, de Bree R, Vugts DJ, et al. Phase 0 microdosing PET study using

the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med.

2013;54(3):397–401.

22. Olson EM, lin NU, Krop IE, Winer EP. The ethical use of mandatory research biop-

sies. Nat Rev Clin Oncol. 2011;8(10):620–625.

23. Freeman GA, Kimmelman J. Publication and reporting conduct for pharmaco-

dynamic analyses of tumor tissue in early-phase oncology trials. Clin Cancer Res.

2012;18(23):6478–6484.

24. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched

evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892.

25. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligo-

nucleotide in head and neck tumors: implications for cancer therapy. Cancer Disc.

2012;2(8):694–705.

26. Muller PY. Comparative requirements for exploratory clinical trials—eIND, eCTA

and microdosing. Adv Drug Del Rev. 2011;63(7):511–517.

27. US Food and Drug Administration. Guidance for industry: INDs-approaches to

complying with CGMP during phase I. 2006; available at http://www.fda.gov/

ohrms/DOCKETS/98fr/05d-0286-gdl0001.pdf. Accessed Sept. 24, 2013.





4

Basics of Phase I Design

First-in-Human Studies

D O N N A M . G R A H A M , A A R O N R . H A N S E N ,

E L I Z A B E T H A . E I S E N H A U E R , A N D L I L L I A N L . S I U ■



4.1 INTRODUCTION

This chapter will focus on the fundamental principles of phase I trials of agents

that are entering the clinic for the first time. Initial preclinical testing of these drugs utilizes in vivo animal models; in vitro studies such as cell lines or functional experiments; and computational algorithms or in silico analyses. Trials that initially test these compounds are commonly referred to as “first-in-human” (or

occasionally “first-in-man”) studies, and this terminology will be utilized in this

chapter. The traditional method of drug development has been challenged by

the advent of effective non-cytotoxic agents and molecular profiling, which is

a bioinformatics approach that analyzes DNA, mRNA, and protein structures

for alterations. Consequently, this chapter will review how this shift away from

classical chemotherapeutics may influence the basic design of a first-in-human

trial. In addition, the TGN1412 tragedy (see below) will be discussed in terms

of how lessons learned from this event should impact future studies of this type.

While combination phase I trials have many concepts in common with first-in-

human studies of single agents, they are the subject of a more detailed descrip-

tion in Chapter 6. Ethical considerations related to phase I trials are discussed in

detail in Chapter 5. Issues pertaining to immunotherapeutic agents are covered

in Chapter 7.

5 8

P H A S E I C A N C E R C l I N I C A l T R I A l S



4.2 GOALS

The primary goal of first-in-human studies is to define the recommended dose

of a new drug in the schedule(s) tested (see Table 4.1). Secondary goals of these

trials are several and usually include at least those in Table 4.1.

Historically, most anticancer drugs have been cytotoxic, and the main “trans-

lational” laboratory studies have been the pharmacokinetics (PK) of the drug

in the blood. The principal pharmacodynamics (PD) readout in such studies

has been toxicity. Increasingly, rationally designed novel agents targeting mul-

tiple intracellular and extracellular pathways are being developed as anticancer

therapeutics; these agents have variously been referred to as non-cytotoxics,

cytostatics, molecularly targeted agents (MTAs), or biological agents. Phase

I trials of MTAs frequently also incorporate non-clinical laboratory PD effects

such as toxic effects, and molecular and imaging changes in normal or tumor tis-

sues to confirm mechanistic effects of the new drug being tested. Importantly,

despite the differing mechanisms of action, antitumor effects, and toxicity pro-

files between MTAs and chemotherapies, the primary goal of a phase I study has

not changed [1] .

Beyond defining drug dose, alternate non-primary outputs from first-in-

human studies may potentially include go/no-go decisions for the future devel-

opment of an agent; recommendations for testing of new schedules that are

either more tolerable or more effective or produce greater levels of target inhibi-

tion; and to direct drug testing in patient populations with specific histologies or

molecular profiles based on preliminary signs of clinical activity. In light of this, phase I studies are becoming increasingly complex and challenging from a scientific, clinical, and logistical perspective. However, the focus must always remain

on patient safety, as the following case will illustrate, since experimental drugs

can cause great harm if not properly administered.

Table 4.1. Goals of First-in-human Phase I Studies

Goals

Primary

To determine recommended dose of the new agent for further study in

the schedule under evaluation

Secondary

To describe the toxic effects including dose-limiting toxicity produced

by the new agent in the schedule under evaluation

To determine the PK of the new agent

To document any evidence of objective antitumor effect

To describe any relationship between dose, or PK parameters, and

effects on toxicity, or measures of molecular drug effect in tissues

(PD effects)

Abbreviations: PK, pharmacokinetic; PD, pharmacodynamics

Basics of Phase I Design: First-in-Man Studies 59



4.3 THE TGN1412 TRAGEDY, AND LESSONS LEARNED



In March 2006, the occurrence of very severe adverse reactions during a first-in-

human clinical trial prompted a review of the event by an expert scientific

group (ESG) who subsequently gave advice and recommendations for future

early-phase trials [2] . The trial under review was performed in a clinical research

unit at Northwick Park Hospital in london and investigated the investigational

humanized immunostimulatory monoclonal antibody TGN1412, planned for

treatment of leukemia and autoimmune diseases. All of the six healthy male vol-

unteers who were enrolled developed a cytokine-release syndrome within hours

of receiving the intravenous medication, requiring treatment in the intensive care

unit (ICU). This inflammatory reaction progressed to multi-organ failure in all

six volunteers. None of the volunteers died, but some were left with long-term

health issues related to the study drug [3].

Review of the incident highlighted a number of areas where modifications

to early clinical trial practice might have been able to limit adverse outcomes.

Following detailed analysis of the case, recommendations relating to first-in-

human studies were made by the ESG. These recommendations relate to three

categories of agents that may have a higher risk of harm to volunteers at first

exposure, or where risk may be difficult to evaluate during preclinical develop-

ment and for which particular cautions should be in place in first-in human trials.

These categories are: (1) biological molecules with novel mechanisms of action,

(2) new agents with a high degree of species specificity, and (3) new agents with

immune system targets. The tragic outcome of this study led to recommenda-

tions that outlined general principles for performing early clinical trials using

higher risk agents.



4.3.1 Preclinical and early clinical development

It is vital that adequate and appropriate preclinical work be performed prior to

human trials (see Chapter 2). With TGN1412, the investigation determined that

the species used for toxicology and dose determination, Cynomolgus macaque

monkeys, did not exhibit the same pattern of response to the antibody as did

humans. The ESG recommended that decisions for preclinical and early clini-

cal development of a new high-risk medication or advanced medicinal product

derived from innovative technologies be scientifically based and justified by indi-

viduals with appropriate training. There should be regular review of the regula-

tory process, and, where higher risk medications are in evaluation and potential

safety concerns exist, collection of information from unpublished preclinical

studies should be expedited by the appropriate bodies. Open communication

6 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

and sharing of information were seen as key for improving preclinical knowledge

and highlighting potential patient risk.



4.3.2 Preparation and review of clinical trial applications

To facilitate information sharing, better communication was strongly recom-

mended between sponsors, manufacturers, and the regulator at earlier stages in

drug development, before an application is filed. This is aimed at ensuring that

there is time for appropriate consideration of any safety concerns without undue

delay to product development, especially with higher risk agents. Methods to

optimize communication between the government regulator and research eth-

ics committees are in place internationally and are critical to safe trial conduct.

Additional opinions from independent specialists in this field or an expert advi-

sory group (EAG) could be provided to the regulator for trials involving higher

risk medications, as is currently the practice in the United Kingdom in the form

of the EAG of the Commission on Human Medicines. longer time-frames for

clinical trial application review when agents or studies have a high degree of com-

plexity might be considered.



4.3.3 Determining doses in phase I trials

Careful determination of the initial dose for first-in-human studies is always

important, and there should be a clear rationale for the proposed mechanism

of action of the substance in its intended clinical use, and appropriate safety and

efficacy information. Agents for which the pharmacological action of the pro-

posed therapeutic effect cannot be reproduced in an animal model and extrapo-

lated to the human setting are especially challenging.

Starting-dose calculations using animal models should be made on a case-by-

case basis and use all relevant information. This includes the novelty of the agent,

its biological potency and mechanism of action, the degree of species-specificity

of the agent, toxicology data, the dose-response curves of biological effects in

human and animal cel s, pharmacokinetic and pharmacodynamics modeling,

calculation of target occupancy versus concentration, and the estimated potential

exposure of target cel s in humans. If differing calculations give different estimates of a safe dose in humans, the lowest value should be the starting dose in first-in-human trials, with a margin of safety incorporated. Where there is any reason to

believe that preclinical information may be a poor guide to effects in humans,

particular caution should be used in calculating starting doses and increments

during dose escalation (see section 4.6.1). The route and rate of administration

Basics of Phase I Design: First-in-Man Studies 61

of the agent should be carefully considered, with close monitoring for adverse or

unexpected effects.

The experience with the TGN1412 trial also highlighted the importance of

ensuring adequate time for observing subjects for adverse effects when sequen-

tial dosing is planned. Most first-in-human trial protocols stipulate the minimum

time intervals between dosing the first and subsequent patients at a particular

dose level, and also between different dose cohorts. These intervals should take

into account the expected timeline for adverse effects and characteristics of

the agent.



4.3.4 The patient population

In the TGN1412 trial, the study population was healthy volunteers. In oncol-

ogy, the potential for adverse effects and availability of proven therapies

for this life-threatening condition make previously treated patients cancer

patients the usual population for first-in-human trials. Whether healthy vol-

unteers or patients are the appropriate population for inclusion is based on

considerations such as the potential risks and potential scientific value of the

information to be gathered. Regardless of the population, their safety and

well-being should be paramount.



4.3.5 The clinical environment for first-in-human studies

Access to 24-hour medical care to address potential adverse reactions should be

considered before the commencement of the study. This may include ensuring

potential “antidotes” or other rescue medications are available, as well as access

to supportive care, including ICU support when agents have potentially serious

organ toxicities. Principal investigators (PIs) must be appropriately qualified and

have adequate knowledge about the agent and its mechanism of action to make

informed clinical judgements.



4.3.6 Summary

As highlighted by the events that unfolded with TGN1412, high-risk agents

showing safety and efficacy in preclinical models may exhibit very different effects

when administered to humans. Endeavors to optimize preclinical models as effi-

cient predictors of drug behavior in humans should be supported [4] . Patient

safety is paramount in early clinical trials, and mechanisms must be in place to

6 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

prevent harm to patients. In first-in-human trials, the approach to determining

the starting dose and dose-escalation schedule must retain safety at their core.

Communication and col aboration between all bodies involved in the conduct of

clinical trials is essential to ensure patient/subject safety. The following sections will detail the methods by which phase I trials can be designed and executed

effectively and safely.



4.4 PATIENT POPULATION



Although healthy volunteer studies may offer some information relating to PK

and safety, undertaking first-in-human trials of new cancer agents in this popula-

tion is unusual, for some of the reasons outlined earlier. Normally, the popula-

tion enrolled in first-in-human phase I trials of new anticancer agents is patients,

with cancer patients for whom no curative or standard therapy remains. This is

justified, as most anticancer agents, regardless of their mechanisms of action,

have adverse effects in normal tissues at doses that are potentially therapeutically

effective, and dose escalation to the highest tolerable dose remains a common

strategy. Furthermore, patients with end-stage disease may potentially derive

some therapeutic benefit from involvement in phase I trials.



4.4.1 Patient entry criteria: general remarks



The patient population under study must be defined prospectively in the proto-

col. In general, the description of the eligible population is divided into several

major areas, as follows.



4.4.1.1 Disease Characteristics



Tumor type

Most phase I trials are undertaken first in patients with solid tumors. A second

study in patients with hematological malignancies may follow, or supplant this,

if the agent in question is destined solely for use in hematological malignancies.

The separation of hematological from non-hematological malignancies in this

way is historical. Cytotoxics were often escalated to higher dose levels in hema-

tological malignancies where, in many cases, the tissue of toxicity (marrow) was

also the tissue of malignancy.



Molecular aberration or genotype

Genomic aberrations may act as drivers of tumor growth, and modulation of

these dysregulated cellular pathways by specific agents may result in potent

Basics of Phase I Design: First-in-Man Studies 63

anticancer activity. Molecular selection of patients with particular aberra-

tions or genotypes has become more frequent in phase I trials of MTAs, but

it is not common, especially for agents that are also first-in-class, unless the

preclinical data supporting genotype selection are compelling. Genotypes

have been incorporated into patient selection for phase I trials in a tumor

histology–specific with vemurafenib for the treatment of BRAF V600E

mutated melanoma, and crizotinib for non–small cell lung cancer (NSClC)

with EML4-ALK rearrangement [5–10]. likewise, a histology-agnostic

approach can be used, such as the alpha isoform specific phosphatidylinosi-

tol 3-kinase (PI3-kinase) inhibitor BYl719 in patients with advanced solid

tumors who have an alteration in the PIK3CA gene (NCT0129699). These

approaches require the availability of archival tumor or a new, fresh tumor

biopsy for genomic testing prior to study enrollment, and is likely to slow

patient accrual if the molecular aberration is uncommon. However, testing a

drug in the most appropriate patient population may establish proof of con-

cept and demonstrate its efficacy more rapidly.



Disease evaluation

Phase I trial entry also generally requires that the disease be clinically or radiologically documented; enrollment of patients whose only evidence of disease is an

elevation of a serum marker is uncommon, although it may be allowed in some

circumstances. Mandating measurable disease according to standard response

criteria may slow recruitment during dose escalation, but it may be required if

response is an important endpoint, especially in an expanded cohort treated at

the recommended phase II dose.



Prior therapy

Phase I cancer trials typically involve patients who have received previous sys-

temic therapy. It is debatable whether patients should have exhausted all possible

forms of therapy. Some would argue that as long as the only treatment other-

wise available for patients is non-curative and without meaningful impact on the

length of life, entry into a phase I trial of a new agent is reasonable. Furthermore, phase I enrollment restricted to heavily pretreated patients may limit the general-izability of the final dose recommendation to less heavily pretreated patients, par-

ticularly if the target organ of toxicity (such as bone marrow) has been impaired

by prior treatment. Thus, studies may specify that prior treatment can be quite

extensive in the initial stages of the trial recruitment, but more limited at the recommended phase II dose. Clear specification of the minimum and maximum

number of prior systemic therapy regimens should be included in the protocol,

if thought to be relevant. likewise, prior radiotherapy may cause increased sus-

ceptibility to the myelosuppressive effects of new therapies; in such instances,

6 4

P H A S E I C A N C E R C l I N I C A l T R I A l S

restriction of entry to patients with prior radiation to a volume less than 25% of

marrow-containing skeleton is common.

Depending on the expected toxic effects, limitations on the cumulative dose

of certain specific agents may be required, such as limits on the total dose of prior taxane if a new tubulin-directed therapy is being evaluated, or on the amount of

prior anthracycline if a cardiotoxic agent is being assessed; these issues are addi-

tionally addressed by mandating organ function within a fixed range of accept-

able values.



4.4.1.2 Patient Characteristics



Balancing the risk of adverse events against limited, if any, clinical benefit from

experimental therapy makes appropriate patient selection critical for phase I trial

enrollment. Following are important factors to consider when selecting patients

for first-in-human studies.



Performance status

This is a general measure of the impact of illness on an individual’s ability to be

mobile and active. Several scales are available, such as those of the World Health

Organization (WHO) [11], the Eastern Cooperative Oncology Group [12], or

the Karnofsky scores [13]. Phase I trials should enroll patients with good perfor-

mance status, as those whose health is rapidly declining may be at increased risk

of harm, and their limited life expectancy may preclude adequate assessment of

a new drug.



Adequate organ function

Until the toxic effects and pharmacological behavior of any new agent are known,

entry onto phase I trials is restricted to patients with adequate, predefined levels

of organ function (measured by maximum or minimum allowable biochemistry

values of liver and kidney biochemistry and by minimum levels of hematological

parameters). Other drug-specific restrictions may also apply. For example, the

patient must have no evidence of neurological or cardiac impairment beyond

certain limits for agents that are predicted to have neurological or cardiac effects, respectively. Once the toxic effects and clinical pharmacology of a drug are better

understood, separate trials in those with organ impairment may be conducted to

develop dosing guidelines (see Chapter 6).



Pregnancy

As anticancer drugs affect cell proliferation, survival, and differentiation, and thus are either known or suspected to be genotoxic or teratotoxic, first-in-human studies must exclude pregnant and breastfeeding women and include a requirement

for the use of effective contraception methods in all relevant enrolled subjects.

Basics of Phase I Design: First-in-Man Studies 65



4.4.1.3 Eligibility for Special Drug Administration

or Procedures for the Trial

In some trials, special measures of a drug or its effects in tumor or normal-tissue

samples are either optional or mandatory; entry criteria must be written accord-

ingly. For example, if fresh tumor biopsies are required to measure PD endpoints,

the patient must have disease accessible for safe biopsy and must consent to the

biopsy. Where only archival tumor samples are needed, the entry criteria should

specify that tumor blocks or unstained slides be available.

In phase I trials of oral drugs, entry criteria should require that patients be able

to take, and absorb, oral therapy. The protocol should also specify whether the

study drug should be taken in the fasted or fed state; some trials incorporate PK

studies to evaluate the effect of food on drug absorbtion. For trials requiring pro-

longed or repeated intravenous administration, patients must have an accessible

intravenous site or indwel ing line to be eligible.



4.4.1.4 Consent and Availability

Although it may be self-evident, the entry criteria should specify that only

patients consenting to all the trial-related procedures are eligible. Many phase

I trials require repeated clinic visits or prolonged inpatient stay, so only patients able to undertake these visits and procedures should be recruited. For some trials, it may be necessary for patients to live within a reasonable geographic dis-

tance of the hospital or clinic where the trial is taking place, if only for a limited period following drug administration.



4.4.1.5 Predictive Tools for Patient Enrollment

Phase I trials usually require that patients have a reasonable anticipated life

expectancy, often at least three months, for study entry. Ethically, this reflects the need to prevent harm to a frail patient from exposure to potentially toxic medication. Practically, enrol ing patients with a very short life expectancy may not

contribute useful information to the study and could hamper the development of

the new agent. A number of models have been designed to predict life expectancy

of patients enrolled in phase I trials and inform patient selection (see Table 4.2)

[14–19,77]. The Royal Marsden Hospital group [14,77] identified low albumin

level, high lactate dehydrogenase (lDH) and greater number of sites of meta-

static disease as predictive of death in less than 90 days.



4.4.1.6 Multi-Institutional Trials

To expedite accrual to phase I trials, involvement of multiple institutions is

increasingly common. A recent review of phase I trials showed that trials with

one, two, or three or more participating institutions completed enrollment in

a median of 21, 20, and 22 months, respectively [20]. One concern regarding

Table 4.2. Prognostic Scores for Phase I Participants

Prognostic score

Scoring system

Scoring system

Outcome

RMH [14,77]

1 point for: lDH > UlN, Alb < 35g/l, Sites of metastases > 2

0–1 (low-risk)

Overall survival

2–3 (high-risk)

(validated)

Nijmegen

1 point for: lDH < UlN, Male: Hb ≤ 8.1, Female: Hb ≤ 7.3,

0–1 (low-risk)

Overall survival,

score [18]

Sodium < 135mmol/l

2–3 (high-risk)

progression-free

survival, and

90-day mortality

PMHI [17]

1 point for: Alb < 35g/l, Sites of metastases > 2, ECOG PS > 0.

0–3

90-day mortality

CHAID [15]

High-risk: Alb < 33g/l, or alb ≥ 33g/l & plts ≥ 400000/mm2

low-risk

90-day mortality

(otherwise, low-risk)

High-risk

European

Model A

Model B

Model A

90-day mortality

Model A and

3 points for: ECOG PS 2

1 point each for: Alb

0–6

Model B [16]

1 point for: ECOG PS 1,

< 3.5g/dl, lDH > UlN,

Alb < 3.5g/dl, lDH>UlN,

Sites of metastases ≥ 3,

Model B

Sites of metastases ≥ 3,

low TPTi (<24 weeks per

0–7

low TPTi (<24 weeks per

treatment), AlP > UlN,

treatment), AlP > UlN

lC < 18%, WBC > 10,500/ μl

MDACC

1 point for: lDH > 618IU/l, Alb < 3.5g/dl

0–5

Overall survival

Score [19]

Sites of metastases > 2

ECOG PS ≥ 1, GI tumor type

Abbreviations: RMH, Royal Marsden Hospital; PMHI, Princess Margaret Hospital Index; CHAID, Chi-Squared Automatic Interaction Detection; MDACC, MD Anderson Cancer Centre; Alb, albumin; Plts, platelets; lDH, lactate dehydrogenase; UlN, upper limit of normal; Hb, hemoglobin; ECOG PS, Eastern Cooperative Oncology Group performance status; AlP, Alkaline phosphatase; lC, lymphocyte; WBC, white blood cell count; TPTi, time per treatment index; GI, gastrointestinal

Basics of Phase I Design: First-in-Man Studies 67

multi-institutional studies is that there may be a dilution of investigator experi-

ence if only a few patients are enrolled [21]; trial logistics are also increasingly

complex with many study sites. However, multi-center participation may be

unavoidable in phase I trials stipulating molecular selection for eligibility, espe-

cially for rare genomic aberrations; in such circumstances, good communication

between investigators and sponsors plays a critical role to ensure patient safety.



4.5 ENDPOINTS



The traditional paradigm of cancer drug dosing is to administer the highest pos-

sible dose with acceptable and reversible toxic effects; therefore, particularly

for cytotoxic drugs, toxicity has been the usual primary endpoint [22–24]. The

introduction of MTAs with mechanisms of action that differ from those of cyto-

toxic chemotherapeutics has raised questions about the utility of toxicity as the

primary endpoint. Underlying this is the belief that, due to their mode of action,

the optimal dose may not be one that is toxic. Indeed, a retrospective analysis of

687 patients treated with MTAs on phase I trials reported that the combined rate

of grade 3 and 4 events was over 15% [25].

Regardless of the primary endpoint used, other secondary measures are also

incorporated into first-in-human studies including measures of clinical efficacy

and PK or PD endpoints (Table 4.3).



4.5.1 Toxicity as the primary endpoint



Chemotherapeutic agents target the process of DNA replication and cell division

by modulating either DNA itself or enzymes involved in DNA replication. As these

Table 4.3. Phase I Trial Endpoints and Measurement Criteria

Endpoint

Measurement (examples)

Toxic effects

Standard toxicity criteria (e.g., CTCAE v4.0; WHO)

PK

C , half-life, area under the curve (AUC), steady-state levels

max

Functional

Change in tumor blood flow

imaging effects

Change in glucose/isotope uptake

Molecular effects

Change in tumor target inhibition

Change in downstream pathway activation

Antitumor effects

Categorization of objective best response according to stan-

dard criteria (WHO, response evaluation criteria in solid

tumors [RECIST])

6 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

targets are present in both normal and tumor cel s, toxicity and efficacy are interrelated. The prevailing assumption is that the higher the dose is, the greater the likelihood of drug efficacy and toxicity (see Figure 4.1). Therefore, the highest tolerable dose is seemingly the logical endpoint for a phase I trial, given that doses above this will probably be too toxic, and doses below are less likely to be as effective. Historical data to support this strategy also exist. Randomized trials in which lower doses of

chemotherapy were given and compared with “full,” and more toxic, standard dose

treatment have shown superior outcomes with the higher dose group [26].

Dose–response relationships may, however, be different with MTAs, as evi-

denced by a review of 24 phase I trials treating 683 patients [27]. Based on a

comparing their dose level to the recommended phase II dose (RP2D), patients

were assigned into low (≤25% maximum tolerated dose [MTD]), medium

(25–75% MTD), or high (≥75% MTD) dose cohorts, and their outcomes com-

pared. Even when patients were treated at doses above the MTD, there was no

difference between the low and high dose cohorts in terms of “disease control”

(stable disease or better) response rate, progression-free survival, and overall sur-

vival. These data raise a question about whether dosing to tolerable toxicity is

necessary with MTAs if a lower, biologically effective dose can be identified. The

argument for escalating the MTA dose to toxicity is that this allows potential tox-

icities to be characterized; it may also enable subsequent evaluation of two dose

levels, one defined by its biological activity and the other by its toxicity.



4.5.1.1 Assessing Toxic Effects

Regardless of the drug class under evaluation, toxicity remains a key endpoint

in phase I first-in-human trials for describing the safety profile of treatment.

toxicity

antitumour

Effect

Dose

Figure 4.1 Dose–effect relationship for cytotoxic agents.

From Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints,

efficacy and existentialism. The Michel Clavel lecture, held at the 10th NCI-EORTC

Conference on New Drugs in Cancer Therapy, Amsterdam, June 16–19, 1998. Ann Oncol.

1998;9(10):1047–1052. Reprinted with permission from Oxford University Press.

Basics of Phase I Design: First-in-Man Studies 69

Standardized assessment tools have been developed to assure a common lan-

guage of description of adverse effects from therapy. Although “toxicity” is

the term commonly used clinically and in medical journals, “adverse event”

is the more appropriate descriptor, as the former implies a causative relation-

ship from the drug, and the latter remains neutral as to cause. Both terms

will be used in this section, as the criteria developed have used the terms

interchangeably.

The history of standardized tools for assessment of adverse events in cancer

clinical trials began with the WHO, which in 1981 published the first widely

used toxicity criteria [11]. These and other criteria developed since that time

categorize and quantify both symptomatic experiences of the patient as well

as objective changes in organ function. The severity of events is described

using a grading system whereby grade 0 means “absent” or “normal”; grade

4 is life-threatening in severity; and grade 5 is fatal. The original WHO scale

had a limited number of events to choose from in describing patient outcomes.

The Common Toxicity Criteria (CTC) were developed by the US National

Cancer Institute in collaboration with other cancer clinical trials organizations

in 1982 and have been both expanded and updated to reflect the effects of a

wide spectrum of new anticancer agents. The Common Terminology Criteria

for Adverse Events (CTCAE), version 4.0, was released in 2009 and has 790

adverse event terms clustered into 28 categories of organ systems; in contrast, the original WHO had only 28 terms in total. Examples of adverse events are

given in Table 4.4.

Table 4.4. Examples of Common Terminology Criteria for Adverse

Events (CTCAEs)

Type of

Objectively

Physician graded

Patient reported

CTCAE

quantifiable

Toxicity

Toxicity

Examples

Hypertension

Diarrhea

Fatigue

Neutropenia

Rash

Pain

Hyperkalemia

Mucositis

Paresthesias

lV dysfunction

Hand-foot syndrome

Anorexia

CTCAE

Each grade

Each grade defined

Each grade defined

Grading,

defined by

by objective physi-

by subjective patient

0 to 5

pre-specified

cian assessment e.g.

responses and resul-

measurable val-

number of bowel

tant impact on func-

ues; e.g., BP in

motions in a day,

tion e.g. paresthesia

mmHg or ANC

body surface area

or fatigue and effect

in cel s/μl

occupied by a rash

on ADls

Abbreviations: lV, left ventricular; BP, blood pressure; ANC, absolute neutrophil

count; ADls, activities of daily living

7 0

P H A S E I C A N C E R C l I N I C A l T R I A l S



4.5.1.2 Dose-Limiting Toxicity, Maximum Administered

Dose, and Recommended Phase Ii Dose

In phase I cancer trials, doses of investigational treatment are escalated in cohorts of patients until predefined criteria are met. When toxicity is used to define study drug doses, these predefined criteria are termed “dose-limiting toxicity” (DlT) criteria.

DlT is generally defined as severe, but reversible, toxicity. These DlTs may

be organ-specific (e.g., grade 4 neutropenia) or symptomatic (e.g., grade 3

fatigue). Phase I protocols must define the events/severity that will be consid-

ered dose-limiting. Generally, precise laboratory levels or grades are defined as

dose-limiting for hematological, renal, and hepatic events. Other major organ

effects that may be dose-limiting are described in general terms only (e.g., “any

other grade 3 major organ toxicity”). Table 4.5 gives examples of common DlT

definitions in phase I protocols. For drugs that are given using a multi-dosing

schedule (daily or weekly) within a cycle, DlT should also be considered to have

occurred if patients miss more than a pre-specified number of doses due to toxic-

ity, as inability to deliver full dose is a marker of limiting effects.

Table 4.5. Examples of Common Dose-limiting Toxicity Definitions

Event

DLT definition

CTCAE grading

DLT Defined by grade

Neutropenia

Grade 4

ANC of <500/mm3; <0.5 x

10e9 /l

Thrombocytopenia

Grade 4

Platelets of <25,000/mm3;

<25.0 x 10e9/l

DLT defined by duration

Elevated

Grade 3 for >5

AlT or AST between

AlT or AST

consecutive days

5–20x UlN

Elevated serum

Asymptomatic grade

lipase > 2.0 to 5.0x UlN

lipase

3 >5 consecutive days

DLT defined by failure to reverse

Hypertension

Persistent hypertension

Grade 3 hypertension is

grade ≥ 3 requiring

defined as SBP ≥160 or DBP

more than one drug or

≥100 mmHg or medical inter-

more intensive therapy

vention indicated

than previously

Diarrhea

Diarrhea grade ≥3 for

Grade 3 diarrhea is defined as

≥48 hrs, despite the

>6 stools above baseline/day

use of anti-diarrhea

or hospitalization indicated.

therapy

Abbreviations: ANC, absolute neutrophil count; AlT, alanine aminotransferase;

AST, aspartate aminotransferase; UlN, upper limit of normal; SBP, systolic blood pressure; DBP, diastolic blood pressure

Basics of Phase I Design: First-in-Man Studies 71

When DlT is defined, not only is the severity of the event taken into consid-

eration, but also its timing. While a patient may have a DlT event at any time

during their time on trial, typically only those that occur within a pre-specified

period after the beginning of dosing affect dose-escalation decisions. That time

period is usually one cycle (for intravenous drugs given in an intermittent fash-

ion) and may be four to eight weeks for agents administered orally on a con-

tinuous basis. Where cumulative and/or delayed toxicity is anticipated, longer

observation periods may be required at each dose level, but inevitably this slows

recruitment. Although DlTs that occur outside of the specified period would not

usually influence dose escalation, they will often be considered when making a

final determination of a RP2D.

There has been considerable uniformity in the definition of DlTs of cytotoxic

agents. By contrast, despite phase I trials of MTAs using the same CTCAE clas-

sification and individual trials specifying criteria for DlTs, definitions of DlT

can vary between trials. A review of 155 phase I studies found substantial vari-

ability in the severity required for an adverse event to be defined as a DlT [29].

Furthermore, the definition of DlT varied according to the administration

schedule of drugs. In about 25% of the trials reviewed, the initial protocol speci-

fied definition of DlT, and the definitions that emerged during the study were

different. This highlights the challenges that transposing DlT definitions from

cytotoxics may pose to MTA phase I trials.

The trial design defines how many patients out of those treated at a given dose

level must experience DlT to halt further escalation. The decision to cease dose

escalation is generally based on two or more patients out of a minimum of three

to six experiencing a DlT. The highest dose level administered in a trial is best

termed the maximum administered dose (MAD), be it determined by toxicity or

by other endpoints. The RP2D will usually be is a dose level below which escala-

tion stopped if this was because a critical number of patients experienced DlT

(i.e., the MAD); where the MAD was not defined by toxicity but another end-

point, the RP2D and the MAD may be the same.

The term “maximum tolerated dose” has been widely used in phase I trials,

but geographical variations in its definition have frequently led to confusion. In

Europe, MTD was typically the dose level in which a pre-specified allowable

number of patients with DlT is exceeded; by contrast, in the United States, the

MTD was typically the dose level at which the incidence of DlT was acceptable.

To avoid this confusion, in this book we use the terms MAD and RP2D as appro-

priate, avoiding use of MTD, and recommending that investigators and sponsors

do likewise. Given the potential for confusion, it is important that protocols and

publications clearly define these and other terms used in each study. Table 4.6

describes these definitions and synonyms, with the ones utilized in this book

highlighted for clarity.

7 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

Table 4.6. Definitions of Phase I Terminology

Term

Abbreviation Definition

Comment

Dose-limiting

DlT

Adverse event of severity or

toxicity

consequence that may limit

dose escalation

Maximum

MTD

Two common usages:

tolerated dose

1. Dose at which

Definition

pre-specified number of

commonly

patients, usually 2 of 3 or

used in studies

2 of 6, exhibit DlT. Dose

from Europe

escalation stops

2. Maximal safe dose: usually Definition more

same as recommended

commonly

phase II dose. Dose level

used in the

at which critical number

studies from

of DlT events is seen as

the United

higher, and has no stan-

States

dard term applied except it

is “above the MTD”

Maximum

MAD

Term suggested to resolve

Adopted for use

administered

confusion with MTD defini-

in this book

dose

tions: MAD is highest dose

administered that has DlT

in pre-specified number of

patients (same meaning as

MTD definition #1)

Recommended

RD or RP2D Dose recommended for

Abbreviation is

phase II dose

further study in single-agent

not standard

trials

but will be used

in this book



4.5.1.3 Chronic Toxicities

The assessment of DlT in the first cycle of treatment only will not account for

cumulative or chronic toxicities. Evaluations of these types of adverse events are

especially relevant for MTAs, which are typically administered in chronically.

In a retrospective review of 445 patients in 36 phase I trials of MTAs from two

institutions, over 50% of grade 3 or 4 events occurred later than cycle 1, with

half of patients experiencing their worst-grade toxicity after the DlT assessment

period [30]. Given the importance of cumulative and chronic toxicities on a

drug’s tolerability, consideration of these events when recommending a RP2D

is important.

Basics of Phase I Design: First-in-Man Studies 73

The Dose-limiting Toxicity and Toxicity Assessment Recommendation

Group for Early Trials of Targeted Therapies (DlT-TARGETT) initiative was

established to define new methods of determining DlT, RP2D, and schedule

of MTAs, by focusing on the severity and timing of adverse events, in addition

to the impact that it has on dosing intensity [31]. Over 2,000 patients from 54

monotherapy MTA trials were included, with approximately 25,000 adverse

events. Again, half of patients experienced their first grade ≥3 toxicity beyond

cycle 1; equally important was that a significant proportion of patients required a

dose reduction for selected grade ≤2 events experienced during cycle 1. Among

the many recommendations, this initiative proposed that particular attention be

paid to any toxicity that leads to reduced dose intensity, regardless of grade, and

that the RP2D should consider toxicities beyond cycle 1 [31].



4.5.2 Non-toxicity measures as primary endpoints



PK measurements have long been incorporated in phase I studies of antiprolif-

erative cytotoxics, influencing dose escalation and identification of the RP2D;

likewise, such phase I trials have often used PD endpoints in the guise of blood

counts. The concept of using such endpoints in phase I trials is, however, usually

considered in the context of either molecular biology or functional imaging stud-

ies in MTA trials.

A plethora of rational targets have been identified, and agents modulating

them are in the clinic or are about to enter clinical evaluation (see Table 4.7 for

selected examples). These new agents may differ in their preclinical dose–effect

relationships from those of cytotoxics [32]. Once the putative target is “satu-

rated and inactivated” in tumor tissue, antitumor effects presumably plateau;

although toxicity may not plateau if the dose is increased. Dose effects may not

follow this same relationship if the target is also present in normal tissue but

not “saturated,” or if off-target effects of the drug produce toxicity. For exam-

ple, the anti-vascular endothelial growth factor receptor (VEGFR) monoclo-

nal antibody bevacizumab produces a higher incidence of hypertension with

higher doses, but no commensurate increase in efficacy [33]. These concepts

are illustrated Figure 4.2, which should be contrasted with that for cytotoxic

agents, in Figure 4.1.

A great deal has been written about which endpoints could substitute for tox-

icity to define the RP2D of MTAs [34–36]. This strategy of identifying the opti-

mal biological dose (OBD) can be defined as establishing the dose that achieves

a pre-specified effect on a biomarker such as in the tumor or surrogate tissue that

becomes the RP2D.

Table 4.7. Examples of New Targets and Agents iIn Recent Clinical Evaluation

Target pathway

Specific target

Agent

MAPK

RAF

Dabrafenib

lGX818

Vemurafenib

MEK

GDC-0973

MEK162

MSC1936369B

Trametinib

PI3K-AKT-mTOR

AKT

GSK2141795

PI3K pan isoforms

BKM120

GDC-0941

Xl147

PI3K alpha isoform

BYl719

PI3K beta sparing

GDC-0032

PI3K beta isoform

AZD8186

GSK2636771

SAR260301

PI3K-mTOR

GDC-0980

PF-05212384

Xl765

Angiogenesis

Angiopoeitin-1,2

Trebananib

Angiopoeitin-2

REGN910

Notch

Gamma secretase

BMS-906024

BMS-986115

MK0752

Cell cycle checkpoints

MDM2

RO5503781

RO6839921

Wee-1 kinase

MK-1775

Multiple CDK

Dinaciclib

CDK4/6

lEE011

PD-0332991

Immune checkpoints

PD-l1

MPDl3280A

MEDI4376

PD-1

MK-3475

Nivolumab

Abbreviations: MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide-

3-kinase; mTOR, mammalian target of TOR; MDM-2, mouse double minute-2; CDK,

cyclin-dependent kinase; PD-l1, programmed death ligand 1; PD-1, programmed

death 1

Basics of Phase I Design: First-in-Man Studies 75

antitumour

toxicity

target

Effect

Dose

Figure 4.2 Dose–effect relationship for non-cytotoxic, targeted agents.

From Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints,

efficacy and existentialism. The Michel Clavel lecture, held at the 10th NCI-EORTC

Conference on New Drugs in Cancer Therapy, Amsterdam, June 16–19, 1998. Ann Oncol.

1998;9(10):1047–1052. Reprinted with permission from Oxford University Press.



4.5.2.1 PD Measures Of Target Effect



Although the most rationally appealing endpoint for agents that have been devel-

oped to inhibit a specific target, no MTA has yet received US Food and Drug

Administration (FDA) approval for use in solid tumors with its RP2D defined

solely by a PD measure. This is not surprising, as there are a number of challenges

to this approach.



Tissue acquisition

Measurement of target inhibition should ideally be undertaken in tumor tissue with

serial biopsies at baseline before treatment and again after treatment. Additional

biopsies may be required before treatment to assess the variability in baseline val-

ues, and after treatment to define the time course of target inhibition and recovery.

This presents obvious logistical challenges, as it would mean that all patients in a

phase I trial would need to have accessible tumors and consent to repeat biopsies,

and that any patient with missing PD data would be replaced, which would limit

recruitment and prolong such trials. An exception would be phase I trials in hema-

tological malignancies where tumor cel s may be accessed simply in a blood sample.

In patients with solid tumors, assessing PD markers in circulating tumor cel s

(CTCs) is emerging as an attractive option. Others have opted to use normal tis-

sues as surrogates in which to measure molecular changes, especially during the

dose-escalation phase of the trial. If the target is expressed in peripheral blood

mononuclear cel s, these are simple to evaluate in serial blood draws. Other

options include buccal mucosa swabs, skin biopsies, or plucked hair fol icles. If

7 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

normal tissue is sampled, the validity of the tissue being evaluated and the assay

being used will need to have been assessed in preclinical models prior to initia-

tion of the study to confirm that the surrogate tissue expresses the target and that

there is dose- or PK-related target inhibition with treatment that parallels what is

seen in tumor in the same species (see Chapter 2).

Obtaining sufficient tumor tissue can be an issue, but several large-scale

reviews (see Table 4.8) suggest that many patients would agree to sequential

tumor biopsies. There are concerns about the safety and tolerability of tumor

biopsies, although the complication rate in experienced centers is low [37,38].

In a survey of patient perceptions, many were receptive to biopsies for research,

provided the research justified the risk [39].



Companion diagnostic assay

Typically, at the time of the first-in-human study of a new agent, no commer-

cial assay validated to good laboratory practice standards (see Appendix I for

references) will be available. It is critical, therefore, that when the trial primary endpoint is based on a PD marker, the assay development and validation be completed before the trial begins. If this is not possible, the PD marker cannot inform

the primary endpoint but may be an exploratory or other endpoint.



Level of target inhibition

It is important to have an indication of the magnitude of target inhibition, or of

the desired molecular effect, that is required for there to be an impact on tumor

Table 4.8. Selected Reviews of Tumor or Normal-Tissue Biopsies on

Early-Phase Clinical Studies

Study

Patients Biopsies Tumor or

Mandatory

Sequential

Serious

normal-tissue or optional

or single

compli-

biopsies

biopsies

biopsies

cations

Dowlati [78]

107

192

192 tumor

NR

87 sequential

0/192

0 normal

20 single

(0%)

El-Osta [79]

155

281

281 tumor

123

118

4/281

0 normal

mandatory

sequential

(1.4%)

40 optional

45 single

Gomez-

155

146

89 tumor

NR

56 sequential

9/146

Roca [80]

57 normal

33 single

(6.2%)

Overman [81] 576

745

745 tumor

NR

169 multiple* 6/745

0 normal

407 single

(0.8%)

* 169 patients had more than one biopsy; however, it is not stipulated if this occurred sequential on one trial or singly on multiple trials.

Abbreviation: NR, not reported

Basics of Phase I Design: First-in-Man Studies 77

growth in preclinical models. Furthermore, the proportion of patients that

should achieve this threshold effect at a given dose level needs to be determined

to represent a RP2D.



Sample size

Where a trial endpoint is avoidance of an adverse outcome in a small proportion

of patients, such as toxicity, fewer patients per dose level are likely to be needed

than when the endpoint is the occurrence of a favorable outcome such as target

inhibition in a majority of patients. For a trial to show a dose response in target

inhibition from 40% at one dose level to 90% inhibition at a higher dose, 17 eval-

uable patients would need to be treated at each level [34]. Consequently, using

PD assessments to guide dose-escalation decisions is unlikely to be feasible. On

the other hand, evaluation of PD effects may be valuable in determining whether

the OBD or a dose level defined by toxicity should be the RP2D.



Proof-of-principle studies

PD assays can also be included in phase I trials as “proof-of-principle” rather than

as primary endpoints for dosing recommendations. Such studies seek to demon-

strate whether the drug has its designed molecular effect and are incorporated as

secondary objectives by providing evidence of target modulation. The absence

of PD effects in a phase I study where there is no hint of preliminary antitumor

activity may be sufficient grounds to halt further development; i.e., a “no-go”

decision.



4.5.2.2 Pharmacokinetics

As measurement of drug disposition during phase I trials is standard, achieve-

ment of a target area under the curve, a minimum trough level, or a steady-state

plasma level of drug above a predefined value may be utilized to define the RP2D.

Generally, surpassing this minimum level is desirable to assure adequate drug

delivery at the level of the tissues.

Preclinical in vivo PK data from an efficacy tumor model are required to

define the minimum plasma values or target levels for extrapolation to humans.

Unfortunately, many preclinical PK studies are done only in the context of toxi-

cology, and not as part of the efficacy evaluation. The latter is most informative,

and should also replicate the schedule and route of administration that will be

studied in the trial. Knowledge of the IC (inhibitory concentration of 50%)

50

from in vitro work is complementary but cannot substitute completely for in vivo data, which more closely mirror the clinical setting. Furthermore, in calculating

the “target” PK value that will determine whether the RP2D has been achieved,

it is important to factor in the amounts of free drug, as protein binding may differ

between species. It is also relevant to measure the concentration not only of the

7 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

parent compound but also important metabolites to understand drug metabo-

lism and elimination. It is uncommon to measure drug levels in tumor, but this

may represent important proof-of-principle when evaluating a pro-drug. Finally,

there must be a validated assay for where PK measurements are an endpoint.



4.5.3 Experience with the use of alternative endpoints

In the era of MTAs, more phase I trials would have been presumed to have uti-

lized non-toxicity endpoints, but despite much discussion about alternative end-

points, toxicity continues to be the major basis of both dose-escalation decisions

and identification of the RP2D. A review of 31 MTAs evaluated in single-agent

phase I trials in solid tumors reported that toxicity was the reason for halting

dose escalation and the most common basis for RP2D in 35 of 50 trials [40].

PK measurements were the second most common basis for RP2D, and only

two studies used PD measures. This was confirmed in a subsequent review of 25

first-in-human monotherapy trials from 1992 to 2008 that reported 76% of phase

I studies were stopped due to toxicity [41]. In a recent review of registration tri-

als and the respective phase I studies of agents approved by the FDA from 1990

to 2012, toxicity was used to define RP2D for 77% of cytotoxic compounds and

58% of MTAs [42].

On-target effects of MTAs in normal tissues can nevertheless be a useful PD

marker of target inhibition. The occurrence of on-target effects can be reassuring

in a phase I trial, whereas the absence of such effects may raise concerns over

a lack of sufficient target modulation. For example, skin toxicity mediated by

epidermal growth factor receptor ( EGFR) inhibition is dose-related and corre-

lates with target inhibition and downstream signaling changes in tumor biopsies

[43,44]. Furthermore, the increases in blood pressure seen with inhibitors of

vascular endothelial growth factor and its receptor are in keeping with its mecha-

nism of action [45–47].

If knowledge about the molecular impact of a novel agent on its putative target

is required for future drug development, a rational approach would be to estab-

lish the MAD based on toxicity and then study tumor PD (or functional imag-

ing) in a more homogeneous group of patients with accessible tissue assigned

to the MAD and a limited number of lower doses postulated to be biologically

active. Table 4.9 lists a selection of MTAs that used non-toxicity endpoints to

determine dosing recommendations.



4.5.4 Summary of endpoints

Traditionally, phase I trials of cytotoxic agents have used toxicity as the primary

endpoint for decisions to halt dose escalation and recommend single-agent

Basics of Phase I Design: First-in-Man Studies 79

Table 4.9. Examples of Drugs that Utilized Non-Toxicity Endpoints to

Define Recommended Phase II Dose

Drug

Maximum Maximum

Dose(s) tested Non-toxicity Registration

tolerated

administered in phase II

endpoint(s)

trial dose

dose in

dose

trials

used to

(reference)

phase I

define RP2D

Gefitinib

700 mg

1000 mg od

250 mg od

PK profile

250 mg od (83)

(ZD1839)

to 1000

500 mg od

and effi-

mg od

cacy (82)

Vismodegib

Not

540 mg od

150 mg od

PK and PD

150 mg od (84)

(GDC-0449)

reached

profiles

Everolimus

Not

10 mg od

10 mg od

PK and PD

10 mg od (85)

(RAD001)

reached

70 mg weekly

70 mg weekly

profiles

Ipilimumab

Not

20 mg/kg

0.3 mg/kg, 3

Efficacy

3 mg/kg q3

(MDX-010)

reached

single dose,

mg/kg and

weekly for 4

10 mg/kg q3

10 mg/kg q3

doses (86)

weekly for 4

weekly for 4

doses

doses then q

3 monthly

Pazopanib

Not

2000 mg od

800 mg od

PK, PD pro-

800 mg od (87)

(GW786034)

reached

files and

efficacy

Abbreviations: od, once daily; NA, not applicable; PK, Pharmacokinetic; PD,

Pharmacodynamic

dosing. The era of novel MTAs has provided an opportunity for review and

debate about relying on toxicity as the main “driver” for identifying the RP2D

in phase I trials [40]. Attempts to incorporate other measures have frequently

been made, and the results have often supported the RP2D based on toxicity, but

rarely have they supplanted it. Molecular (or imaging) PD studies may also be

useful as secondary endpoints to obtain preliminary proof-of-principle data in an

expanded cohort, or phase Ib. This approach is illustrated in Figure 4.3.



4.6 TRIAL DESIGN



When a new agent is studied in patients for the first time, more than one schedule

of administration may be evaluated, based on preclinical efficacy and PK studies,

unless preclinical studies make it clear that only a single schedule is worthwhile.

Where an intravenous agent has a short half-life, for example, it may be evaluated

in repeated dosing or prolonged infusion schedules. For oral agents, continuous

and intermittent dosing schedules may be evaluated.

8 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

Dose Seeking Phase I

Standard Design

Dose ‘range’ identified toxicity (or PK) endpoint

Option: assess feasibility of molecular/imaging studies

‘Phase Ib’

‘Phase Ib’

Selected doses (2–4) from range

Selected doses (2–4) from range

May randomize

May randomize

More patients per level

More patients per level

Uniform population

Uniform population

Molecular endpoint(s), PK

Imaging endpoint(s), PK

Final dose identified based on multiple inputs

Phase II trials and combination Phase I trials begin.

Figure 4.3 Proposed sequential integration of non-toxicity endpoints in drug

development.

There is a variety first-in-human phase I trial designs, but they have several

features in common; namely, selection of a “safe” starting dose, dose escalation

in sequential small cohorts of patients (and sometimes within cohorts), and

determination of a RP2D based on a pre-specified primary endpoint. Good

phase I design should yield relatively precise determination of the RP2D and

must address the competing issues of safety and efficiency; individual patients

should not be exposed to doses of drug that are likely to be excessively toxic, but

at the same time, the RP2D should be identified in a timely fashion, with as few

patients as possible receiving doses likely to be sub-therapeutic. While efficiency

is enhanced by higher starting doses, fewer patients per dose level, and larger

escalation steps, patient safety is enhanced by lower starting doses, more patients

per dose level, and smaller dosing increments [50].

All the “rules” mentioned below must be clearly defined in the protocol docu-

ment. Examples are given in Chapter 9.



4.6.1 Starting dose

The starting dose for first-in-human studies is determined by preclinical toxi-

cology studies. These studies may also give insight into potential toxicities (see

Chapter 2); their importance, and potential limitations, have been highlighted by

the experience with TGN1412 described earlier [2] .

The European Medicines Agency (EMA) and the FDA recommend that new

anticancer agents be assessed in both rodent and non-rodent species before

Basics of Phase I Design: First-in-Man Studies 81

first-in-human studies are performed [51–53]. Generally, the starting dose for

human trials is equivalent to one-tenth of the dose that is lethal in 10% of mice

(i.e., the lD ) [54]. If non-rodent species such as dogs, rabbits, or monkeys

10

are more sensitive to toxicity than mice, one-sixth to one-third of the lowest

dose that results in any toxicity (the toxic dose low or TDl) or the no observed

adverse effect level (NOAEl) in the more sensitive species should be used [55].

PK and PD effects, particular aspects of the agent and the trial design, may also

inform the starting dose.

These conventions may not be appropriate for some agents, such as immuno-

modulatory drugs given their particular toxicities that may occur and the spe-

cies specificity, which may present challenges in identifying appropriate animal

toxicity models. The EMA has highlighted particular features that suggest higher

levels of risk for adverse events in first-in-human studies (see section 4.3) where

the minimal anticipated biological effect level (MABEl) in humans is recom-

mended [56,57] based on all in vitro and in vivo information, including:

• target binding and receptor occupancy studies in vitro in cel s from

human and the relevant animal species;

• concentration-response curves in vitro in cancer cel s from human and

the relevant animal species and dose/exposure-response in vivo in the

relevant animal species;

• drug exposures at pharmacological doses in the relevant animal species.

In addition, a safety margin may be applied to the calculation of the first-in-

human dose from the MABEl. When the methods of calculation for starting

dose (e.g., NOAEl, MABEl) give different estimations of dose, the lower value

should be used, unless justified [56,57].



4.6.2 Escalation plan

Chapter 8 describes dose-escalation designs in detail, so only general remarks wil

be made here. There are two broad classes of phase I trial design: rule-based and

model-based designs. The rule-based designs assign patients to dose levels according

to pre-specified rules based on actual observations of target events (e.g., DlT) from the clinical data; the MAD or RP2D is also typically determined by pre-specified

rules. Model-based designs assign patients to dose levels and define the RP2D

based on an estimation of the target toxicity level by depicting the dose–toxicity

relationship. Safeguards are established in most model-based designs to prevent

escalation above a safe dose and exposure of patients to undue harm [58].

8 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

Designs of phase I combination studies of cytotoxic agents, MTAs, and

biological agents yield additional complexities beyond that of single-agent

studies. The decision to combine two agents should be preceded by strong

preclinical and biological rationale rather than empiricism. Drug–drug inter-

actions, overlapping toxicities, and the range of potential schedules add to

the complexity of such studies [59], which are discussed in greater detail in

Chapter 6.



4.6.3 Cohort size

Cohort size in phase I clinical trials is largely determined by the choice of trial

design and the primary intent of the trial, as detailed in Chapter 8. The number

of patients entered per dose level has its roots in empiricism. Historically, a mini-

mum of three patients per level have been recruited [60], but with more modern

trial designs aiming to reduce the number of patients treated at sub-therapeutic

doses, as few as one patient per level may be enrolled at initial dose levels, and

the number treated in each cohort increased at dose levels as toxicities start to

emerge [61]. Aggressive dose-titration schedules, incorporating, for example,

dose doubling in successive cohorts, may be useful where robust preclinical data

exist to suggest a wide therapeutic window and low patient toxicity is expected

[50]. However, where there is less certainty about toxicity of the drug in humans,

or a narrow therapeutic window is predicted, a more cautious dose-escalation

strategy should be employed [41,56,62].

Patients who fail to complete the observation period necessary to assure DlT

is not seen, or who did not complete at least 80–90% of the treatment prescribed

for non-toxicity reasons (e.g., early dropouts for disease progression) must be

replaced on that dose level. If a DlT is seen in one patient of a three-patient

cohort, it is usual to enter a total of six patients in that cohort to confirm or otherwise that the MAD has been identified. Finally, it is advisable to expand the

cohort (e.g., 10 or more patients) receiving what is believed to be the RP2D and

include patients representative of those anticipated to be treated in phase II trials.

This expanded cohort allows increased confidence in the safety and appropriate-

ness of the final RP2D; sometimes a second dose level below the RP2D dose

level may be expanded. Expansion cohorts may also provide evidence of early

antitumor activity and early insight into proof of on-target efficacy through PD

studies [63]. Objectives in the expanded cohort should be predetermined and

clearly stated, and sample size justified by the question(s) posed [64], but the

expanded cohort should not be considered a substitute for a properly designed

phase II trial.

Basics of Phase I Design: First-in-Man Studies 83



4.6.4 Intra-patient dose escalation

The likelihood that patients will receive sub-therapeutic doses of the investiga-

tional agent in the initial stages of a phase I trial remains an ethical consideration.

Most patients enter these studies with some hope that the treatment offered may

benefit them [65,66]. Approaches to enhance the overall proportion of patients

in a phase I trial who are exposed to potentially “therapeutic” dose levels include

not only limiting enrollment in lower dose levels, but also allowing escalation

within individual patients (intra-patient dose escalation). The protocol may be

written in such a way so that, in addition to new patients’ being enrolled at increasing dose levels, the patients already in the trial may also be escalated to higher

dose levels, provided they have not exhibited any substantial toxicity themselves.

Generally, they may escalate to the highest level already demonstrated to be safe

in a fully evaluable cohort of patients who have cleared DlT.

Potential designs allowing intra-patient dose escalation in phase I clinical tri-

als have been proposed [61]. Intra-patient dose escalation was modeled into

the design, escalation of an individual patient to the next dose level being per-

mitted if no toxicity exceeding grade 1 was seen in the preceding cycle at the

assigned dose level. Based on simulation, while intra-patient dose escalation did

not appreciably shorten the study duration, it was safe and allowed fewer patients

to be “undertreated” in comparison with trials that applied standard interpatient

dose escalation alone.

Although the idea of intra-patient dose escalation is appealing, it is not widely

applied for both theoretical and practical reasons. It may be difficult to deter-

mine if significant toxicity experienced by patients undergoing intra-patient

escalation is due to the higher administered dose at that cycle or to the cumu-

lative dose for that treatment. Additionally, it is unclear how observations for

patients who have received an escalated dose should be reported in the study

report; data may be presented by assigned dose, the escalated dose, or a mixture

of the two. It is important, however, that a minimum number of newly recruited

patients be treated at each dose level, to evaluate the tolerability or otherwise of

a dose level in those individuals, rather than risk confusion by combining the

intra-patient escalated and de novo new patients. In practice, intra-patient dose

escalation will often be irrelevant because information about the safety of the

drug at the next dose level is usually required prior to dose escalation, by which

time many phase I patients will have progressed. Arguably, as the actual chance

of benefit (in terms of response rate) on a phase I trial is in the range of 5%

[67–70], the added benefit likely to accrue to an individual patient by escala-

tion of one or two dose levels is very small. As patients suitable for intra-patient

dose escalation will be stable or benefiting from the trial agent prior to dose

8 4

P H A S E I C A N C E R C l I N I C A l T R I A l S

escalation, the incremental gains to such patients may be small compared to the

risk of increased toxicity.

For all these reasons, most phase I protocols continue to be written prohibit-

ing intra-patient escalation.



4.6.5 Biomarker-driven studies

As genomic testing becomes progressively integrated into clinical oncology prac-

tice, there is an increasing pressure to identify biomarkers to provide prognos-

tic and predictive information to patients. Biomarkers that may be incorporated

into phase I trial design can be classified as integral, integrated, or exploratory.

Markers are integral when they are essential for conducting the study, being

used to define patient eligibility, treatment stratification, or measure outcomes.

Integrated markers are used when testing a hypothesis based on preclinical data; when generating a hypothesis, biomarkers are exploratory.

Patient selection for phase I trials based on genomic profiles is an investiga-

tional strategy at the present time, but the increasing speed and decreasing cost

of such tests make it increasingly feasible. Some phase I trials have successfully

incorporated integral biomarkers to identify patient subsets likely to be highly

sensitive to a novel agent. Early evidence of an antitumor effect may be delayed if

such selection is not undertaken, but to do so the biomarker must be well char-

acterized, with validated assays established. The risk is that with most MTAs

having multiple targets, if the “wrong” biomarker is chosen for patient selection,

clinically meaningful activity may be missed. A second concern is that limiting

recruitment in this way may slow down recruitment and delay identification of

the MAD and RP2D, which are the main aims of the study. A compromise may

be to have broad patient eligibility in the dose-escalation part of a phase I trial,

but to restrict according to the biomarker in the expanded cohort(s) at the RP2D

in which clinical and PD evidence of activity are most likely to be seen.

The expedited phase I development of crizotinib for treatment of a small sub-

group of NSClC in just over one year was facilitated by the early identification

of the target—echinoderm microtubule-associated protein-like 4-anaplastic

lymphoma kinase rearrangement ( EML4-ALK) [6,71]. The population was

not, however, predefined at the outset; rather, evaluation of tumor tissue from a

responding patient defined the biomarker that was subsequently used to selected

patients. More generally, some have reported that patients receiving molecularly

matched therapy in a phase I setting have higher response rates and better clinical

outcomes than those on unmatched treatment [72,73]. This complex strategy

wil , however, only be possible if a wide array of phase I agents is available for

evaluation.

Basics of Phase I Design: First-in-Man Studies 85

An integrated biomarker design allows both biomarker-positive



and -negative patients to enter a study, enabling assessment of clinical and

PD effects in both groups. Finally, hypothesis-generating, exploratory bio-

markers may also be assessed in phase I trials. These need not be mandatory

for all patients entering the study and may be analyzed retrospectively. In all

cases, evaluation of the biomarker should be clearly described in the protocol,

including plans for specimen collection and processing, laboratory measure-

ments, and statistical analysis.



4.7 SUMMARY

The primary goal of a phase I trial is to establish the RP2D of a new agent or new

combination regimen. Usually these trials enroll patients with cancer who have

adequate organ function and performance status, and provide informed consent

for all study specific investigations, interventions, and follow-up. While there is

interest in exploring new endpoints to define the RP2D, especially in the era of

MTAs, toxicity remains the most commonly used primary measure to define the

RP2D. Special caution in phase I trial conduct is required for “high-risk” agents,

and lessons learned from the TGN1412 tragedy provide guidance in the conduct

of phase I clinical trials, especially in this setting. Phase I trial designs should incorporate all relevant information collected in preclinical models to predict a safe starting dose/schedule in humans. Studies should deploy a dose-escalation scheme

that efficiently defines the RP2D while minimizing the number of subjects who are

exposed to either sub-therapeutic or excessively toxic doses. PK studies are inte-

gral to phase I trials, and PD endpoints can provide preliminary proof-of-principle

readouts such as demonstration of target inhibition in the tumor or surrogate tissue.

As the number of novel anticancer agents entering human testing continues

to increase due to our improved understanding of molecular biology, the design

and conduct of phase I trials should continue to be flexible, dynamic, and adap-

tive to embrace emerging new knowledge such as molecular characterization and

precision medicine, while at the same time maintaining the important principle

of human subject protection.



REFERENCES

1. Booth CM, Calvert AH, Giaccone G, lobbezoo MW, Seymour lK, Eisenhauer EA.

Endpoints and other considerations in phase I studies of targeted anticancer ther-

apy: recommendations from the task force on Methodology for the Development of

Innovative Cancer Therapies (MDICT). Eur J Cancer. 2008;44(1):19–24.

8 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

2. Expert Scientific Group on Phase One Clinical Trials. Expert Scientific Group on

Phase One Clinical Trials: final report. The Stationery Office, United Kingdom, 2006.

3. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028.

4. Ocana A, Pandiel a A, Siu ll, Tannock IF. Preclinical development of

molecular-targeted agents for cancer. Nat Rev Clin Oncol. 2010;8(4):200–209.

5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.

6. Kwak El, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in

non–small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.

7. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–144.

8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353(2):123–132.

9. Sosman JA, Kim KB, Schuchter l, et al. Survival in BRAF V600-mutant advanced

melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.

10. Hollebecque A, Postel-Vinay S, Verweij J, et al. Modifying phase I method-

ology to facilitate enrolment of molecularly selected patients. Eur J Cancer.

2013;49(7):1515–1520.

11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.

12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the

Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.

13. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic

agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents.

New York: Columbia University Press; 1949:199–205.

14. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognos-

tic score to improve patient selection for oncology phase I trials. J Clin Oncol.

2009;27(16):2692–2696.

15. Ploquin A, Olmos D, lacombe D, et al. Prediction of early death among patients

enrolled in phase I trials: development and validation of a new model based on plate-

let count and albumin. Br J Cancer. 2012;107(7):1025–1030.

16. Olmos D, A’Hern RP, Marsoni S, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012;30(9):996–1004.

17. Chau NG, Florescu A, Chan KK, et al. Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer.

2011;11:426.

18. Fussenich lM, Desar IM, Peters ME, et al. A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer. 2011;47(8):1152–1160.

19. Wheler J, Tsimberidou AM, Hong D, et al. Survival of 1,181 patients in a phase

I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012;18(10):2922–2929.

20. Dowlati A, Manda S, Gibbons J, Remick SC, Patrick l, Fu P. Multi-institutional

phase I trials of anticancer agents. J Clin Oncol. 2008;26(12):1926–1931.

21. Ivy SP, Siu ll, Garrett-Mayer E, Rubinstein l. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from

Basics of Phase I Design: First-in-Man Studies 87

the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010;16(6):1726–1736.

22. Carter S. Clinical trials in cancer chemotherapy. Cancer. 1977;40:544–557.

23. Geller Nl. Design of phase I and II clinical trials in cancer: a statistician’s view.

Cancer Invest. 1984;2(6):483–491.

24. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey J. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18:684–692.

25. Molife lR, Alam S, Olmos D, et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol.

2012;23(8):1968–1973.

26. Tannock IF, Boyd N, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluouracil chemotherapy for patients with meta-

static breast cancer. J Clin Oncol. 1988;6(9):1377–1387.

27. Jain RK, lee JJ, Hong D, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res.

2010;16(4):1289–1297.

28. NCI: Common terminology criteria for adverse events. last accessed October

2013; available from:

http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.

03_2010-06-14_QuickReference_5x7.pdf.

29. le Tourneau C, Razak AR, Gan HK, et al. Heterogeneity in the definition of

dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer. 2011;47(10):1468–1475.

30. Postel-Vinay S, Gomez-Roca C, Molife lR, et al. Phase I trials of molecularly

targeted agents: should we pay more attention to late toxicities? J Clin Oncol.

2011;29(13):1728–1735.

31. Sophie Postel-Vinay ER, le Tourneau C, Olmos D, et al. Towards new meth-

ods for the determination of dose limiting toxicities and recommended dose of

molecularly targeted agents. European Cancer Congress (ECCO-ESMO-ESTRO);

Amsterdam, 2013.

32. Eisenhauer EA. Phase I and II trials of novel anti-cancer anti-cancer agents: endpoints, efficacy an existentialism. Ann Oncol. 1998;9:1047–1052.

33. Zhu X, Wu S, Dahut Wl, Parikh CR. Risks of proteinuria and hypertension with

bevacizumab, an antibody against vascular endothelial growth factor: systematic

review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–193.

34. Korn El, Arbuck S, Pluda J, Simon R, Kaplan R, Christian M. Clinical

trial design for cytostatic agents: are new approaches needed? J Clin Oncol.

2001;19:265–272.

35. Gelmon KA, Eisenhauer EA, Harris A, Ratain MJ, Workmann P. Anticancer agents

targeting signalling molecules and cancer cell environment: challenges for drug

development? JNCI. 1999;91:1281–1287.

36. Parulekar W, Eisenhauer E. Novel endpoints and design of early clinical trials. Ann Oncol. 2002;13(suppl 4):139–143.

37. Tabernero J, Rojo F, Marimón I, et al. Phase I pharmacokinetic and pharmaco-

dynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farne-

syltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol.

2005;23(11):2521–2533.

8 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

38. Goss G, Hirte H, Miller W Jr, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND. 122, a study of the Investigational New Drug

Program of the National Cancer Institute of Canada Clinical Trials Group. Invest

New Drugs. 2005;23(2):147–155.

39. Agulnik M, Oza AM, Pond GR, Siu ll. Impact and perceptions of mandatory tumor

biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006;24(30):4801–4807.

40. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. JNCI. 2004;96(13):990–997.

41. le Tourneau C, lee JJ, Siu ll. Dose escalation methods in phase I cancer clinical trials. JNCI. 2009;101(10):708–720.

42. Jardim D, Hess K, loRusso P, Kurzrock R, Hong D. Predictive value of phase I trials for safety and final approved dose in later trials: analysis of 33,845 patients. J Clin Oncol. 2013;31, 2013 (suppl; abstr 2509).

43. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyro-

sine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol.

2002;20(21):4292–4302.

44. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced

solid tumors that express the epidermal growth factor receptor. J Clin Oncol.

2004;22(1):175–184.

45. Thomas Al, Morgan B, Drevs J, et al., eds. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol; 2003;30(suppl

6):32–38:

46. Miller KD, Chap lI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated

metastatic breast cancer. J Clin Oncol. 2005;23(4):792–799.

47. Hurwitz H, Fehrenbacher l, Novotny W, et al. Bevacizumab plus irinotecan,

fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.

2004;350(23):2335–2342.

48. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer.

J Clin Oncol. 2003;21(12):2237–2246.

49. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small

cell lung cancer. JAMA. 2003;290(16):2149–2158.

50. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18(3):684–692.

51. U.S. Department of Health and Human Services. Guidance for Industry: M3(R2)

nonclinical safety studies for the conduct of human clinical trials and market-

ing authorization for pharmaceuticals. In: Food and Drug Administration (FDA),

ed.: Center for Drug Evaluation and Research (CDER); 2010:2–7.

52. European Medicines Agency (EMA). ICH guideline M3(R2) on non-clinical safety

studies for the conduct of human clinical trials and marketing authorisation for

pharmaceuticals. 2009.

Basics of Phase I Design: First-in-Man Studies 89

53. Tomaszewski JE. Multi-species toxicology approaches for oncology drugs: the US

perspective. Eur J Cancer. 2004;40(6):907–913.

54. Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer.

1999;81(5):760–768.

55. Rozencweig M, Von Hoff DD, Staquet MJ, et al. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials. 1981;4(1):21–28.

56. Committee for Medicinal Products for Human use (CHMP). Guideline on strate-

gies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. July 19, 2007. Report No. EMEA/CHMP/SWP/28367/07.

57. Agoram BM. Use of pharmacokinetic/pharmacodynamic model ing for starting

dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol.

2009;67(2):153–160.

58. le Tourneau C, lee JJ, Siu ll. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–720.

59. Huo l, Yuan Y, Yin G. Bayesian dose finding for combined drugs with discrete and continuous doses. Bayesian Anal. 2012;7(4):1035–1052.

60. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45(3): 925–937.

61. Simon R, Freidlin B, Rubinstein l, Arbuck SG, Col ins J, Christian MC.

Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst.

1997;89(15):1138–1147.

62. Seymour l, Eisenhauer E. A review of dose-limiting events in phase I trials: anti-metabolites show unpredictable relationships between dose and toxicity. Cancer

Chemother Pharmacol. 2001;47(1):2–10.

63. Ivy SP, Siu ll, Garrett-Mayer E, Rubinstein l. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the Clinical Trial Design Task Force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1726–1736.

64. Manji A, Brana I, Amir E, et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

J Clin Oncol. 2013;31(33):4260–4267.

65. Ratain MJ, Mick R, Schilsky Rl, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993;85(20):1637–1643.

66. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase

I oncology research: a comparison of investigators and institutional review board

chairpersons. J Clin Oncol. 1992;10(11):1810–1816.

67. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1(3):175–181.

68. Von Hoff DD, Turner J. Response rates, duration of response, and dose response

effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9(1):

115–122.

69. Sekine I, Yamamoto N, Kunitoh H, et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol. 2002;13(8):1300–1306.

9 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

70. Roberts TG Jr, Goulart BH, Squitieri l, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292(17):2130–2140.

71. Timofeevski Sl, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met

receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine

and triazolopyrazine inhibitors. Biochemistry. 2009;48(23):5339–5349.

72. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–4883.

73. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase

I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res.

2012;18(22):6373–6383.

74. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers

Col aborative Consensus report: advancing the use of biomarkers in cancer drug

development. Clin Cancer Res. 2010;16(13):3299–3318.

75. Rodon J, Saura C, Dienstmann R, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol. 2012;9(6):359–366.

76. Department of Health and Human Sciences. Biomarker, Imaging, and Quality of

life Studies Funding Program (BIQSFP). 2013 [updated May 1, 2013; Oct. 25,

2013]; Available from: http://ctep.cancer.gov/protocolDevelopment/default.htm.

77. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and

prognostic factors for patients treated within the context of a phase I study: the

Royal Marsden Hospital experience. Br J Cancer. 2008;98(6):1029–1033.

78. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase

clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res.

2001;7(10):2971–2976.

79. El-Osta H, Hong D, Wheler J, et al. Outcomes of research biopsies in phase

I clinical trials: the MD Anderson Cancer Center experience. Oncologist.

2011;16(9):1292–1298.

80. Gomez-Roca CA, lacroix l, Massard C, et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol. 2012;23(5):1301–1306.

81. Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013;31(1):17–22.

82. lorusso PM. Phase I studies of ZD1839 in patients with common solid tumors.

Semin Oncol. 2003;30(1 Suppl 1):21–29. Epub March 20, 2003.

83. Mok TS, Wu Y-l, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.

84. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.

85. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet.

2008;372(9637):449–456.

86. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in

patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.

87. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or meta-

static renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol.

2010;28(6):1061–1068.





5

Ethical Issues in First-in-Human

Phase I Cancer Trials

E L I Z A B E T H A . E I S E N H A U E R ■



5.1 INTRODUCTION

There are international and national standards addressing the ethical conduct of

clinical trials and the protection of human subjects in research. Historical abuses

of human subject experimentation including those perpetrated against concen-

tration camp prisoners in World War II, the testing of the poison sarin on Royal

Air Force volunteers in 1951–1953 and the “Tuskegee” experiment on the nat-

ural progression of untreated syphilis in rural African American men between

1932 and 1972. These and others underscored the need for international codes

and standards to protect human research subjects. The Nuremberg Code (1947)

[1] and the Declaration of Helsinki (initially published in 1964 and revised

numerous times since) [2] defined principles to govern biomedical research and

protect the rights, safety, and wel -being of trial subjects. The Belmont Report

in the United States [3] defined three ethical principles that underpin human

subjects research, drawing on these earlier documents. These are: respect for

persons (individuals are to be treated as autonomous beings, capable of making informed choices, and those with diminished autonomy must be offered protection); beneficence (maximize the possible benefits and minimize harms); and justice (treat research participants fairly and distribute the benefits and burdens of research equitably).

The Guideline for Good Clinical Practice of the International Conference

on Harmonization [4] , adopted by most jurisdictions, including the European

Union, Japan, the United States, and Canada, reaffirms the principles of the

9 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

Nuremberg Code and the Declaration of Helsinki. Furthermore, it details the

process of ethical committee review of research, the content of informed consent

forms, the obligations of the investigator and the sponsor in clinical trials, the

required elements of clinical research protocols, and the documents that must

be in place prior to beginning a clinical trial. All of these elements and processes

apply to phase I cancer trials. The following sections do not provide a comprehen-

sive review of clinical trial ethical issues; rather, they will highlight those aspects of particular importance in first-in-human oncology trials. Furthermore, the discussion that follows applies to considerations of research in adult trial subjects.



5.2 GENERAL ETHICAL ISSUES IN FIRST-IN-HUMAN

PHASE I ONCOLOGY TRIALS



Beyond the general aspects of research conduct referred to above, phase I first-in-

human trials in oncology have been the focus of special ethical scrutiny for a

number of reasons, well summarized in a review by Agrawal and Emanuel [5] :

1. there is concern that the risk–benefit ratio for many cancer drugs does

not justify phase I studies;

2. secondly, that disclosure of information, i.e., the informed consent pro-

cess, is inadequate;

3. finally, because subjects are cancer patients whose disease is no lon-

ger curable and for whom other therapeutic options are very limited,

the population has been seen as “vulnerable” and in need of special

protection.

Each of these concerns will be discussed in the sections that follow. In all cases,

the discussion focuses only on first-in-human phase I trials.



5.2.1 Risk/benefit

There are no universal standards to apply to the question of risk versus ben-

efit in phase I oncology trials (or for that matter, in oncology trials in general).

Although the benefit, in terms of antitumor effect, for a specific agent undergoing its first-in-human phase I study is unknown, the benefit that can be expected, based on hundreds of phase I trials, can be estimated. Several major reviews

have shown that benefit, as measured by objective response, is in the range of 5%

overall [6–10]. In a recent review of 460 phase I trials (193 single-agent trials)

by Horstmann, the overall response rate was 10.6%, and in single-agent trials

Ethical Issues in First-in-Human Phase I Cancer Trials 93

ranged from 3.4–11.3% for various agent classes. Although it can be argued that

“objective response” may not equal “benefit” in the most abstract sense, it is

certainly an objective measure of change that is acceptable to the US Food and

Drug Administration and the broader community for accelerated approval of

new cancer drugs [11]. Furthermore, the response rate documented in these

reviews of about 5–10% is in keeping with that expected from certain “standard”

single-agent oncology therapeutics, such as gemcitabine in pancreatic cancer

[12] or erlotinib in non–small cell lung cancer (NSClC) [13]. Thus the “ben-

efit” as assessed by this objective means is small but is in a range that is not trivial by some external standards. Moreover, other benefits may accrue to patients

enrolled in phase I studies besides objective tumor shrinkage, though these are

more challenging to document. In a review of patients enrolled in cancer phase

I trials, Daugherty et al. documented that 70% of patients expected to receive

psychological benefit by participating (though no follow-up data are presented

to show it transpired) [14]. As reviewed by Agrawal and Emanuel [5] , some

investigators have observed improvement in the quality of life of patients over

the period of time they were on phase I cancer trials, but given the design of

such studies, it is not clear if this was related to the agent itself, related to the frequent medical interactions (and thus opportunities for the patient’s healthcare team to offer symptom management, for example) that phase I trials entail,

or related to benefits from the hopeful beliefs held by patients enrolled in such

studies (see more on this below). However, as argued by Agrawal and Emanuel,

regardless of whether observed quality of life improvements were truly a result

of the intervention of the phase I drug or not, “participating in phase I trials and

focusing on quality of life are not necessarily—and should not be—inherently

incompatible goals” [5].

The other consideration relevant to the discussion the risk/benefit ratio is of

course the risk of serious adverse events to patients receiving a new agent for the

first time. While this risk cannot be accurately quantified for a specific agent as

it enters phase I trials, since by definition no human data are available, appro-

priate preclinical toxicology data and good trial design (safe starting dose, care-

ful dose-escalation, ongoing safety monitoring) mitigate this risk. A review by

Roberts et al. found that overall, the risk of toxic death in phase I trials is about 0.5%; and the risk of this outcome is even lower (0.06%) in trials conducted in

the recent past (1999–2002) [9] , suggesting that the true risk of toxic death is

extremely low in phase I trials. Thus, the expected risk/benefit ratio, based on

objective data, of a properly designed and conducted phase I trial is acceptable,

using the aforementioned endpoints. Clearly data from historic series are infor-

mative but not absolutely predictive of what the risk is to an individual patient in

an individual phase I trial. However, the historical summary data are reasonable

sources of information upon which an informed discussion can be held.

9 4

P H A S E I C A N C E R C l I N I C A l T R I A l S



5.2.2 Disclosure of information: informed consent

Informed consent is another topic of ethical debate in phase I cancer trials.

Several authors have documented high expectations of benefit in patients con-

senting to phase I trials, which, given the data cited above, could be interpreted

to indicate that the informed consent process was inadequate. Daugherty et al.

found that 85% of patients enrolled in a phase I trial chose to do so because of

possible therapeutic benefit [14]. Cohen et al. have found that a similar propor-

tion (87%) of subjects in phase I trials believed the treatment might cure them

[15], and Pentz found that 81% of phase I trial participants mentioned that they

hoped for some “direct medical benefit” from participation [16].

Thus, if 80% or more of patients on phase I trials believe they might experi-

ence therapeutic benefit, and the true response rate expected is only about 5%,

should it be concluded patients have been misinformed? Perhaps not, since dis-

cordance between actual prognosis and belief in benefit may not represent mis-

information. Indeed, a review of consent forms from 272 oncology phase I trials

from the US National Cancer Institute–designated cancer centers found that

only one of the 272 consent forms stated that subjects were expected to benefit

[17]. The remainder either indicated that there would be no benefit to participat-

ing (4%), that benefit was uncertain (94%), or were silent on the subject (2%).

Ninety-two percent of consent forms indicated that the trial’s main purpose was

dose-escalation, safety, or toxicity. These data seem at odds with the reported

motivation by patients for enrol ing in such studies.

It is clear that the consent form document is not equivalent to the entire

process of informed consent: the discussion between the investigator or other

healthcare professionals and the patient may have different content. However,

when this has been examined more directly, through either recording of conver-

sations, surveys on informed consent discussion content, or structured patient

information interviews, the data indicate that the majority of conversations

regarding phase I trials correctly identify the investigational nature of the therapy, and the unknowns in risk and benefit that might accrue to the patient [18,19].

Furthermore, some research suggests that the hope for benefit expressed by some patients is not equivalent to believing it will happen: for example, in Daugherty’s series, 85% of patients were motivated to join a phase I trial because of possible

therapeutic benefit, but only 22% believed they would receive any therapeutic benefit by participating (70% said they believed they would, however, receive

psychological benefit).

This divide between patient’s expectation or hope of benefit and the real

probability of benefit has been termed a “therapeutic misconception” and may

be interpreted as a sign of failure of the informed consent process. However, as

argued by Weinfurt et al., this may not be the case: it may in fact reflect linguistic

Ethical Issues in First-in-Human Phase I Cancer Trials 95

issues [20]. When patients have a frequency-type piece of information given

them, they may respond using belief-type statements. That is, the belief (hope)

that may be recalled in citing reasons for consenting to a phase I trial may not

reflect the information given (or even understood) but rather the hoped-for out-

come of the decision. Agrawal and Emanuel characterize this as a “motivation to

maintain hope in a difficult situation rather than a misunderstanding of the infor-

mation” [5] . A relationship has been observed between the presence of hope,

overestimation of prognosis, and good measures of coping in cancer patients

participating in phase I trials [21]. It is plausible that the motivations described

by patients for their enrollment in phase I trials reflect the fact that maintain-

ing hope is important to them and the trial provides a vehicle for hope’s expres-

sion: even if the factual information they received and understood made it clear

that therapeutic benefit was an improbable outcome.

The age of consent is discussed in greater detail in Chapter 6. In general, most

adult trials consider those 18 years of age or over to be eligible. Some institutions allow individuals age 16 or older to provide their own informed consent, but,

depending on the protocol, such individuals may still not be eligible for an adult

study (i.e., the age of consent may not be equivalent to eligibility for enrollment).



5.2.3 Vulnerable population?

The observation that hope may motivate consent to phase I enrollment is one

of the reasons some argue that cancer patients who are phase I candidates are,

as a group, “vulnerable” and worthy of special protection by ethics committees

or other bodies. The basis of this argument is not clear: seriously ill patients of

all types are faced daily with important decisions regarding treatment options,

which, if they are adequately informed and competent, it is presumed and

expected they will make for themselves. A recent report by Seidenfeld in which characteristics of nearly 10,000 phase I oncology trial participants were reviewed

did not find evidence that this population had socio-demographic features that

would categorize them as vulnerable [22]. It may be that those who are con-

cerned about the vulnerability of this population may be reflecting more on the

nature of the choice put before such patients (phase I trial “yes or no”) rather than the capacity of these individuals to make informed choices. This argument is not credible, as it seems to stem from the opinion that if patients agree to such

trials, and think they might benefit, they are either il -informed (which the data

cited earlier suggest is not the case) or unable to take decisions for themselves.

There is no evidence to support the latter argument, nor is it plausible to sup-

pose a special condition of cancer patients renders them incapable of weighing

risks and benefits wisely. To deny competent patients the right to make informed

9 6

P H A S E I C A N C E R C l I N I C A l T R I A l S

decisions about their care or about participation in legitimate clinical research is

counter to the principles of Nuremberg and Helsinki referred to earlier.



5.3 ETHICAL CONSIDERATIONS IN EXCLUSION CRITERIA

As is described in Chapter 4, inclusion and exclusion criteria must be care-

fully considered in designing a phase I first-in-human trial. The fact that access

to phase I agents is restricted to only a subset of patients can be argued to be

unethical if it is even remotely possible the new drug may help. This argument

is discussed in a UNESCO report, “Ethical Considerations Regarding Access to

Experimental Treatment and Experimentation on Human Subjects” [23]. This

line of reasoning is based on the principle of justice, where the burden of research

(and thus access to research options) ought to be fairly distributed. However, this

argument can be countered on several fronts.

First, eligibility criteria serve the dual purpose of ensuring patient safety (for

example, individuals with impairment of the very organs thought to be important

in drug metabolism might suffer serious toxic effects) and also allowing recruit-

ment of a population most likely to address the primary study question: defining the recommended dose. This is accomplished by recruiting patients who

are likely to survive long enough for the required observation period. Patients

with very poor performance status, those with significant comorbidity or organ

impairment, may die soon after treatment is given, so they cannot contribute

meaningfully to the study question, and it will not be clear if their death might

be treatment-related. While early death can occur in phase I studies even when

appropriate inclusion criteria are in place, it is less frequent than would be the

case if criteria were much more broadly written.

Secondly, and more importantly, it cannot be argued that restrictive enrollment

is discriminatory if the “treatment” has not yet demonstrated any evidence of effi-

cacy in patients. While it may be wrong to withhold documented effective treatment from those who could benefit, phase I agents are of unknown toxicity and efficacy. In fact, the opposite position can be argued: that it is unethical to expose large numbers of patients to a drug unless it is known to be both safe and effective.

Finally, practically speaking, at the time first-in-human phase I trials are initi-

ated, the availability of drug is extremely limited: usually supplies for the first

few studies are available, but no more, so widespread prescription would not be

feasible without extra resources.

Thus exclusion criteria, provided they are based on reasonable medical and

physiological parameters (and not social, economic, or other parameters) are not

inherently unethical.

Ethical Issues in First-in-Human Phase I Cancer Trials 97



5.4 CONSENT FOR TISSUE PROCUREMENT

AND INVASIVE PROCEDURES

Increasingly, early clinical trials of all types include analyses of tissue or imaging studies to evaluate potential signs of a new agent’s biological effects on molecular

and other endpoints. It has always been understood that a phase I trial would

include extra investigations such as more frequent blood samples or standard

radiological studies, but the growing use of more-invasive procedures merits spe-

cial consideration.

Two questions are at the center of the discussion. First are the ethical and con-

sent issues around undertaking invasive procedures that are non-therapeutic, in

particular, repeated biopsies of tumor or normal tissue. Second are the ethical

and consent issues surrounding research studies on tissue and its possible bank-

ing for future, unknown, research.

With respect to the former question, as in all research procedures, there is a

requirement to balance the incremental risk such procedures pose (such as bleeding) against the potential benefit for discovery of useful information that helps inform decisions about how best to use the drug. Studies including fresh tumor

sampling must have clearly written eligibility criteria to ensure that patients are

appropriately selected to minimize risk. Although risk can be quantified, there is

essentially no possibility of direct benefit to the patient through having research

studies undertaken on their tumor or normal tissue sample, so it is important that

the research questions proposed must be truly meaningful and require the use of

patient material to answer. With respect to informed consent, the same principles

apply as for all human subjects research: patients must be informed about the

procedural risks, the lack of therapeutic benefit expected from the procedure,

and the scientific reason for requesting it; and their consent must be given freely.

This raises the question about whether trials incorporating fresh biopsy studies

should always be written to make the biopsy aspect optional with a consent pro-

cess separate from that of the main study. There is no clear direction given about

this: each study must be evaluated individually. As not all cancer patients will be

eligible for enrollment in phase I trials in any case, further restriction of entry

criteria to include only those who have lesions to biopsy and consent to undergo

this procedure may be reasonable in some circumstances. However, if this is

planned, there needs to be strict attention paid to the consent form and planned

consent process: patients should not be coerced into undergoing invasive proce-

dures in order to get what they may hope to be a useful therapy.

This brings us to the second question: How tissue procured in these studies

will be handled and stored, and what research investigations will be undertaken.

Concern is several-fold: about the nature of the investigations to be conducted

9 8

P H A S E I C A N C E R C l I N I C A l T R I A l S

on the tissue; the storage and use of the tissue in future, unspecified, research

projects; assurance of privacy and confidentiality; and the patient’s rights regard-

ing commercialization of discoveries.

It is clear that patients must be informed about what laboratory investigation

is planned for their tissue (whether freshly biopsied or archived from earlier

diagnostic or treatment procedures). However, there is variability among experts

and government authorities with respect to the detail required in providing this information: some require consent forms to have a detailed listing of all planned

laboratory tests, and would not permit additional studies without re-consent.

Others accept more general language, provided the intent of the testing is clear; for example, for phase I trials when mechanistic questions about the new agent

are being addressed: “laboratory studies will be undertaken to help determine

if the drug has effects on my cancer cel s as predicted”; or “laboratory studies

will be undertaken to understand better how the drug works in kil ing cancer

cel s and whether this is related to the dose of the drug.” In these examples, even

though the language is vague, the use is directed toward a specific set of research

questions.

If the text above were all the information supplied in the consent form, it would not be possible to use the tissue to study other general questions of cancer biology or other non-malignant disease without the patient’s re-consent. Therefore,

if it is anticipated there will be tissue remaining after the planned phase I study

questions are addressed, the options for storage and future study of that tissue

must be provided to the patient for consideration and consent. Will leftover tis-

sue be stored in a tissue bank, returned to the hospital from which it came (if

applicable), or destroyed? Even though the tissue is no longer part of the patient,

research on it, particularly if linked to (even anonymized) individual character-

istics, is considered “human subjects” research [24], and thus requires informed

consent. To enable future research (in cancer or other diseases) on stored tissue,

it is common practice to request consent for this possibility at the time the original consent for study-related research is given. The use of this approach is variable, and not all hospitals or ethical committees are agreed on it: some argue that new consent is required each time a new laboratory research study is proposed and are

uncomfortable with prospective consent being given to “any future study” (see,

for example, [25]). However, two papers suggest that the majority of patients

who donate their tissue for a specific research project are also agreeable to having

it used for future, unspecified, research (including research on different diseases)

[26,27]. If future research includes the possibility of testing for germ-line genetic changes, this normally requires explicit description and consent, because identification of a heritable mutation could have far-reaching impact on the patient and/

or the family, if they could be identified. In order to encompass all the possible

options for stored tissue, it has been recommended that the consent form contain

Ethical Issues in First-in-Human Phase I Cancer Trials 99

a checklist of options so the patient can indicate their preferences. This approach

has the advantage of simplicity and efficiency, but is only useful if patients are

reminded to complete it in full.

The study protocol and consent form must address not only what research

will/might take place on tissue, but also where tissues will be stored and how

anonymity will be assured. Plans for patient confidentiality and privacy protec-

tion should be carefully scrutinized by the ethical committee in order to ensure

compliance with applicable laws or regulations.

Finally, the consent form must also address two other issues: whether there is

a possibility the patient’s tissue will be sold, and whether the patient can expect any payment in the case a discovery is made based on the results of the research on their tissue that leads to successful commercialization. Many jurisdictions

prohibit the sale of human tissues or body parts.

Regulation of the use of banked human tissue is evolving, so the foregoing

serves only to highlight some of the issues in a general fashion. Useful docu-

ments on this topic include guidances from the US Office for Human Research

Protection [28], the Opinion of the European Group on Ethics and New

Technologies to the European Commission on Ethical Aspects of Human Tissue

Banking [29], the United Kingdom Human Tissue Act [30], and the Canadian

Tri-Council Policy [31].



5.5 ETHICAL REVIEW AND INFORMED

CONSENT AS PROCESSES

As noted earlier, there are several international codes of conduct that speak to the

proper process for ethics committee review of protocols as well as the consent

form’s content. Besides the international codes, many countries (and even insti-

tutions) have their own regulations that stipulate in greater detail the constitu-

tion and function of ethical review committees and the content of consent forms.

These apply equally to all phases of clinical investigation.

It is important to note that both ethical review and consent are ongoing

processes, not one-time events in the story of a study or a patient. In first-in-

human oncology trials in particular, it is important to keep the ethics committee

informed of emerging safety information from the study. When, even before an

annual report is due, study data show that the drug is producing important toxic

effects, normally the consent form should be modified to reflect these so that the

ethics committee and new patients will be aware of the risks of treatment.

In terms of patient interactions, initial consent to the study may be best accom-

plished in more than one meeting with the investigator and study team. Having

the consent process performed in stages allows time for the patients and family to

1 0 0

P H A S E I C A N C E R C l I N I C A l T R I A l S

“digest” the information, develop additional questions, and seek outside (e.g., the

family physician’s) advice about participating. Indeed, evidence suggests that one

of the most effective ways of improving the understanding of research subjects is

to have a study team member or neutral educator spend more one-on-one time

with study participants [32].

Ongoing contact with the patient is standard during the treatment phase of

studies, but in addition to seeking information from the patient on how he or

she is tolerating the drug, such encounters also offer the opportunity to provide

the patient with updated information on drug safety if it is available. Indeed, the

investigator is obliged to make the patient aware of significant new findings that might affect his/her wil ingness to continue the study drug, and to document such discussions in the medical record. For phase I trials, this generally

means new information about serious toxicity (which may, depending on the

nature of the effect and the ethical committee advice, require formal re-consent).

However, in addition to providing information about serious toxicity, the patient

should also be informed about other toxic effects, such as nausea or fatigue, that

the cumulative study data suggest are treatment-related. This continuous provi-

sion of new information fosters strong relationships between patients and the

investigator, and offers the opportunity for the patient to become truly a part of

the study team.



5.6 SUMMARY

As for other types of human subjects research, phase I oncology trials must be

underpinned by three fundamental ethical principles articulated in the chap-

ter introduction: respect for persons, beneficence, and justice. Although some have argued that cancer patients eligible for these trials may be a vulnerable group

and in need of special protection, there is no evidence to support this conten-

tion. Cancer patients are capable of making informed choices about their care,

including decisions about enrollment in clinical trials. First-in-human trials do

have some special aspects, however: they involve administration of agent(s) with

unknown effects having the potential for toxicity, the primary goal of the study is

not efficacy, and the trial may include non-therapeutic invasive procedures.

The arguments and evidence supplied in this chapter provide background on

the special issues faced by ethical committees and investigators in assuring ethical

conduct of phase I trials. Educators, investigators, ethical committee members,

and institutions must have in place not only procedures to assure appropriate

consent form content and protocol review, but also appropriate training for and

oversight of the informed consent process for those engaged in patient recruit-

ment. Trials themselves must be founded on good science and appropriate and

Ethical Issues in First-in-Human Phase I Cancer Trials 101

adequate preclinical data, display acceptable risk/benefit, and have embedded

in them ongoing monitoring of patient safety to minimize risks to subjects as

new information emerges in the course of the trial. The review of research by

an independent ethical review committee helps assure the balance in risk/ben-

efit and adherence to the principles and regulations that govern human subjects

research. When there is doubt about a course of action, acting in the best inter-

ests of the individual patient should take precedence over the concerns for the

study. Respect for and protection of patients remains the cornerstone of ethical

conduct in clinical research.



REFERENCES

1. The Nuremburg Code: http://www.hhs.gov/ohrp/archive/nurcode.html (last accessed November 2013).

2. World Medical Association Declaration of Helsinki: ethical principles for medi-

cal research involving human subjects. Available at http://www.wma.net/

en/30publications/10policies/b3/ (last accessed November 2013).

3. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. The National Commission for the Protection of Human

Subjects of Biomedical and Behavioral Research. Available at: http://www.hhs.gov/

ohrp/humansubjects/guidance/belmont.html (last accessed November 2013).

4. International Conference on Harmonization: guidelines for good clinical practice.

Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/

Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (last accessed November 2013).

5. Agrawal M, Emanuel EJ. Ethics of phase I oncology studies: reexamining the argu-

ments and data. JAMA. 2003;290:1075–1082.

6. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical

trials. Ann Oncol. 1990;1:175–181.

7. Von Hoff DD, Turner J. Response rates, duration of response and dose response

effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115–122.

8. Sekine I, Yamamoto H, Kunitoh H, et al. Relationship between objective responses

in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol. 2002;13:1300–1306.

9. Roberts TG, Goulart BH, Stallings SC, et al. Trends in the risks and benefits to patients with cancer participating in phase I clinical trials. JAMA. 2004;292:2130–2140.

10. Horstmann E, McCabe MS, Grochow l, et al. Risks and benefits of phase I oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–904.

11. Dagher R, Johnson J, Wil iams G, Keegan P, Pazdur R. Accelerated approval of

oncology products: a decade of experience. J Natl Cancer Inst. 2004;96:1500–1509.

12. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas

cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.

1 0 2

P H A S E I C A N C E R C l I N I C A l T R I A l S

13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123–132.

14. Daugherty C, Ratain MJ, Growchowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062–1072.

15. Cohen l, de Moor C, Amato RJ. The association between treatment-specific opti-

mism and depressive symptomatology in patients enrolled in a phase I cancer clini-

cal trial. Cancer. 2001;91:1949–1955.

16. Pentz RD, White M, Harvey D, et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase I trials. Cancer. 2012;118:4571–4578.

17. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C. Descriptions

of benefits and risks in consent forms for phase I oncology trials. N Engl J Med.

2002;347:2134–2140.

18. Rodenhuis S, van den Heuvel WJA, Annyas AA, Koops HS, Sleijfer DT, Mulder NH.

Patient motivation and informed consent in a phase I study of an anticancer agent.

Eur J Cancer Clin Oncol. 1984;20:457–462.

19. Tomamichel M, Sessa C, Herzig S, et al. Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol.

1995;6:363–369.

20. Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Patient expectations of ben-

efit from phase I clinical trials: linguistic considerations in diagnosing therapeutic misconception. Theor Med Bioeth. 2003;24:329–344.

21. Helft PR, Hlubocky F, Wen M, Daugherty CK. Associations among awareness of

prognosis, hopefulness, and coping in patients with advanced cancer participating in

phase I clinical trials. Support Care Cancer. 2003;11:644–651.

22. Seidenfeld J, Horstmann E, Emanuel EJ, Grady C. Participants in phase I oncology research trials. Are they vulnerable? Arch Intern Med. 2008;168:16–20.

23. UNESCO International Bioethics Committee (1996). Ethical considerations

regarding access to experimental treatment and experimentation on human subjects.

Available at: http://unesdoc.unesco.org/images/0013/001323/132338e.pdf (last accessed November 2013).

24. Clayton EW. Informed consent and biobanks. J Law Med Ethics. 2005;33:15–21.

25. Sade RM. Research on stored biological samples is still research. Arch Intern Med.

2002;162:1439–1440.

26. Chen DT, Rosenstein Dl, Muthappan P, et al. Research with stored biological sam-

ples: what do research participants want? Arch Intern Med. 2005;165:652–655.

27. Malone T, Catalano PJ, O’Dwyer PJ, Giantonio B. High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experi-

ence. J Natl Cancer Inst. 2002;94:769–771.

28. Office for Human Research Protection (OHRP) and Department of Health and

Human Services (HHS). Guidance on research involving coded private information

or biological specimens. Available at: http://www.hhs.gov/ohrp/policy/cdebiol.

html (last accessed November 2013).

29. The opinion of the European Group on ethics and new technologies to the European Commission on Ethical Aspects of Human Tissue Banking. Available at: http://

ec.europa.eu/bepa/european-group-ethics/docs/avis11_en.pdf (last accessed November 2013).

Ethical Issues in First-in-Human Phase I Cancer Trials 103

30. The United Kingdom Human Tissue Act (2004). Available at: http://www.legisla-

tion.gov.uk/ukpga/2004/30/contents (last accessed November 2013).

31. The Canadian Tri-Council Policy Statement: ethical conduct for research involving humans. Available at: http://www.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAl_

Web.pdf (last accessed November 2013).

32. Flory J, Emanuel E. Interventions to improve research participants’ understanding in informed consent for research: a systematic review. JAMA. 2004;292:1593–1601.





6

Phase I Trials in Special

Populations and Circumstances

R A J I V K U M A R , C H R I S T W E L V E S ,

A N D U D A I B A N E R J I ■



6.1 INTRODUCTION

In the interests of safety, most phase I cancer trials are carried out in patients

who fulfill strict criteria. These patients are not, therefore, representative of the patients treated in routine practice. Thus, clinicians and regulators require evidence that novel compounds are safe in these special populations and circum-

stances. This chapter addresses the question of how to design the neccessary

phase I trials, which are especially relevant in oncology due to the narrow thera-

peutic window of many cytotoxic and targeted anticancer drugs.

The special populations represent groups of patients for whom adequate

safety and pharmacokinetic (PK) data are not provided by standard phase I tri-

als. The best recognized of these are patients with impaired renal and hepatic

function, who are generally excluded from standard phase I trials and may not

tolerate doses defined by such trials. Children represent another group usually

excluded from phase I trials, but they may require higher drug doses to achieve

equivalent systemic exposure and/or pharmacodynamic (PD) effect; the impor-

tance of specific trials in elderly patients is less clear. Patients with intracerebral tumors, and those with hematological malignancies, are also frequently excluded

from phase I studies; the latter represents a group in whom eligibility and defini-

tion of both the maximum tolerated dose (MTD) and recommended phase II

dose (RP2D) may be affected by their underlying disease.

The term “special circumstances” covers several areas. The effect of food

on pharmacokinetics is increasingly relevant with many new agents being

Phase I Trials in Special Populations and Circumstances 105

administered orally. Drug–drug interactions, such as those mediated through the

CYP P450 family of enzymes, are also an issue for oral drugs. New agents are

frequently used in combination with other systemic treatments (new or estab-

lished) or radiotherapy, and specific combination phase I studies are increasingly

common. Finally, concerns about the potential of new drugs to cause serious car-

diac dysrhythmias have led to an increasing number of “QTc” studies.



6.2 ORGAN IMPAIRMENT



Patients eligible for first-in-human (FIH) phase I trials usually have “normal” or

“acceptable” renal and hepatic functions. In routine clinical practice, however,

renal impairment and abnormal liver biochemistry tests are common. Examples

of established anticancer drugs needing dose reductions in patients with impaired

renal function include etoposide [1] , and for impaired liver function, epirubicin

[2] and docetaxel [3].



6.2.1 Renal and hepatic impairment

Renal and hepatic impairment can significantly affect the pharmacokinetics

and safety of anticancer drugs. Government authorities, such as the European

Medicines Agency (EMA) [4,5], the US Food and Drug Administration (FDA)

[6,7], but also the National Cancer Institute (NCI) Organ Dysfunction Working

Group [8] have made specific recommendations for trials in patients with organ

impairment.

Since many drugs are excreted by the kidneys, there is potential for renal

impairment to influence their pharmacokinetics. Renal dysfunction, especially

when severe, can also affect safety and efficacy indirectly through changes in

drug absorption, metabolism, and protein binding. Renal insufficiency can be

the result of the underlying cancer, prior treatment, comorbid conditions and

their treatment, or a mixture of these factors [9] .

The liver also affects drug disposition and elimination. The most com-

mon cause of hepatic dysfunction in patients with cancer is liver metastases,

although there are other nonmalignant causes of liver impairment [10]. Liver

function may be preserved even in the presence of extensive disease, due to

its considerable metabolic reserve and, in the case of established cirrhosis,

the regeneration of hepatocytes. Mechanisms that may contribute to altered

pharmacokinetics and pharmacodynamics in patients with hepatic dysfunc-

tion include impaired hepatocellular function, reduced biliary elimination,

and decreased protein binding.

1 0 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

The definition of “acceptable” or “normal” renal and hepatic tests in stan-

dard phase I trials varies and is largely empirical. Typical eligibility criteria

for renal function would be a serum creatinine <1.5 × upper limit of nor-

mal (ULN) or creatinine clearance >60 mL/min. Acceptable liver tests are

typically a serum bilirubin or ≤1.5 × ULN, and aspartate aminotransferase

(AST)/alanine aminotransferase (ALT) ≤5 × ULN in the presence of liver

metastases or ≤2.5 × ULN in their absence. The basis for greater flexibility in

patients who have liver metastases is unclear, but it may be rationalized by the

poor prognosis and limited capacity for hepatocyte regeneration in patients

with metastatic disease. Interestingly, the effect of hepatic dysfunction on gefi-

tinib pharmacokinetics differs depending on whether the underlying cause is

cirrhosis or liver metastases [11].



6.2.2 When are organ impairment studies needed?

FDA and EMA guidelines on the circumstances under which a renal [4,6] or

hepatic [5,7] impairment study may be needed are summarized in Box 6.1, parts

A and B, respectively. Such studies are not mandatory, provided that a justifica-

tion is provided to the regulatory authorities. For example, they are unlikely to be

relevant if the organ concerned plays little or no part in drug elimination, where

the therapeutic index is wide, or if the drug will not be used in patients with renal or hepatic impairment.

When an organ impairment study is required, the EMA emphasizes the desir-

ability of addressing organ impairment prior to opening phase III studies to avoid

unnecessary restrictions to eligibility criteria in those studies. In contrast, FDA

recommendations imply that renal impairment studies will be carried out after

standard phase III trials have demonstrated safety and efficacy in patients with

“normal” renal function. In some cases, the realization that organ impairment is

an issue comes through toxicities seen in a phase III trial. However, where renal

or liver impairment is identified as a probable issue earlier in the development

of a drug, there is a strong case for doing specific studies sooner rather than later so that appropriate dose recommendations can be made as part of the initial

approval process.



6.2.3 Design of organ impairment studies



General study designs have been proposed by the FDA [6,7] and EMA [4,5], with

specific guidance for oncology trials provided by the NCI Organ Dysfunction

Group [8] .

Phase I Trials in Special Populations and Circumstances 107

Box 6.1

Considerations for Specific Organ Impairment Studies (A) in

Patients with Renal Impairment, and (B) in Patients with Hepatic

Impairment

A.• The drug is likely to be used in patients with renal impairment.

• Renal impairment is likely to significantly alter the pharmacokinetics

of a drug and/or its active/toxic metabolites.

• A dose adjustment is likely to be necessary for safe and effective use

in such patients.

• The drug and/or its metabolites have a narrow therapeutic index.

• Excretion and/or metabolism are primarily renal.

• A drug has both high hepatic clearance and significant protein binding.

B.• The drug is likely to be used in patients with hepatic impairment.

• Hepatic metabolism and/or excretion accounts substantially (>20%)

for the metabolism and/or elimination of a drug and/or its active/

toxic metabolites.

• Hepatic elimination and/or its active/toxic metabolites account for

<20%, but there is a narrow therapeutic index.

• If the route of metabolism is unknown and it cannot be shown that

hepatic elimination is minor.



6.2.3.1 Aims

The specific aims are to establish the MTD and dose-limiting toxicities (DLT),

and to characterize the pharmacokinetics and pharmacodynamics of the agent

in patients with organ dysfunction [8] . Both the EMA and FDA emphasize the

need to determine whether the pharmacokinetics of a drug, and/or its active

metabolites, are altered to such an extent as to require a dose different from that

established in a standard trial population. The definition of a “clinically signifi-

cant” alteration in kinetics will depend, among other factors, on the therapeu-

tic index of a compound and the inter-subject variability in pharmacokinetics in

patients with normal organ function.



6.2.3.2 Classification of renal dysfunction

Renal dysfunction is ideally classified according to glomerular filtration rate (GFR).

This can be measured directly as 51Cr-EDTA or 99mTc-DTPA clearance, but inu-

lin clearance and 125I-iothalamate clearance are arguably more accurate. A simple

1 0 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

alternative is to estimate creatinine clearance using a formula such as those of

Cockcroft and Gault [12], Jel iffe [13], or Wright et al. [14]. These formulae are,

however, less accurate than direct measurement of GFR, probably underestimat-

ing GFR by 20–30%. The Cockcroft-Gault formula has not been validated in those

with very severe renal impairment, children, or patients older than 85 years [15].

The NCI Organ Dysfunction Group emphasizes the need for accurate esti-

mation of creatinine clearance and that it be stable, recommending that it be

calculated from at least two separate 24-hour urine collections [8] . They also

recommend adjustment for body surface area (BSA) to increase the accuracy

of estimation and because many anticancer drugs are dosed according to BSA:

BSA-indexed Cr Cl = creatinine clearance (ml/min) × (1.73/actual BSA)

Definitions of renal dysfunction are shown in Table 6.1.



6.2.3.3 Classification of Hepatic Dysfunction

Hepatic impairment studies are complicated by the complexities of measuring

hepatic function in a clinically meaningful way. Several systems have been used

to classify liver dysfunction, but none has been adequately validated as a marker

of clinically relevant changes in drug metabolism. The Child-Pugh classification

is widely recommended by regulatory authorities, but its clinical relevance in

oncology is dubious. More sophisticated direct measures of liver function exist,

but all have limitations [16]. The use of standard liver biochemistry tests is sim-

pler and recommended by the NCI Organ Dysfunction Working Group.

Table 6.1. Measures of Renal Impairment

Group Description

Estimated creatinine Estimated creatinine

clearance—FDA§/

clearance—NCI¥ Organ

EMA¶ (mL/

Dysfunction Group

min/1.73m2)

(mL/ min/1.73m2/BSA†)

1

Normal renal function

>80 mL/min

≥60 mL/min

2

Mild renal impairment

50–80 mL/min

40–59 mL/min

3

Moderate renal

30–50 mL/min

20–39 mL/min

impairment

4

Severe renal impairment <30 mL/min

<20 mL/min

5

Requiring dialysis

End-stage renal disease Any

§ Food and Drug Administration

¶ European Medicines Agency

¥ National Cancer Institute

† Body surface area

Phase I Trials in Special Populations and Circumstances 109

The Child-Pugh classification was developed as a prognostic marker in patients

undergoing transection of hepatic varices [17]. Patients are scored according to

clinical (encephalopathy and ascites) and biochemical (bilirubin, albumin, and

prothrombin time) signs of liver failure, then categorized as having mild, moder-

ate, or severe hepatic dysfunction. This classification has several limitations as a

means of predicting drug elimination. For example, a subject with no clinical or

biochemical signs of liver disease is classified as having “mild” liver impairment.

On the other hand, in patients with cancer, the score may be affected inappropri-

ately by extrahepatic disease such as peritoneal or cerebral metastases. Finally,

the biochemical parameters used in the Child-Pugh classification are not part

of the eligibility criteria for most cancer trials. The Child-Pugh classification

fails, therefore, to identify patients who do not have hepatic failure but do have

liver biochemistry tests outside the usual limits, who are the patients for whom a

hepatic impairment study is most clinically relevant.

There are other, more sophisticated and direct measures of liver function.

Where the metabolism of a drug is understood in detail, it may be possible to

co-administer a specific “probe” that is metabolized by the same enzyme(s) as the

novel agent, but these have limitations [16] in practice. For example, indocyanine

green clearance is only weakly correlated with doxorubicin clearance [18], and the

metabolism of lignocaine to monoethylglycinexylidide does not correlate with

epirubicin clearance [19]. Antipyrine and galactose clearance have also been used,

but bromsulphthalein clearance has been largely abandoned due to toxicity [20].

Serum levels of bilirubin and AST, as proposed by the NCI Organ Dysfunction

Working Group (see Table 6.2), have the advantage of being simpler and more

clinically relevant, linking directly to the standard eligibility criteria of clinical trials [21,22,23]. An additional group, those who have undergone liver transplan-

tation, is also proposed by the NCI Organ Dysfunction Group, although it is

unclear how often this cancer and would be relevant. Using liver biochemistry

tests distributes cancer patients with liver dysfunction more evenly across the

four groups of liver impairment than the Child-Pugh classification [23].

Table 6.2. Biochemical Classification of Liver Dysfunction as Proposed

by the NCI Organ Dysfunction Working Group

Group

Description

Liver biochemistry tests

1

Normal liver function

Bilirubin ≤ ULN, AST ≤ ULN

2

Mild liver dysfunction

Bilirubin 1–1.5 × ULN, or AST > ULN

3

Moderate liver dysfunction

Bilirubin 1.5–3 × ULN, Any AST

4

Severe liver dysfunction

Bilirubin 3–10 × ULN, Any AST

AST = aspartate transaminase

ULN = upper limits of normal

1 1 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

Despite the limitations of the Child-Pugh classification, the regulatory author-

ities still advocate its use, where appropriate in conjunction with other, more

appropriate, markers of liver dysfunction. In practice, this may entail using a

biochemical classification to categorize patients with cancer while still recording

their Child-Pugh score.



6.2.3.4 Types of Organ Impairment Study

The various types of organ dysfunction studies are described below. The NCI

Organ Dysfunction Working Group provides a specific protocol template [8] ,

but other trial designs are possible within the regulatory guidelines.

A full study design as defined by the FDA and EMA, and the design proposed

by the NCI Organ Dysfunction Working Group, refers to studying patients with

a “full” range of organ impairment (see Tables 6.1 and 6.2). On the principle that

drugs should be evaluated in populations in whom they are likely to be used,

patients on dialysis or with severe liver impairment by Child-Pugh criteria would

usually be excluded. Most renal and hepatic impairment studies in oncology will

be adapted from the “full” design.

The reduced/staged study design is suggested where there is good reason to

believe that organ impairment will not affect pharmacokinetics sufficiently to

warrant dose modifications. Such studies are conducted in a “reduced” study

population, comparing the pharmacokinetics of a drug in patients with normal

organ function to those in patients with severe impairment. Again, evaluation in

patients on dialysis or who have severe liver dysfunction is unlikely to be appro-

priate. Where pharmacokinetics have been studied in patients with moderate

organ dysfunction using a reduced study design, the findings in that population

would usually be applied to patients with mild organ dysfunction; dosing in

patients with severe organ dysfunction would then generally be contraindicated.

Population PK studies of patients in phase II and III trials with normal organ function or limited impairment can also be used to evaluate the impact of liver or

renal dysfunction. Such studies underpin the docetaxel dose recommendations

for patients with abnormal liver biochemistry [24]. Dose recommendations for

patients with more severe organ impairment, who will have been excluded from

phase II and III trials, are unlikely to result from population PK studies; such studies may, however, highlight the need for more detailed organ dysfunction studies

as described above.



6.2.3.5 Trial Design

Patients will usually be stratified according to their degree of renal or hepatic

impairment (Tables 6.1 and 6.2). Other eligibility criteria are similar to those of

other early clinical trials in oncology. Recruitment to such studies can, therefore,

be challenging, as these patients must have significant organ dysfunction but also

Phase I Trials in Special Populations and Circumstances 111

need to be relatively fit while having exhausted standard therapies. Organ impair-

ment studies wil , therefore, usually need to recruit at multiple clinical sites.

The study drug may be given as a single dose, provided pharmacokinetics are

known to be linear and time-independent, which will generate PK but not toler-

ability data. Where appropriate, as with repeated administration of an oral drug,

a multiple-dose study will usually be preferred.

There are differing approaches to the starting dose and dose escalation in these

studies. The NCI Organ Dysfunction Working Group envisages a comprehen-

sive approach, with parallel dose escalation schemes across a range of cohorts,

each with differing degrees of organ dysfunction. This implies up to four or five

parallel phase I hepatic and renal impairment trials, each with several dose levels.

In practice, this may prove disproportionately time-consuming and impractical.

The RP2D in patients with normal renal or hepatic function (RP2D

) will

normal

usually be known from standard phase I (and II) trials when an organ impairment

study is designed. A dose lower than this, determined by the therapeutic window

of the agent being studied and the anticipated impact of organ dysfunction on

PK, may be selected as the starting dose in patients with organ dysfunction.

Another approach is to escalate the degree of organ dysfunction impairment

in patients being treated in a sequential manner. This can be done by first treat-

ing groups with normal renal/hepatic function and mild impairment at the

RP2D

. If the RP2D

is tolerated by patients with mild organ impairment,

normal

normal

a cohort with moderate impairment is then treated at the same dose. On the

other hand, if RP2D

is not tolerated in patients with mild organ dysfunc-

normal

tion, the dose would be de-escalated to predetermined dose levels in cohorts of

patients with mild the same mild degree of organ dysfunction until a tolerable

dose is identified. Having established a reduced but tolerable dose (RP2D ), a

−x

cohort of patients with moderate organ dysfunction would be treated, starting at

the RP2D dose, and the process repeated.

−x

Irrespective of the dose-escalation scheme, DLTs will be defined in the usual

way and evaluated specifically over the first cycle of treatment. Although contin-

ued elevation of raised baseline renal/liver biochemistry tests within the limits

that defined trial eligibility at baseline would not constitute a DLT, deterioration

in renal function or liver biochemistry with a temporal relationship to adminis-

tration of the study drug may constitute a DLT if judged to be drug-related. The

MTD and RP2D within each organ impairment group are defined according to

standard phase I practice.

The usual phase I “3 + 3” cohort size can be applied to organ impairment stud-

ies. The NCI group proposes a more flexible, expansive model in which, once

initial estimates of tolerability and pharmacokinetics have been made in a cohort

of three to six patients, an expanded cohort of 12–15 patients should be treated

to confirm these findings in each renal impairment group.

1 1 2

P H A S E I C A N C E R C L I N I C A L T R I A L S



6.2.3.6 Pharmacokinetics and Pharmacodynamics



Detailed PK evaluations of the parent drug and/or its active metabolites are fun-

damental to these studies; this means taking multiple timed blood samples.



Pharmacokinetics: renal impairment

Mathematical models may be constructed relating renal function, usu-

ally creatinine clearance, to the relevant PK or clinical parameters. The PK

parameters of interest are usually clearance of the drug and/or active metabo-

lites, dose-normalized area under the concentration–time curve (AUC) or

dose-normalized peak concentration (C ); renal clearance can be calculated

max

from urinary excretion data. Where protein binding is high, free-drug concentra-

tions should be measured. Such models aim to predict pharmacokinetics from

renal function as a quantitative basis for rational dose recommendations.

In the regulatory context, if a sponsor is to claim that dose adjustment for

renal impairment is not required because pharmacokinetics are not altered, this

requires a statistical rationale. The FDA describes one approach by which “no

effect” boundaries can be established for the ratio of key PK measurements from

patients with impaired and normal renal function, respectively. The “no effect”

boundaries should be defined prior to the study, based on information from pre-

vious studies on within- and between-patient PK variability and PK/PD rela-

tionships. If, for example, the 90% confidence interval for the ratio of defined

PK measurements fell within these boundaries, it could be claimed that there

was “no effect” of renal impairment on pharmacokinetics and no basis for dose

modification. An alternative approach would be to assume a priori “no effect”

boundaries of 70–143% for C or 80–125% for AUC without further justifica-

max

tion, accepting that this may reflect the limitations of small sample size in renal

impairment studies, and that wide between-patient variability may preclude

meeting these boundaries.



Pharmacokinetics: hepatic impairment

Relating altered PKs to impaired hepatic function has generally proved more dif-

ficult, but such relationships should be investigated along the lines described for

renal impairment. Where there is an obvious twofold or greater increase in drug

exposure, the FDA recommends dose reductions. Similar considerations apply

in concluding there is “no effect” for hepatic dysfunction as for renal impairment.



Pharmacodynamics

PD endpoints in an organ dysfunction study would usually be standard toxicity

assessments rather than direct measures of drug–target interactions. PD effects,

whereby patients with organ dysfunction experience more toxicity than those

with “normal” organ function despite drug pharmacokinetics’ not being altered,

Phase I Trials in Special Populations and Circumstances 113

may be as important as altered PKs (especially in patients with hepatic impair-

ment). The importance of clinical toxicities is emphasized by the NCI Organ

Dysfunction guideline where establishing the MTD and DLTs in patients with

varying degrees of organ dysfunction is the key aim.



6.2.3.7 Examples of Organ Impairment Studies in Oncology

Organ impairment studies in oncology are steadily increasing in number.

Examples of novel targeted therapy and selected cytotoxic renal and hepatic dys-

function studies are shown in Tables 6.3 and 6.4, respectively.



6.2.4 Other organs



Impairment of other organ functions generally does not affect the PK of a drug or

its metabolites. Although specifically not carried out in a population with organ

dysfunction, studies evaluating the potential of novel agents to cause cardiac

arrhythmias have become increasingly common. Of particular relevance of is the

effect of new agents on the “QTc interval” [25].



6.2.4.1 Cardiac Arrhythmias andThorough QTc Studies



A lengthened QT interval is a marker, albeit an imperfect one, of the potential for

ventricular tachyarrhythmias such as torsades de pointes (TdP) and one of many risk factors for sudden death. Although perhaps of limited relevance in the palliative setting, agents that are effective in patients with metastatic disease may later be evaluated in the adjuvant setting, where potentially lethal cardiac arrhythmias

would be unacceptable.

Preclinical toxicity models and assays can predict for cardiac arrhythmias.

hERG (human Ether-à-go-go-Related Gene) is the gene that codes for a subunit

of a potassium ion channel and “coordinates” cardiac repolarization. Inhibition

of this channel, either inherited or drug-induced, can cause the long QT syn-

drome. For drugs that inhibit the hERG channel in preclinical testing, thorough

QTc studies may be triggered earlier in the drug development.

QTc is influenced by heart rate, which is corrected for using either Bazett’s

formula (QT ):

B

QT

QT =

B

RR

or Fridericia’s [3] formula (QT ):

f

QT

QT =

B

3 RR

Table 6.3. Selected renal Dysfunction Studies

Drug

Study design

Outcome

Reference

Capecitabine

Oral capecitabine 2500 mg/m2 daily for 2 weeks

Renal impairment led to increased exposure to precur- Poole et al.,

1) Normal renal function (n = 6)

sor (5′-DFUR) and metabolite (FBAL) of 5-FU. The 2002 [48].

2) Mild (8)

AUC of 5′-DFUR was strongly correlated with grade

3) Moderate (6)

3 or 4 AEs.

4) Severe renal impairment [4]

Lenalidomide Population PK study—3 groups:

No difference in PFS, and response rate. Renal

Dimopoulos

1) CrCl >60 mL/min,

impairment resulted in more thrombocytopenia,

et al., 2010

2) 30–60 mL/min,

dose reductions, and interruptions. Advocate careful

[86].

3) <30 mL/min.

monitoring of CrCl and dose reduction required.

All patients received lenalidomide 25 mg and

dexamethasone 40 mg.

Bortezomib

Bortezomib i.v. at 0.7–1.5 mg/m2 on days 1, 4, 8, and

Decreased CrCl did not affect bortezomib pharma-

Leal et al.,

11, q3wks.

cokinetics or pharmacodynamics. Bortezomib 1.3

2011 [87].

Stratified CrCl normalized to BSA into five cohorts:

mg/m2 is well tolerated, and dose reductions are not

1) ≥60 mL/min/1.73 m2);

necessary in patients with renal dysfunction.

2) 40–59 mL/min/1.73 m2;

3) 20–39 mL/min/1.73 m2;

4) <20 mL/min/1.73 m2; and

5) dialysis.

Dose escalation was planned for cohorts 2–5.

Imatinib

Imatinib in advanced solid tumors. Dose escalation

Despite having increased imatinib exposure, 800

Gibbons et al.,

from 100 mg to 800 mg.

mg OD was tolerated in Group 2 and 600 mg was

2008 [88].

4 groups:

tolerated in Group 3. No MTD defined. No dose

1) CrCl ≥ 60 mL/min;

modification required for renal impairment.

2) CrCl 40 to 59 mL/min;

3) CrCl 20 to 39 mL/min; and

4) CrCl< 20 mL/min).

Sorafenib

Sorafenib 400 mg on day 1 for pharmacokinetic assess- No significant association between AUC (for sorafenib Miller et al., ment, with continuous daily dosing started on day 8.

and N-oxide metabolite) and renal cohort.

2009 [89].

Patients were divided into 5 cohorts:

However, the following empirical starting doses were

1) CrCl ≥60 mL/min;

recommended based on tolerance.

2) CrCl 40–59 mL/min;

Groups 1 and 2, 400 mg BD;

3) CrCl 20–39 mL/min;

Group 3, 200 mg BD;

4) <20 mL/min; and

Group 4, not defined;

5) hemodialysis.

Group 5, 200 mg OD.

Sunitinib

Sunitinib single-dose study of 50 mg.

Pharmacokinetics in groups 1 and 2 similar. Plasma

Khosravan et al.,

Three groups compared:

exposure to sunitinib less in group 3 compared with

2010 [90].

1) CrCl >80 mL/min,

groups 1 and 2. Single dose well tolerated. No dose

2) CrCl <30 mL/min,

modification required. Dose modification should be

3) On hemodialysis.

based on tolerance.

Erlotinib

Patients treated with escalating doses from 75 mg,

No DLT was seen in group 2. Patients with renal dys- Miller et al.,

100 mg, and 150 mg.

function tolerate 150 mg of erlotinib daily and have

2007 [91].

2 groups were compared:

drug clearance similar to normal renal function.

1) Normal creatinine;

2) Creatinine 141–442 umol/L.

Table 6.4 Selected Hepatic Dysfunction Studies

Drug

Study design

Outcome

Reference

Eribulin

3 groups compared:

Despite stepped graded initial dosing, AUC for

Devriese et al.,

1) normal liver function tests,

Child-Pugh A was 1.75-fold higher and 2.48-fold higher

2012 [92].

2) Child-Pugh A,

for Child-Pugh B.

3) Child-Pugh B.

Dosing was well tolerated at the prescribed dosing,

Dosed at 1.4, 1.1, 0.7 mg/m2, on Days 1

therefore dose reduction recommended for hepatic

and 8, q3 weekly, respectively.

impairment.

Ixabepilone

Modified NCI Organ Dysfunction Working Dose reduction required in moderate to severe hepatic Takimoto et al.,

Group Schema. Dose escalation in 3+3

dysfunction. Groups 3 and 4 require dose reduction to

2006 [93].

design from 10 to 40 mg/m2, q3 weekly.

30 mg/m2 and 20 mg/m2, respectively.

Bortezomib

NCI Organ Dysfunction Working Group

Patients with mild hepatic dysfunction do not require dose LoRusso et al.,

Schema for normal, mild, moderate, and

modification. Those with moderate or severe hepatic dys-

2012 [94].

severe hepatic impairment, with bortezomib

function should be started at a reduced dose of 0.7 mg/m2.

given at 1.3, 1.0, 0.7, 0.5 mg/m2, respectively.

Imatinib

NCI Organ Dysfunction Working Group

Maximum recommended dose for mild liver dysfunc-

Ramanathan

Schema for normal, mild, moderate, and

tion was 500 mg/day. Patients with moderate or severe

et al., 2008 [95].

severe hepatic impairment, with varying

hepatic dysfunction (MTD not determined) could either

starting doses and dose escalations start-

be dosed at 400 mg/day, with careful monitoring of liver

ing at 100 mg/day.

function and toxicity, or commenced on 300 mg/day,

with a view to rapidly escalating to 400 mg/day in the

absence of severe toxicity.

Sorafenib

NCI Organ Dysfunction Working Group

Following starting doses are recommended for sorafenib:

Miller et al.,

Schema for normal, mild, moderate, and

Normal, mild category: 400 mg BD;

2009 [89].

severe hepatic impairment, with the addi-

Moderate category: 200 mg BD;

tion of a very severe category, defined as

Severe category: not even 200 mg every third day was

albumin <25 mg/dL with any bilirubin/

tolerated;

AST.

Very severe category: 200 mg/day.

Sunitinib

Patients were treated with normal hepatic

No notable differences in the pharmacokinetic profile, and Bello et al.,

function, Child-Pugh A and B. All patients sunitinib was well tolerated. No need to adjust the cur-2010 [96].

received a single dose of sunitinib 50 mg

rently approved starting dose of 50 mg daily on schedule

with pharmacokinetic assessments.

4/2, for patients with mild to moderate liver impairment.

Vorinostat

NCI Organ Dysfunction Working Group

Patients with varying degrees of hepatic dysfunction

Ramalingam

Schema for normal, mild, moderate, and

require appropriate dose reduction even though vorino-

et al., 2010 [97].

severe hepatic impairment. Patients were

stat pharmacokinetics were unaltered. The recommended

given a single dose of 400 mg with pharma- vorinostat doses in mild, moderate, and severe hepatic cokinetic sampling. Continuous dosing

dysfunction were 300 mg, 200 mg, and 100 mg, respec-

started 1 week later, with starting doses of

tively, on the daily continuous schedule.

400, 300, 200, and 100 mg, respectively.

Erlotinib

3 cohorts defined as:

Patients with hepatic impairment had a longer half-life

Miller et al., 2007

1) AST ≥ 3xULN, normal direct bilirubin;

and reduced clearance. The 150 mg recommended for

[91].

2) direct bilirubin 1–7 mg/dL, any AST;

patients with normal organ function was not tolerable.

3) albumin <25 mg/dL, direct bilirubin

Patients with hepatic dysfunction should be treated at a

<1.0 mg/dL, any AST.

reduced dose (75 mg daily) consistent with their reduced

Dose-escalation plan: 50 mg, 75 mg,

clearance.

100 mg, 150 mg.

Pazopanib

NCI Organ Dysfunction Working Group

Patients with mild liver dysfunction tolerated the approved Shibata et al.,

Schema for normal, mild, moderate, and

dose of 800 mg/day. Patients with moderate to severe

2013 [98].

severe hepatic impairment. Pazopanib was

liver dysfunction tolerated 200 mg/day. AUC and C at

max

given orally once a day on a 21-day cycle.

these doses were comparable.

A modified 3+3 design was used.

1 1 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

where RR is the interval from the onset of one QRS complex to the onset of the next; other correction methods have also been used. It is important to specify

which formula is to be used and whether the QTc will be generated automati-

cally by the electrocardiogram (ECG) machine, calculated by the investigator (or

determined centrally).

All novel compounds are expected to undergo some clinical electrocardio-

graphic evaluation, either within a standard phase I trial or in a specific trial dedicated to evaluating their effect on cardiac repolarization; i.e., a “thorough QT/

QTc study.” Until the effects of the drug on the QT/QTc interval have been char-

acterized, the following exclusion criteria are frequently used:

• A marked baseline prolongation of QT/QTc interval (e.g., repeated

demonstration of a QTc interval >450 ms);

• A history of additional risk factors for TdP (e.g., heart failure, hypokale-

mia, family history of long QT syndrome);

• The use of concomitant medications that prolong the QT/QTc interval.

“Thorough QTc studies,” as mandated by the FDA and EMA, are outlined in

the International Conference on Harmonisation (ICH)-E14 document [26].



Design of thorough QTc studies

The timing of the collection of ECGs, typically in triplicate, and the study design

(i.e., single or multiple dose; duration) should be guided by the PK profile of

the drug. For drugs with short half-lives and no active metabolites, a single-dose

study might be sufficient. While the peak serum concentration does not always

correspond to the maximal effect on QT/QTc interval, care should be taken to

perform ECG recordings at time points around the C .

max

The trial protocol should specify the procedures to follow if a patient experi-

ences an adverse event suggestive of TdP. Discontinuation of a subject from a

clinical trial should be considered if there is a marked prolongation of the QT/

QTc interval during treatment with the study drug, especially if the measurement

is obtained on more than one ECG. Commonly used thresholds for potential

discontinuation include increases in QT/QTc to >500 ms or of >60 ms over

baseline.



6.3 AGE AND EARLY CLINICAL TRIALS



Patients at the extremes of age present particular challenges in clinical practice

and early clinical trials. Older patients are underrepresented in clinical trials and especially phase I trials, but they constitute the majority of patients in clinical

Phase I Trials in Special Populations and Circumstances 119

practice; this represents a challenge across oncology clinical trials rather than one specific to phase I studies. There is, however, a recognized need for early clinical trials in children and young adults who historically have had access to novel

agents only after they have been evaluated in adult populations [27].



6.3.1 Pediatric and teenage patients



6.3.1.1 Background

Cancers in children and young adults are uncommon but have a dispropor-

tionate impact; again, many within this age group are excluded from phase

I trials. The exclusion of teenagers is, perhaps, more because of potential

legal issues in gaining consent for complex trials from “minors” than because

of concerns that dosing requirements may be different. There are moves to

reduce the lower age limit of “adult” trials to 16 years or lower. There are, how-

ever, genuine physiological issues in younger children, especially those less

than one year old.

Entry to clinical trials through cooperative groups is standard practice in

pediatric oncology. Cancer drug development does, however, present specific

practical and ethical challenges in children. In addition, pediatric tumors are

quite distinct histologically and in terms of their molecular biology. Although

traditional screening programs have identified drugs with activity against can-

cers in children, the NCI 60-cell panel does not include pediatric cancers.

Xenograft models and transgenic models of pediatric malignancies are now being

developed [28].

New anticancer drugs have invariably been developed first in adults, but

children differ from adults in terms of their physiology and the sensitivity of

target organs. Moreover, children differ from each other, depending on their

stage of development; the physiology of a neonate is quite different from that

of an adolescent (see below). For example, the ratio of BSA to weight is sub-

stantially higher in young children than in adults. Use of BSA adjustment may

have contributed to infants treated with vincristine, asparaginase, and predni-

sone experiencing a high frequency of neurotoxicity [29]. Drug metabolism

may be impaired in neonates; for example, clearance of doxorubicin is reduced

in children under the age of two years [30]. Likewise, renal function is markedly

reduced in neonates. In later childhood, drug metabolism may be more rapid

than in adults, necessitating higher doses per unit of BSA or weight to achieve

the same PK exposure or PD effects. Other physiological differences include

total body water being higher, and drug binding by plasma proteins lower, in

neonates; gastric pH and motility also change with age and may alter drug expo-

sure following oral administration.

1 2 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

The importance of conducting specific pediatric phase I trials is illustrated by

comparing the MTD of anticancer drugs in children and adults. Traditionally, chil-

dren appeared to tolerate higher doses of cytotoxics, with MTDs exceeding those

in adults by 10–200% [31]. More recently, other phase I trials in children have

identified MTDs equivalent to or lower than those in adults. This may reflect, at

least in part, children now being more heavily pretreated before entering phase I trials. While DLTs are generally the same in children and adults, there are exceptions;

myelosuppression was dose-limiting for dexrazoxane in adults, whereas hepato-

toxicity was the DLT in children [32]. A recent meta-analysis of neoadjuvant che-

motherapy osteosarcoma studies and registries showed differences in toxicity and

efficacy reflecting fundamental differences in the way chemotherapy is handled in

children compared with older populations. These differences may influence sur-

vival in a disease in which chemotherapy is critical to overall outcomes [33].

Guidance has been published for the conduct of studies in children by the

FDA [34] and the EMA [35]; these recommendations are generic and not spe-

cific to cancer therapy. The FDA has also issued specific guidance for industry in

relation to pediatric oncology studies [36].



6.3.1.2 Ethics of Phase I Trials in Children

Definitions of “childhood” vary, and pediatric studies may include patients up to

the age of 21, although more often the upper age limit is 18 years. The FDA and

EMA both stipulate that written informed consent should be obtained from the

child. It is important that, wherever possible, language is used that the child can

understand, and that they are aware of their right to decline participation in the

trial and their right to withdraw.

Although response rates in pediatric phase I trials are low, such studies are gen-

erally safe. A review of pediatric phase I studies described 56 single-agent trials in 1,606 children, published between 1978 and 1996 [37]. Although 7% of patients

died on study, only 0.7% died from drug toxicity compared with 5.6% from pro-

gressive disease. These figures are not too different from those of an adult phase

I population [38]. The EMA states explicitly that, to minimize the risk of distress

to the child, trials should be designed and performed only by those experienced

in the treatment of children.



6.3.1.3 When in the Development of a New Drug

Should Pediatric Studies be Done?

A general principle established by the EMA is that, in order to minimize risk to

children, safety studies should be carried out first in animals as part of routine

preclinical development, next in adults, and only then in children. However, if a

compound is being developed initially for the treatment of a childhood-specific

illness, pediatric development may start ahead of any exposure in adults (see

Phase I Trials in Special Populations and Circumstances 121

Table 6.5). Recent regulatory changes are designed to encourage and accelerate

pediatric drug development.



6.3.1.4 Design of Pediatric Phase I Studies

The term “children” covers a wide range of ages, with differing maturity and phys-

iology. Moreover, not all children of a given age have the same degree of matu-

rity. FDA documents suggest classifying younger patients as newborn (birth to 1 month of age), infant (1 month to 2 years), child (2 to 12 years), and adolescent (12 to 21 years). The EMA proposes another possible categorization: newborn

infants (0 to 27 days), infants and toddlers (28 days to 23 months), children (2 to 11 years), and adolescents (12 to 16–18 years, dependent on geographical region).

As with adult phase I trials, the key aims of a pediatric phase I study are to

define the recommended phase II dose, identify/define toxicities and specifically

DLTs, study, PK/PD and observe any preliminary evidence of antitumor activity.



6.3.1.5 Specific Features of Pediatric Studies

For children aged 10 years or younger, the Lansky scale evaluates activities appro-

priate for their age, such as the amount of time spent at play [39]. The Karnofsky

Table 6.5. Timing and Aims of Pediatric Studies

Indication

Timing of pediatric

Aims

studies

Disease exclusively

Trials in children can start To demonstrate efficacy and

affecting children

before any adult human

show the safety profile

exposure

Disease affects children Trials in children needed

To demonstrate efficacy and

mainly, with particular early, following dem-

show the safety profile

severity or a different

onstration of safety and

natural history

reasonable (phase I/II)

efficacy in adults

Disease occurs in adults Trials in children needed

To demonstrate a safe and effec-

and children for which early, following dem-

tive dosage schedule; to detect

currently no treatment onstration of safety and

unforeseen or unique effects in

reasonable (phase I/II)

childhood

efficacy in adults

Disease occurs in adults Trials in children usually

To demonstrate comparable

and children for which follow completion of

safety, efficacy, or convenience

there currently is

adult phase III trials

in children relative to existing

treatment

treatment; to determine a safe,

effective dosage schedule; to

detect unforeseen or unique

effects in childhood

1 2 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

or Eastern Cooperative Oncology Group (ECOG) performance status scales can

be used for children older than 10 years. A formula has been derived to calculate

GFR from serum creatinine specifically in children [40].

In most cases a drug will have been evaluated in adults, and those studies will

inform subsequent pediatric studies. Rather than starting at one-tenth of the dose

lethal in mice LD , the pediatric starting dose is often set at 80% of the adult

10

MTD or RD. The use of BSA to adjust dose may be inappropriate, especially in

children less than one year of age or weighing less than 10 kg, for whom dos-

ing according to body weight should be considered. Furthermore, PK data are

often expressed as dose per body weight (e.g., 1 mg/kg), due to significant range

in patient size [41]. Rather than using a “Fibonacci” scheme, dose escalation in

pediatric phase I studies is typically by 20–30% increments. Pharmacologically

guided dose escalation has been used to a limited degree [42]. Within-patient

dose escalation is not, however, usually permitted. Studies generally require no

more than five dose levels [43]; this should increase the proportion of children

treated at higher, and potentially therapeutic, dose levels.

PK studies are integral to phase I studies, including those in pediatric/young

adult patients. The volume of blood that can safely be sampled is limited in small

children, but with high sensitivity of modern assay methodologies, using sam-

ples as small as 20–100 µl, this should not preclude detailed characterization of

pharmacokinetics. Interestingly, the FDA included cytotoxics among the “hit

and run” agents where they stated serum assays to be of “little or no value.” They

concluded that requirements for assay methodology may be relaxed or waived in

favor of measuring biological effect. Given the difficulties of measuring biologi-

cal activity in a meaningful way, most clinicians would consider PK studies a vital

part of pediatric phase I trials. The EMA recognizes that where a broad pediatric

study has been completed, there may not be enough patients in each age group to

define differences in tolerability or efficacy. Under those circumstances, PK data

may be important in identifying differences between the age groups.



6.3.1.6 Teenage and Young Adult Patients

Teenagers and young adults (TYA) with cancer are a challenging population in

clinical practice and also in drug development. This group straddles the pediatric

and adult cancer services and clinical trials infrastructure, and are recognized as a group with particular needs. This reflects in part the types of cancer seen in such

patients, but also their needs in terms of communication, support, and follow-up.

TYAs are generally underrepresented in clinical trials; indeed, trial recruit-

ment has been poorer in TYAs than in either adult or pediatric cancer [44]. The

lower age limit for most “adult” phase I trials is almost always 18, notwithstanding

geographic variations in the age of majority; i.e., the legal threshold of adulthood.

Teenagers risk, therefore, being excluded from most such trials. This is especially

Phase I Trials in Special Populations and Circumstances 123

problematic for patients with cancers such as Ewing’s sarcoma, who may be

either “adults” or “children,” but those under 18 years will often be excluded from

clinical trials. A more flexible approach, with the lower age limit of trials reduced to 16 years or less (where appropriate), is to be commended.



6.3.2 Older patients

Although cancer is substantially a disease of older patients, most phase I trials

are, arguably, not very informative for them. Acute myeloid leukemia is a good

example, the median age of patients being 65 to 70 years, whereas patients in

clinical studies are about 15 to 20 years younger [45].

Some of these issues are illustrated by the development of the oral fluoroyrimi-

dine capecitabine. Phase I and II trials included only a minority of older patients;

likewise, two subsequent large phase II trials in patients with metastatic colon

cancer that compared capecitabine with bolus 5FU/LV. In univariate analyses,

increased toxicity was seen in both study arms in patients aged over 80 years and

those with moderate renal impairment; in a multivariate analysis, the effect of

renal function, but not age, was maintained [46]. In a second study, Bejetta et al.

[47] reported an unacceptably high incidence of toxicity with capecitabine at the

standard dose of 2500 mg/m2 in women with breast cancer aged over 65 (median

age 73). A subsequent unrelated renal impairment trial demonstrated the need

for dose reductions in patients with creatinine clearance 30–49 ml/min [48].

The practicalities of additional hospital visits, especially in phase I trials, may

deter older, less independent patients for whom living alone or being caregivers

are among several reasons deterring them from entering trials [49]. Concerns

that older patients may tolerate treatment less well [50] may also deter clini-

cians from approaching them about trials, although this assumption has been

questioned [51].

Trial eligibility criteria will exclude a substantial proportion of older patients,

not directly because of their age but because of organ function or comorbidities.

For example, GFR falls by about 1 ml/min for each year in patients over 40 years

old [52]. The implications of renal impairment in relation to early trials were

discussed above. The standard Cockcroft-Gault formula is, however, not vali-

dated for patients over the age of 85; in these patients the Wright formula [14]

appears more accurate, especially in those with renal impairment [15]. Other

age-related physiological changes that may affect pharmacokinetics of a novel

agent include: altered gastric pH, emptying, and motility; changes in liver mass,

perfusion, and metabolic activity; lower cardiac output and reserve; reduced

plasma proteins, total body water, and fat-free mass.

Increased age may also confer increased PD sensitivity to a drug, the kinet-

ics of which are not altered in older patients. For example, docetaxel PK are not

1 2 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

altered in patients aged 65 or over, but they are much more likely to experience

grade 4 or febrile neutropenia than are younger patients [53]. Likewise, patients

aged over 65 years are twice as likely to experience severe diarrhea when treated

with irinotecan, although PK of irinotecan and SN-38 are similar to those in

younger patients [54].

The EMA and FDA have both published guidelines in support of studies in the

geriatric population, but with emphasis on phase III studies [55,56]. Given the

general principle that drugs should be studied in the patient groups in whom they

will subsequently be used, the major focus should be on including more older

patients in oncology phase I trials. There may also be an argument for carrying

out dose-finding trials in older, frailer patients classified or stratified according to one of the geriatric assessment tools [57,58].



6.4 OTHER POPULATIONS



The principle that study populations reflect the patients who would ultimately

receive a drug means that an appropriate proportion of male and female patients,

and also different ethnicities, should be included in phase I trials. However more

deprived patients, and those from ethnic minorities, are underrepresented in

early clinical trials [59].

Many later phase clinical trials are international, and it is not practical to con-

duct early clinical trials in each and every ethnic group. The EMA guidelines

(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_

guideline/2009/09/WC500002842.pdf) state that results from foreign clinical trials can comprise most, or in some cases, all of the clinical data package

for approval in the new region, as long as they are carried out according to

the requirements of that region; “bridging” data may be needed to extrapolate

safety and efficacy data between regions. Regulatory authorities may, however,

mandate clinical trials in their own ethnic population(s). A practical concern is

that obtaining informed consent, and provision of validated translated patient

information sheets, in a range of ethnic minorities can be difficult.



6.4.1 Patients with hematological malignancies

Hematological malignancies are diverse but have certain features in common.

Although phase I trials in hematological malignancies are similar to those in

patients with solid tumors, there are also differences.

Hematological malignancies are not common, and early-phase trials in spe-

cific patient groups will usually need to be multi-center and may be facilitated

Phase I Trials in Special Populations and Circumstances 125

by col aborative groups such as the Myeloma UK Early Phase Clinical Trial

Network. In hematological malignancies, bone marrow failure is often disease

related, and this may be reflected in eligibility criteria permitting substantially

lower blood counts than in solid-tumor phase I studies. Likewise, renal impair-

ment is frequently seen in multiple myeloma, and patients may be eligible with

a lower creatinine clearance than usual. Whereas patients who have undergone a

prior bone marrow transplant would usually be excluded from solid-tumor phase

I trials, that may not be the case in hematological malignancies.

Phase I trials in hematological malignancies follow similar solid-tumor stud-

ies, so they will incorporate prior knowledge experience in the study design,

including a higher starting dose than would otherwise be the case; this will often

result in there being fewer dose-escalation steps. Again, due to the nature of the

underlying disease, low blood counts may not constitute DLTs in phase I hema-

tology trials.

One of the key features of hematological malignancies is the easy availability

of tumor material from blood or bone marrow sampling, which facilitates trans-

lational studies. In terms of assessing efficacy, this is arguably less standardized

than the use of Response Evaluation Criteria In Solid Tumors (RECIST) and

will need to incorporate current guidelines.



6.4.2 Patients with intracerebral tumors

Primary brain cancers are uncommon, but represent a major unmet need, often

with poor outcomes despite aggressive local treatment with surgery and radio-

therapy, and only modest benefits from systemic treatment. Brain metastases are

more common, being reported in 10–15% of all patients with cancer [60].

Currently, although some phase I clinical trials include patients with brain

metastases [61] or primary brain cancers, most do not. This is often rationalized

by the inherently poor prognosis of many such patients. However, with improve-

ments in the treatment of primary and metastatic brain tumors, anticipated

survival may be more greater than three months [62]. Indeed, the outcome for

carefully selected patients with brain metastases in phase I studies may not be

inferior to that of those who do not have intracranial disease [61,63]. A second

concern has been that the blood–brain barrier may limit access of drugs to the

brain, but several studies have demonstrated efficacy of systemic agents. Other

challenges include the possibility of serious adverse events (SAEs) secondary

to the underlying disease, and the potential for drug–drug interactions with the

anticonvulsants that are prescribed for many such patients.

The inclusion of patients with primary brain cancers and brain metastases

in phase I trials is to be encouraged, given the need to identify effective new

1 2 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

treatments for diseases such as glioblastoma multiforme. Numerous prognostic

tools have been developed [64], with the recursive partitioning analysis (RPA)

being widely adopted [65], that can aid patient selection. Where otherwise eligi-

ble, specific eligibility criteria may exclude patients with a history of bleeding into the brain tumor(s) and untreated, symptomatic, or uncontrolled intracerebral

disease and require that the patient be on a stable or reducing dose of steroids.



6.5 INTERACTION STUDIES, INCLUDING

COMBINATION TRIALS



Anticancer drugs are often taken in combination, so it is important to demon-

strate the tolerability and dosing of new drugs in clinically relevant combina-

tions. Most cytotoxics are taken in combination with other chemotherapy, and

in the past these combinations could be developed empirically after regulatory

approval as a single agent. The increasing need for regulatory approval as a pre-

requisite for reimbursement is one factor making formal dose-finding studies of

combinations more important. Although biological or targeted therapies may

have activity given alone, the majority are also given in combination, either with

established cytotoxics or with other targeted therapies; combinations of novel

drugs with radiotherapy are also becoming increasingly relevant. The ethical and

practical issues surrounding the addition of a novel agent to an established drug

are quite distinct from those of FIH, single-agent phase I trials.

Food interaction and bioequivalence studies are becoming routine in the era

of oral cytotoxic and novel targeted drugs. There is also greater awareness of the

potential for interactions, not only between anticancer drugs, but also involving

other medications that may alter drug metabolism. Again, this may necessitate

specific trials early in the development of a new anticancer drug.



6.5.1 Food-effect studies



Although it is possible to predict from the chemical characteristics of a new com-

pound whether it is likely or not to be orally bioavailable, preclinical models do

not accurately predict the extent of absorption. Likewise, despite a large litera-

ture on the effect of food on drug absorption, there is no reliable way to predict

accurately its impact for a specific chemical entity. Such interactions may be clini-

cally important, as most anticancer drugs either have a low therapeutic index, in

the case of cytotoxics, or are administered over a prolonged period, especially

with biological agents. The FDA issued Guidance for Industry in 2002; these are

not, however, specific to oncology [66].

Phase I Trials in Special Populations and Circumstances 127



6.5.1.1 Background

There are several mechanisms by which food may affect drug absorption [67].

Food increases gastric pH, which may affect drug stability, and delays gastric

emptying. Bile flow and splanchnic blood flow are also increased after food

intake. There may also be a direct physical or chemical interaction between food

and the drug.

Food is likely to have its greatest effect when a drug is taken soon after eat-

ing. The nature of the meal, in terms of its calorific and nutrient content, com-

position, and volume, can also affect the nature and extent of any interaction.

Similarly, the physical–chemical characteristics of a drug and its dosage form will

influence the effect of food. Drugs that dissolve rapidly, are highly soluble and

highly permeable, may be less prone to food effects. By contrast, there is more

potential for food effects with intermediate-release or modified-release products

because of the greater complexity of drug dissolution and absorption.



6.5.1.2 Types of Study

There are three distinct types of food-effect study:

• Food-effect bioavailability studies are usually carried out with novel oral compounds to compare the rate and extent of absorption under fed and

fasting conditions. This can guide recommendations for administration

in subsequent trials, and also in general clinical use. Although it may be

convenient to administer a once-daily oral compound after an overnight

fast, if that compound subsequently needs to be given more frequently,

repeated fasting may not be feasible.

• A conventional bioavailability study may facilitate the development of an

oral formulation of an anticancer drug previously administered intra-

venously, by studying the pharmacokinetics after intravenous and oral

administration. This can establish whether there is clinically significant

absorption of the oral dose form ahead of a decision to pursue a full oral

development program. It can allow more rational selection of a starting

dose, based on oral bioavailability and comparison with the pharmaco-

kinetics and tolerability of the intravenous dose form, expediting the

oral phase I study.

• Finally, fed bioequivalence studies are performed to demonstrate that

a new oral formulation has bioequivalence with the standard oral

formulation.

For novel immediate-release and modified-release compounds, the FDA rec-

ommends that a food-effect bioavailability study be carried out early in devel-

opment to inform selection of formulations for further development. Both fed

1 2 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

and fasting bioequivalence studies are recommended for new formulations of

immediate-release and modified-release compounds. An exception is made for

immediate-release compounds under specific circumstances, such as the label

specifying administration only on an empty stomach, where a fasted-only study

may suffice.



6.5.1.3 Study Design

The optimal design of a food-effect study is a randomized, balanced, single-dose,

two-treatment, two-period, two-sequence crossover design. In each case there

must be an appropriate interval, determined from knowledge of pharmacokinet-

ics, for drug washout, between the two treatments:

• For a food-effect bioavailability study, subjects take a single dose of

drug under fed and fasted conditions, the sequence being determined

randomly.

• In a conventional bioavailability study, subjects receive a single dose of

the drug administered both intravenously and orally, ideally with the

sequence of administration randomized.

• For a fed bioequivalence study, the test and reference oral dose forms

are administered in randomized sequence following a test meal.

In each case, samples, usually plasma, are collected for characterization of phar-

macokinetics, the comparison of which between the two treatment periods

forms the basis for analysis.

It may be possible to incorporate bioavailability studies within a phase I trial.

For example, a patient may receive a single dose of study drug with and without

food on two successive weeks before starting regular oral dosing on the phase

I trial another week later. A conventional bioavailability study can be carried out

if a single oral dose is administered one week, a single intravenous dose a week

later, and then the phase I intravenous study commenced. The disadvantages of

such an approach include the possibility that toxicity may be seen during the

bioavailability part of the study, complicating dose escalation. This additional

complexity may theoretically impair or delay study recruitment; the additional

blood sampling may raise concerns from ethics committees. Nevertheless, this

approach has been used successfully to save time and expense. One compromise

may be to study bioavailability only at a limited number of dose levels. Regulatory

authorities wil , however, expect to see food-effect bioavailability data at the

doses intended to be marketed.

Eligibility criteria for these studies should specify that the patient is able to

take oral medication, is not vomiting, and has not undergone surgical resection

that may affect drug absorption nor has any other medical condition (such as

Phase I Trials in Special Populations and Circumstances 129

malabsorption) that would complicate interpretation of the study. It should, how-

ever, be remembered that where patients with upper gastrointestinal cancer may

be candidates for inclusion later in development, it may be important to know

whether absorption of the drug is affected by gastrectomy, bariatric surgery, or

pancreatectomy. The size of the study will depend on the anticipated magnitude

of any interaction, but empirically is generally anticipated to be a minimum of 12

subjects.

The FDA [66] recommends that food-effect studies be conducted with meals

that maximize the anticipated effects on gastrointestinal physiology, and hence

on drug exposure, rather than reflect the average breakfast. The recommended

meal is high in fat (which contributes approximately 50% of total calorie con-

tent) and calories (800–1000 calories). This corresponds to two eggs fried in

butter, two strips of bacon, two slices of toast with butter, four ounces (120 g) of

hash brown potatoes, and 8 ounces of whole milk (almost 250 ml). Other meal

compositions can therefore be used, although a scientific rationale for any major

deviation would be expected.

This meal specification has significant practical implications. Firstly, it will usu-

ally require that the patient have breakfast at the hospital, and perhaps be admit-

ted the night before. Secondly, close liaison with the hospital kitchen is needed

to ensure that the specifications are met. Thirdly, the recommended breakfast

is unlikely to represent the normal diet of patients with advanced cancer, even

those participating in a clinical trial. One compromise is to specify a “standard”

breakfast in the protocol; this may not match the stated FDA preference, but it

will more closely reflect reality and should be justified as such.

For both the “fasted” and “fed” studies, it is recommended that the overnight

fast be of at least 10 hours, with no food for at least 4 hours pre-dose or post-dose.

Water is allowed, but not in the hour before or after drug administration. For the

“fed” study, subjects should start their meal 30 minutes before drug administra-

tion, complete it in 30 minutes or less, and take the study drug 30 minutes after

the start of the meal. These restrictions may be inappropriate for patients with

cancer; any other drugs or fluids they need to take over the study period should

be recorded and the reason stated.

Timed samples, usually plasma, are collected for characterization of pharma-

cokinetics for the two treatment periods; i.e., with or without food (food-effect

bioavailability), intravenous and oral (conventional bioavailability), or two dif-

ferent oral dose forms (fed bioequivalence).

Definitions for the interpretation of the PK data are provided by the FDA,

based on the ratio of the mean PK parameters of the two treatment periods. For

example, food can be said not to have had an effect if the 90% confidence interval (CI) for the geometric means for this ratio, under fed and fasted conditions, falls

within the equivalence limits of 80–125% for AUC and C .

max

1 3 0

P H A S E I C A N C E R C L I N I C A L T R I A L S



6.5.1.4 Examples of Food-Effect Studies

The increasing number of oral anticancer drugs, both conventional cytotoxics

and targeted biological therapies, is making food-effect studies more important.

Where food does appear to have an impact on pharmacokinetics, this may not

translate into a clinically significant effect. For example, endocrine agents have a

wide therapeutic index, so the effect of food on exemestane kinetics is not clini-

cally important [68]. A selection of food-effect studies is shown in Table 6.6 [69–

71, 72–74, 99, 100].



6.5.2 Drug–drug interactions



Despite their narrow therapeutic index, and the many concomitant medications

taken by patients with cancer, surprisingly little attention has been paid to drug

interactions. In many cases, drug interactions are not identified during the initial

development of a drug but become apparent when it enters general clinical use.

Recently, more attention has been paid to differences in drug metabolism, and in

particular the role of the CYP P450 family of enzymes, as a source of inter-patient

variability in exposure. In most cases, the question will be whether the metabo-

lism of a novel anticancer drug is influenced by concomitant medications that

induce or inhibit its metabolism. On occasion, however, the new agent itself may

be a potential enzyme inducer or inhibitor, and a study may evaluate whether it

influences the metabolism of other drugs. Drug interactions in oncology were

reviewed in detail by Beijnen and Schellens [76].



6.5.2.1 Background

Where drug interactions are a concern, patients taking potential inducers/inhibi-

tors will most likely be excluded from the phase I trials. This is understandable,

but it has significant implications. First, the list of potential inducers and inhibitors is long and for many their clinical relevance unclear. Trial recruitment may

therefore be slowed unnecessarily if patents taking a long list of other medica-

tions are excluded. Secondly, this can lead to an RP2D being identified that has

not been tested in patients taking specific concomitant medication, who would

then be excluded from subsequent studies. It is important, therefore, that poten-

tial interactions be explored. In some circumstances, this may best be done by

including all patients, irrespective of concomitant medication, including the

medreactions as variables when evaluating toxicity, efficacy, and pharmacoki-

netics throughout the development process. Given the current level of concern

regarding drug interactions, this inclusive approach may be unattractive, so it is

important that specific drug interaction studies be carried out early in the devel-

opment process to establish whether or not interactions are clinically important.

Table 6.6. Selected Food-Effect Studies

Drugs

Study design

Outcome

Reference

Axitinib

2 separate open-label randomized,

AUC was decreased by 23% with food for Form IV

Pithavala et al., 2012 [73].

single-dose, three-period, crossover

and increased by 19% with food for the Form XLI.

design, comparing Forms IV and XLI.

C was increased by 11% for the Form XLI.

max

5 mg of axitinib in 18 patients to compare High-fat, high calorie meal: Form XLI AUC 19%

fed-vs-fasted states and 24 patients to

increase and C 11% increase.

max

look at effect of timing of food con-

Moderate fat, standard calorie meal: Form XLI AUC

sumption on axitinib pharmacokinetics.

10% lower and C 16% lower.

max

Conclusion: Axitinib can be administered with or

without food.

Cediranib

60 patients randomized to 2 single doses Plasma AUC and C of cediranib were lower in the Mitchell et al., 2011 [71].

max

of cediranib in fed-fast or fast-fed

presence of food by a mean of 24% and 33% (94%

cohorts.

CI: AUC, 12–34% and C max, 20–43%).

Conclusion: Food reduces cediranib plasma exposure.

Cediranib should be administered at least 1 hour

before or 2 hours after food.

Pazopanib

Open-label randomized, crossover, phase C and AUC were increased 2-fold by high- and Heath et al., 2010 [69].

max

I design. Single dose of pazopanib.

low-fat meal. Conclusion: Pazopanib should be

Patients randomized to 400 mg of

dosed in fasted state.

pazopanib in high-fat meal or 800 mg

in fed condition (high- or low-fat meal)

or fasting condition, random sequence

14 days apart.

( continued)

Table 6.6 (Continued)

Drugs

Study design

Outcome

Reference

Capecitabine

Two-way crossover design in 11 patients PK of capecitabine, and its metabolites all alterd by Reigner et al., 1998 [99]

with PK on day 1 and 4, randomly allo-

food. C and AUC were lower after food, the effects

max

cated as fed or fasted.

being greatest on capecitabine and substantially less

on the immediate precursor of 5-FU (5′-DFUR).

Recommended that capecitabine be dosed with food.

Vismodegib

Randomized, single-dose, food-effect

Mean C ratio = 1.75 (90% CI = 1.30, 2.34) and

Sharma et al., 2013 [74].

max

study. Patients randomized to fasting

mean AUC ratio = 1.74 (90% CI = 1.25, 2.42), com-

(n = 25) and fed (n = 27) states, and

paring high-fat and fasted states.

also allocated to high-fat (n = 20),

Conclusion: Vismodegib may be taken with or with-

low-fat (n = 18) and fasted (n = 22)

out food for daily dosing.

states.

All patients received a single dose of

vismodegib 150 mg OD.

Selumetinib

Open-label, randomized crossover

In the presence of food, the C was reduced by 62% Leijen et al., 2011 [70].

max

design, looking at food-effect.

and the AUC was reduced by 19%. The drug was wel

Fed-fast cohort: n = 15

tolerated.

Fast-fed cohort: n = 16

Conclusion: Food reduces the absorption of selu-

Single dose of selumetinib 75 mg was

metinib, and therefore it should be taken on an

given on days 1 and 8.

empty stomach.

Lapatinib

Open-label, randomized crossover

Low-fat breakfast increased the AUC by 2.67-fold and Koch et al., 2009 [100].

design, looking at food-effect. n = 27.

the C 2.42-fold. High-fat breakfast increased the

max

Lapatinib dosed at 1500 mg.

AUC by 4.25-fold and the C by 3.03-fold.

max

Cohort 1: overnight fast

Given the variability in fed state, lapatinib should be

Cohort 2: low-fat breakfast

dosed in fasted state.

Cohort 3: high-fat breakfast

Phase I Trials in Special Populations and Circumstances 133

The CYP P450 family is involved in the metabolism of many established anti-

cancer drugs. These enzymes are located primarily in the liver, where they are

responsible for much hepatic drug clearance, but also within the gut mucosa,

where they can influence drug absorption.

CYP3A4 appears to be the most important isoform and has been the most

widely studied. Its activity varies by as much as 20-fold, not only due to genetic

polymorphisms but also because it can be inhibited or inducted by concomitant

medications. The activity of CYP P450 can be measured indirectly, using the

clearance of a “probe” that is known to be metabolized by the specific isoform

[77]. For example, after administering a trace dose of 14C radiolabeled erythromy-

cin, the exhaled isotope reflects hepatic metabolism of erythromycin by CYP3A4.

Docetaxel is metabolized by CYP P4503A, and its activity, determined by the

erythromycin breath test, correlates with docetaxel clearance [53]. Another

CYP3A4 probe, a hydrocortisone metabolite excreted in the urine, has been used

prospectively to individualize docetaxel doses and reduce PK variability [78].

Many drugs can inhibit or induce CYP3A4 (see Table 6.7 for a list of commonly

used agents), with the potential to significantly increase or decrease exposure to

an anticancer drug metabolized by CYP3A4. To study potential interactions, an

inducer and/or inhibitor of CYP3A4 may be given on separate occasions along

with the study drug, and the pharmacokinetics of the study drug evaluated.



6.5.2.2 Types of Study

The FDA updated its Guidance for Industry in 2012 [79]. This emphasis the role

of in vitro studies in identifying the clinical studies that should be undertaken.

Table 6.7. Examples of Selected Inducers

and Inhibitors of Cyp450 Isoenzyme*

Inhibitors

Amiodarone

Itraconazole

Clarithromycin

Ketoconazole

Erythromycin

Omeprazole (weak)

Fluconazole

Metronidazole

Fluoxetine

Miconazole

Grapefruit juice

Nefazodone

Cranberry juice

Norfloxacin

Inducers

Carbamazepine

Sertraline

Cotrimoxazole

Phenobarbitol

Dexamethasone

Phenytoin

Methadone

Rifabutin

Metyrapone

Rifampicin

* Please note, this list is not exhaustive

1 3 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

At a later stage in development, once a drug is in clinical use, detailed popula-

tion PK analyses may help characterize known interactions or identify previously

unknown interactions or genotypic variations.

Clinical studies of inhibitors/inducers of a particular CYP P450 enzyme sys-

tem are not needed if that enzyme does not metabolize in vitro the novel anticancer drug under consideration. In contrast, where studies in vitro do show the anticancer drug to be metabolized by CYP P450, clinical studies with inhibitors/

inducers of that particular enzyme system are required to quantify the poten-

tial importance of interactions. Similarly, clinical studies to assess the impact of a novel anticancer drug on the metabolism of other drugs would be indicated only

if an effect had been demonstrated in vitro on drug metabolizing enzymes.

Drug interaction studies can have different designs, but all are based on com-

paring the pharmacokinetics of the study drug in the presence and absence of an

enzyme inhibitor/inducer.

• The study drug may be given to the same patient on two occasions,

with and without the inducer/inhibitor, the sequence either being

randomized or not (randomized and one-sequence crossover designs,

respectively).

• Two separate populations, one receiving the study drug alone and the

other the study drug and inducer/inhibitor, may be studied (a parallel

design).

Such studies have similarities to the food-effect studies described above, but are

likely to be more complex. First, the enzyme inducer/inhibitor must be given

for a sufficiently long time, and at an adequate dose, to achieve its desired effect

before assessing its impact (or otherwise) on the pharmacokinetics of the study

drug; enzyme inducers usually take longer to exert their effect than inhibitors.

Where appropriate, there needs to be an adequate washout period between the

two study treatments to allow clearance of the study drug and also for the effects

of the inducer/inhibitor to resolve. Single doses of the study drug will often

be the clinically relevant mode of administration and has practical advantages;

where the therapeutic index is narrow there is a risk of toxicity unless the study

drug dose is modified. Prolonged administration of an oral study drug, to achieve

steady state before administration of the inhibitor/ inducer, may reflect its clini-

cal use but is likely to result in a long and cumbersome study.

Because of their complexity, the need for extensive blood sampling, and the

expectation that the inhibitor/inducer will significantly alter drug exposure, drug

interactions are evaluated in specific studies rather than within other early trials.

The size of the study will depend on the anticipated magnitude of any interac-

tion, but is generally at least 12 subjects.

Phase I Trials in Special Populations and Circumstances 135

A wide range of drugs can act as inducers or inhibitors. Not all are, how-

ever, equally potent. Initial studies would usually be carried out with inducers/

inhibitors that are both specific and potent. For example, with CYP3A4, keto-

conazole is accepted as an appropriate enzyme inhibitor and rifampicin as an

inducer. If they fail to modify metabolism of the study drug, it is reasonable

to conclude there is no significant interaction via CYP3A4. Should an interac-

tion with a potent induce/inhibitor be demonstrated, it does not follow that less

potent or less specific inducers/inhibitors would have the same effect. Hence,

specific studies with concomitant medications of particular interest (e.g., phe-

nytoin where the study drug may be used in patients with brain tumors) may be

appropriate.

Where the question being asked is whether the novel agent itself acts an

enzyme inducer/inhibitor, the probe will be determined by the enzyme sys-

tem in question. For example, midazolam and erythromycin are metabolized by

CYP3A4 in the liver and liver/gastrointestinal tract, respectively. Other potential

probes include theophyl ine (for CYP1A2), S-warfarin (CYP2C9), and desipra-

mine (CYP2D6).

Pharmacokinetics are characterized for the two treatment periods; i.e., with

and without the inducer/inhibitor. These can be expressed as the ratio of the

mean PK parameters with 90% CIs. The interpretation of any apparent differ-

ences will be influenced not only by the magnitude of that effect, but also by the

pattern of toxicity, therapeutic index, and PD relationships of the study drug.



6.5.2.3 Examples of Drug Interaction Studies

Most of the important CYP isoenzymes can be induced by corticosteroids

and anticonvulsants. Interactions have also been reported between warfarin

and several cytotoxics. Warfarin is metabolized by the CYP450 system but is

also highly protein bound. Competition either for CYP metabolism on pro-

tein binding sites may explain these interactions.



6.5.3 Combination phase I/dose-finding trials



Most anticancer drugs are given in combination, and historically these combina-

tions were derived empirically. However, regulatory requirements are increasing,

and there is often now a need for a drug to be approved for a specific indication in

a particular combination for reimbursement. Examples of combination studies are

shown in Table 6.8 [80–83, 101]. In addition, there is the hope that new, targeted,

rationally designed anticancer drugs will be used with existing agents in a more logical manner. These pressures and expectations have led to an increasing emphasis

on specific phase I trials of two- or three-drug combinations, and of new agents in

Table 6.8. Drug Combination Studies

Drugs

Study design

Outcome

Reference

Sorafenib and

Everolimus 10 mg continuous dosing.

Cohort 1: 1 DLT

Chan et al.,

everolimus

Sorafenib—Cohort 1: 200 mg BD; Cohort 2: 200 mg

Cohort 2: 3 DLTs

2013 [81].

mane, 400 mg nocte.

Recommended doses for further study:

Pharmacokinetics not assessed.

Everolimus 10 mg OD

Sorafenib 200 mg BD

Vinblastine and

Phase I dose-escalation study.

Variable inter-patient relationship between dosing and concen-

Morgenstern

sirolimus

Sirolimus PO daily (adjusted to achieve serum trough

tration of sirolimus, particularly between nasogastric and oral

et al., 2013

pediatric study

concentration of 10–15 nM; Initial loading dose of

MTD and recommended dose:

[83].

0.42 mg/kg, followed by maintenance of 0.14 mg/kg,

sirolimus dose to target of 10–15 nM.

max daily dose 8 mg).

Vinblastine 6 mg/m2 IV weekly.

Vinblastine IV weekly— Cohort 1: 4 mg/m2;

Cohort 2: 5 mg/m2;

Cohort 3: 6 mg/m2. Pharmacokinetics not assessed.

Everolimus and

Temozolomide 150 mg/m2 PO days 1–7, days 15–21.

Recommended dose:

Chan et al.,

temozolomide

q28 days.

Temozolomide 150 mg/m2 PO days 1–7, days 15–21.

2013 [80].

pancreatic

Everolimus

Everolimus 10 mg daily.

neuroendocrine

Cohort 1: 5 mg PO daily (n = 7);

tumor

Cohort 2: 10 mg PO daily (n = 36).

Pharmacokinetics not assessed.

Vorinostat and

Phase I study—rol ing 6 design. Vorinostat—

DLT of myelosuppression

Hummel et al.,

temozolomide

Cohort 1: 230 mg/m2/day; Cohort 2: 300 mg/m2/day; Recommended dose:

2013 [82].

pediatric study

Cohort 3: Vorinostat 300 mg/m2/day and temozolo-

Vorinostat 300 mg/m2/day D1–5 q28 days

mide -150 mg/m2 days 1–5 q28days for cohorts 1

Temozolomide 150 mg/m2/day D1–5 q28 days

and 2; and 200 mg/m2 days 1–5 q28 days for cohort

3. n = 19. Pharmacokinetic assessments performed.

Dabrafenib and

Phase I/II study—n = 247.

Dabrafenib and trametinib were safely combined at full mono-

Flaherty et al.,

trametinib

Cohort 1: Dabrafenib 150 mg BD and Trametinib

therapy doses. Rate of pyrexia was increased with combina-

2012 [101].

melanoma study

1 mg or 2 mg daily.

tion therapy, whereas the rate of proliferative skin lesions

Cohort 2: Dabrafenib 150 mg BD.

was non-significantly reduced. Combination dose of 150

Pharmacokinetic assessments performed.

mg/2 mg was chosen for ongoing study, as increase in pyrexia

was manageable with low-dose glucocorticoids, and usually

occurred outside the 21-day DLT period.

Phase I Trials in Special Populations and Circumstances 137

combination with radiotherapy. They can be categorized as (a) novel cytotoxic and

established cytotoxic (or radiotherapy); (b) novel “biologic” and established cyto-

toxic (or radiotherapy); and (c) novel “biologic” and established or novel “biologic.”

There are important differences between first-in-human phase I trials and

combination phase I trials. The implications, in terms of stage of disease, sub-

sequent treatment options, and prognosis, may be quite different for patients

entering the two types of phase I trial. For example, FIH are usually carried out

in those who have exhausted standard therapies whereas this is often not the case

for combination phase I trials. Indeed, it may be unhelpful to use the term “phase

I trial” in the context of a combination study because of its implications; the term

“dose-finding” may be more appropriate. Combination trials are described here

because an important aim of these studies is to identify potential interactions

between the novel and established agents.



6.5.3.1 Background

Combination phase I studies have similarities to, but also significant differences

from, the FIH studies described in Chapter 3; this section will concentrate on

these differences. The most crucial difference is that almost always the novel

agent will have undergone a classical phase I trial prior to the combination stud-

ies. Hence, there is already at least some knowledge of dose, toxicity, pharma-

cokinetics, and antitumor activity for the new agent; the established drugs with

which it is being combined will usually have completed their development and

be well characterized. The same applies where two “novel” agents are combined

in that each will usually have been studied as a single agent.

The ideal combination is one that is based on the mechanisms of action of the

two drugs, with preclinical evidence of synergy, activity of both drugs as single

agents, and an absence of overlapping toxicities. In practice, agents are often com-

bined empirically based on clinical experience, preclinical studies, and pragma-

tism. Study design is also largely based on existing clinical experience, although

sequence of administration may be influenced by preclinical data.

Combination phase I studies may be carried out as stand-alone trials, espe-

cially where there is clear potential for overlapping toxicities. In other circum-

stances, a phase II trial of a novel combination may include an initial cohort(s)

in whom tolerability of the combination is confirmed. This will require modi-

fications compared to a standard phase II protocol, including more detailed

monitoring, sequential enrollment of patients, and review after an initial cohort

(frequently of six patients) has been treated. This initial dose-finding element of

the study is usually best conducted at a limited number of sites with experience

of phase I trials before opening the study up to other sites once the RP2D of the

combination has been determined.

1 3 8

P H A S E I C A N C E R C L I N I C A L T R I A L S



6.5.3.2 Aims

In common with classic phase I trials, the primary aim is to define a RP2D, here

for a new drug in combination with established treatment. Pharmacokinetics,

which are invariably central to first-in-man studies, are not always included in

combination trials. Antitumor activity is usually assessed in these studies, often

in the hope of identifying a “signal” for the efficacy of the combination.



6.5.3.3 Study Design



Starting dose and dose escalation

Starting doses will take into account the single-agent doses of each agent and

their individual toxicities. Caution should be exercised if there are overlapping

toxicities such as skin rash and diarrhea (especially in the case of tyrosine kinase

inhibitors) or myelosuppression (usually with cytotoxics). Trial design could

include starting at 50% of each MTD and incrementally increasing the dose of

one drug at a time (see Figure 6.1A). For some targeted or biological drugs, there

may be clear evidence that a certain dose or plasma concentration is required

to achieve the biological effect, in which case the minimal biologically active

dose may be selected as the starting dose for a combination study. Conversely,

if the “standard” drug, typically a cytotoxic, is clearly active and that activity is thought to be closely related to dose, it may be used at full dose, while increasing

the dose of the novel agent (see Figure 6.1B). In either case, the starting doses of

both elements of the combination will be relatively higher than in a single-agent

FIH trial, so usually there are fewer dose levels. Once a RP2D has been deter-

mined, serious consideration should be given to confirming tolerability in an

expanded cohort of patients. Failure to do so in the phase I study of docetaxel

A

B

B

B

ug

ug

Dose of Dr

Dose of Dr

Dose of Drug A

Dose of Drug A

Figure 6.1 Dose-escalation strategies for combination studies. (A) Drug A and Drug B

each have run-in doses and then the dose of drugs is incrementally increased one at a time.

(B) Drug B is known to be clearly active and therefore it is fixed at the effective dose. The dose of Drug A is incrementally increased. Again, each drug has a run-in dose.

Phase I Trials in Special Populations and Circumstances 139

and capecitabine may explain, in part, why the combination was not well toler-

ated in subsequent studies [84]; there have been similar experiences combining

targeted agents. An alternative to reducing both drugs if overlapping toxicity is

seen would be to change the schedule of one or both drugs to give them intermit-

tently or sequentially.



Patient eligibility

Many of the eligibility criteria for FIH phase I trials will apply, such as perfor-

mance status, life expectancy and organ function. Since, however, most com-

bination phase I trials comprise a novel and a standard therapy, a population

less heavily pretreated than in single-agent FIH studies may be appropriate.

For example, eligible patients might be those in whom the standard element of

the combination would be appropriate, as well as those for whom there is no

proven effective treatment. Likewise, in terms of tumor types that are eligible,

this may be determined by the standard element of the combination and/or

expression of the molecular target for the novel agent. If restricting eligibility

in this way is seen as a major obstacle, it may be appropriate to have broader

eligibility during dose escalation but restrict eligibility for the expanded RP2D

cohort. Where eligibility specifies particular tumor types, and/or patients with

less advanced disease are being treated, the referral pathways will be different

from those for FIH single-agent studies, and there will need to be close liaison

between the early trials team and site-specific oncologists.



Toxicities

The definition of DLT and RP2D will be similar to that in FIH studies, but

an additional challenge is the attribution of toxicities to the individual com-

ponents of a combination. Where their respective toxicities are distinct and

characteristic, this may not be a problem; where, however, toxicities overlap

or are less specific (e.g., fatigue), attribution can be difficult. Appropriate attribution of toxicities is important, as it will determine dose modifications in

the patient(s) experiencing the toxicity and will also affect decisions about

subsequent dose levels.

Until relatively recently, the expectation had been that combining

non-cytotoxics would be relatively straightforward. In some cases this has been

so, although even with trastuzumab the issue of cardiotoxicity only emerged in

phase III trials. Experience is, however, showing that such combinations can also

be problematic and that doses need to be carefully defined.



Pharmacokinetics

Where there are reasons to think there may be a PK interaction between the

two drugs, detailed PK assessment is mandatory. In other situations, there is an

1 4 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

argument for at least some PK evaluation as this, lest any unexpected toxicities

are seen. To compare them for PK interactions, ideally two separate run-in doses

of drugs need to be given during a day -7 to -14 window, and PK samples need to

be taken, then again when both drugs are given together.



Efficacy

Combination phase II studies will often mandate measurable disease, some-

times only in the expanded RP2D cohort, and systematic evaluation of effi-

cacy in the hope of identifying a “signal” of enhanced efficacy. Since these

studies usually combine the novel agent with another that has proven effi-

cacy, and patients often have cancers more likely to respond than in other

FIH studies, objective responses may well be seen and indeed expected. It is,

however, much more difficult to attribute such efficacy to the novel agent or

synergies within the combination, so responses need to be interpreted with

caution.



6.5.3.4 Combinations with Radiotherapy

Early clinical trials of novel radiotherapy modalities (e.g., photons), techniques

(e.g., stereotactic ablative radiotherapy), and fractionation are beyond the scope

of this book. The combination of novel targeted or cytotoxic therapies with

radiotherapy is, however, relevant.

Guidelines for preclinical and early-phase clinical evaluation of novel radio-

sensitizers have been published that highlight differences between studies

combining drugs and those where radiotherapy is involved [85]. Initial “proof

of principle” and preliminary safety data may be obtained combining a novel

agent with palliative radiotherapy to bone metastases, and brain, lung, or skin

lesions. Much radiotherapy is, however, given in the context of early-stage,

curable disease; it is to be expected, therefore, that the combination will need

to be evaluated in a phase I trial in the relevant population receiving appro-

priate radiotherapy. However, conducting radiotherapy combination trials in

patients with early-stage disease carries the risk of toxicity, leading to omis-

sion or modification of planned radiotherapy that may adversely affect clinical

outcomes.

As in other combination trials, there would usually be information on the

side-effect profile of the novel systemic agent when given alone that will inform

the starting dose in a trial in combination with radiotherapy. Dose escalation can

be along conventional lines, with successive cohorts of patients receiving increas-

ing doses of the study drug throughout the duration of radiotherapy; the sys-

temic agent may or may not be administered on days without radiotherapy; e.g.,

weekends. Alternatively, the dose of the systemic agent may be the same but the

duration of treatment increased in successive patient cohorts.

Phase I Trials in Special Populations and Circumstances 141

The definition of DLTs may also differ in radiotherapy combination trials.

In phase I trials of systemic therapies, non-proliferative toxicities of grade 3 or

greater generally constitute a DLT, but grade 3 stomatitis or diarrhea may be

considered routine during radiotherapy. Moreover, it may be difficult to assess

whether a toxicity is greater than would be expected in the absence of the sys-

temic agent. The duration over which toxicities are observed is also different

with radiotherapy. A course of radiotherapy may last several weeks, with the

recovery period adding additional weeks, so it may not be possible to fully eval-

uate acute toxicities for up to three months, resulting in slow recruitment and

prolonged gaps if conventional trial designs are used. Late toxicities, occurring

months or years later, can be seen with radiotherapy, and it is not practical to

include their assessment during dose escalation in a phase I combination trial.

Because radiotherapy toxicities relate largely to the site of irradiation, toler-

ability of a systemic treatment in combination with radiotherapy may only be

defined for that particular site of irradiation.

The problems of slow recruitment can be mitigated by the use of continuous

reassessment methods or adaptive dose-finding. A “flip-flop” study design has

also been advocated to expedite recruitment. In this situation, two or more radio-

therapy combination studies are open at the same time. A cohort of patients is

entered onto one study, and while recruitment is suspended to evaluate toxic-

ity, the next series of patients enters another study. Successive cohorts “flip-flop”

between the studies, maintaining recruitment. This approach has been used, but

it requires simultaneous studies in the same patient group; over a fixed period

of time two (or more) studies may be completed, but the duration of each indi-

vidual study will not be truncated.



6.6 CONCLUSION

Phase I studies, and subsequent registration studies, are often carried out

in patient populations that exclude patients with organ impairment and the

extremes of age, although each group is important in clinical practice. Specific

phase I trials will often be needed in these special populations at an appropriate

stage of their development, and guided by an understanding of the pharmacol-

ogy of the new agent and the clinical context of its anticipated use. In addition,

patients with cancer often have comorbidities necessitating taking other medi-

cations, and potential drug interactions need to be evaluated in a trial settings.

Likewise, many novel agents will be evaluated and ultimately used in combina-

tion with other anticancer treatments (cytotoxic, targeted, and/or radiotherapy),

so it is important to establish a manner in which they can be safely and effectively

combined.

1 4 2

P H A S E I C A N C E R C L I N I C A L T R I A L S



REFERENCES

1. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol. 1996;14(1):257–267.

2. Twelves CJ, Dobbs NA, Michael Y, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer. 1992;66(4):765–769.

3. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacody-

namics of docetaxel in phase II studies in patients with cancer. J Clin Oncol.

1998;16(1):187–196.

4. EMA. Note for guidance on the evaluation of the pharmacokinetics of medicinal

products in patients with impaired renal function. 2004. Available at http://www.

emea.eu.int. Accessed October 1, 2013.

5. EMA. Guidelines on the evaluation of the pharmokinetics of medicinal products in

patients with impaired hepatic function. 2005. Available at http://www.emea.eu.int.

Accessed October 1, 2013.

6. FDA. Guidance for industry: Pharmacokinetics in patients with impaired renal

function—study design, data analysis, and impact on dosing and labeling. 2010.

Available at http://www.fda.gov/. Accessed October 1, 2013.

7. FDA. Guidance for industry: Pharmacokinetics in patients with impaired hepatic

function: study design, data analysis, and impact on dosing and labeling. 2003.

Available at http://www.fda.gov/. Accessed October 1, 2013.

8. NCI organ dysfunction guidelines, 2011. Available at http://www.ctep.cancer.gov.

Accessed October 1, 2013.

9. Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: specific

aspects of acute renal failure in cancer patients. Crit Care. 2006;10(2):211.

10. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008;9(11):1092–1101.

11. Horak J, White J, Harris AL, et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemo Pharmacol. 2011;68(6): 1485–1495.

12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.

Nephron. 1976;16(1):31–41.

13. Jel iffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med.

1973;79(4):604–605.

14. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of

glomerular filtration rate in cancer patients. Br J Cancer. 2001;84(4):452–459.

15. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jel iffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol.

2004;15(2):291–295.

16. Figg WD, Dukes GE, Lesesne HR, et al. Comparison of quantitative methods to

assess hepatic function: Pugh’s classification, indocyanine green, antipyrine, and

dextromethorphan. Pharmacotherapy. 1995;15(6):693–700.

17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Wil iams R. Transection of

the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649.

18. Gil ies HC, Rogers HJ, Ohashi K, Liang R, Harper PG, Rubens RD. Correlation

between elimination of indocyanine and doxorubicin or idarubicin. Proc Am Soc Clin Oncol. 1986;5:56.

Phase I Trials in Special Populations and Circumstances 143

19. Dobbs NA, Twelves CJ, Rizzi P, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemo Pharmacol. 1994;34(5):405–410.

20. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic

dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.

21. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5(7):1696–1702.

22. Takimoto CH, Saif MW, Lorusso PM, et al. A pharmacokinetic (PK) dose escalation

study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: a com-

parison of the NCI hepatic dysfunction criteria and the Child-Pugh classification.

J Clin Oncol. 2014;22(14S):2017.

23. Patel H, Egorin MJ, Remick SC, et al. Comparison of Child-Pugh (CP) cri-

teria and NCI organ dysfunction working group (NCI-ODWG) criteria for

hepatic dysfunction (HD): implications for chemotherapy dosing. J Clin Oncol, 2004;22(14S):6051.

24. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmaco-

kinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest

New Drug. 2001;19(2):163–169.

25. Curigliano G, Spitaleri G, Fingert HJ, et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J

Cancer. 2008;44(4):494–500.

26. Guidance for industry E14: Clinical evaluation of QT/QTc interval prolongation

and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Accessed October

1, 2013.

27. Weitman S, Carlson L, Pratt CB. New drug development for pediatric oncology.

Invest New Drug. 1996;14(1):1–10.

28. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8(12):3646–3657.

29. Woods WG, O’Leary M, Nesbit ME. Life-threatening neuropathy and hepatotoxic-

ity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr.

1981;98(4):642–645.

30. McLeod HL, Rel ing MV, Crom WR, et al. Disposition of antineoplastic agents in

the very young child. Br J Cancer. Suppl, 1992;18:S23–S29.

31. Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD. Tolerance

to antineoplastic agents in children and adults. Cancer Treat Rep. 1985;69(11): 1263–1269.

32. Von Hoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol. 1998;25(4 Suppl 10):31–36.

33. Col ins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings

from a meta-analysis. J Clin Oncol. 20, 2013;31(18):2303–2312.

34. FDA. Guidance for industry: Pediatric study plans—content of and process for

submitting initial pediatric study plans and amended pediatric study plans. 2013.

Available at http://www.fda.gov. Accessed October 1, 2013.

35. Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. 2007. Available at http://www.ema.europa.eu/docs/. Accessed October 1, 2013.

1 4 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

36. FDA briefing document. 2012. Available at http://www.fda.gov/. Accessed October 1, 2013.

37. Shah S, Weitman S, Langevin AM, Bernstein M, Furman W, Pratt C. Phase I therapy

trials in children with cancer. J Pediatr Hematol Oncol. 1998;20(5):431–438.

38. Molife LR, Alam S, Olmos D, et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol.

2012;23(8):1968–1973.

39. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987;60(7):1651–1656.

40. Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in

children: the development of a pediatric dosing formula. The United Kingdom

Children's Cancer Study Group. J Clin Oncol. 1993;11(12):2314–2323.

41. Cel a M, Knibbe C, Danhof M, Del a Pasqua O. What is the right dose for children?

Br J Clin Pharmacol. 2010;70(4):597–603.

42. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid

tumors. J Clin Oncol. 1993;11(3):554–560.

43. Vassal G, Pein F, Gouyette A, et al. Development of new anticancer agents in children: methodology, difficulties and strategies. Ann Pediatr. 1994;41:477–484.

44. Fern L, Davies S, Eden T, et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the

National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical

Studies Development Group. Br J Cancer 16, 2008;99(12):1967–1974.

45. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in

elderly patients. J Clin Oncol 1999;17(11):3569–3576.

46. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous

5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–575.

47. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin

Oncol. 2005;23(10):2155–2161.

48. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemo Pharmacol. 2002;49(3):225–234.

49. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be

a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10(3):198–204.

50. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer.

J Support Oncol. 2003;1(4 Suppl 2):18–24.

51. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Performance status rather than

age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer. 2002;94(7):1961–1967.

52. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med.

1986;80(3):435–442.

53. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol, 2005;23(6): 1070–1077.

Phase I Trials in Special Populations and Circumstances 145

54. Pitot HC, Goldberg RM, Reid JM, et al. Phase I Dose-finding and pharmacokinetic

trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dos-

ing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res.

2000;6(6):2236–2244.

55. EMA. ICH Topic E 7—Studies in support of special populations: Geriatrics. 1994.

Available at http://www.emea.eu.int. Accessed October 1, 2013.

56. FDA. Guideline for industry—Studies in support of special populations: Geriatrics ICH-E7. Available at http://www.fda.gov. Accessed October 1, 2013.

57. Aapro MS. The frail are not always elderly. J Clin Oncol. 2005;23(10):2121–2122.

58. Baka S, Ashcroft L, Anderson H, et al. Randomized phase II study of two gem-

citabine schedules for patients with impaired performance status (Karnofsky per-

formance status </ = 70) and advanced non-small-cell lung cancer. J Clin Oncol.

2005;23(10):2136–2144.

59. Mohd Noor A, Sarker D, Vizor S, et al. Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol 10, 2013;31(2):224–230.

60. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases

in solid-tumor patients: natural history and results of treatment. Cancer. 1981; 48(2):384–394.

61. Tsimberidou AM, Letourneau K, Wen S, et al. Phase I clinical trial outcomes in 93

patients with brain metastases: the MD Anderson Cancer Center experience. Clin

Cancer Res. 2011;17(12):4110–4118.

62. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.

63. Carden CP, Agarwal R, Saran F, Judson IR. Eligibility of patients with brain metastases for phase I trials: time for a rethink? Lancet Oncol 2008;9(10):1012–1017.

64. Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int.

2013;4(Suppl 4):S192–S202.

65. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive par-

titioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47(4):1001–1006.

66. Food-effect bioavailability and fed bioequivalence studies. 2002. Available at: http://

www.fda.gov/downloads/RegulatoryInformation/Guidances/. Accessed October 1, 2013.

67. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anti-

cancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinetics. 2004;43(15):1127–1156.

68. Valle M, Di Salle E, Jannuzzo MG, et al. A predictive model for exemestane phar-

macokinetics/pharmacodynamics incorporating the effect of food and formulation.

Br J Clin Pharmacol. 2005;59(3):355–364.

69. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(6):818–823.

70. Leijen S, Soetekouw PM, Jeffry Evans TR, et al. A phase I, open-label, random-

ized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor

selumetinib (AZD6244; ARRY-142866) in the presence and absence of food

1 4 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

in patients with advanced solid tumors. Cancer Chemo Pharmacol. 2011;68(6):

1619–1628.

71. Mitchell CL, O'Connor JP, Roberts C, et al. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemo Pharmacol. 2011;68(3):631–641.

72. Oostendorp RL, Loftiss J, Goel S, et al. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2009;47(3):195–206.

73. Pithavala YK, Chen Y, Toh M, et al. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemo Pharmacol.

2012;70(1):103–112.

74. Sharma MR, Karrison TG, Kell B, et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013;19(11): 3059–3067.

75. Ware J, Dalziel G, Jin JY, et al. Impact of food and the proton pump inhibitor rabepra-zole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside

investigation of pH-dependent solubility. Mol Pharmaceut. 2013.

76. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5(8): 489–496.

77. Streetman DS, Bertino JSJ, Nafziger AN. Phenotyping of drug-metabolizing

enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Pharmacogenetics Genom. 2000;10(3):187–216.

78. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacokinetic and

pharmacodynamic study of docetaxel: dosing based on body-surface area com-

pared with individualized dosing based on cytochrome P450 activity estimated

using a urinary metabolite of exogenous cortisol. J Clin Oncol, 2005;23(6):

1061–1069.

79. Guidance for industry: Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. Available at: http://www.

fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/.

Accessed October 1, 2013.

80. Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Cancer. 2013;119(17):3212–3218.

81. Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study

of sorafenib in combination with everolimus (RAD001) in patients with advanced

neuroendocrine tumors. Cancer Chemo Pharmacol. 2013;71(5):1241–1246.

82. Hummel TR, Wagner L, Ahern C, et al. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a

Children's Oncology Group phase I consortium study. Pediatr Blood Cancer.

2013;60(9):1452–1457.

83. Morgenstern DA, Marzouki M, Bartels U, et al. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2014;61(1):128–133.

Phase I Trials in Special Populations and Circumstances 147

84. Vasey PA, Roche H, Bisset D, et al. Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Br J

Cancer. 4, 2002;87(10):1072–1078.

85. Harrington KJ, Bil ingham LJ, Brunner TB, et al. Guidelines for preclinical

and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 23, 2011;105(5):628–639.

86. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients

with impaired renal function. Cancer. 15, 2010;116(16):3807–3814.

87. Leal TB, Remick SC, Takimoto CH, et al. Dose-escalating and pharmacologi-

cal study of bortezomib in adult cancer patients with impaired renal function: a

National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemo

Pharmacol. 2011;68(6):1439–1447.

88. Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study

of imatinib mesylate in patients with advanced malignancies and varying degrees

of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction

Working Group. J Clin Oncol, 2008;26(4):570–576.

89. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of

sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol.

2009;27(11):1800–1805.

90. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of suni-

tinib malate in subjects with impaired renal function. J Clin Pharmacol.

2010;50(4):472–481.

91. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007;25(21):3055–3060.

92. Devriese LA, Witteveen PO, Marchetti S, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemo Pharmacol.

2012;70(6):823–832.

93. Takimoto CH, Liu PY, Lenz H, et al. A phase I pharmacokinetic (PK) study of

the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with

advanced malignancies and varying degrees of hepatic impairment. A SWOG Early

Therapeutics Committee and NCI Organ Dysfunction Working Group trial. J Clin

Oncol, 2006;24(18S):2004.

94. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and

safety of bortezomib in patients with advanced malignancies and varying degrees of

liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Clin Cancer Res. 2012;18(10):2954–2963.

95. Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study

of imatinib mesylate in patients with advanced malignancies and varying degrees

of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction

Working Group. J Clin Oncol, 2008;26(4):563–569.

96. Bello CL, Garrett M, Sherman L, Smeraglia J, Ryan B, Toh M. Pharmacokinetics

of sunitinib malate in subjects with hepatic impairment. Cancer Chemo Pharmacol.

2010;66(4):699–707.

1 4 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

97. Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorino-

stat in patients with advanced solid tumors and hepatic dysfunction: a National

Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol.

2010;28(29):4507–4512.

98. Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ

Dysfunction Working Group study. Clin Cancer Res. 2013;19(13):3631–3639.

99. Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of

capecitabine and its metabolites following oral administration in cancer patients.

Clin Cancer Res. 1998;4(4):941–948.

100. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009;27(8):1191–1196.

101. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in

melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.





7

Phase I Trials of

Immunotherapeutics

C H R I S T Y R A L P H , E M M A K I N G , C H R I S T W E L V E S ,

A N D C H R I S T I A N O T T E N S M E I E R ■



7.1 INTRODUCTION



7.1.1 The need for new therapeutic options

Cancer remains a leading cause of morbidity and mortality in adults. The inci-

dence of cancer rises with age, and across the world populations are aging, so can-

cer will for the foreseeable future be an increasing problem. Despite advances in

screening and diagnosis, many patients present with, or later develop, incurable

disease. The successes, but also the limitations, of systemic chemotherapy have

long been apparent; median survival from first-line palliative therapy for patients

with non–small cell lung and bowel cancer is around 10 and 19.5 months,

respectively [1,2]. The last decade has seen rapid expansion in the development

of “targeted” agents following the dramatic impact of imatinib in acute myeloid

leukemia and gastrointestinal stromal tumors. In the clinic, most targeted agents

have been tyrosine kinase inhibitors (TKIs) with proven efficacy against tumor

types refractory to cytotoxic chemotherapy, such as lung cancer, renal cell car-

cinoma, and melanoma. There is, however, a growing recognition that both

tumor heterogeneity and emerging resistance limit the efficacy of these drugs.

For example, despite stunning response rates to vemurafenib in patients with

V600E BRAF mutant metastatic melanoma, median progression-free survival is

just 5.3 months [3] .

Patients with metastatic cancer, therefore, need alternative treatments.

Immunotherapy covers a diverse range of therapeutic approaches that aim to

1 5 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

harness the immune system against cancer with the hope of durable benefit.

Recent successes have led to licensing of anti-CTLA4 antibody ipilimumab for

melanoma and the whole cell vaccine sipuleucel-T for prostate cancer. A range of

immunotherapy approaches are showing promise, and the number of early clini-

cal trials of such agents is increasing.



7.1.2 Background data supporting use

of cancer immunotherapy

In health, the immune system can recognize and target a wide range of micro-

bial pathogens without damaging the infected individual. The classical model

of the immune system divides the cellular and humoral components into innate

and adaptive arms. The innate arm acts through pattern recognition, while the

adaptive arm responds after priming and maintenance of memory though spe-

cialized lymphocytes. To respond appropriately to tissue damage and infection,

both types of immune response involve rapid activation cascades; equally, potent

checkpoints and regulatory feedback pathways exist to counteract “overzealous”

immune activation (e.g., cytokine storm) and damaging autoimmunity.

In both model systems and in man, the immune system can also recognize can-

cer through both the innate and adaptive pathways. Emerging evidence suggests

the immune system also has a significant role in both preventing and control ing

cancer. Results from model systems suggest that adaptive immunity can maintain

occult cancer metastases in a state of equilibrium [4] . In patients with advanced

cancer, evidence of immune dysfunction is widespread. In many human solid

tumors, immune infiltrates in the tumor can have a major impact on outcome,

even in patients with advanced disease [5]. In contrast, chronic systemic inflam-

mation is emerging as a potent adverse prognostic factor in patients with early

and advanced cancer [6].

Both cytotoxic chemotherapy and targeted agents can have potentially ben-

eficial immunological effects. Chemotherapy with carboplatin and paclitaxel can

result in the recovery of CD8+ T cell function in patients with advanced ovarian

cancer [7] , and the monoclonal antibody trastuzumab that targets the HER-2

receptor may act in part through antibody-dependent cellular cytotoxicity

(ADCC), and it has activating effects on both adaptive and regulatory immune

cel s [8,9].

Harnessing these intrinsic systems for cancer therapy is appealing. From the

perspective of efficacy, the success of vaccination in eradicating smallpox dem-

onstrates that the immune system can protect against both current and future

insults. An ideal cancer immunotherapy would exploit the innate immune system

to allow rapid replication of targeted immune effector cel s against cancer cel s,

Phase I Trials of Immunotherapeutics 151

and also allow the adaptive system to establish a protective “memory” response.

In terms of toxicity, in health, negative feedback loops maintain the immune sys-

tem in appropriate equilibrium and should limit the development of significant

immune-mediated toxicities arising from immunotherapies. It has become clear,

however, that it is not always possible to overcome the immune tolerance that

develops in cancer patients without such toxicities [10]. In some instances, acti-

vation of an immune cascade can lead to catastrophic adverse events, as seen in

resultant cytokine storms after a single infusion of the anti-CD28 monoclonal

antibody TGN1412 [11].



7.2 SAFETY IN CANCER IMMUNOTHERAPY TRIALS

The balance of toxicity and benefit from immunotherapies remains a longstand-

ing concern. Nevertheless, high-dose IL-2 is still used because it is one of the few

therapies to induce durable, complete responses in a small subgroup of patients

with metastatic renal cancer and melanoma, in spite of considerable side effects

[12]; it remains unclear what characterizes and distinguishes these responders

from non-responders.

The design of any early phase trial of a novel immune agent obviously needs

to take specific safety risks into account. The regulatory environment for many

immunotherapy (and other “high-risk”) trials in Europe and elsewhere has been

shaped by responses to the TGN1412 incident in 2006. TGN1412 was a novel

“super-agonist” anti-CD28 monoclonal antibody with potential utility in the

treatment of patients with chronic B cell lymphocytic leukemia and autoim-

mune inflammatory arthritis. During a first-in-human (FIH) study, six healthy

male volunteers received infusions of TGN1412 at ten-minute intervals. All six

rapidly developed acute respiratory distress and evidence of massive cytokine

release and required treatment in intensive care with cardiopulmonary support,

high-dose methylprednisolone, and an anti-interleukin-2 receptor antibody

antagonist. Though all the men survived, it is still not known whether there will

be significant long-term sequelae [11].

The subsequent investigation by an expert scientific group (ESG) chaired by

Professor Gordon Duff on behalf of the UK Medicines and Healthcare Products

Regulatory Authority (MHRA) led to key recommendations designed to mini-

mize the risk to future participants in certain immunotherapy trials and trials

of other high-risk treatments [13,14]. The report concluded that available pre-

clinical studies met regulatory requirements but did not predict a safe dose in

man. Toxicology studies in rodents and non-human primates may not predict

cytokine release storms due to phylogenetic differences, relatively pathogen-free

1 5 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

husbandry, and species-specific pharmacological activity of some agents such as

monoclonal antibodies. Broadly, the report stressed the shared responsibilities

of researchers, industry drug developers, funding bodies, and regulators in the

safe development of novel therapeutics, and recommended early communica-

tion and expedited sharing of both preclinical and phase I safety data. The report

advised regular review of the regulatory process and involvement of expert

advisory groups to keep up with changing therapies. Specific recommendations

stressed the importance of scientific rationale and relevant team expertise in

preclinical development of new agents, and built on the development of alter-

native approaches to calculate the FIH dose and to define safe dose escalation.

These recommendations are discussed in more detail, and in a wider context,

in Chapter 4. Others have argued that, with greater awareness of the develop-

ment of parallel monoclonal antibodies and better designed animal studies, this

life-threatening toxicity could have been anticipated [13].



7.3 IMMUNOTHERAPY TREATMENT MODALITIES



Novel cancer immunotherapies comprise a broad range of approaches and thera-

pies, each of which will require a different approach in early phase clinical trial

design.



7.3.1 Monoclonal antibodies

Therapeutic monoclonal antibodies (mAb) are exquisitely specific for the target

antigen. In simple terms, novel therapeutic antibodies consist of a target and a

skeleton. To predict potential on-target toxicity requires knowledge of the dis-

tribution of the antigen in human tissues in both health and disease, and also

careful choice of a relevant animal model to confirm and identify pharmacologi-

cal action and toxicity. Choice of skeleton, both in terms of species and isotype,

will affect the risk of infusion reactions, potential activation of complement and

antigen-dependent cellular cytotoxicity, and the likely half-life of the antibody,

which can be as long as several weeks. Infusion reactions are not uncommon;

they may be due to immunogenicity or directly related to the mechanism of

action and desired pharmacological effect. Immunogenic or hypersensitivity

infusion reactions occur on secondary exposure and are due to immunogenicity

of the monoclonal antibody; the development of humanized, chimeric, and fully

human mAb technology has reduced, but cannot eliminate prevent, the risk of

reactions that also depend on specifics of the antibody structure and dose and

the patient’s immune system and concomitant medication.

Phase I Trials of Immunotherapeutics 153

In theory, receptor-targeted monoclonal antibodies should be safe and well

tolerated due to their specificity. Many on-target side effects can be predicted

from preclinical studies and managed in the clinic, such as skin reactions with

EGF-receptor-targeted antibodies. Preclinical safety studies require that the

mAb cross-react with antigen and be functionally active in the species studied.

Where the human antibody does not cross-react with other species, functionally

comparable surrogate antibodies and/or transgenic animals may be generated to

investigate preclinical pharmacology and toxicity. For example, infliximab, a chi-

meric immunoglobulin G subclass 1 (IgG1) antibody targeting tumor necrosis

factor alpha (TNFα), has biological effects restricted to human and chimpanzee;

preclinical development included a surrogate murine IgG2a antibody cV1Q and

transgenic mouse models [15,16].

These pharmacology and toxicity issues for novel mAb are even more impor-

tant when the immune system is both the mechanism and target of the therapy;

an immune-modulating mAb is likely to have more pleiotropic effects. Improved

understanding of the mechanisms by which tumors evade the immune system

has led to the development of immune-modulating therapies such as ipilimumab,

the anti-cytotoxic T lymphocyte–associated antigen 4 (CTLA4) antibody.

Ipilimumab agent confers a significant survival advantage in the treatment of

advanced melanoma both as second-line monotherapy [17] and first-line in

combination with dacarbazine [18]. The development of this drug was, however,

complex. Novel toxicities such as autoimmune hypophysitis had not been antici-

pated, and with both toxicity and efficacy being manifest some months after

treatment, defining an appropriate dose and schedule for further investigation

was difficult and took a number of years.



7.3.2 Cell-based therapies

Translation of cel -based therapies from the laboratory to the clinic is not

straightforward. These are often complex interventions and may require indi-

vidual leukapheresis, elaborate conditioning regimes, ex-vivo expansion of the

cellular therapy product, and sometimes multiple infusions and the addition of

immune adjuvants. Each step in this process has technical and safety challenges.

Significant toxicity can occur due to choice of target and due to the off-target

effects of conditioning and adjuvants. Infusions of tumor-infiltrating lympho-

cytes (TILs) have led to durable remissions in metastatic melanoma, and genetic

modification of T cel s to express stable chimeric antigen receptors (CARs)

shows promise in B cell malignancies. At this time, the technologies require spe-

cialist on-site production, which has limited their clinical development [19]. The

novel autologous cellular therapy sipuleucel-T was licensed by the US Food and

1 5 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

Drug Administration (FDA) after demonstrating a significant survival advantage

over placebo for men with castrate-refractory metastatic prostate cancer [20].

Patient’s peripheral blood mononuclear cel s (PBMC) are collected by leuka-

pheresis and activated ex-vivo by incubation with a recombinant fusion protein

(PA2024) that comprises the antigen prostatic acid phosphatase (PAP) and the

immune signaling factor granulocyte-macrophage–colony-stimulating factor

(GM-CSF). The modified blood product can then be reinfused in an outpatient

setting to induce an immune response against cancer cel s carrying the PAP

antigen.



7.3.3 Radio-immunotherapy (RIT)

The first RIT was approved by the FDA in 2002 to treat lymphoma and comprises

a mouse anti-CD20 monoclonal antibody conjugated to tiuxetan. This chelates

the radioactive isotope yttrium-90 (ibritumomab tiuxetan). The following year,

tositumomab was approved by the FDA; this is a second murine CD20 mono-

clonal antibody that is infused covalently bound to the radionuclide iodine-131.

In an early review of safety data from five 90Y-ibritumomab tiuxetan studies, only

7% of patients were hospitalized due to infection during the treatment period,

and 90Y-ibritumomab tiuxetan therapy was not shown to increase the risk of

developing secondary malignancies (myelodysplastic syndrome/acute myeloid

leukemia), or preclude subsequent therapy upon relapse [21]. The same precau-

tions relating to administration and post-treatment contamination used in clini-

cal practice for radio-ablation of thyroid malignancy are required.



7.3.4 Cytokines

Cytokines are a group of small proteins that have a role in cel -to-cell signaling

and modulate host response to infection, inflammation, immune activation,

and trauma. They include interferons, G-CSF, and (indirectly) imiquimod.

Imiquimod acts on the innate arm of the immune system through the tol -like

receptor 7 (TLR7) to activate cel s that secrete cytokines and can be used topi-

cally to treat non-melanoma skin tumors. Most cytokines are, however, pleiotro-

pic; for example, interleukin 2 (IL2) potentially has multiple effector functions,

not all of them therapeutic. IL2 may expand lymphocyte populations in vivo and

promote lymphocyte effector function, but it can also sustain IL2-dependent

regulatory lymphocytes (Treg) that abrogate anti-tumor immunity [22,23]. In

patients, IL2 shows dose-dependent toxicity, causing fevers, chil s, hypotension,

lymphopenia, and “vascular leak” syndrome. Single-dose phase I studies may

Phase I Trials of Immunotherapeutics 155

have underestimated toxicity; safe management of multiple doses requires spe-

cialist inpatient experience and access to intensive monitoring [24].



7.3.5 Vaccines

There are many types of cancer vaccine in development (tumor cell vaccine, pep-

tide vaccine, DNA vaccine, and vector-based vaccine), but the only licensed vac-

cine to date is sipuleucel-T (see above). Overall, vaccines have been very well

tolerated, with minimal toxicity. Initial concerns of inducing clinically relevant

immune-related side effects when targeting self-antigens have not been con-

firmed. It remains uncertain whether this is mainly a function of low immuno-

logical efficacy, or whether vaccines are less toxic because they work within the

constraints of a “normal” adaptive immune response. Initial concerns about the

lack of an expandable T cell repertoire have been refuted, and anti-cancer vaccines

are increasingly seen as the biological tool to direct immune attack in the context

of broader, non-specific immune stimulation, such as with immune-modulatory

antibodies.



7.3.6 Viruses

Viruses can be used as vectors for antigen-specific vaccines or as primary onco-

lytic (“cancer-kil ing”) agents; they may also act indirectly by inducing an

immune response.

Oncolytic viruses have a natural or genetically engineered tropism for can-

cer cel s that allows them to preferentially infect and kill cancer cel s. Several

oncolytic viruses are under investigation. Early studies concentrated on the

intra-tumoral (IT) route; challenges included the dosing and distribution of

virus, and common toxicities were local tissue reactions and pyrexia. Although

it was postulated that IT administration may induce systemic therapeutic

effects, intravenous (IV) administration of viruses is arguably a more appropri-

ate approach for disseminated cancers. The demonstration that reovirus can

preferentially infect colorectal cancer liver metastases supports the IV admin-

istration of oncolytic viruses and emphasizes the importance of translational

proof-of-principle studies [25]. Systemic administration may, however, lead

to additional systemic toxicity. For example, relatively rapid administration of

a high viral load of an oncolytic Ad11/Ad3 chimeric group B adenovirus was

associated with significant pulmonary toxicity that was abrogated by a longer

infusion time and lower viral load [26]. Systemic administration of virus may

also require additional safety measures for staff and close contacts. While many

1 5 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

viral vaccines are inactivated, most oncolytic viruses are live, though often atten-

uated. This reduces the risk of infection and replication in normal human cel s,

minimizing the chances of viral shedding and spread to others; nevertheless,

close monitoring for viral shedding and spread to staff and household contacts

is a routine part of early-phase viral studies.

The virulence, prevalence, and genetic modification of a novel virus all have

to be considered in trial design and risk assessment, which should include

an assessment of the risk of environmental contamination and cross-species

infection. The regulatory environment for these trials can be additionally

complex and may require additional licensing and/or application through vet-

erinary regulators. For example, recombinant vesicular stomatitis virus (VSV)

is currently in a phase Itrial in the United States (NCT01628640) but cannot

be imported to the United Kingdom due to concerns about foot-and-mouth

disease in cattle.



7.4 PRACTICALITIES OF EARLY-PHASE

IMMUNOTHERAPY TRIALS



Prior to initiating FIH, dose-finding clinical studies under an investigational new

drug (IND) application, preliminary specifications for product characterization

should be in place. The product-release specifications for immunotherapeutic

products are established based on the IND sponsor’s previous experience with

their product (and similar products, if applicable) and include analytical proce-

dures based on the Code of Federal Regulations requirements [27]. The regulatory

requirements for biological product characterization include appropriate tests for:

1. Identity—the biological product must be verified by assays that will iden-

tify the product for appropriate labeling, and (importantly) can be distin-

guished from other products being manufactured in the same facility

2. Purity—assays for pyrogenicity/endotoxin and for contaminants such

as unintended cell populations

3. Safety—clearly especially important after the TGN1412 incident

4. Potency—the specific ability or capacity of the product, as indicated

by appropriate laboratory tests or by adequately controlled clinical

data obtained through the administration of the product in the manner

intended, to effect a given result

Identity can be a more complex issue for immune agents that require, or rely on,

tailored individual immune response than for cytotoxics or molecularly targeted

agents (MTA). For example, it may be difficult to identify the relevant antigens

Phase I Trials of Immunotherapeutics 157

or effectors in cellular therapies. More commonly, scale-up of manufacturing to

provide sufficient clinical-grade agent may require additional identity, safety,

and efficacy testing in man. For example, the pharmacokinetics and safety com-

parison of hybridoma- and transfectoma-derived ipilimumab was completed in

order to support clinical development of the latter, more scalable, version [28].

Contamination is a risk with all immunotherapeutic products, but the risk of bio-

logical contamination may be increased with the more complex immunothera-

pies and/or those manufactured using biological methods such as antibodies

purified from hybridomas and viruses expanded in cel -based systems.

The European Medicines Agency (EMA) has issued guidelines for onco-

lytic viruses (http://www.ema.europa.eu/docs/en_GB/document_library/

Scientific_guideline/2009/09/WC500003915.pdf). Potential concerns include viral shedding, or the dissemination of the oncolytic virus through excreta of the

patient, and the potential to expose others to the virus, including pharmacy, nurs-

ing, and medical staff, as well as friends and family; precautions are especially

important for those with suppressed or compromised immune systems. It is vital

to establish at an early stage the requirements for handling of the virus and its

containment with the relevant competent authorities.



7.4.1 Starting dose

The overall goal of preclinical studies for immunotherapeutic products is essen-

tially the same as that for other types of products, namely data to support the

safety of the product in humans by defining its toxicological and pharmacologic

characteristics.

Safety and potency data may be relatively limited prior to phase I testing,

as animal models do not always accurately reflect human immunological

responses. Reliance on immune-compromised rodent models is inappropriate

in most cases, and careful risk assessment of the available data, relevant species

and time course, and the proposed mechanism of action is always necessary. In

some cases, cross-species reactivity is expected and may interfere with predict-

ing the likely human toxicity, as with fully humanized monoclonal antibodies;

more commonly, specificity may limit and underestimate human toxicity, as in

the case of HLA-specific vaccines, human cytokines. Functionally relevant sur-

rogates may be required, and mice, reconstituted with a fully human immune

system, may offer a tool to mitigate clinical risk [29,30]. Another tool is the eval-

uation in fully human ex-vivo systems, using, for example, blood-derived cells.

Practically, these discrepancies between rodent and human toxicity data

have led to a cautious approach to determining the FIH starting dose. This

requires modeling and definition of both potential toxicity of dose and the likely

1 5 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

pharmacologically active dose (PAD). The Duff Report [14] recommends that

FIH starting dose of immunotheraputics should:

1. Be based on minimum biological effect rather than toxicity. Use of

the minimum anticipated biological effect level (MABEL) requires

(or assumes) that the mechanism of action is known prior to the trial

and that efficacy and toxicity are linked to dose.

2. Be conservative.

3. Consider “micro-dosing”; i.e., use of a dose calculated to have no

expected pharmacological activity, if there is perceived to be a high risk

of rapid-onset toxicity such as activating cytokines; examples include:

a. 1/100th of no observable adverse effect level (NOAEL; FDA 2006 [31])

b. 1/50th of lower rodent/non-rodent NOAEL, or

c. 1/100th minimum therapeutically effective dose (MTED; EMA

2004 [32])

The use of pharmacological rather than classical toxicology-based algorithms

may allow safer modeling of FIH starting doses of immunotherapies.



7.4.2 Escalation plan

A much wider range of dose escalation plans may be employed with immuno-

therapy than is usual with MTAs and cytotoxics. It is not unusual, for example, to

escalate viral load by logarithmic scale (i.e., tenfold) increments.

The Duff Report recommended cautious escalation with consideration of

expert toxicology and modeling from statisticians where there is a risk of cascade

immune activation. Again, modeling based on pharmacology rather toxicity is

attractive in determining dose levels, but in the absence of routine validated bio-

markers for immunological response, toxicity continues to appeal as an indicator

of biological activity.

The period of observation once a cohort of patients has been treated, and

before a decision is made regarding dose escalation should reflect the likely time

course of toxicities. This is difficult with immunotheraputics, as toxicities may

be delayed and unexpected, as with ipilimumab; toxicities from all treatment

courses should, therefore, be recorded and reviewed.



7.4.3 Cohort size

The TGN1412 experience, where successive previously healthy volunteers within

a cohort were treated rapidly in succession, brought home the importance having

of an adequate interval between treating subjects in order that potential toxicities

Phase I Trials of Immunotherapeutics 159

can be identified and the risk for subsequent patients can be minimized. These

are lessons that should, arguably, have been learnt from phase I trials of more

conventional agents. Reflecting this, most FIH immunotherapy trials have mir-

rored a classical cytotoxic-development 3 + 3 design, often accompanied by an

expansion cohort with some preliminary efficacy and/or immunological end-

points, such as cytokine release, lymphocyte phenotype, antibody and lympho-

cyte antigen responses. Complex immunotherapy trials may treat patients one

at a time or require a minimum follow-up period for the first patient in a cohort

before consent and treatment of the second [33].



7.4.4 Patient population



There are similarities but also differences in the patient populations most suitable

for phase I trials of immunotherapies and those included in early trials of other

treatment modalities.

A satisfactory performance status is a requirement of immunotherapy trials,

as is an adequate prognosis. Indeed, the potential for delayed toxicity (and effi-

cacy) would suggest that patients should have a better prognosis when entering

immunotherapy trials, though this is rarely mandated. Adequate organ func-

tion is usually also a requirement. For some immunotherapy treatment modali-

ties, such as small molecules that are metabolized by the liver or excreted by

the kidneys, this may be entirely reasonable. For many others, such as onco-

lytic viruses, there is less rationale if there is no reason to believe that organ

function has any impact on elimination of the immunotherapy under evalua-

tion. As in other early-phase trials, eligibility criteria for immunotherapies also

need to reflect the requirements for pharmacokinetic/pharmacodynamic stud-

ies, including venous access for repeated sampling. Likewise, pregnant patients

would invariably be excluded and effective contraception required; some stud-

ies using genetically modified therapies are even wary of patients who wish to

keep future fertility as an option. The possibility of immune-mediated toxicities

may exclude patients with a past medical history of other conditions such as

autoimmune disease.

The requirements for informed consent are the same as for phase I trials of

other experimental therapies.



7.4.4.1 Stage of Disease and Extent of Prior Therapy

Patients with advanced cancer have evidence of both global and specific immune

deficits, such as lymphopenia, and increasing numbers of regulatory cel s such

as Treg [34], or deficits in the antigen-processing machinery. These deficits

become more prevalent with cancer progression, especially in patients who have

received multiple courses of myelosuppressive treatment and those with marrow

1 6 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

infiltration or cancer cachexia. Patients traditionally offered participation in

phase I studies would be expected to exhibit at least some of these deficits. Both

efficacy and toxicity may, therefore, be altered in this population compared to an

adjuvant or neo-adjuvant setting.

Data with DNA vaccination targeting carcinoembryonic antigen (CEA)

demonstrate this effect. In the adjuvant setting, almost all (92%) of patients

mounted measurable immune responses to the vaccine and half had a mea-

surable CD8 T cell response. By contrast, in the advanced disease setting,

after failure of all standard lines of treatment, only half of patients responded

to the vaccine, and less than a quarter developed a measurable CD8 T cell

response [35]. Patients with more advanced disease are, therefore, less likely

to be immune-competent and “respond” immunologically, which may be an

important pharmacodynamics marker of biological activity. Likewise, where

toxicity is the key endpoint, these may be an “on-target but off tumor” immune

effect, due, for example, to antigen expression in non-malignant tissues; if

so, side effects may also be more pronounced in heavily pre-treated patients.

Long-term follow-up may be important where late emergent responses and

toxicity can occur, as with immune checkpoint blockade with ipilimumam,

which can cause a range of potentially life-threatening immune gastrointes-

tinal and endocrine side effects that may not develop until months or even

years after treatment in a small proportion of patients [36]. In immunotherapy

trials, the greater immune competence, and better prognosis, of less heavily

pre-treated patients both argue for considering patients who have not neces-

sarily exhausted all standard treatments.

Pre- and post-treatment biopsies can be important in immunotherapy trials,

as in other phase I trials. Immunotherapy studies prior to surgery, either more

prolonged neo-adjuvant studies or briefer “window of opportunity” trials [37]

have the twin advantages of the patients’ not having received prior immunosup-

pressive treatment and also of allowing early assessment of immune targeting by

comparing the diagnostic biopsy with the surgically resected tumor obtained after

the study intervention. These studies are logistically challenging, and have usually

been undertaken as supplementary translational studies using the recommended

phase II dose. They may be more acceptable to patients, clinicians, and regulatory

authorities in situations where there is already experience with other neo-adjuvant

interventions such as prior to cystectomy for patients with bladder cancer [38].



7.4.4.2 Comorbidities and Concomitant Medications

Typically, phase I immunotherapy trials have additional exclusion criteria to

those of other phase I trials. Patients with chronic infection (including hepatitis

B, C; and HIV), long-term corticosteroid use, chronic immunosuppressed states,

or chronic overactive immune states (i.e., autoimmunity) are all often excluded.

Phase I Trials of Immunotherapeutics 161

Oncolytic virus trials may also exclude patients with eczema or other chronic

skin conditions that may increase theoretical risk of viral shedding.



7.4.5 Pharmacokinetics

Pharmacokinetic (PK) studies are important in immunotherapy trials, both

to evaluate exposure to the immunotherapy agent and to detect drug–drug

interactions.

For the safe combination of immunotherapeutic with other drugs, the possi-

bility of drug–drug interactions must be considered. Methotrexate, but also other

immunosuppressive treatments, can to alter the pharmacokinetics of monoclo-

nal antibodies [39]. Conversely, some monoclonal antibodies can alter the phar-

macokinetics of small molecules metabolized by cytochrome P450 enzymes by

modulating cytokines [40].

Combining one monoclonal antibody with another can affect the tumor

distribution of both molecules [41]. An anti-CEA antibody co-administered

with an anti-vascular endothelial growth factor (VEGF) antibody, in a pre-

clinical model, significantly reduced tumor levels of the anti-CEA antibody,

although there was no change in the plasma pharmacokinetics of the anti-CEA

antibody. There are gender-based differences in expression of metabolic

enzyme levels and transporters in both the liver and the kidney, leading to

differences in pharmacokinetics of cytotoxics [42], with increased half-lives

in women resulting in increased toxicity. There can also be gender-associated

differences in the sites of side effects, with women appearing to have a higher

incidence of oral mucositis but lower rates of gastrointestinal toxicity. Such

differences may also affect immunotherapy agents and could contribute to

diversity in biological effects.



7.4.6 Endpoints for early immunotherapy trials



Endpoints in early phase trials are at least as great an issue for immunotherapies

as for other therapeutic areas.



7.4.6.1 Immune Assays

Informative and predictive immune readouts can be the goal of immunotherapy

studies. To date, they principally consist of blood markers including peripheral

blood mononuclear cel s (PBMCs), specifically helper, cytotoxic, and regulatory

T cel s, and antibody or cytokine levels. A key development is the evaluation of

tissue-based immune effects, which may allow better patient stratification on one

1 6 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

hand, and better understanding of toxicity on the other. The need for standardized

methods for tissue sampling and processing, as well as validated assays, applies

to immunological assays as it does to those for MTAs or cytotoxics described

elsewhere. Extensive work has been undertaken by many groups [43–50] to stan-

dardize assays to measure such endpoints, and consensus is emerging [47].

For example, in the context of vaccination, if a transcutaneous approach is

employed, the site of administration can be exploited to monitor for a cytotoxic

infiltrate, part of a type IV delayed hypersensitivity response. This may more

accurately identify immune responders than blood-based analyses, perhaps a

reflection of the requirement of the T cel s to track to the site of antigen expres-

sion, similar to the events that would allow them to locate antigen in the tumor.

If tumor tissue can be accessed post-vaccination, specific subsets of TILs can be

quantified to define the balance of effector (CD8+) and suppressor (regulatory

CD4+FOXP3+CD25+) cel s and, where known, to characterize antigen-specific

immune cel s [51,52]. Considerations about which compartment to sample are

also important from an immunological perspective; antigen-specific and, there-

fore, also immunotherapy-induced immune events may be quite different in the

tumor and than in the blood [53]. Interestingly, if the balance changes in favor of

an effector response as a result of immunotherapy, the tumor is likely to at least

transiently increase in size (pseudo-progression) due to the ingress of cytotoxic

T cel s [54]. The development of new techniques has allowed the isolation of

individual cell subsets from small biopsies [55,56]. This enables the functional

capabilities of each subset to be defined. In addition, protein and RNA signatures

can be outlined pre- and post-vaccination to describe the cellular response to an

immunotherapy intervention.

Predictive biomarkers for benefit from immunotherapy have to date been gen-

erally elusive [57]. Recent data, however, support low-baseline prostate-specific

antigen affording a 50% relative increase in three-year survival after sipuleucel-T for prostatic adenocarcinoma [58]. In addition, a pre-treatment gene expression signature predictive of response to MAGE-A3 antigen immunotherapy has recently

been described; 84 genes, associated with immune response and the tumor

micro-environment, were thought to be predictive in both adjunctive treatment

for non–small-cell lung cancer and melanoma, although in the latter condition the

randomized phase III trial failed to validate this concept. Messenger RNA array

analysis in patients with melanoma appears to identify patients who will respond to

ipilimumab [59,60]. Clearly, each new immunotherapeutic agent would gain value

from a validated, predictive biomarker to enable better patient selection.



7.4.6.2 Safety

As in other phase I settings, safety remains the primary outcome and concern

in these trials. Many early immunotherapy trials probably failed due to a lack

Phase I Trials of Immunotherapeutics 163

of an appropriate regulatory framework, and used neither validated nor compli-

ant manufacturing processes. Now, however, immunotherapy manufacture and

clinical trials are more tightly regulated. There remains a need to be vigilant for

immune-mediated side effects that may require additional screening investiga-

tions and can occur beyond the usual 30-day observation window of standard

phase I studies. For example, late fatigue after the anti-CTLA4 antibodies ipilim-

umab and tremelimumab can be due to delayed pan-hypopituitarism stemming

from hypophysitis [61].



7.4.6.3 Imaging and Response Evaluation

During the clinical development of anti-CTLA4 antibodies for cancer immu-

notherapy, both IgG1 ipilimumab [62] and the alternative IgG2 tremelim-

Κ

umab [63] achieved modest responses of around 10–15% when measured

using classical computer tomography (CT) response criteria. Indeed, some

responses occurred either late, or after apparent disease progression. An

analysis of kinetics of objective responses to ipilimumab in 41 of 269 patients

with stage III or IV melanoma in five trials, reported late-onset complete

response (CR), and partial response (PR) occurring after 10–106 weeks and

5–62 weeks, respectively [64]; published case reports demonstrated CR after

apparent clinical, serological, and radiological disease progression [65]. This

unusual time course of responses has led to concern that reliance on estab-

lished CT response guidelines such as Response Evaluation Criteria In Solid

Tumors (RECIST) [66] or World Health Organization (WHO) [67], devel-

oped to validate rapid responses to traditional cytotoxic chemotherapy, may

underestimate the activity of immunotherapies.

Increases in OS without improvements in PFS have been reported in immu-

notherapy trials; thus, it has been questioned whether PFS is a meaningful

endpoint in such trials of immunotherapies, where a tumor “flare,” character-

ized by enhancement and increased tumor mass, may be seen before immune

responses have had time to develop. Hodi’s group [68] characterized responses

in a large cohort of melanoma patients treated in three randomized phase II trials

of ipilimumab as occurring in four patterns: (1) shrinkage of baseline lesions;

(2) durable stable disease; (3) late response after apparent disease progres-

sion; and (4) reduction in total disease burden despite the appearance of new

(often nodal) lesions, all of which were associated with favorable survival. The

immune-related response criteria (irRC) are compared to conventional RECIST

in Table 7.1.

In addition, do not necessarily select the largest lesions as targets. Select

those that are best defined and reproducibly measurable, and use the same

lesions as targets for the entire trial. Measure where the target lesion is largest,

even when the slice and orientation are different compared to baseline. Do not

1 6 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 7.1. Comparing World Health Organization RECIST

and irRC Criteria

WHO

irRC

New, measurable

Always represent PD

Incorporated into tumor

lesions (i.e., ≥5 ×

burden

5 mm)

New, non-

Always represent PD

Do not define progression (but

measurable lesions

preclude irRC)

(i.e., <5 × 5 mm)

Non-index lesions Changes contribute to defining

Contribute to defining irRC

BOR of CR, PR, SD, and PD

(complete disappearance

required)

CR

Disappearance of all lesions in

Disappearance of all lesions in

two consecutive observations

two consecutive observations

not less than 4 wks apart

not less than 4 wks apart

PR

≥50% decrease in SPD of all

≥50% decrease in tumor bur-

index lesions compared with

den compared with baseline

baseline in two observations at

in two observations at least 4

least 4 wks apart, in absence of

wks apart

new lesions or unequivocal pro-

gression of non-index lesions

SD

50% decrease in SPD com-

50% decrease in tumor burden

pared with baseline cannot be

compared with baseline can-

established nor 25% increase

not be established nor 25%

compared with nadir, in absence increase compared with nadir

of new lesions or unequivocal

progression of non-index lesions

PD

At least 25% increase in SPD

At least 25% increase in tumor

compared with nadir and/

burden compared with nadir

or unequivocal progression

(at any single time point) in

of non-index lesions and/or

two consecutive observations

appearance of new lesions

at least 4 wks apart

(at any single time point)

Abbreviations: CR = Complete response, PR = partial response, SD = Stable disease,

PD = progressive disease, BOR = Best overall response, SPD = Sum of perpendicular

diameters

Adapted from Wolchok JD, et al. Guidelines for the evaluation of immune ther-

apy activity in solid tumors: immune-related response criteria. Clin Cancer Res.

2009;15(23):7412–7420.

necessarily use the required imaging studies for lesion measurement. If a lesion

is more reproducibly measured by caliper measurement (e.g., flat skin lesions),

use caliper measurement. The progression should be unequivocal to determine a

Phase I Trials of Immunotherapeutics 165

“substantial worsening” and would merit a change in treatment. For progressive

disease (PD) of non-target lesion, there must be unequivocal progression with

substantial worsening.



7.4.7 Combination studies

Immunotherapies will often be used in combination with other immunothera-

pies or other treatments, and early-phase combination studies will be required.

As described above, PK studies are important in this context.

Combination studies may also reveal pharmacodynamic interactions and

toxicities. A recent example was the observation of substantial liver toxicity in

a phase I trial of vemurafenib and ipilumumab in patients with advanced mela-

noma [69]. Similarly, the combination of ipilumumab with dacarbazine showed

increased liver toxicity—perhaps not surprisingly, as each individual agent is

hepatotoxic. In contrast, two recent studies have shown that ipilimumab can

be combined safely with carboplatin and paclitaxel [70]. Interestingly, however,

the scheduling of ipilimumab had a significant impact in the other study; addi-

tion at cycle three, but not at cycle one, of chemotherapy was associated with

increased clinical benefit [71,72]. These data argue strongly for careful, prefer-

ably preclinical, evaluation of combinations including immunotherapeutics to

minimize patient risk.



7.5 SUMMARY

As cancer immunotherapy is increasingly accepted as a treatment modality, the

careful design of early-phase as well as late-phase clinical trials is critical in order to address their particular challenges. A key element is the choice of patients who

have an intact immune system that is able to “respond” effectively. Measuring

that response, in terms of either an immunological effect or a tumor response,

has required the development of new pharmacodynamics immune assays and

immune response criteria.



REFERENCES

References noted as [Electronic] or [Print] are US National Library of Medicine (NLM) catalog numbers.

1. Scagliotti GV, et al. Phase III randomized trial comparing three platinum-based dou-blets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285–4291.

1 6 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

2. Goldberg RM, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.

3. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF

V600E mutation. N Engl J Med. 2011;364(26):2507–2516.

4. Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium

state. Nature. 2007;450(7171):903–907.

5. Gooden MJ, et al. The prognostic influence of tumour-infiltrating lymphocytes in

cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.

6. Chua W, Charles KA, et al. Neutrophil/lymphocyte ratio predicts chemo-

therapy outcomes in patients with advanced colorectal cancer. Br J Cancer.

2011;104(8):1288–1295.

7. Coleman S, et al. Recovery of CD8+ T-cell function during systemic chemotherapy

in advanced ovarian cancer. Cancer Res. 2005;65(15):7000–7006.

8. Nuti M, et al. Immune effects of trastuzumab. J Cancer. 2011;2:317–323.

9. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab

therapy for human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2009;27(34):5838–5847.

10. Weber JS, Kahler KC, A. Kahler KC, Hauschild A. Management of immune-related

adverse events and kinetics of response with ipilimumab. (1527-7755 [Electronic])

11. Suntharalingam G, Perry MR, et al. Cytokine storm in a phase 1 trial of the anti-CD28

monoclonal antibody TGN1412. (1533-4406 [Electronic])

12. Shablak A, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.

J Immunother. 2011;34(1):107–112.

13. Horvath CJ, Milton MN. The TeGenero incident and the Duff Report con-

clusions: a series of unfortunate events or an avoidable event? (1533-1601

[Electronic])

14. Duff, Gordon W. Expert Group on Phase One Clinical Trials: final report 2006: TSO

(The Stationary Office), UK. http://webarchive.nationalarchives.gov.uk/+/dh.gov.

uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/

dh_063117

15. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNF-alpha monoclonal antibody.

Hum Exp Toxicol. 2000;19(4):226–228.

16. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025–4031.

17. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.

18. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.

19. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cel s expressing

anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267–276.

20. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (1533-4406 [Electronic])

Phase I Trials of Immunotherapeutics 167

21. Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab

tiuxetan in clinical practice. Leuk Lymphoma. 2003;44(Suppl 4):S37–47.

22. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for

cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595–601.

23. Liao, W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13–25.

24. Thompson JA, et al. Recombinant interleukin 2 toxicity, pharmacokinetics,

and immunomodulatory effects in a phase I trial. Cancer Res. 1987;47(15):

4202–4207.

25. Adair RA, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. (1946-6242 [Electronic])

26. Calvo E, et al. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in

patients with metastatic epithelial tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 3103).

27. Vatsan RS, et al. Regulation of immunotherapeutic products for cancer and

FDA’s role in product development and clinical evaluation. J Immunother Cancer.

2013:1–5.

28. Weber JS, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. (1527-7755 [Electronic])

29. Ito M, et al. NOD/SCID/γnul mouse: an excellent recipient mouse model for

engraftment of human cel s. Blood. 2002;100(9):3175–3182.

30. Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid

IL2R gamma null mice engrafted with mobilized human hemopoietic stem cel s.

J Immunol. 2005;174(10):6477–6489.

31. FDA. 2006. http://www.fda.gov/downloads/drugs/guidancecomplianceregulato-

ryinformation/guidances/ucm078933.pdf

32. European Medicines Agency (EMEA). 2004. Position Paper on Non-Clinical Safety

Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599/02/

Rev 1.

33. Kochenderfer JN, et al. Eradication of B-lineage cel s and regression of lymphoma in a patient treated with autologous T cel s genetically engineered to recognize CD19.

Blood. 2010;116(20):4099–4102.

34. Liyanage UK, et al. Prevalence of regulatory T cel s is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

J Immunol. 2002;169(5):2756–2761.

35. Ottensmeier CH, et al. Clinical and immunological responses to a DNA

fusion vaccine in patients with carcinoembryonic antigen-expressing

tumors: a Cancer Research UK phase I/II study. ASCO Meeting Abstracts.

2010;28(15_suppl):2579.

36. Voskens CJ, Goldinger SM, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. (1932-6203 [Electronic])

37. Adair RA, Roulstone V, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. (1946-6242 [Electronic])

1 6 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

38. Carthon BC, Wolchok JD, et al. Preoperative CTLA-4 blockade: tolerability and

immune monitoring in the setting of a presurgical clinical trial. (1078-0432 [Print]) 39. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic

drug–drug interactions for therapeutic monoclonal antibodies. (1878-5832

[Electronic])

40. Huang Sm, Zhao H, et al. Therapeutic protein–drug interactions and implications

for drug development. (1532-6535 [Electronic])

41. Abuqayyas L, Balthasar JP. Pharmacokinetic mAb–mAb interaction: anti-VEGF

mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.

(1550-7416 [Electronic])

42. Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases.

Handb Exp Pharmacol. 2012(214):411–442.

43. Ward MJ, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110(2):489–500.

44. Singh SK, et al. The development of standard samples with a defined number of

antigen-specific T cel s to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother. 2013;62(3):489–501.

45. Filbert H, et al. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

Cancer Immunol Immunother. 2013;62(4):615–627.

46. Welters MJ, et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother. 2012;61(7):967–978.

47. Britten CM, et al. T cell assays and MIATA: the essential minimum for maximum

impact. Immunity. 2012;37(1):1–2.

48. van der Burg SH, et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med. 2011;3(108):44.

49. Moodie Z, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010;59(10):1489–1501.

50. Mander A, et al. Serum is not required for ex vivo IFN-gamma ELISPOT: a col-

laborative study of different protocols from the European CIMT Immunoguiding

Program. Cancer Immunol Immunother. 2010;59(4):619–627.

51. Heusinkveld M, et al. Systemic and local human papilloma virus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer. 2012;131(2):E74–E85.

52. Kenter GG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847.

53. Baitsch L, et al. Exhaustion of tumor-specific CD8(+) T cel s in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350–2360.

54. Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.

55. Vijayanand P, et al. Invariant natural killer T cel s in asthma and chronic obstructive pulmonary disease. N Engl J Med. 2007;356(14):1410–1422.

56. Seumois G, et al. An integrated nano-scale approach to profile miRNAs in limited clinical samples. Am J Clin Exp Immunol. 2012;1(2):70–89.

57. Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials.

Oncoimmunology. 2013;2(8):e26012.

Phase I Trials of Immunotherapeutics 169

58. Schel hammer Pf, Chodak G, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy

for Prostate Adenocarcinoma Treatment (IMPACT) trial. (1527-9995 [Electronic])

59. Ji RR, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019–1031.

60. Ulloa-Montoya F, Louahed J, et al. Predictive gene signature in MAGE-A3

antigen-specific cancer immunotherapy. (1527-7755 [Electronic])

61. Dil ard T, Yedinak CG, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer

subtypes. (1573-7403 [Electronic])

62. Weber J. Ipilimumab: controversies in its development, utility and autoimmune

adverse events. Cancer Immunol Immunother. 2009;58(5):823–830.

63. Camacho LH, et al. Phase I/II trial of tremelimumab in patients with metastatic

melanoma. J Clin Oncol. 2009;27(7):1075–1081.

64. Hamid O, et al. Kinetics of response to ipilimumab (MDX-010) in patients with

stage III/IV melanoma. In ASCO Annual Meeting 2007. J Clin Oncol. 2007;

25(18S):8525.

65. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilim-

umab in metastatic melanoma: patient cases. Cancer Immun. 2008;8:1.

66. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 200945(2):228–247.

67. Miller AB, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.

68. Hodi FS, et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. In ASCO Annual

Meeting 2008.

69. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combina-

tion of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–1366.

70. Lynch TJ, Bondarenko I, et al. Ipilimumab in combination with paclitaxel and

carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung can-

cer: results from a randomized, double-blind, multicenter phase II study.

(1527–7755 [Electronic])

71. Lynch TJ, et al. Ipilimumab in combination with paclitaxel and carbopla-

tin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results

from a randomized, double-blind, multicenter phase II study. J Clin Oncol.

2012;30(17):2046–2054.

72. Weber J, Hamid O, et al. Randomized phase I pharmacokinetic study of ipilim-

umab with or without one of two different chemotherapy regimens in patients with

untreated advanced melanoma. (1424–9634 [Electronic])





8

Statistical Designs for

First-in-Man Phase I Cancer Trials

X A V I E R P A O L E T T I A N D M A R C B U Y S E ■



8.1 BASIC DESIGN REQUIREMENTS

For decades, the fundamental underlying assumption in oncology has been

that “more is better.” According to this assumption, the “optimal” dose recom-

mended for phase II trials is defined as the dose just under the maximum toler-

ated dose, also called the “maximum administered dose” in the remainder of this

book (MAD). The primary objective of first-in-man phase I trials is to define a

recommended dose safely (i.e., with the smallest possible number of patients

experiencing severe toxicities), efficiently (i.e., with the smallest possible total number of patients), and reliably (i.e., with high statistical confidence, which would generally require large numbers of patients). These three requirements

are mutually contradictory, and phase I designs must find the best possible

compromise between them. The safety requirement dominates the other two

requirements, as it is ethically essential to avoid submitting patients to undue

toxicity, yet the very purpose of the phase I trial is to find a dose that exerts

antitumor activity, which, for many anticancer compounds, is usually associated

with acute systemic toxicity. The efficiency requirement mandates that the trial

accrue a limited number of patients and use a reasonably rapid dose-escalation

scheme, otherwise many patients would potentially be exposed to nontoxic,

but sub-therapeutic doses. The reliability requirement means treating a suffi-

cient number of patients at or near the recommended dose, otherwise this dose

may be incorrectly chosen, or uncertainty about the true toxicity profile of the

drug may be too high to develop it further. All of these considerations, which

Statistical Designs for First-in-Human Phase I Trials 171

are essentially pragmatic and ethical, have a bearing on the statistical design of

phase I trials.

For most designs considered in this chapter, toxicity will be the endpoint of

interest. The purpose of these designs, except those appropriate for biological

agents that do not have dose-limiting toxicities (see Section 8.12 in this chapter),

is to identify dose levels at which significant toxicities are observed. As outlined

in Chapter 4, the nature of these toxicities depends on the mechanism of action

of the drug under investigation. However, the idea underlying the trial design is

common to all drugs for which higher doses are associated with a higher probabil-

ity of toxicity and severe dose-limiting toxicity. The designs that are appropriate

under these circumstances consist of escalating (and sometimes de-escalating)

the dose until significant toxic events are observed.



8.2 ENDPOINT AND DOSE–RESPONSE RELATIONSHIP

Adverse events are graded on the scale of Common Toxicity Criteria for Adverse

Events (CTC-AE) developed by the National Cancer Institute; grades range

from 0 (no toxicity) to 4 (very severe or toxicity). Toxic deaths are sometimes

graded 5. During the course of the phase I trial, all AEs are recorded after each

cycle of treatment. However, the primary outcome is the dose-limiting toxicity

(DLT), which is commonly defined as the occurrence of a severe toxicity (typi-

cally grade 3 or 4 non-hematological toxicity of grade 4 hematological toxicity)

during the first cycle of treatment. This definition of the DLT implies a serious

loss of the total toxicity information collected. Due to the specificities of treat-

ments currently under development, the current definition of DLT has been

recently challenged. The DLT-Targett group, a task force led by the European

Organization for research and Treatment of Cancer (EORTC), has issued rec-

ommendations on the definition of DLT [1] that will be briefly discussed in

Section 8.14.

Prior to commencing a phase I trial, some information must be available,

from preclinical experiments or other sources, about the range of doses that may

potentially be tested. As discussed in Chapter 4, the minimum dose of interest is

usually based on toxicology experiments carried out in sensitive animal species.

The minimum dose will generally be the starting dose of the phase I trial. For

some drugs, a maximum dose may be imposed by practical considerations such

as drug availability or constraints in drug delivery, while for others, no maximum

is specified, and the plan is open-ended. The choice of the maximum planned

dose is in fact less important than the choice of a minimum dose, since the trial

will be likely to hit toxicities and terminate before the maximum dose is reached.

Once minimum and maximum dose levels are determined, dose levels must be

1 7 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

chosen that are in between these two extremes. A common choice is to use a

spacing inspired by the Fibonacci series, in which the relative increase between

successive dose levels is constant. For instance, it may be appropriate to increase

the dose by 50% at low dose levels, and to increase it by only 33% beyond a cer-

tain threshold. Moreover, the dose levels can be rounded off, such that, for exam-

ple, a dose of 50 would be used instead of 48.

At each dose, a certain percentage of patients is expected to experi-

ence DLT. This risk (or probability) of DLT is assumed to increase with the

dose. For instance, the line with solid circles in Figure 8.1 could describe the

dose–response relationship for some new drug: the lowest dose level has a prob-

ability of only 5% of inducing DLT; the next dose has a probability of 10%;

the following dose has a probability of just over 20%, etc. This relationship may

be difficult to determine before any data are available in man. The other lines

drawn on Figure 8.1 will be useful later in this chapter to discuss the continual

reassessment method. The MAD is usually defined as the dose associated with

a pre-specified probability of DLT. Two families of methods have been devel-

oped to find this dose, respectively called “algorithmic” and “model-based”

dose-escalation designs. The former will be discussed in sections 8.3 to 8.5, the

latter in sections 8.6 to 8.8.

1

0.9

0.8

0.7

0.6

0.5

0.4

Probability of DLT

0.3

0.2

0.1

0

Dose

0.4

0.6

0.8

1.0

1.2

1.5

2.0

Figure 8.1 Probability of DLT (p) as a function of dose (d), for different values of parameter θ. The dose–response relationship is characterized by the logistic function p = exp( k + θ × d)/[1 + exp( k + θ × d)].

Statistical Designs for First-in-Human Phase I Trials 173



8.3 THE CLASSICAL “3+3” DESIGN

Many phase I clinical trials of cytotoxic agents are carried out using a standard or

classical “3+3” design based on empirical considerations. This design is justified

by the fact that the MAD is usually defined as the dose at which one-third (33%)

of patients experience DLT (should interest focus on some other proportion,

say one-quarter or one-fifth, the design could be adapted accordingly, although

in practice the “3+3” design is used without mention of the assumptions that

underlie its use).

The design proceeds in cohorts of three patients, in which the first cohort is

treated at the initial dose of interest, and the next cohorts are treated at increasing dose levels, as shown on the flowchart of Figure 8.2. The dose escalation stops as

soon as at least two patients experience DLT, either in the first cohort of three

patients treated at that dose level, or in the two cohorts of three patients treated

at that dose level. The recommended dose is usually defined as the dose level just

below the level at which DLTs were observed in at least two patients. This recom-

mended dose is considered to induce DLT in 15–25% of patients.

Although the classical “3+3” design is commonly used in phase I trials, it has

a number of limitations:

(a) Too many patients tend to be treated at low doses, with virtually no

chance of efficacy.

Start at minimum

dose level

Treat 3 patients

at this dose level

0 of 3

> 1 of 3

Nr with DLT

Go to next higher

MTD identified

dose level

No

1 of 3

Maximum dose

Treat 3 more patients

level (if any) ?

at this dose level

Yes

MTD not found

> 1 of 6

Nr with DLT

MTD identified

1 of 6

Figure 8.2 Flowchart for classical “3+3” dose-escalation scheme (DLT = dose-limiting toxicity, MAD = maximum administered dose).

1 7 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

(b) Dose escalation may be too slow because of an excessive number of

escalation steps, resulting in trials that take longer than needed to

reach the MAD.

(c) Too few patients tend to be treated near the MAD, which may result in

substantial residual uncertainty about the dose recommended for further

trials. If the recommended dose is too low, it may fail to demonstrate any

efficacy in phase II trials, while if the recommended dose is too high, it

may put patients at unacceptable levels of risk in phase II trials.

(d) The design carries a risk of recommending a dose below the MAD.

(e) The design lacks flexibility.

Some of these drawbacks are illustrated by the actual phase I trial of gemcitabine,

as shown in Figure 8.3 [2] . The first DLT did not occur until the ninth dose level

and the 27th patient. A total of 47 patients were treated at 13 dose levels, with

at least three patients at each dose level, before the MAD could be determined.



8.4 IMPROVEMENTS TO THE “3+3” DESIGN



Ad hoc solutions have been proposed to address some of the limitations of the

“3+3” design.



8.4.1 Accelerated titration

Using simulations based on a stochastic model fit to 20 phase I trials, Simon et al.

showed that “accelerated titration” may result in substantial savings in terms of

12

11

10

9

8

7

6

5

Dose level 4

3

2

1

0 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49

Subject number

Figure 8.3 Dose escalation using the classical design [2] . Patients experiencing a

dose-limiting toxicity are indicated by an open square.

Statistical Designs for First-in-Human Phase I Trials 175

number of patients treated at low doses as well as overall number of patients, at the expense of a slightly higher number of patients’ experiencing grade 3 or 4 toxicities

[3] . These authors considered several accelerated titration schemes, with the gen-

eral idea of initially treating only one patient per dose level, increasing the number of patients per cohort to three and reverting to a classical design as soon as the dose level is considered to have a high probability of being toxic; for instance, when a

DLT is observed in one patient, or grade 2 toxicities are observed in two patients.

Variations included doubling dose steps initially, and introducing intra-patient

dose escalation if only grade 0–1 toxicities were seen at the previous course.



8.4.2 Rolling six

An adaptation of the classical “3+3” design has been proposed to take advantage

of the following specificities (and related constraints) of phase I trials in children

[4] : (1) trials in children are initiated only after information on the safety and efficacy of the compound has already been documented in adults; (2) due to a strong

correlation between the MAD in adults and in children [5,6], only doses expected

to be active are explored; (3) phase I trials are integrated into clinical care of children with late-stage disease, and pediatricians as well as parents may favor continu-

ous accrual without suspension between two groups of three patients. The rol ing

six design allows for accrual of two to six patients concurrently onto a dose level

based on the number of patients currently enrolled and evaluable, the number of

patients experiencing DLTs, and the number of patients who have not completed

the evaluation period at the time of new patient entry. If data are not yet available for one or more of the first three participants, or if DLT has been observed, the

new participant is entered at the same dose level. Skolnik et al. [4] showed that

they obtained similar operating characteristics as with the “3+3” design (includ-

ing the same limits in terms of the chance of identifying the correct dose), while

reducing the number of patients skipped and shortening the overall trial duration.

However, Doussau et al. [7] showed that most of the patients who would have

been skipped were actually treated at doses below the optimal dose, thereby limit-

ing the expected benefit. The time-to-event continual reassessment method (see

Section 8.7) is an alternative approach in this context; it has been found to be

superior to the rol ing six design in terms of correct MAD identification.



8.4.3 Expanded cohort at recommended dose

It is often recommended, after DLTs have occurred, to treat an expanded cohort

(for example, 5 to 20 additional patients) at the recommended dose in order to

1 7 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

increase the level of confidence that this dose is indeed safe. Although this step is often carried out outside of any predefined designs [8] , it has recently been the

subject of more detailed attention. A formal justification for the size of this addi-

tional cohort may sometimes be provided, as outlined in Section 8.11.

These ad hoc solutions address some, but not all, of the problems associated

with the classical design. In fact, there is no formal statistical justification for the classical design. It is especially worrisome that this design does not guarantee

that the dose recommended corresponds to any given percentile of the distri-

bution function of the DLT probability [9] . Combined with the limitations

outlined above, this fact has led to a large body of literature devoted to designs

with better operating characteristics and a sounder statistical foundation. These

model-based designs will be discussed in sections 8.6 to 8.8.



8.5 OPERATING CHARACTERISTICS



8.5.1 Principles

Before turning to model-based designs, it may be useful to examine some of the “oper-

ating characteristics” of the classical design, and of variations of it [10]. Operating characteristics include the probabilities of stopping at each of the dose levels (i.e., the probabilities of finding the correct dose, and the probabilities of recommending

a dose that is too low or too high), the expected number of patients in the whole trial (which is a random variable), the expected number of patients treated at each dose

level, the expected number of patients with toxicities overall and at each dose level, and any other statistical quantity of interest. These operating characteristics can be either computed or obtained by simulation for various designs and for an assumed

distribution of the probability of a DLT at each dose level.



8.5.2 Comparisons of various algorithmic designs

For example, assume we wish to test seven increasing dose levels corresponding

to the dose–response relationship depicted by the blue dots in Figure 8.4. Note

that dose level 4 has a 33% probability of DLT, and is therefore the target dose at

which the trial should ideally stop. Figure 8.4 shows the cumulative probabilities

of stopping (i.e., the probabilities of stopping at a dose or at any previous dose)

for several designs, based on the following stopping rules.

(a) The ideal rule is one that stops exactly at dose level 4 (black line on

Figure 8.4); this rule has a probability of zero of stopping at any dose



Statistical Designs for First-in-Human Phase I Trials 177

99%

66%

Assumed probability of DLT

Rule of 3 + 3 , E(N)=11.7

Rule of 3, E(N)=6.5

Rule of 3 + 3 + 3, E(N)=16.1

Rule of 2 + 4, E(N)=12.6

Probability 33%

Rule of 3 + 1 + 1, E(N)=9.7

Ideal rule

0%

1

2

3

4

5

6

7

Dose level

Figure 8.4 Cumulative probabilities of stopping for various rules (E( N) = expected number of patients).

other than dose level 4. This ideal rule would require a very large

(strictly speaking, infinite) number of patients, so we need to find a

pragmatic rule that has acceptable operating characteristics with a

very small number of patients. Note that it is essential to use a fully

pre-specified stopping rule, unlike in Dagwood’s cartoon (Figure 8.5)!

(b) The simplest rule would be to stop as soon as at least one toxicity is

observed among three patients (upper gray line on Figure 8.4). As might

be expected, this rule is exceedingly conservative, and has an unaccept-

ably high probability of stopping before dose level 4 is reached.

(c) The 3+3 rule used in the classical design (red line on Figure 8.4). It has a

37% probability of stopping exactly at dose level 4 (the target dose with

33% DLTs), a 27% probability of stopping at dose level 3, and a 24%

probability of stopping at dose level 5; i.e., an 88% probability of stop-

ping at the target dose or at one of the adjacent dose levels. It has a 34%

probability of stopping below the target dose and a 29% probability of

stopping above the target dose. The expected sample size for this rule is

equal to 11.7 patients. Since the probabilities of stopping either too early

or too late with this rule are not negligible, is it possible to improve on it?

Figure 8.5 The dangers of using conditional tests to stop an experiment.

BLONDIE ©1996 by King Features Syndicate, Inc. World rights reserved.

1 7 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

(d) One could think of adding a third cohort of three patients if two out

of six patients experienced DLT at a certain dose level: this is the

3+3+3 rule. This rule mandates stopping as soon as at least three of

nine patients experience DLT. This rule has a lower probability than

the classical 3+3 rule of stopping earlier than at dose level 4, but it has

a larger probability of “overshooting” (stopping at a dose level higher

than 4) and a larger expected sample size (16.1 as compared to 11.7

for the classical 3+3 rule).

(e) One could use a 3+1+1 rule, also referred to as “best of five” in the

literature [9] . It is more aggressive than the other rules; i.e., it will tend

to stop with smaller numbers of patients and at higher doses.

(f) In theory, one could identify alternative rules that have operating char-

acteristics close to those of the classical 3+3 rule, but are better suited

to the specific drug being tested (e.g., more aggressive rules if the drug

is not expected to be very toxic). For instance, the 2+4 rule would

mandate that an additional cohort of four patients be added if 1 DLT

is observed in a first cohort of two patients, with the same stopping

criterion as for the classical 3+3 rule. Figure 8.4 shows that the prob-

abilities of stopping for this rule are very close to those for the rule of

3+3+3, but with a lower expected sample size (12.6 patients), which

may make it more desirable.

Considerable experience has been acquired with the classical design, and it has

been shown to work reasonably well empirically, which is why it remains the

standard for many phase I clinical trials. However, alternative designs based on a

more solid statistical foundation are worth exploring and should gain popularity

in the future.



8.6 CONTINUAL REASSESSMENT METHOD

The “continual reassessment method” (CRM), originally proposed by O’Quigley

and colleagues in the early 1990s, is a statistical approach based on the principle

that each patient should be allocated to the dose most likely to be the MAD;

in other words, the best current estimate of the MAD. Note that the American

definition of the MAD is used here—i.e., the dose recommended for phase II

trials. The current MAD is the dose for which the estimated risk of DLT is clos-

est to a predefined target (usually 20% to match the definition of the standard

design). Estimates of the risk of DLT are based on an assumed dose–response

relationship (the working model), which is described by a mathematical func-

tion linking the probability of dose-limiting toxicity and dose level [11]. There is

Statistical Designs for First-in-Human Phase I Trials 179

considerable freedom in the choice of a suitable mathematical function, the only

two requirements being that:

(a) the function should be monotonically increasing; i.e., such that the

probability of dose-limiting toxicity at any dose level is at least equal to

the probability of DLT at any lower dose level;

(b) the function should depend on only one “parameter,” which we

denote θ. This parameter is the quantity that determines the exact

shape of the dose–response relationship, as illustrated in the following

example.

A popular choice for the dose–response relationship is the logistic function,

which is shown n Figure 8.1 for the following family of functions:



p = exp k

( + θ × d) 1

/[ + exp k

( + θ × d)]

(1)

where p is the probability of DLT, d is the dose level, θ is the parameter, and k is some predefined value that should be chosen for each trial, depending on the

range of doses explored. Figure 8.1 shows that, for small values of θ, the probability of DLT increases very slowly at increasing dose levels, while for large values

of θ, the probability of DLT increases very sharply. This feature may make the logistic function undesirable, and many other functions can be entertained to

model the dose–response relationship. In particular another logistic parametri-

zation has been shown to be superior to the model (1) [28].



p = exp( θ + k × d) 1

/[ + exp( θ + k × d)]

(2)

Interestingly, it has been demonstrated that even under model misspecifica-

tions, with large sample sizes, the estimate of the MAD converges to the

“true” MAD [12], and with small sample sizes, the operating characteristics

are not strongly affected. This is an attractive property in first-in-man trials,

as the shape of the relationship between dose and toxic side effects—which

can be of any type induced by different mechanisms of action—is unlikely to

be known before treating the first patients. The particular choice made here

yields dose–response curves that appear plausible and that have been studied

in detail [13]. Careful evaluation of the selected design by simulation is never-

theless desirable.

Two approaches have been proposed to estimate parameter θ: the Bayesian

and the likelihood inference. The Bayesian formulation requires that an initial

guess be available for the probabilities of DLT as a function of dose. Such a guess

1 8 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

will generally be elicited from experts familiar with preclinical data, or clinical

data on similar drugs. In the example of Figure 8.1, it is assumed that seven dose

levels will be tested, with the following prior probabilities of DLT:

0.05 for dose level 1

0.10 for dose level 2

0.19 for dose level 3

0.33 for dose level 4 (target dose)

0.50 for dose level 5

0.70 for dose level 6

0.88 for dose level 7

In this example, dose level 4 is the target MAD—i.e., the dose level for which

33% of patients wil experience DLT. These prior probabilities of DLT fit the

model given by equation (1) with k = 3 and θ = 1, depicted as the line with solid circles in Figure 8.1.

Before any actual patient data have been observed, the value of θ is therefore equal to 1. A distribution is also specified for θ, which quantifies the uncertainty around this guess; for instance, a flat distribution (if all values of θ are thought to be equally likely) or a gamma distribution with mean 1 and a small variance (if it

is thought very likely that θ is close to 1), or a gamma distribution with mean 1

and a large variance (if the most likely value of θ is thought to be 1, but with other positive values for θ also likely). This is called a “prior” distribution for θ.

The CRM then proceeds as follows:

(a) The first patient is treated at the dose thought to be closest to the

MAD (i.e., the dose at which 33% of patients experience DLT). In our

example, before any patient is treated, the MAD is thought to be dose

level 4; hence the first patient should be treated at dose level 4.

(b) This patient may or may not experience DLT.

(c) Having observed whether or not this patient experienced DLT, the

posterior distribution of parameter θ is calculated (using a so-called

Bayesian method and all previous observations). The mean of this

posterior distribution yields an updated value of θ, which is in turn

used to update the probabilities of DLT at each dose level.

(d) The process is repeated from step (a) for the next patients, until a

pre-specified condition is met; for instance, that a certain number of

patients be treated at the same dose level, or that the probability to

maintain the same dose level in the next k patients (for instance, k = 5)

exceeds some probability such as 90% [14], at which point the trial

may stop.

Statistical Designs for First-in-Human Phase I Trials 181

The MAD is more accurately estimated when more patients are enrolled,

allowing this dose to be recommended to newcomers if the risk of DLT is

confirmed.

Alternatively, likelihood inference can be used to estimate θ, and the resulting method is sometimes denoted CRML (for Continual Reassessment Method

using Likelihood) [15]. Step (c) is then replaced by maximization of the likeli-

hood to update the estimate of θ and the probabilities of DLT at each step. No prior distribution is required. The main difference is that the likelihood cannot

be maximized before at least one DLT and one non-DLT have observed. The trial

is then split into two stages:

• the pre-DLT stage designed empirically using ad hoc rules. For instance,

dose levels are escalated after each new patient tolerates a level;

• the model-guided stage following the steps described above.

Operating characteristics are similar to those of the CRM. However, the Bayesian

approach may be misleading if the initial guess for the dose range is erroneous;

i.e., when the MAD proves to be much higher than anticipated.



8.7 VARIATIONS ON THE CONTINUAL

REASSESSMENT METHOD

The CRM is a general framework, and modifications can easily be implemented

to fit specific situations [13,16–19]:

(a) The first patient is treated at the lowest dose level based on animal

toxicology data (instead of the dose level thought to be closest to

the MAD).

(b) Several patients (e.g., 2) are treated at each dose level.

(c) Constraints are put on dose increases; e.g., the dose may increase by

only one level at a time.

Obviously, the advantage of the CRM in terms of expected sample size may then

be reduced. Figure 8.6 shows an example of dose escalation using a “modified”

CRM. The first three patients are treated at dose levels 1, 2, and 3, respectively,

without DLT. The fourth patient is treated at dose level 4 and experiences DLT,

at which time the dose is reduced to dose level 3 for the next three patients, none

of whom experience DLT. The dose is increased again to dose level 4, and back

to dose level 3 after observation of two further DLTs. Dose level 3 is finally pro-

posed as the recommended dose.

1 8 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

4

3

l

2

Dose leve

1

0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Subject number

Figure 8.6 Dose escalation using the continual reassessment method. Patients

experiencing a dose-limiting toxicity are indicated by an open square.

Simulation studies show that the CRM generally outperforms the classical

design [20,21]. Furthermore, the flexibility of model-based methods makes

them suitable for a wider range of situations:

• targeting a dose with a level of toxicity other than 20%;

• incorporating all observations, whether or not the design was strictly

followed (for instance, in the case of an error in drug delivery or an

additional patient);

• swift transition between dose escalation and the expansion cohort while

control ing for toxicity;

• extending the model to account for stratification (see below).

Although the CRM has met with some success, it has not been as popular as

it should have been in view of its potential benefits. Even though, a literature

review of phase I trials supported a more extensive implementation of innovative

dose escalation designs such as mCRM [22], two main reasons may explain the

limited success of the CRM (or modified CRM): first, the fear that the observa-

tion of a DLT at a low dose may penalize the CRM and end up with too low a

recommended dose (in contrast, the classical design is “memoryless” and will

continue to increase the dose regardless of DLTs at low dose levels); and sec-

ond, the empirical observation that the CRM may not lead to more rapid study

completion than the classical design, which has caused some investigators to

question whether its use in the clinic was worth the effort [23]. The actual reason

for the limited use of the CRM may, however, be that the method requires help

from a statistician, or the use of specialized software to carry out the calculations

Statistical Designs for First-in-Human Phase I Trials 183

needed after treatment of each patient. Free availability of such software on the

web might encourage wider use of the CRM (see, for instance, implementations

of the CRM that can be downloaded from the MD Anderson software download

website [24], from the Comprehensive R Archive Network (CRAN) website

[25], from the Cedars-Sinai download website [26] or from reference [27].

Further refinements and extensions of the CRM based on the flexibility of

model ing have been described in the literature:

(a) The CRM can use an ordinal response (such as grades 1 through to

4 toxicity), rather than a simple binary response (such as grade 3 or

4 DLT), assuming that increasing the dose has a similar impact on

the risk of grade 2 and grade 3 toxicity (odds-proportional assump-

tion). Although this approach may accelerate the dose-escalation

stage by rapidly escalating for as long as only mild toxicity is observed,

it does not provide any substantial benefit in terms of correct

recommendations [28].

(b) The CRM can be extended to use two-parameter models, rather than

the single parameter θ, to describe the dose–response relationship

[29]. The operating characteristics are then more dependent upon the

prior specification of the expected risk of DLT at each dose level. With

non-informative priors, a one-parameter model outperforms more

flexible models [30].

(c) The stratified CRM (or “two-sample” CRM) allows the population of

patients to be subdivided into two or more groups with distinct risks

of DLT: a group of “healthier” patients and a group of “sicker” patients

(due to renal dysfunction, heavier pre-treatment etc.). The trial starts

without distinguishing between the two strata, but dose escalation

becomes stratum-specific following the observation of toxicities, so

that the recommended dose may be different in the two strata. Prior

expectations on the group difference can be incorporated [31]. For

instance, the MAD in heavily pre-treated patients should be less than

or equal to the MAD of the less heavily pre-treated patients.

(d) The standard CRM pauses until each patient or group of patients has

been observed long enough to have had an opportunity to develop

DLT. A modification using time-to-event information (TITE-CRM)

allows continual enrollment of patients, assigning fractional weights to

patients who have not experienced toxicity but have not yet com-

pleted the observation period [32,33]. For instance, suppose an obser-

vation period lasts four months but reassessment is carried out after a

patient has tolerated the treatment for two months and is followed up;

this patient will be down-weighted and count as “half” a patient until

1 8 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

follow-up is extended. This modification proves to be of great inter-

est in radiotherapy trials with delayed toxicity, or in pediatric trials to

maximize patient accrual and limit trial duration [34].



8.8 OTHER MODEL-BASED DESIGNS



The CRM is not the only design based on a mathematical model [35]. Other

designs have been proposed and compared with the CRM. Although there are

situations in which they perform better than the CRM, it is unlikely that any

design would be uniformly better in all situations, and differences in operating

characteristics are usually modest.



8.8.1 Escalation with overdose control (EWOC)

These designs use a Bayesian approach to constrain the proportion of patients

who will receive a dose higher than the MAD [36]. They are designed to reach

the MAD as rapidly as possible, subject to the constraint that the predicted pro-

portion of patients who receive a dose exceeding the MAD does not exceed a

predefined value. Instead of providing the point estimate of the risk of DLT at

a given dose, the full distribution of the probability of toxicity is used to quan-

tify the probability that a dose will be too high or too low. Simulations of this

approach show that fewer patients are treated at severely toxic levels. However,

it tends to be more conservative and requires more flexible models and hence

more informative priors. In particular, good asymptotic properties are no longer

obtained under model misspecification. This is the method of choice of some

pharmaceutical companies [37]. Extension to time-to-event outcome has also

been proposed [38].



8.8.2 Isotonic regression

The idea behind isotonic regression is to estimate the probabilities of toxicity

at each dose level subject to the constraint that the dose–response relationship

is monotonically increasing [39]. One instance in which such an approach may

be particularly advantageous is when two risk groups can be formed, in which

case dose escalations in the two risk groups are linked through a two-way iso-

tonic regression [40]. One very attractive feature of this approach is that it

requires almost no assumptions and proceeds only on the basis of observed

toxicity rates.

Statistical Designs for First-in-Human Phase I Trials 185



8.8.3 Modified toxicity probability interval (mTPI)

The modified toxicity probability interval (mTPI) method defines an equiva-

lence interval (EI) for the target DLT probability. For instance, if the target DLT

probability is 33%, EI could be defined as 28% to 38%, and any dose in EI could

be designated as the MAD. Dose adaptations consider the three intervals rang-

ing from 0 to the lower limit of EI, the EI itself, and from the upper limit of EI

to 1. Patients are sequentially enrolled by groups of one to three patients, and

posterior probabilities for EI are calculated using a Bayesian model and observed

toxicity data at each dose level [41]. No assumption on the dose–toxicity rela-

tionship is requested, but inference at each dose level only uses data collected

at this level. Prior specification at each dose level may be challenging. An Excel

spreadsheet is available to implement this method [42].



8.9 HOW WELL CAN WE EVER DO?

The question “How well does a specific approach do?” leads to the other ques-

tion: “How well can we ever do?” In Section 8.5.2, we described an ideal rule

that would always identify the correct dose—providing we could accrue a large

number of patients. In small samples, this rule is unrealistic due to the random

fluctuations inherent to any biological experiment. Alternatively, a so-called opti-

mal method has been proposed to serve as a benchmark in simulation studies to

quantify the best performance that can be obtained, given a dose–toxicity rela-

tionship and a fixed sample size [43]. The optimal-method approach relies on a

notion of “complete” information, as if a patient could be independently treated

at each dose level. Complete information is then summarized by the lowest dose

at which the patient would experiment DLT, which could be generated if the true

dose–toxicity relationship were known. Note that the method cannot be used in

real trials (where a patient is exposed to a single dose), but it can serve in a simulation setting. Complete information for a simulated sample of patients provides

the observed frequency of DLT at each level: see Table 8.1 for an example in 16

patients. One can select the dose closest to the target as the best estimate of the

MAD given a particular sample size and given a dose–toxicity relationship. In

the example of Table 8.1, the third dose appears the closest to our pre-specified

target of 20%. This optimal method illustrates the limitations of the dose-finding

process [44]. In a large set of scenarios, the highest probability of selecting the

right dose without an informative prior after 25 patients was less than 60%. Any

dose-finding method is limited by the variability induced by the binary outcome

of interest (DLT or no DLT). In statistical terms, the primary outcome of phase

I trials is poorly informative. It is in fact regrettable that so few data are used for

1 8 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 8.1. Complete Information Generated for a Simulated

Sample of 16 Patients Exposed to an Agent With a Known Dose–

Toxicity Relationship

Toxicity at dose level

d

d

d

d

d

d

1

2

3

4

5

6

True probability

0.05

0.11

0.22

0.35

0.45

0.60

of toxicity

Patient j

sj

1

6

0

0

0

0

0

1

2

2

0

1

1

1

1

1

3

4

0

0

0

1

1

1

4

5

0

0

0

0

1

1

5

–

0

0

0

0

0

0

6

1

1

1

1

1

1

1

7

–

0

0

0

0

0

0

8

3

0

0

1

1

1

1

9

–

0

0

0

0

0

0

10

6

0

0

0

0

0

1

11

4

0

0

0

1

1

1

12

–

0

0

0

0

0

0

13

3

0

0

1

1

1

1

14

–

0

0

0

0

0

0

15

6

0

0

0

0

0

1

16

4

0

0

0

1

1

1

Empirical frequencies

0.06

0.13

0.25

0.44

0.50

0.69

Abbreviations: s is the lowest dose at which patient j would experiment DLT; j

d , d , . . ., d denote the six dose levels. Empirical frequencies are the observed fre-1

2

6

quencies of DLT observed in this simulated sample.

decision-making in phase I trials, with so much further data (e.g., lower-grade

toxicities or laboratory values) available. Future improvements in dose-finding

designs will result from the incorporation of more information, rather than from

a refinement of the methods described above.



8.10 DOSE-ESCALATION DESIGNS FOR

COMBINATION TREATMENTS



Combination treatments raise specific concerns, as two compounds can possibly

be escalated to identify the pair of doses that is the MAD. Suppose that four doses

of each treatment can be escalated: then 16 combinations theoretically exist.

Statistical Designs for First-in-Human Phase I Trials 187

Dose-finding is bi-dimensional, but information on the dose–toxicity relationship

of each single agent is usually available at the time of initiation of the trial. Three situations can be identified: the first two situations correspond to one-dimensional

dose-finding where the previously described methods can apply.



8.10.1 Investigational agent X added to some backbone therapy A

In this scenario, activity of the “backbone therapy” (A) is known, and dose

reduction is not envisaged. The objective of the phase I trial is then to introduce

the new agent, X, in addition to A, and only X will be escalated. The main issue

is the definition of the target. If A is given at full dose, 20–30% of patients may

experience toxicity due to A. Any addition of an extra agent may then increase

toxicity beyond tolerable levels. To address this issue, the DLT can be defined as

any toxicity specifically related to X. However, this relationship is often extremely difficult to assess. In addition, it can be argued that the causality of toxic side

effects to either agent does not make any difference to patients. Alternatively, a

higher target can be pre-specified, providing it is still tolerable.



8.10.2 Ordered combinations: investigational

agent X added to adaptable therapy A

In this scenario, both agents can be escalated, but priority is given to increas-

ing the dose of A (typically, A has already been demonstrated to be active). An

ordering can then be constructed so that the risk of toxicity increases for each

new combination studied: (d(X), d(A)) < (d(X), d(A)) < (d(X), d(A)) < . . .

1

2

3

An illustration of two possible escalation schemes verifying this ordering is pre-

sented in Figure 8.7. Once again, no specific dose-finding methods are necessary.

With the CRM, any pair of doses (d(X), d(A)) can be coded d and the same

i

i

model-based approach as for a single agent will be followed. Prior information

derived from single-agent trials can easily be integrated by assuming possible

interactions between the two agents [45].



8.10.3 No ordering: two investigational agents X and Y

In the third scenario, dose-finding is performed freely in two dimensions, which

increases the number of potential dose combinations to be tested (three doses

of each agent would yield nine possible combinations). Specific methods have

been proposed to model the risk of DLT in terms of each compound’s accounting

for potential interactions. More parameters are then necessary, raising additional

difficulties. A first approach is to create partial ordering; in practice, a series of

1 8 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

Agent A

d1

d2

d3

d4

d4

d

X

3

Agent

d2

d1

Figure 8.7 Grid for associations of two agents, A and X, with two possible partial

orderings: orange where A is known to be active at the MAD and needs to be escalated

first, and blue where escalating both agents is desirable, with a preference for A.

one-dimensional sub-trials is run with the CRM by fixing one drug at a single

dose and by escalating the other. The MAD identified from one “sub-trial” can

be used to limit the dose range for the next “sub-trial” [46]. A second approach

is to search in all directions, selecting pairs as close as possible to the target.

Furthermore, pairs with the same estimated level of DLT may be qualified as

equally desirable and can be ranked on secondary endpoints. These approaches

are sophisticated and require excellent statistical support. Specific “user-friendly”

software for this is not available at the present time.



8.11 EXPANSION COHORTS AND PHASE I AND II TRIALS



As discussed in Section 8.10, small sample sizes entail large uncertainty in the

final recommendations of a phase I trial. Therefore it is common practice to

enroll additional patients at the MAD in a so-called expansion cohort. Statistical

objectives and endpoints should be predefined for expansion cohorts, which is

unfortunately not always done [10]. The most common endpoints include toxic-

ity, preliminary signs of activity, and pharmacokinetic assessment.



8.11.1 Refining the toxicity assessment

To more accurately characterize the toxicity profile and reassess the MAD, a

fixed, dynamic, or randomized design can be envisaged [47]. The most common

Statistical Designs for First-in-Human Phase I Trials 189

approach is to treat a fixed cohort of patients at the MAD and to retrospectively

analyze the data. The sample size can be computed either to reach a certain level

of precision on the confidence interval of the risk of DLT, or to detect an event

of interest with a certain probability. If no event has been observed among N

patients treated at the explored dose, there is 95% confidence that the true event

rate does not exceed 1-N√0.05 (see next subsection).

In a literature review, 13% of the expansion cohorts led to a reduction of the

dose recommended for phase II [8] . To limit the risk of over-exposing patients,

a dynamic design can be used with reassessment of the risk of DLT after each

observation or group of observations. Model-based designs such as the CRM or

sequential probability ratio tests can also be implemented.

Randomization between two doses is attractive, as discussed in Section 8.13.

Although uncommon, this approach is increasingly considered in the context of

biological agents where the optimum biological dose or the minimum biological

dose (i.e., the minimum dose that provides maximum inhibition of the target)

is lower than the MAD, and both are good candidates for further explorations.



8.11.2 Assessing the activity



Although the purpose of phase I trials is not to test the antitumor activity of a

new therapy, it is of interest to document any signs of activity, which may help in

planning further trials with the therapy, despite the small size of phase I trials. For instance, the sample size may comprise 16 patients (six patients initially treated at that dose, plus an additional cohort of ten patients). If that cohort is enriched or

restricted to the patient types that are likely to respond to the agent, it may closely resemble a small phase II trial embedded in the phase I trial; therefore, similar

statistical considerations as for phase II trials may be contemplated. It is debatable whether this approach is preferable to running an independent, definitive phase II

trial with proper size and clear inclusion criteria. However, considerations of cost

and speed may make this approach attractive, in which case it is important to out-

line explicit plans for it in the trial protocol. The boundary between phase I and

II trials is particularly questionable in the development of targeted agents [48].

Let us assume in what follows that activity can be measured by a binary out-

come called a “response” (such as a response of measurable disease by Response

Evaluation Criteria in Solid Tumors (RECIST), a response of a relevant tumor

marker, inhibition of a target, etc.).



8.11.2.1 No Signs of Activity

If no response has been seen among N patients treated at the recommended dose, there is 95% confidence that the true response rate does not exceed 1-N√0.05.

1 9 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 8.2. Response Rates That Can Be Excluded With Given

Confidence if no Response is Seen Among N Patients

N

95% confidence

90% confidence

80% confidence

10

26%

21%

15%

11

24%

19%

14%

12

23%

18%

13%

13

21%

17%

12%

14

20%

16%

11%

15

19%

15%

11%

16

18%

14%

10%

17

17%

13%

9%

18

16%

12%

9%

19

15%

12%

9%

20

14%

11%

8%

25

12%

9%

7%

30

10%

8%

6%

35

9%

7%

5%

40

8%

6%

4%

More generally, if no sign of activity has been seen among N patients treated at the recommended dose, there is (1−c)% confidence that the true response rate

does not exceed 1−N√c. Table 8.2 shows the response rate that can be excluded

with a given confidence if no response has been observed among N patients.



8.11.2.2 Some Signs of Activity

More promising is the situation in which some responses are seen among N

patients treated at the recommended dose. Table 8.3 provides the exact (bino-

mial) confidence limits of the response rate for various numbers of patients and

of responses that are likely to be seen in phase I trials. In practice, early signs of activity are important, but the confidence limits of the observed response rate

are not.

Thus, in contrast to phase II trials in which responses are the primary out-

come, responses observed in phase I trial are generally anecdotal and not sub-

ject to a rigorous statistical assessment, unless the trial protocol has a clear

phase II section focused on assessment of the drug’s activity. One of the major

constraints of this approach, once again, is the binary nature of the outcome.

Binary response is not informative enough, statistically speaking, to explore a

dose–activity relationship [49,50], clinical benefit, or mechanisms of action. In

phase I trials, endpoints more closely related to tumor biology are preferable,

when available.

Table 8.3. Response Rates That Can Be Excluded With Given

Confidence, as a Function of the Number of Patients Treated and

the Number of Responses Observed

Number of

Number of With 90% confidence, the true response rate is:

patients

responses

at least equal to

at most equal to

10

0

0%

21%

1

0%

39%

2

4%

51%

3

9%

61%

4

15%

70%

5

22%

78%

6

30%

85%

7

39%

91%

8

49%

96%

9

61%

99%

10

79%

100%

13

0

0%

16%

1

0%

32%

2

3%

41%

3

7%

49%

4

11%

57%

5

17%

65%

6

22%

71%

7

29%

78%

8

35%

83%

9

43%

89%

10

51%

93%

11

59%

97%

12

68%

100%

13

84%

100%

16

0

0%

13%

1

0%

26%

2

2%

34%

3

5%

42%

4

9%

48%

5

13%

55%

6

18%

61%

( continued)

1 9 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 8.3. (Continued)

Number of

Number of With 90% confidence, the true response rate is:

patients

responses

at least equal to

at most equal to

7

23%

67%

8

28%

72%

9

33%

77%

10

39%

82%

11

45%

87%

12

52%

91%

13

58%

95%

14

66%

98%

15

74%

100%

16

87%

100%



8.12 INTEGRATING BIOLOGICAL

MEASURES INTO PHASE I DESIGNS



Translational research and measures of biomarkers (or biological endpoints) are

an integral part of most phase I trials of targeted agents. For the purposes of this

discussion, “targeted agents” refers to targeted non-cytotoxic drugs or agents that

act via immunological mechanisms. Biomarkers may have several roles; in the

remainder of this section, we identify three settings requiring different types of

designs.



8.12.1 Elucidating the mechanism of action

Under the paradigm that targeted treatments are expected to be effective only in

a subpopulation of all patients, the objective is to identify patients who benefit

from treatment. Biomarkers that reflect the biological activity of the compound

(inhibition of the target in the tumor or surrogate tissues, imaging changes, etc.)

are measured. These biomarkers are further correlated with clinical activity, if

any, to select populations that can then be investigated in expansion cohort(s). In

such situations, the design is a phase I/II design: the MAD is identified in patients with any tumor type, using previously described methods. Data generated during the escalation stage are retrospectively assessed to characterize responders.

The expansion cohort in this subpopulation is then aimed at documenting the

response rate and/or confirming activity in a specific patient subpopulation. The

expansion cohort can be designed as a phase II trial, using classical designs as

Statistical Designs for First-in-Human Phase I Trials 193

proposed by Gehan, Fleming, or Simon. Biomarkers can be assessed retrospec-

tively, often using material collected at baseline only. Crizotinib is a successful

example of this type of design [51]. Limitations of this approach are that the

prevalence of the target may be quite low, the predictive accuracy of the biomarker

may be moderate in refractory patients, and identification of the adequate target

may be challenging. In the example of crizotinib, one clinical response was luck-

ily observed during the dose-finding part of the trial. More than 2,000 patients

had to be screened in order to enroll 149 patients in the expansion cohort.



8.12.2 Enriching phase I populations

Although the primary objective of phase I trials is to determine the optimal dose,

the main expectation of patients and investigators is to observe clinical activity.

Under the assumption that the presence of the target maximizes the chance of

clinical benefit, patients presenting the target are selected. As the prevalence of

the molecular abnormalities of tumors targeted by treatments is often low, some

phase I centers propose testing the cancer genetics and linking this screening to

a panel of phase I trials of drugs, each designed to target a specific abnormal-

ity. Measuring a panel of potential targets together with a large portfolio of tri-

als increases the range of possible matching, a strategy currently implemented in

several large cancer centers.

The primary endpoint of enriched phase I trials remains toxicity, but greater

emphasis is placed on secondary endpoints, including clinical response and

tumor growth index. The tumor growth index is an attempt to control for patient

heterogeneity by using the patient as his/her own control. Promising drugs

should slow down tumor growth compared to the “natural history of the disease.”

Enriched phase I trials make the very strong assumption that the target is fully

characterized before initiation of the trial, which is more likely to be the case for second-in-class agents. Enriching the population as early as in phase I reduces the

chance of discovering different mechanisms of action and potential responders.

As such, it may be a counterproductive strategy for first-in-class agents.



8.12.3 Guiding dose escalation

The mechanism of action of cytotoxic agents inducing tumor shrinkage is similar

to that inducing toxicity: the optimal dose is defined as the maximum dose. In

contrast, the optimal dose for biological agents may be the minimum dose that produces a desirable biological outcome in a sufficiently large pre-specified proportion of patients. The biological outcome of interest depends on the mode of

1 9 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

action of the agent under consideration, and defining such an outcome may be

the most challenging aspect of designing a relevant trial. For now, let us assume

that there exists an assay that is feasible, reproducible, and with real-time results, to assess the biological effect of the agent. This assay may reflect changes in a

target biomarker in the tumor or surrogate tissues, changes in imaging, or clinical

manifestations of the agent’s activity.

One could hypothesize a dose–response curve giving the probability of observ-

ing biological activity (BA) at each dose level tested, as described for the prob-

ability of observing DLT in Section 8.3. The dose of interest could be either the

minimum biologically active dose (MBAD), i.e., the lowest dose that produces

the desired biological activity in a given proportion of patients; or the optimum

biologically active dose (OBAD), i.e., the dose that produces the desired biologi-

cal activity in the largest proportion of patients (assuming that the dose–response

relationship for biological activity is no longer monotonically increasing as was

assumed for toxicity). The latter goal is more challenging and generally requires

many more patients than are typically studied in phase I trials [52].

If we focus on identification of the MBAD, designs similar to the classical

design outlined in Section 8.4 can be entertained. Figure 8.8 shows a flowchart

appropriate for the determination of the MBAD. Note that this design is based

on intuitively reasonable rules rather than on formally justifiable statistical criteria. This design is known as the “5/6 design,” since it stops when biological activ-

ity is seen in five out of six patients. Its characteristics, and those of other, similar designs appropriate to detection of biological activity, have been studied by simulation [53]. This design has a 96% probability of escalating if the true proportion

of patients with biological activity is 0.9, and an 11% probability of escalating if

the true proportion of patients with biological activity is 0.4. A maximum dose

level can be pre-specified to avoid trials that continue to escalate the dose after

the level of biological activity has reached a plateau below the target level.

The MBAD should obviously be sought subject to a toxicity constraint. This

design could in fact be used in conjunction with one of the designs discussed

above to identify the maximum tolerated dose. At each dose level, one looks for

either biological activity or DLT, with the latter prevailing, in such a way that

dose escalation stops as soon as the MAD is reached. As mentioned above, it

may be difficult to identify an outcome that reliably reflects biological activity,

and even more difficult to pre-specify the level of activity, and it may therefore

be appropriate to use a MAD-driven design to escalate to a maximum dose that

is tolerable, with biological effect being a secondary outcome [54]. However,

biologically based escalation designs have the potential of recommending lower

doses than would be obtained from MAD-driven designs, which may be quite an

advantage if the agent needs be associated with other toxic treatments. It is also

noteworthy that the compliance of some active targeted agents, such as imatinib

Statistical Designs for First-in-Human Phase I Trials 195

Start at minimum

dose level

Treat 3 patients

at this dose level

0–1 of 3

Nr with BA

Go to next higher

dose level

No

2–3 of 3

Maximum dose

Treat 3 more patients

level (if any) ?

at this dose level

Yes

5–6 of 6

MBAD not found

Nr with BA

MBAD identified

2–4 of 6

Figure 8.8 Flowchart for biologically based dose-escalation scheme. (BA = biological activity, MBAD = minimum biologically active dose)

in gastrointestinal stromal tumors, or aromatase inhibitors in breast cancer, is

as low as 50%, which shows the importance of identifying the MBAD of these

agents reliably in phase I trials.



8.13 RANDOMIZATION AND STRATIFICATION

Phase I trials have seldom used randomization and stratification. Randomization

can be considered not only to produce comparable groups, which is generally

not required in phase I trials, but also to reduce the opportunity for selection

bias whereby patients who enter the trial are selected differently depending on

the dose level. For instance, healthier patients could be selected when the dose

gets close to the MAD. Randomized schemes could be considered; e.g., as part

of a CRM design.

Stratification could also be useful when distinct subsets of patients are known

to exist; e.g., “healthier” patients versus “sicker” patients. In this case, the stratified CRM (Section 8.7) or isotonic regression (Section 8.8.2) could be used

to determine stratum-specific MADs using prior information on the expected

between-strata difference. Another situation that may become increasingly com-

mon is when a subset of patients expresses a target of interest, but the phase I trial does not have to be limited to that subset. Instead, patients could be stratified

based on target expression.

1 9 6

P H A S E I C A N C E R C L I N I C A L T R I A L S



8.14 TOWARDS NEW DEFINITIONS

OF DOSE-LIMITING TOXICITY

Classical paradigms are challenged with targeted agents, as these agents are often

administered until progression, display wider therapeutic ranges, and are associ-

ated with a certain risk of cumulative or late toxicity. Evaluation of moderate but

chronic toxicity is becoming a key issue. To date, the definition of DLT—i.e.,

clinical and biological events that require reducing the dose—as well as the tim-

ing for evaluating DLT are very heterogeneous across trials [55]. Although the

toxicity profile is different from drug to drug, the DLT must be defined upfront

in the protocol. Some recommendations to ensure comparability across trials

have been proposed by an EORTC-led task force [1] :

1. Timing of dose escalation should be based on data from cycle 1.

2. DLT assessment needs to take into account selected lower-grade toxicities

leading to significant reductions in relative dose intensity (RDI < 75%).

3. Dose expansion cohorts should focus on fine-tuning the dose-defining

process.

4. The dose recommended for further studies:

• should incorporate all available information, notably toxicities

observed after cycle 1,

• should be based on achieving > 75% RDI.

Although no follow-up on these recommendations is available at this time,

using information collected at all cycles to recommend the best dose for phase II

appears very reasonable. The cumulative risk of events can be estimated from the

data using models such as in the TITE-CRM. This method addresses the issue of

patients who go off-study due to progressive disease after one or two cycles and

who cannot be evaluated for toxicity for longer periods. Statistical methods have

also been proposed to estimate the risk of toxic events per cycle. Longitudinal

models for binary or ordinal endpoints are applicable and allow investigation

of the time-course of the risk of DLT in order to detect cumulative or delayed

adverse events. However, due to the small median number of cycles of treatment

administered in most phase I trials, the power of any statistical method to detect

late/cumulative effects will be low, and such effects will generally have to be stud-

ied in later-phase trials.



REFERENCES

1. Postel-Vinay S, Collette L, Paoletti X, et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for

Statistical Designs for First-in-Human Phase I Trials 197

further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity

Assessment Recommendation Group for Early Trials of Targeted Therapies, and

European Organisation for Research and Treatment of Cancer-led study. Eur J

Cancer. 2014;50:2040–2049.

2. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498.

3. Simon R, Friedlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138–1147.

4. Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase I trials: the rol ing six design. J Clin Oncol. 2008;26:190–195.

5. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol. 2005;23:8431–8441.

6. Paoletti X, Geoerger B, Doz F, Baruchel A, Lokiec F, Le Tourneau C. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’

trials. Eur J Cancer. 2013;49:2392–2402.

7. Doussau A, Asselain B, Le Deley MC et al. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework. Contemp Clin Trials. 2012;33:657–665.

8. Manji A, Brana I, Amir E et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

J Clin Oncol. 2013;31:4260–4267.

9. Storer BE. An evaluation of phase I clinical trial designs in the continuous

dose-response setting. Stat Med. 2001;20:2399–2408.

10. Reiner E, Paoletti X, O’Quigley J. Operating characteristics of the standard phase I clinical trial design. Comput Stat Data An. 1999;30:303–315.

11. O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33–48.

12. Shen L, O’Quigley J. Consistency of continual reassessment method under model

misspecification. Biometrika. 1996;83:395–405.

13. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the con-

tinual reassessment method for phase I studies. Stat Med. 1995;14:1149–1161.

14. O’Quigley J and Reiner E. A stopping rule for the continual reassessment method.

Biometrika. 1998;85:741–748.

15. Shen LR, O’Quigley J. Continual reassessment method: a likelihood approach.

Biometrics. 1996;52:673–684.

16. Faries D. Practical modification of the continual reassessment method for phase

I cancer clinical trials. J Biopharm Stat. 1994;4:147–164.

17. Möller S. An extension of the continual reassessment method using a preliminary up and down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med. 1998;14:911–922.

18. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified con-

tinual reassessment method for dose-finding trials. Cancer Chemo Pharmacol.

1998;41:429–436.

19. Heyd JM, Carlin BP. Adaptive design improvement in the continual reassessment

method for phase I studies. Stat Med. 1999;18:1307–1321.

1 9 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

20. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive com-

parison of the continual reassessment method to the standard 3 + 3 dose escalation

scheme in Phase I dose-finding studies. Clin Trial. 2008;5:465–477.

21. Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med.

1998;17:1537–1549.

22. Le Tourneau C, Gan HK, Razak AR, Paoletti X. Efficiency of new dose escalation

designs in dose-finding phase I trials of molecularly targeted agents. PLOS One.

2012; 7(12): e51039.

23. Eckhardt S, Siu L, Clark G, et al. The continual reassessment method for dose escalation in phase I trials in San Antonio does not result in more rapid study completion.

Proc Am Soc Clin Oncol. 1999;18:163.

24. An Optimal Bayesian phase I clinical trial design for finding the maximum tolerated dose (MTD). http://biostatistics.mdanderson.org/SoftwareDownload/ (accessed October 19, 2014).

25. Dose-finding by the continual reassessment method. http://cran.r-project.org/

web/packages/dfcrm/index.html (accessed October 19, 2014).

26. The Integrated Web Portal for Escalation with Overdose Control (EWOC) http://

biostatistics.csmc.edu/ewoc/ (accessed October 20, 2014). The Open Medical Informatics Journal, 2013; 7: 18–23.

27. Kramar A, Houédé N, Paoletti X. NP1: a computer program for dose escalation

strategies in phase I clinical trials. Comput Meth Prog Bio. 2007;88:8–17.

28. Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Proportional odds model

for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med.

2011;30:2070–2080.

29. Braun TM. The bivariate-continual reassessment method. Extending the

CRM to phase I trials of two competing outcomes. Control Clin Trials.

2002;23:240–256.

30. Paoletti X, Kramar A. A comparison of model choices for the continual reassessment method in phase I cancer trials. Stat Med. 2009;28:3012–3028.

31. O’Quigley J, Paoletti X. Continual reassessment method for ordered groups.

Biometrics. 2003;59:430–440.

32. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177–1182.

33. Muller J, McGinn C, Normolle D, et al. A phase I trial using the time-to-event continual reassessment strategy to escalate cisplatin with gemcitabine and radiation

therapy for pancreatic cancer. J Clin Oncol. 2004;22:238–243.

34. Polley MY. Practical modifications to the time-to-event continual reassessment

method for phase I cancer trials with fast patient accrual and late-onset toxicities.

Stat Med. 2011;30:2130–2143.

35. Storer BE. Phase I clinical trials. In: Encyclopedia of Biostatistics. New York: Wiley; 1998:3365–3370.

36. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103–1120.

37. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian

approach to phase I cancer trials. Stat Med. 2008;27:2420–2439.

Statistical Designs for First-in-Human Phase I Trials 199

38. Mauguen A, Le Deley MC, Zohar S. Dose-finding approach for dose escalation

with overdose control considering incomplete observations. Stat Med. 2011;30: 1584–1594.

39. Leung D, Wang Y. Isotonic designs for phase I trials. Control Clin Trials. 2001; 22:126–138.

40. Yuan Z, Chappell R. Isotonic designs for phase I cancer clinical trials with multiple risk groups. Clin Trials. 2004;1:499–508.

41. Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7:653–663.

42. Ji Y, Wang S-J. Modified toxicity probability interval design: a safer and more

reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol.

2013;31:1785–1791.

43. Paoletti X, O’Quigley J, Maccario J. Design efficiency in dose finding studies. CSDA.

2004;45:197–214.

44. Christian MC, Korn EL. The limited precision of phase I trials. J Natl Cancer Inst.

1994;86:22.

45. Kramar A, Lebecq A, Candalh E. Continual reassessment methods in phase I trials

of the combination of two drugs in oncology. Stat Med. 1999;18:1849–1864.

46. Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Stat Med. 2008;27:5664–5678.

47. Iasonos A, O’Quigley J. Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol. 2013;31:4014–4021.

48. Col ins JM. Innovations in phase I trial design: where do we go next? Clin Cancer Res.

2000;6:3801–3802.

49. Postel-Vinay S, Arkenau HT, Olmos D et al. Clinical benefit in Phase-I tri-

als of novel molecularly targeted agents: does dose matter ? Br J Cancer.

2009;100:1373–1378.

50. Gupta S, Hunsberger S, Boerner SA, et al. Meta-analysis of the relationship

between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst.

2012;104:1860–1866.

51. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Lancet Oncol. 2012;13:1011–1019.

52. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265–272.

53. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med. 2005;24:2171–2181.

54. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst. 2004;96:997–998.

55. Le Tourneau C, Razak AR, Gan HK, et al. Heterogeneity in the definition of

dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents.

Eur J Cancer. 2011;47: 1468–1475.





9

Writing the Protocol

P E N E L O P E A . B R A D B U R Y A N D

E L I Z A B E T H A . E I S E N H A U E R ■



9.1 INTRODUCTION

A carefully conceived and written protocol document is essential for the conduct

of the phase I trial. The rationale for the study, background drug information,

population to be included, selection of starting dose, how escalation will pro-

ceed, and the endpoints that will be employed are all vital elements. Furthermore,

description of how data will be analyzed and decisions made regarding dose esca-

lation and phase II dose recommendations must be included. This chapter will

detail and offer examples of all these basic protocol elements for a phase I first-in-human trial. Where relevant, comments on how these elements should be modi-

fied for combination phase I trials will be included.



9.2 OUTLINE OF THE PROTOCOL

Table 9.1 provides a list of major section headings found in a phase I protocol.

There is no internationally accepted standard protocol template, so some vary in

terms of the order in which these sections are provided, but the content of the

protocol includes sections as described in Table 9.1. The descriptions of protocol

sections that follow will be in the same order as is shown in Table 9.1.



9.3 BACKGROUND INFORMATION



9.3.1 First-in-human studies

For first-in-human studies of new agents, the disease-background section is generally short, since many trials include a variety of cancer types. If not, and if entry is

Table 9.1. Elements of the Phase I Protocol Document

Section

Description

Study schema

Summary of the essential elements of the study. This should be

simple and reflect the study objectives. It should highlight the

population, treatment plan, and follow-up.

Background and

For the disease (if disease-specific trial): for combination

rationale

trials—description of standard treatment of disease and why the

combination agent is justified. Where will it lead?

For a new single-agent drug: In addition to disease background

(if appropriate), basic information on new drug chemistry,

preclinical efficacy, toxicology, pharmacology, and if appropriate,

results of other clinical work.

Objectives

Describes the primary and secondary objectives of the study.

The primary objective of a phase I trial is to define the recom-

mended dose of the new drug when given according to the

protocol schedule.

Patient population Inclusion and exclusion criteria should be easily verifiable at the time of patient enrollment. Generally divided into major concep-tual categories:

a) Criteria regarding the patient status (e.g., performance status,

organ function, non-pregnant, etc.)

b) Criteria regarding the disease status (e.g., number of and

nature of prior treatment permitted, time since last treatment)

c) Criteria specific to the drug: (e.g., able to swallow oral meds,

minimum levels of special studies such as LVEF [left ventricu-

lar ejection fraction])

d) Criteria specific to the study (e.g., consent obtained for tissue

biopsy)

Trial design

Define primary endpoint (usually DLT).

Define starting dose.

Define DLT (or however else escalation will be limited), maxi-

mum tolerated dose (or maximum available dose), recommended

phase II dose.

Describe escalation scheme, number of patients per dose level,

how decisions about entry in next level or expansion of dose

levels will be determined. Indicate if patient entry on to cohorts

will be randomized or assigned.

Treatment

Treatment for individual patients. Pre-medication,

post-medication. Retreatment and rules for dose modification.

Trial procedures

Tests to be done prior to entry, during treatment, post-treatment,

and their frequency.

Endpoints and

Primary and secondary endpoints; criteria for evaluation to be

evaluation criteria used (e.g., CTCAE version 4.0 for toxic effects, RECIST 1.1

criteria for objective response).

( continued)

2 0 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 9.1. (Continued)

Section

Description

Statistical

Review basic principles of trial design, and describe plans for

considerations

analysis of clinical data, PK, and correlative studies.

Pharmacokinetics Special samples (blood or tissue): how to collect, frequency of coland correlative

lection, how to process and ship.

studies

Serious adverse

What events must be reported and timelines, and to whom.

event reporting

Data collection

Describe methods for data collection.

Administrative

Trial responsibilities, documentation needed before starting, regu-

issues

latory and ethical requirements. Quality assurance issues.

Informed consent Content must comply with good clinical practice and other appli-

cable regulations. See checklist in Table 7.10.

Appendices

Appendices may include measurement scales to be used, more

detailed information on laboratory analysis plans for special stud-

ies, calendar for case report form-submission and reports.

restricted to patients with only one tumor type, specific background information on

that tumor should be included, as outlined below under “combination phase I trials.”

In contrast, the drug background section of phase I first-in-human stud-

ies should be sufficiently explicit to justify the choice of the drug, relevance of its target, starting dose, and schedule to be studied. To be described in separate subsections are:

• Chemical structure and physical properties of the agent.

• General remarks on why this agent is of interest. For example, is it of novel structure or does it have new target? Is it an analogue that overcomes

resistance?

• Description of the molecular target of the drug. What is its relevance to

cancer? Is it known to be prognostic? Does its inhibition and/or expres-

sion alter biological behavior in preclinical models? If the agent’s target

is unknown, what studies to elucidate the drug mechanism and target

have been undertaken, and how are they interpreted?

• Antitumor efficacy information. Brief descriptions of the efficacy data

(in vivo and in vitro) that support the study of the agent in human trials

must be found in this section. Data on the effects on target vis-à-vis efficacy

are important to include, if known. Effects of schedule and route of admin-

istration should be described. A summary table of the data is useful here.

• Animal toxicology. Include the summary of key findings of single-dose

and repeat-dose toxicology studies in two species. It is best to focus on

Writing the Protocol 203

the toxicology studies undertaken using the clinical formulation and

planned schedule to be tested in the protocol.

• Preclinical pharmacology (PK). Provide summaries of any PK studies

in animals. Information of importance is the expected half-life and key

PK values that relate to efficacy (antitumor in vivo effects), target inhi-

bition (which should link with efficacy), and toxicity. Data on protein

binding, measured or theoretical effects of other drugs on metabolism

(e.g., P450 substrate/inducer), and excretion should be detailed here.

This section is especially important if there may be inferences made

about recommended dose on the basis of PK. Linking a preclinical PK

parameter (e.g., steady state above a minimum value for a minimum

period of time) with information on in vivo efficacy and on inhibition

of the molecular target(s) should be described here, particularly if it

will be used to justify a “target” plasma level as an endpoint for dose

escalation.

• Clinical data. If other phase I trials have been performed or are ongoing, summarize their results, including any PK data. If those trials are not yet

complete, it is still helpful to have information on what the starting dose

was and if any toxic effects have been seen up to the dose level for which

there is information. Finally, if the drug to be studied is a member of a

class that has expected class effects (e.g., oligodeoxynucleotide effects

on coagulation), it may be helpful to summarize if this will help predict

the likely clinical behavior of the new drug.

• Summary and justification of starting dose and schedule. The background

information section should finish with a summary in which key aspects

of the preclinical data are reviewed to justify the schedule and starting

dose selected for study. (See Table 9.2 for an example of the steps to

follow and the information required to justify the human starting dose.

Note that in this example, the agent is an oral tablet, and the starting

dose has been converted from mg/m2 to a flat dose based on average

body surface area of an adult [1.7 m2]. This approach is often used

when tablet sizes are fixed, as precise surface area calculations are not

possible.)



9.3.2 Combination phase I trials

Combination phase I studies usually evaluate a new agent along with one or

more other agents or therapies that are part of the standard of care. They may

also evaluate two or more investigational drugs in combination, though that is a

less common scenario. Combination phase I trials are generally disease-oriented,

2 0 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 9.2. Human Starting Dose: Sample Justification With

Fictional Agent LTK007

Outcome

Comment

Mouse single-dose 1000 mg/kg

Using surface area conversion factor of

oral LD10

3, this represents 3000 mg/m2

Mouse oral

400 mg/kg daily × 5

This represents 1200 mg/m2 using

daily × 5 LD10

conversion factor of 3

Dog oral × daily

70 mg/kg daily × 5

This represents 1400 mg/m2 using

× 5: Toxic dose low

conversion factor of 20

Planned human

Daily × 5

Use the toxicology data of the daily

schedule

administration in the most sensitive

species to calculate human starting

dose: in this case mouse

Starting dose

200 mg/day × 5 days 1/10th the mouse equivalent LD10

(divide into two equal (120 mg/m2) × average surface area

doses = 100 mg b.i.d.) of 1.7 = 204 mg flat dose Round to

nearest 50 mg (tablet size) = 200 mg

or confined to a subset of those conditions in which the “standard” therapy is

given. For example, a trial of a new agent plus docetaxel could enroll patients

with any tumor type for which docetaxel is a reasonable therapeutic option, pro-

vided they have not already received that agent. The background section in this

type of protocol should include why this combination is of interest (e.g., preclini-

cal synergy studies) as well as most of the other information listed above under

first-in-human studies, with the addition of the single-agent phase I results (and

phase II or III results, if known) of the novel agent to be combined with stan-

dard therapy that help justify the combination under evaluation and the doses

to be used. If two investigational agents are to be combined, justification of this

approach based on appropriate combination animal efficacy and toxicology data

must be given.



9.4 STUDY OBJECTIVES

The objectives section of the protocol should be concise and divided into two

parts: primary and secondary objectives.

The primary objective of phase I studies is usually stated as follows: “To define the recommended dose of [ new agent] when given in a [ specify route and schedule].” For combination phase I trials, the primary objective is often stated as “To determine the dose of [ new agent] to be used when given in a [ schedule] together with [ standard therapy].”

Writing the Protocol 205

Secondary objectives list all of the planned ancil ary outcomes that will be

assessed. These can include all or some of the following, depending on the agent

undergoing evaluation. The standard language usually goes as follows:

• To determine the toxic effects of the new agent and their reversibility,

association with dose and PK measures.

• To determine the PK profile of the new agent.

• To measure the effect of the new drug on molecular measures of target

effect in [ name tissue] by [ name assay method].

• To explore the relationship between dose or PK measures with

toxicity and with changes in molecular measures of target effect

(PK–pharmacodynamics [PD] effects).

• To establish proof-of-principle for the new agent in inhibiting its target

in human tissue.

• To assess preliminary evidence of antitumor effects in those patients

with measurable disease by documentation of objective responses using

standardized criteria.

Tertiary or Exploratory objectives may also be included; for example, when a potential PD endpoint has not been validated prior to its use in the study.



9.5 STUDY POPULATION

This section of the protocol defines which subjects, usually patients, are to be

entered into the study. Some investigators prefer to list all criteria in terms of “inclusion” criteria, whereas others elect to describe both inclusion and exclusion criteria separately. As noted in Chapter 4, first-in-human phase I trials nearly always enrol

patients with a cancer diagnosis, although there are some circumstances in which

healthy volunteers might be considered. Phase I studies that combine drugs or

other cancer therapies with a new agent are always conducted in cancer patients.

• Example: a first-in-human trial with healthy volunteers as subjects. For

example, a new aromatase inhibitor (anti-estrogen), intended for study

in breast cancer patients, may undergo a dose-seeking trial in healthy

female subjects before evaluation in cancer patients. This type of agent

is not usually dosed to toxicity; rather, measures of plasma estrogens

serve as a surrogate for adequacy of dosing. This is a reasonably safe

undertaking for short-term treatment of healthy, non-pregnant subjects.

In this example, the inclusion criteria should specify the age range and

menopausal status of patients.

2 0 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

• Example: a first-in-human trial with cancer patients as subjects. A new oral agent targeted to cyclin-dependent kinases is entering the clinic (fictionally named: LTK007). This agent produces myelosuppression (primar-

ily neutropenia) and diarrhea in animal toxicology testing. In the trial,

patients with advanced or metastatic solid tumors, incurable with stan-

dard measures, are to be entered. The primary endpoint of the trial will

be treatment-related toxic effects, and secondary endpoints will include

assessment of PK, tumor response, and effects on downstream measures

of cell cycle in serial tumor biopsies. In this example, patients must have

recovered from toxic effects of earlier treatment, be able to swallow oral

medications, have baseline chemistry and hematology values within the

normal range, and have tumor lesions accessible for repeated biopsies.

Table 9.3 outlines, in the form of a checklist, the major headings to consider in

inclusion and exclusion criteria.



9.6 STUDY DESIGN

The design section provides the “meat” of how the trial will run. Indicate the

starting dose, how many patients per dose level will be entered, how long they

will be followed to assess dose-limiting events, what observation(s) will limit or

permit dose escalation, and when and how patients will be enrolled in the next

dose level. Safety permitting, it is sometimes a useful strategy to permit an extra

patient to be entered in a dose level if the cycle-length is very long. In that way, if one of the cohort patients drops out early for disease progression, there is already

a patient available to replace them. If this is planned, it must be included in the

protocol as part of the design.

This part of the protocol must also describe how the recommended phase II

dose will be determined. Note that even if the plan is to make dose recommendations and escalation decisions on the basis of non-toxicity measures, the protocol must contain a section describing how dose escalation will take into account

toxic effects seen in patients. Even when drugs are thought to have limited tox-

icity, the study design must assure patient safety when making dose escalation

and dose recommendation determinations. This section must clearly define the

terms to be used in the protocol: maximum administered or maximum tolerated

dose, dose-limiting criteria, and so on. (See Table 4.6 in Chapter 4 for terminol-

ogy. The highlighted terms found there are used in this book.)

Box 9.1 and Appendix 9.1 to this chapter give subject headings and a worked

example, respectively, of a design section with the fictitious cyclin-dependent

kinase inhibitor, LTK007, mentioned earlier.

Table 9.3. Major Headings for Inclusion and Exclusion Criteria Example

Timing

Inclusion Tumour type

Solid tumours

Disease

Incurable by standard ther-

extent

apy. Must have evidence

of disease clinically or

radiographically (disease

identified only by serum

marker is not allowed)

Prior

Chemotherapy Up to 3 prior chemother-

≥4 weeks since

therapy

apy regimens

last dose

Radiation

Permitted—Must have

≥4 weeks since

therapy

recovered from toxicity

last fraction,

unless pallia-

tive low dose

Surgery

Permitted

≥4 weeks since

last major

surgery

Hormone

Permitted

therapy

Age

≥18 years

Performance

ECOG performance status Within 7 days

status

0, 1, or 2

prior to study

Haematology

Absolute granulocyte

count ≥1.5 × 109/L

Absolute platelet count

≥100 × 109/L

Biochemistry

AST (aspartate amino-

transferase) <2 × upper

limit of normal (ULN)

Serum bilirubin <ULN

Serum creatinine <ULN

Cardiac

Normal left ventricu-

lar ejection fraction

(by MUGA scan or

echocardiogram)

Pregnancy In women of

Serum pregnancy test

test

childbearing

negative

potential

Consent

Written Informed consent

prior to patient entry.

Consent form used

Must be approved by

the appropriate ethical

committee

( continued)

2 0 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 9.3. (Continued)

Example

Timing

Inclusion Availability

Patients must be available

for

and wil ing to undergo

fol ow-up

study procedures at the

treating center

Exclusion Concomitant

Patients undergoing

therapy

simultaneous therapy

with other anticancer

agents: standard or

investigational

Al ergy

Patients with any prior

allergy to the class of

medication to be given

Serious

Patients with concurrent

illness

serious medical illness

such as congestive heart

failure, active serious

infection, etc.

Able to take

Patients must be able to

medication

swallow the oral investiga-

tional agent under study



9.7 TREATMENT

This section describes in detail the treatment to be given to each patient.

Although the dose level will be assigned when the patient enters the study,

the pre-medication, post-medication, and dose adjustments must be out-

lined. The content must be consistent with the design section and the defini-

tion of dose-limiting toxicity: that is, adverse events that would be considered

dose-limiting in the Design section must lead to dose reduction or discontinuation in the Treatment section. The converse need not always apply; that is, events leading

to dose reduction may not always be considered dose-limiting, but this should be

well thought through. Internal consistency between the dose-reduction plan and

the definition(s) of dose-limiting toxicity is important.

The number of cycles (or total treatment duration) allowed, and rules for stop-

ping treatment (maximum number of cycles, adverse events, and/or disease pro-

gression) must be described. Dose-reduction steps should, ideally, be the same as

the dose levels. Table 9.4 gives an example.

Although many cancer drugs were historically dosed in “cycles” of therapy—i.e.,

a treatment period followed by a rest and observation period—many agents, par-

ticularly oral drugs, are now being given continuously. An issue with continuous

Writing the Protocol 209

Box 9.1

Design Section (See Worked Example in Appendix 9.1 to This Chapter)

(a) Subject headings

1. Starting dose/route: What is it, and how is it justified?

2. Dose escalation: What are the planned dose-escalation steps (use a

table)? Include a –1 dose level, as the starting dose may be too high.

Also include ability to create intermediate dose levels.

3. Methods:

What is minimum number of patients per dose level? How will

patients be entered on each dose level (assigned or randomized). On

what basis (endpoints) will dose escalation, reduction, expansion take

place? How long will each cohort be followed before decisions about

next step (to expand, escalate, reduce) are taken? Who will make deci-

sions? When/how will patients be replaced if they do not complete

the required observation period? Will intrapatient dose escalation be

al owed?

4. Definitions:

Define the following for your protocol:

• Maximum administered dose 1 (MAD)

• Dose-limiting toxicity and adverse event criteria used in the protocol (applicable when toxic effects are planned to limit escalation); or

• Dose-limiting pharmacokinetic measures (applicable when pharma-

cokinetic measure such as steady-state concentration is planned to

limit escalation); or

• Dose-limiting biologic measures (applicable when molecular mea-

surement of drug effect is planned to limit escalation)

• Recommended phase II dose: how the recommended dose will be

established. Note here if there is a planned expansion of this dose

level to gain further information on its safety or other parameters;

this step is highly recommended for all trials.

Note to reader: in some locales, this is referred to as maximum tolerated dose (MTD), but this book has adopted the convention of MAD for this concept

dosing regimens, be they intravenous (e.g., weekly treatment) or oral (e.g., daily

treatment), is how to, or even if to, define a “cycle” or “treatment period.” The advantage of arbitrarily defining a cycle as, for example, a four-week period of therapy, is that the concept is well engrained and it defines periods of time in which

Table 9.4. Examples: Dose Adjustment

Hematological adverse events (for an intravenous agent)

Nadir counts

Absolute granulocytes

Platelets

Dose drug next cycle

(× 109/l)

(× 109/l)

≥0.5

AND ≥25

No change

<0.5 for <5 days

AND ≥25

No change

<0.5 for ≥5 days

OR

<25 or

Reduce 1 dose level

or neutropenic

thrombocy-

topenic

infection or febrile

bleeding

neutropenia

Treatment day counts

Day 1

dose

Absolute granulocytes

Platelets

Dose drug this cycle

adjustments (× 109/l)

(× 109/l)

≥1.5

AND ≥100

Treat on time; no change

in dose

<1.5

OR

<100

Hold until recovery

Adjust dose level accord-

ing to nadir counts as

above. If no recovery

after 2 weeks, patient

should be removed from

protocol therapy

Another example for chronic oral dosing

Grade of

Management/next dose

event

≤ grade 1

Symptomatic—no change

in dose

Grade 2

Hold until ≤ grade

1— resume at same dose

Grade 3

Hold* until < grade

2—resume at 1 dose

level lower if indicated†

Grade 4

Off protocol therapy

*Patients requiring a delay of > 2 weeks should go off protocol therapy.

†Patients requiring > 2 dose reductions should go off protocol therapy.

Writing the Protocol 211

investigations can be conducted. It is clear that this is an artificial concept in this setting, so it is up to investigators and sponsors whether they take this approach.

Another practical issue is how to handle dose reductions in the setting of a

split-dose treatment. Treating a patient on days 1, 8, and 15 of a 28-day cycle is

an example: here, in order to preserve the planned dosing intervals in the face of

toxicity, usually dose reductions on days 8 and 15 are advised and, if toxicity pro-

hibits restarting treatment on day 1 of the next cycle, it is delayed until recovery, and the dose for all days on that cycle is adjusted depending on the magnitude

and nature of the toxic effects incurred.



9.8 TRIAL PROCEDURES

This protocol section describes the tests to be done before entry, as well as dur-

ing and after treatment. Those to be done before entry must be consistent with

the inclusion/exclusion criteria. If for example, a minimum creatinine level is

required for patient entry, then serum creatinine must be one of the specified

pre-study tests. The converse need not be true: not all baseline tests must be

matched to an entry criterion. Pre-treatment and on-treatment investigations

are usually summarized in a table, an example of which is found in Table 9.5.

Post-study testing is usually quite abbreviated in phase I trials: generally, a patient is brought back for assessment four weeks after completing therapy, and thereafter follow-up ceases, except to report late toxic effects.



9.9 ENDPOINTS



Toxic effects (adverse events) are among the most important phase I trial

endpoints. Even if not a primary endpoint, assessment of adverse events is an

essential component of first-in-human and combination phase I trials. Other

important trial endpoints include objective response, measures of PK, measures

of molecular effects of the drug in normal or tumor tissue (including proof-of-

concept studies), and functional imaging studies of drug effects. This section of

the protocol should describe the criteria and methods that will be used to docu-

ment the trial endpoints. If there are no reference standards (often the case when

investigational molecular measures or functional imaging studies are under-

taken), the methods to be used to categorize or quantify these measures should

be recorded here, or in a methodology appendix.

2 1 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 9.5. Example: Pre-Treatment and on-Treatment Investigations

Table

Required investigations

Pre-study

Indicate frequency

timing

on study here

Physical

Physical exam

Blood pressure, heart rate

Hematology

CBC and differential

Coagulation studies: PTT, INR

Biochemistry

AST, bilirubin, creatinine, alkaline phosphatase,

albumin, calcium Electrolytes (Na+,K+,Cl—)

Radiology*

CT scan chest and abdomen

Other imaging studies as indicated clinically

Other investigations

Serum marker studies

24-hour urine collection

Special investigations

Blood sampling for pharmacokinetic assays

Skin biopsies for special translational studies

Adverse events

Assessed using CTCAE version 4.0

Abbreviations : CBC, complete blood count; PTT, partial thromboplastin time; INR, International Normalized Ratio

*Patients with a CR or PR should have scans repeated after four weeks to confirm response.



9.9.1 Adverse events

Regardless of whether toxicity is the primary endpoint of the phase I trial, assess-

ment of toxic effects, or more properly, adverse events (AEs), is of paramount

importance. For new agents, the description of drug-related AEs begins in the

first-in-human phase I trial; however, because of the small sample size of these

studies, the knowledge of toxic effects is not likely to be comprehensive by the

end of phase I. Furthermore, it may not be easy to identify which AEs are truly

drug-related unless they have been predicted by animal studies. The protocol

must make it clear that all AEs must be documented so that, with time and more complete dose-level information, there will be an opportunity to sift through the

data to identify those most likely to be drug-related. To accomplish this, standard

AE criteria should be used, and an investigator-declared relationship of the event

Writing the Protocol 213

to study treatment should also be recorded. See also Section 9.13 of this chapter,

where definitions of serious AEs and expedited reporting are discussed.



9.9.2 Standard toxicity criteria

“Toxicity criteria” describe AEs in categories and grades, with grade 0 meaning

“normal” or “none” and grade 4 meaning “life-threatening toxicity.” Although

the World Health Organization (WHO) criteria were created first [1] , these

have been supplanted in most cancer settings by the Common Toxicity Criteria

(CTC) developed by the US National Cancer Institute. Through subsequent revi-

sions, these are now called Common Terminology Criteria for Adverse Events

or CTCAE. The modifications have added new terms to categorize new effects

of treatment and to enable more comprehensive reporting. The current Version

4.0 contains over 790 adverse event terms (no longer called “toxicities”) grouped

into 26 categories termed “system organ classes.” Adverse event terms include

toxic effects of treatment, symptoms of disease, or other medical events, as well as

objective findings (such as chemistry and hematology results). A phase I protocol

should require patients to have a baseline assessment to document symptoms or residual toxic effects from previous treatment, and then conduct periodic assessments of toxicity over the course of the therapy. In general, toxicity is recorded as the worst grade for each effect for each patient in each reporting interval.



9.9.3 Response criteria

Objective tumor response is often a secondary outcome measure in phase I tri-

als. Tumor response refers to the description of objective change in measured tumor burden during the course of therapy. Criteria for response in solid tumors

were first developed in the 1970s, and those of the WHO Criteria were the

most commonly utilized for many years [1] . Because many academic groups

and pharmaceutical firms adapted these over time, there emerged confusion in

interpretation of trial results [2], leading to the development of RECIST crite-

ria (Response Evaluation Criteria In Solid Tumors), first published in 2000 [3].

A revision of these (RECIST 1.1) was published in 2009 [4]. RECIST response

assessment requires baseline measurement of malignant lesions and periodic

reevaluations to determine the maximal degree of shrinkage (if any) or growth

of the overall tumor burden. RECIST criteria define measurable disease on the

basis of only a single diameter and determine the tumor burden by summing the

longest diameters, or short axis for lymph nodes (RECIST 1.1) of measurable

lesions. Like the WHO criteria before it, RECIST defines four main response

2 1 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

Table 9.6. Response Definitions by RECIST 1.1 Criteria

Target

Non-target

New

Overall best Best response for

lesions

lesions

lesions

response

this category may also

require**

CR

CR

No

CR

≥4 weeks confirmation

CR

Non-CR/non-PDNo

PR

≥4 weeks confirmation

CR

Not evaluated

No

PR

PR

Non-PD or not No

PR

≥4 weeks confirmation

all evaluated

SD

Non-PD or not No

SD

Documented at least

all evaluated

once ≥4 wks. from

baseline

PD

Any

Yes or No

PD

No prior SD, PR, or CR

Any

PD*

Yes or No

PD

No prior SD, PR, or CR

Any

Any

Yes

PD

No prior SD, PR, or CR

Not all

Non-PD

No

NE

—

evaluated

*In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

** RECIST 1.1 has removed the requirement for response to be confirmed in randomized

trials, but it is still required for non-randomized where response is the primary endpoint of the trial.

Adapted from Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline version 1.1. Eur J Cancer. 2009;45:228–247, with permission from Elsevier.

categories: complete response, partial response, stable disease, and progressive

disease (see Table 9.6 for definitions). The protocol section describing assess-

ment of objective response must comply with these guidelines. The US National

Cancer Institute’s Cancer Therapy Evaluation Program (CTEP) has developed

a protocol section to incorporate in trials that employ RECIST 1.1 as a tool for

investigators (see http://www.google.com/url?url=http://ctep.cancer.gov/pro-

tocoldevelopment/docs/ph2_comb_temp.doc&rct=j&frm=1&q=&esrc=s&s

a=U&ei=BzNJVPnLHdOmyAS2goLADA&ved=0CBQQFjAA&usg=AFQjC

NEKR2mK1u0aexbH9HJhV-KVDqqY1A). The text found at this source may be “cut and pasted” into the protocol document’s section on endpoints when

RECIST criteria are used.

Given the nature of the patient population in most phase I trials, solid tumor

response criteria are the most likely to be employed to assess this secondary end-

point, but there are also standard criteria for non-Hodgkin’s lymphoma [5] , acute

myeloid leukemia [6], malignant glioma [7], and tumor marker response such as

prostate-specific antigen (PSA) and cancer antigen-125 (CA-125) [8,9]. If the phase

I population is confined to one tumor type in which RECIST are not appropriate

Writing the Protocol 215

Table 9.7. Selected Standard Response Criteria

Site

Standard response criteria

Reference number

Solid tumors

RECIST 1.1: Eisenhauer E,

[4]

Eur J Cancer, 2009

Malignant

Cheson BD, J Clin Oncol, 2007

[5]

lymphoma

Acute myeloid leukemia

Cheson BD, J Clin Oncol, 2003

[6]

Malignant glioma

Macdonald DR, J Clin Oncol, 1990

[7]

CA125 response

Rustin GJ, Int J Gynecol

[8]

(ovarian cancer)

Cancer, 2011

Prostate cancer

Scher HI, J Clin Oncol, 2008

[9]

(including PSA)

criteria, the relevant response criteria should be used. Table 9.7 supplies a quick

reference list of the most current criteria for reporting response in various circum-

stances. Response criteria for immunological agents are described in Chapter 7.

As noted, objective response is often a secondary endpoint in phase I trials: in

first-in-human studies, the observation of responses in even a few patients may

help direct future development decisions for the drug. In combination phase

I trials, the use of known active therapies in conjunction with a new drug implies

that responses are expected, and in these trials, sometimes documentation of

response is sufficiently important to what might happen next with the combina-

tion that patient entry is, in fact, restricted to those in whom measurable disease

is present so that response can be assessed in all patients.



9.9.4 Other endpoints

Other measures used in phase I trials, such as those for laboratory measures of tar-

get effect, PK, and functional imaging, are described in the relevant protocol sec-

tions for the tests in which both methodology and endpoints should be detailed.



9.10 STATISTICAL CONSIDERATIONS:

DESIGN AND ANALYSIS

This section reiterates the major features of the trial design and indicates how the clinical data from the trial will be tabulated and analyzed. Any statistical tests to be done on the clinical, PK, or correlative assay data should be described here. In general, formal statistical comparisons between dose groups are discouraged, as in the typical

phase I trial these are small cohorts and non-randomized. However, within-patient

comparisons of data such as before and after biopsy results, or PK assessment at

2 1 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

two different time points, may be more formally compared. If formal testing is to

be done, this should be confined to one or two variables, and be pre-specified in the protocol. Statistical tests should not be applied post-hoc once results are reviewed, to avoid problems of multiple comparisons and data-driven analysis. If the phase I trial is one in which there is randomization between dose levels (such as in phase Ib trials conducted after the first-in-human study is completed), comparisons between dose

groups is permitted, but it must be remembered that the cohort size must be large

enough to allow adequate power to undertake such comparisons.



9.11 PHARMACOKINETICS



This important section of the protocol describes the measurement of PK

(the study of drug absorption, distribution, metabolism, and/or excretion).

Chapter 10 describes the principles of PK evaluation in great detail. Here we

consider the information that must be supplied in the protocol.



9.11.1 Sample collection

In this protocol section, detailed sampling instructions should be provided,

including: volume(s) of blood, type of tube or container, at what intervals before

and after drug administration, and how it is to be handled, processed, and stored.

Be sure that it is clear what “time Zero” is for the table describing PK collection.

Information on where the samples are to be shipped should be clearly indicated.



9.11.2 Pharmacokinetic assay methods

If necessary, the methods for PK analysis can be added in this section, attached as

an appendix, or simply referred to, if previously published.



9.11.3 Pharmacokinetic data analysis

The methods for analysis of the data should be described here, including the mod-

el ing to be used and how summary information by dose level will be generated.



9.12 CORRELATIVE, SPECIAL IMAGING,

OR TRANSLATIONAL STUDIES



Many phase I studies will incorporate pharmacodynamically driven imaging

studies or special assays of normal tissue (e.g., peripheral blood mononuclear

Writing the Protocol 217

cel s, skin) or fresh tumor tissue. The purpose of these tests may vary and should

be clearly stated in the preamble to this section. For example, it may be the case

that measures undertaken will be used to determine the effect of a drug on down-

stream measures of target inhibition. Alternatively, the results of such tests may

be intended as proof-of-concept or proof-of-principle: i.e., they indicate that,

at least in some patients, the drug is having its intended molecular target effect.

Following the statement of purpose, this section of the protocol must detail the

procedures to be undertaken.



9.12.1 Tissue sampling

Describe the type of tissue (e.g., peripheral blood mononuclear cel s, buccal

mucosa, tumor); the method of sampling, including the type of biopsy permit-

ted (e.g., fine needle aspirate, core biopsy, open biopsy); how much tissue is to be

taken (for blood samples, the volume and type of tube); how it is to be processed,

fixed, and stored. Clear label ing and shipping instructions should be provided.

The frequency of sampling should also be addressed. If a separate consent form is

needed, that should be clearly indicated.



9.12.2 Assay methods

Describe the assay method to be used and in which laboratory it will be under-

taken. Indicate here what the controls will be (usually reference tissues of known

characteristics) and how results will be quantified, if applicable. Sources of

critical reagents such as antibodies, gene array chips, etc., should be specified.

Furthermore, references should be supplied, if available, for the assay develop-

ment and validation. If the assay was used in the preclinical assessment of the

drug, that is important to note.



9.12.3 Assay results and analysis

The plan of analysis should be described. How will summary data be pre-

sented? How will relationships between dose, PK variables, and assay output

be described? Will within-patient results be displayed (e.g., before/after treat-

ment)? Is there an a priori critical level or change in expression of a key marker that will be sought?

2 1 8

P H A S E I C A N C E R C L I N I C A L T R I A L S



9.12.4 Imaging studies and analysis

As for blood sampling, any special imaging studies designed to evaluate tissue

distribution of drug, target inhibition, blood flow, etc., should be described in

detail. If applicable, information on the characteristics of the probes used, their

source, safety and administration must be detailed. Finally, describe the process

of image acquisition and analysis.



9.13 SERIOUS ADVERSE EVENTS AND

EXPEDITED REPORTING CRITERIA

“Serious” adverse events (SAEs) are those that require hospitalization (or

prolong existing hospitalization), and/or lead to death or disability. The

International Conference on Harmonization (ICH) criteria for an event

to be considered serious are found in Table 9.8. SAEs that are deemed to be

drug-related and unexpected (serious unexpected adverse drug reactions are

also referred to as “suspected unexpected serious adverse reactions” or SUSARs)

must be reported in strict, expedited timelines to the relevant government regu-

latory authority and the ethics committee(s) overseeing a trial. Expected events

are those that have been seen in clinical trials in the past and are recorded in

the investigator brochure (and should thus be in the consent form). As first-in-

human phase I trials are administering a new drug for the first time, any serious

event is, by definition, “unexpected,” as there is no clinical experience with the

agent. All protocols must have a section detailing what the definition of SAEs

and SUSARs are and how and to whom to report them. Many cancer trial pro-

tocols are written so that they exclude from the “serious” definition any hospi-

talizations that are scheduled for trial-related procedures or for terminal cancer

care after progressive disease.



9.14 DATA COLLECTION

This section will describe the method of data collection (e.g., by electronic data

capture). The frequency and type of data collection may be included in a table in

this section or as a protocol appendix. Methods for col ating data and programs

used to compile and analyze it for reporting purposes can also be described here.



9.15 ADMINISTRATIVE ISSUES



This section describes important practical and quality control information.

Writing the Protocol 219

Table 9.8. ICH Definition of “Serious” for Adverse Event Reporting

A serious adverse event is any

Comments

untoward medical occurrence that:

Results in death

Is life-threatening

The term “life-threatening” in the definition

of “serious” refers to an event in which

the patient was at risk of death at the time

of the event; it does not refer to an event

which hypothetically might have caused

death if it were more severe

Requires inpatient hospitalization or

prolongation of existing hospitaliza-

tion Results in persistent or significant

disability/incapacity

Is a congenital abnormality/birth defect

Other important medical events

Medical and scientific judgement should

be exercised in deciding whether expe-

dited reporting is appropriate in other

situations, such as important medical

events that may not be immediately

life-threatening or result in death or hospi-

talization but may jeopardize the patients

or may require intervention to prevent

one of the other outcomes listed in the

definition. These should also usually be

considered serious (e.g., intensive emer-

gency room treatment for bronchospasm;

blood dyscrasias, or convulsions).

From ICH Harmonized Tripartite Guideline: clinical safety data management: defini-

tions and standards for expedited reporting E2A. See Appendix.



9.15.1 Trial sponsorship

Indicate who has legal responsibility for the overall conduct of the study: i.e.,

who is the trial sponsor (see also Chapter 11).



9.15.2 Pre-trial documentation

List the documents required before the/any institution may begin to enroll

patients in the study. At a minimum, these must include full ethical approval

of the final protocol and consent form(s), approval of the protocol by the rel-

evant government authority, and collection of the investigator statements and

2 2 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

curriculum vitae as required by regulations. Confidentiality and other agree-

ments, such as contractual arrangements, will also need to be in place (see

Chapter 11 for details).



9.15.3 Investigator responsibilities

These are taken from good clinical practice (GCP) but should be articulated

here. Other types of trial personnel should be described if appropriate.



9.15.4 Ethics process

The protocol must indicate the nature of ethics review required for the proto-

col and amendments as well as how the ethics committee should be constituted.

Compliance with relevant local and national standards is a must.



9.15.5 Patient entry

Practical information about how patients will be entered (e.g., via telephone reg-

istration, web-based process, or other) are to be described here.



9.15.6 Quality control

Measures that will be used to assure the accuracy of the clinical data collection

are detailed in this section. Brief outlines of on-site monitoring plans, audits, central review of any data, etc., should be indicated.



9.15.7 Publication policy

Journals generally provide guidance on the roles for which authorship is appro-

priate. The protocol should include a statement regarding authorship and who is

responsible for final authorship decisions.



9.16 CONSENT FORM

A sample consent form should be part of (or appendix to) any multicenter pro-

tocol, as it will be modified according to local criteria for ethical committee

Writing the Protocol 221

review. If the study is a single-center trial, the consent form included in this sec-

tion of the protocol will be the version that will be submitted for ethical review.

The consent form should use simple language to describe the purpose of the

study and the measures and treatments that will be undertaken. Table 9.9 lists

the elements of a consent form as stipulated by GCP, which may have some local

adaptations (The Appendix of this book contains direct web links to GCP and

other ICH documents). Depending on the local requirements, extra research

investigations such as tumor biopsy studies may be part of the main study con-

sent form or separate documents.

Table 9.9. Checklist for Informed Consent Document

(ICH Good Clinical Practice)

Element

Comments for phase I (note: ICH refers to “subjects”;

this table has substituted “patients”)

The trial involves research The opening statement should be an acknowledgement of

the patient’s illness and state of disease—“I understand

I have a cancer that is no longer curable with standard

treatments”—and give the background about the new

agent, why it is being tested (e.g., “it has shown promise in

studies of animal cancers”) and, for first-in-human studies,

acknowledge it has never before been given to patients with

cancer.

The purpose of the trial

The purpose is to define the recommended dose of the new

agent, document its toxic effects, and other purposes as

defined by goals of the protocol.

What are the trial

Caution regarding use of the word “treatment” since it

“treatments”

implies efficacy. “Investigational agent” or “investigational

drug” are preferred. Consent form must be clear that the

dose will be increased during the course of the study, so

the dose for each new patient is assigned when they go on

the trial. The form should indicate what will determine

how high the dose goes (toxicity or something else).

Trial procedures to be

Sometimes a separate page showing the schema or list of

followed; including all

tests is helpful to the patient.

invasive procedures

Patient’s responsibilities

The consent form should state that the patient understands

he/she must return to the treating center to undergo

assessments and tests as described.

The aspects of the trial

The drug itself is experimental.

that are experimental

( continued)

Table 9.9. (Continued)

Element

Comments for phase I (note: ICH refers to “subjects”;

this table has substituted “patients”)

The foreseeable risks or

For first-in-human studies, the list of possible effects comes

inconveniences

from the toxicology.

It is also useful to include a statement that “other serious

unforeseen effects besides those listed may result from

treatment, since this is the first time this drug has been

given to humans.” State what will happen in event of toxicity

(decrease or discontinue drug) in general terms. Include a

statement that patients will be informed of new serious or

frequent toxic effects that arise during the course of the trial.

The reasonably expected Benefit cannot be promised, or implied as likely, in a

benefits

first-in-human study.

It is reasonable to state that the possibility of benefit may

exist, but it is unlikely and unknown if it will occur. If a fig-

ure is needed, the overall rate of tumor regression (usually

temporary) in trials such as this is about 5%.

The alternative treatments State what they are. If applicable, include a statement that available to the patient

no further active cancer therapy is an option.

The compensation and/or State here if the patient’s care will or will not be covered in treatment for trial-related the event of adverse events requiring treatment. State if injury

other “compensation” for injury is available.

Payment to the subject

Although healthy volunteers are often reimbursed, patients

are not.

Anticipated expenses

Patients should be made aware if participating in the trial

means extra costs such as travel, parking, hotel stays,

meals, etc., and if those costs are covered in any way.

Voluntary participation

Participation is entirely voluntary, and patients may with-

draw, without penalty or loss of benefits to which they are

otherwise entitled, at any time.

Access to records

State who will see information concerning their case (on

forms) and who may review their medical records (e.g.,

pharmaceutical company, government auditor), and that

such individuals/groups observe strict confidentiality.

Confidentiality

Records on the patients will be kept confidential. In any

publication, their identity will not be revealed.

New information

New information arising that might be relevant to the patient’s

decision to continue therapy will be made available: in phase

1 trials this generally means new toxicity information.

Contacts

Whom to contact for further information, for discussion of

the rights of trial subjects, in event of injury.

Study duration

When/how/why will study drug be stopped. How long will

the study and the follow-up be.

Number of patients

Estimate numbers needed to finalize dose

planned for the trial

recommendation.

Writing the Protocol 223



9.17 APPENDICES

Protocol appendices may contain a variety of items that do not “fit” easily else-

where. For example, toxicity and response criteria can appear as appendices, as

can performance status definitions. Case report form-submission schedule, a

telephone/contact list, and the consent form itself may also all appear as appen-

dices. In general, the appendices should contain “reference” items to facilitate the

study conduct, but should not contain the critical elements without which the

study could not be completed.



REFERENCES

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214.

2. Baar J, Tannock I. Analyzing the same data in two ways: a demonstration

model to illustrate the reporting and misreporting of clinical trials. J Clin Oncol.

1989;7:969–978.

3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the

response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst.

2000;92:205–216.

4. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline version 1.1. Eur J Cancer. 2009;45:228–247.

5. Cheson BD, Pfistner B, Malik E et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.

6. Cheson B, Bennett JM, Kopecky KJ, et al. Revised recommendations of the

International Working Group for diagnosis, standardization of response criteria,

treatment outcomes, and reporting standards for therapeutic trials in acute myeloid

leukemia. J Clin Oncol. 2003;15:4642–4649.

7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for

phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280.

8. Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the

Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419–423.

9. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol.

2008;26:1148–1159.

2 2 4

P H A S E I C A N C E R C L I N I C A L T R I A L S



APPENDIX 9.1 DESIGN SECTION: WORKED EXAMPLE

WITH FICTIONAL AGENT LTK007



STARTING DOSE

The starting dose of LTK007 will be 100 mg p.o. b.i.d. × 5 days every 28 days.

(LTK = Licensed to Kil .) This dose is based on animal toxicology (see Protocol

Section XX) and represents one-tenth the mouse equivalent LD10 (MELD10)

dosage in the daily oral schedule.



DOSE ESCALATION

The dose of LTK007 will be escalated in increments according to the

dose-escalation scheme outlined in Table 9A.1.

Intermediate dose levels or further splitting of the total dose into t.i.d. or q.i.d.

dosing may occur, depending on emerging safety information and/or pharmaco-

kinetic data if available.



METHODS

The rate of subject entry and escalation to the next dose level will depend upon

assessment of the safety profile of patients entered at the previous dose level.

Toxicity will be evaluated according to the NCI CTCAE, Version 4.0.

Table 9A.1 Dose-Escalation Scheme

Dose level

Dose of LTK007 given orally, twice

Minimum no. of

daily × 5 days every 28 days (total daily dose)

patients

−1

75 mg b.i.d. (150 mg total)

3

1 (starting)

100 mg b.i.d. (200 mg total)

3

2

200 mg b.i.d. (400 mg total)

3

3

400 mg b.i.d. (800 mg total)

Continue to double dose until grade 2 toxicity

related to drug is seen at level n, then begin

escalation as shown below.

Round calculated dose to nearest 50 mg.

n + 1

1.4 × n

3

n + 2

1.4 × n + 1

3

Continue escalating at 1.4 × preceding

[etc.]

dose until MAD

Writing the Protocol 225

A minimum of three patients will be entered on each dose level. All three

will be followed for one completed cycle of therapy (28 days), and subsequent

enrollment of new cohorts will be based on the toxicity assessment in that first

cycle and the documentation of any dose-limiting toxicities (for definitions, see

below). The investigator and sub-investigators will review all the data of each

cohort together by teleconference with the study sponsor before making a deci-

sion regarding the next steps to be taken.

Intrapatient dose escalation is permitted as described below.



DEFINITIONS



Maximum Administered Dose (MAD)

1. If none of three patients exhibits DLT at this dose level:

• Dose escalation to the next dose level may begin in a new cohort of patients

• Patients enrolled on the previous dose level who are still receiving

therapy may now undergo intrapatient dose escalation to this dose

level, provided they have experienced no drug-related toxicity grade 2

or more.

2. If one of three patients exhibits DLT at this dose level:

• Expand dose level to a total of six patients.

• If no further DLT events are seen, dose escalation to the next dose

level may begin in a new cohort of patients, and patients enrolled

on the previous dose level who are still receiving therapy may now

undergo intrapatient escalation to this dose level, provided they have

experienced no drug-related toxicity grade 2 or more.

• If one or more further DLT events are seen (i.e., two or more of six

patients), this dose level will be considered the MAD.

3. If two of three patients exhibit DLT:

• This dose level wil be considered the MAD.

Before opening the next-higher dose level, all toxic effects at the preceding dose

level will be reviewed, and expansion or escalation will be undertaken as appro-

priate. Conference calls between investigators and sponsor will be organized.



DOSE-LIMITING TOXICITY



Toxicity will be graded using CTCAE version 4.0. Any DLT must be a toxicity

that is considered related to the study drug. DLT is defined as follows.

2 2 6

P H A S E I C A N C E R C L I N I C A L T R I A L S



During cycle 1—any of the following:

1. Hematological—one or more of:

• absolute granulocyte count (AGC) < 0.5 × 109/L

• febrile neutropenia (absolute neutrophil count [ANC]

< 1.0 × 109/L with fever > 38.5°C)

• platelets < 25 × 109/L

• bleeding due to thrombocytopenia

2. Non-hematological—one or more of:

• diarrhea ≥ grade 3 despite use of antidiarrheal medication

• rash ≥ grade 3 (or grade 2 if it is medically concerning or unaccept-

able to the patient)

• other grade 3 organ effects thought to be treatment-related

• missing >2 doses of treatment for toxicity reasons



RECOMMENDED PHASE II DOSE

As described above, the MAD is that dose in which two of three or two of six

patients experience DLT.

Normally, one dose level below that dose will be considered the recommended

phase II dose. If the MAD is seen at the starting dose level, then dose level “−1”

will be the recommended dose.

If clinically appropriate, intermediate dose levels may be studied to ensure that

the recommended dose is the highest tolerable. Further, if pharmacokinetic data

suggest that saturable absorption of drug is occurring on a b.i.d. oral administra-

tion level, further dose-splitting to t.i.d. or q.i.d. schedules may be considered if DLT has not been seen.

Up to a total of ten patients may be treated at the recommended dose to ensure

information on the safety profile at that dose is complete.



PATIENT REPLACEMENT

Three patients within a dose level must be observed for one cycle (28 days)

before accrual to the next-higher dose level may begin. If a patient is with-

drawn from the study prior to completing five days of therapy and a further

17 days of follow-up without experiencing a DLT prior to withdrawal, an

additional patient may be added to that dose level. Patients missing two or

more doses due to toxicity will not be replaced, as these patients will be con-

sidered to have experienced a DLT.





10

Practical Aspects of

Pharmacokinetics and

Pharmacodynamics

C H R I S T W E L V E S , M A R I A J O V E ,

A N D P A U L L O A D M A N ■



10.1 INTRODUCTION

Pharmacology studies are an integral part of early clinical trials and contribute vital information for the subsequent development of a drug. Pharmacokinetic (PK)

studies may, somewhat simplistically, be defined as describing “what the body

does to a drug,” whereas pharmacodynamic (PD) studies describe “what a drug

does to the body.” Historically, in the development of antiproliferative cytotoxics,

the main focus was on PK. In the modern era, with mainly rationally designed,

targeted therapies being developed, PD studies are increasingly important.

Clinical pharmacology studies are planned and carried out in the context of

information gained in preclinical evaluation. In vivo preclinical PK, usually in the

rat or mouse, may indicate how a drug will be handled in man and can suggest the

minimum plasma values or “target” PK exposure that may determine whether a

potentially therapeutic dose level has been achieved. Likewise, PD markers indi-

cating that a drug has inhibited its target can only be meaningfully incorporated

in clinical trials if they have been fully evaluated in preclinical models.

Pharmacology studies add considerable time and expense to early trials, so

why are they so important? In the first instance, plasma PK provides a descrip-

tion of the general behavior of a drug and answers clinically important ques-

tions: How much drug is there in the blood? Are concentrations achieved that

are active in preclinical models? For how long is drug present? How is the drug

2 2 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

metabolized and eliminated from the body? As dose is increased in the phase I

trial, are the PK linear? i.e., is there a proportionate increase in drug exposure

and therefore are the pharmacokinetics predictable? This information may

influence how the phase I trial is conducted. Pharmacokinetically guided dose

escalation, where dose increments are specifically directed towards a target PK

exposure based on what is associated with toxicity in preclinical models [1] , has

not found widespread acceptance. In such trials a PK target is identified from

preclinical data and dose escalation directly targets achieving the same PK in

patients. However, some trials of non-cytotoxic agents or biological therapies,

such as that of the anti-epidermal growth factor receptor monoclonal antibody

cetuximab, have used PK data to define the dose for further studies. More often,

however, PK data inform decisions regarding by what route and how frequently

a drug is administered, or even that a drug should not be developed further, if

potentially therapeutic plasma concentrations cannot be achieved. It may also be

possible to identify the factors accounting for variability in how a drug is handled

by different individuals. Causes of this inter-individual variability include organ

impairment, drug interactions, or genetic polymorphisms in drug-metabolizing

enzymes.

PD studies may indicate whether a drug is having its desired effect. A descrip-

tive approach asks simply whether the tumor shrinks, whereas a mechanistic

approach seeks to identify molecular endpoints. This may involve sampling

tumor or surrogate “normal” tissue and measuring the effect of a drug on a spe-

cific molecular target or pathway, and relating this to the intended biological

effect, such as inhibition of cell proliferation. Alternatively, functional or molec-

ular imaging techniques such as magnetic resonance imaging/spectroscopy

(MRI/MRS) or positron emission tomography (PET) may detect biochemical

or functional changes induced by a novel compound. Where the effects of a drug

(either efficacy or toxicity) can be measured, correlations may be sought with

plasma or tissue drug levels. These PK–PD relationships may again influence the

choice of dose or schedule for subsequent trials.

PK and PD analyses require considerable technical expertise, but the clinician

plays a key role, in recognizing the need to incorporate such studies, and then in

ensuring that the additional studies are practical and clinically relevant:

• First, a decision has to be made as to what it is appropriate and feasible

to measure in a particular population of patients, how many samples

or measurements are needed, and when should they be made. For

example, collection of blood samples overnight is easy to include in

a protocol but more difficult to deliver in practice. Likewise, multiple

tumor biopsies may be intellectually attractive to the investigator but

less appealing to a patient with advanced cancer.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 229

• Next, the clinical investigator requires a method and a col aborator, or

team, to perform the PK or PD studies and to analyze the results. It is

pointless agreeing to participate in a trial incorporating PK or PD studies if

a center does not have the human and other resources or skil s necessary.

• It is important to ask if the results of these studies wil be believed and

utilized appropriately. The assay or imaging technique needs to be

validated, increasingly to specific standards with detailed quality control

and standard operating procedures (SOPs) covering sample handling,

assay reproducibility, sensitivity, and specificity. These practicalities may

not appear to be a priority to clinical investigators, but they are vital if

decisions on subsequent drug development will be based at least in part

on the outcome of these laboratory investigations. Moreover, regulatory

authorities recognize the importance of quality control, so these issues

are not optional when translational data are to be included in licensing

applications.

• Finally, although most phase I trials do, quite appropriately, include

pharmacological studies, it is not possible to incorporate all studies

in all trials. It may, therefore, be best to address certain questions in

specific cohorts within a phase I trial or in a separate study. For example,

a biochemical signal may be sought to demonstrate “proof-of-concept”;

i.e., that a drug is hitting the desired target, but not to determine dose

escalation; under those circumstances, tumor biopsies or functional

imaging studies may best be obtained in the expanded cohort treated at

the recommended phase II dose.



10.2 PHARMACOKINETICS



10.2.1 Principles of pharmacokinetics

It is beyond the scope of this book to teach PK, which is covered in detail in

many texts [2] . It is, however, useful to review briefly the terms and principles

that investigators will come across when writing or reviewing a protocol.

PK is the study of drug absorption, distribution, metabolism, and excretion

(ADME). These factors are usually characterized by taking a series of timed

blood samples, measuring the concentration of parent compound and relevant

metabolites, then plotting a curve of concentration (typically on a logarithmic

scale) versus time. This was done manually in the past, but straightforward com-

puter programs now perform this task. After intravenous (i.v.) administration,

there is usually an initial rapid fall in plasma concentration as the drug distributes into the tissues. Later, the fall in plasma concentration is slower as the drug is

2 3 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

eliminated. The more samples that are taken over a longer period of time, the

greater the accuracy of the picture of a drug’s fate. This must, however, be bal-

anced against the practicalities of taking and processing the samples. Although

most PK studies are of drug and metabolite levels in plasma, measurements can

also be made in other fluids (urine, ascites, cerebrospinal fluid) or solid tissues

(normal or malignant).

The fundamental parameters that describe a drug’s behavior are the area

under the concentration–time curve (AUC), peak plasma concentration (C ),

max

total plasma clearance (CL), volume of distribution (V ), and terminal half-life

D

(t ). These parameters can now be easily calculated with the use of software

1/2

described later.

As the term suggests, AUC represents the area below the curve when a series

of drug concentrations are plotted versus time. AUC reflects total drug exposure

and is determined by the dose and clearance of a drug. The AUC can be calcu-

lated simply, without deriving a PK model; a more sophisticated approach is to

fit the concentration–time data to a PK model and derive AUC from the model.

The AUC can be calculated up to the final sample time point (AUC ), or the

t

concentration–time curve can be extrapolated to infinity (AUC ). In both cases,

inf

but especially where there is considerable extrapolation, the final component of

the AUC will be influenced heavily by the later concentration time points, usu-

ally low values where any inaccuracy in measuring drug levels may have a dispro-

portionate impact on apparent drug exposure. Therefore, although late samples

some days after drug administration are inconvenient for the patient, they are

often a very important part of the PK study. AUC, as an expression of total drug

exposure, is often studied in relation to efficacy or toxicity. In some cases, where

a drug has to be above a threshold concentration for activity, the observation of

AUC above that threshold or the time that the drug concentration surpasses the

PK threshold may be used for such correlative studies. It may also be that the

concentrations of metabolite play an important role in toxicity or efficacy.

CL reflects the rate at which a drug is removed from the plasma as it distrib-

utes into the tissues, is metabolized, and then eliminated. It reflects the volume of plasma “cleared” of drug per unit time (e.g., mL/min or L/h). There is an inverse

relationship between CL and AUC (AUC = dose/CL). CL often varies widely

between individuals treated at a given dose, so understanding the reasons behind

differences in CL is important in explaining variability in drug exposure between

patients.

The terminal half-life (t ) represents the time for drug concentration to fall by

1/2

half over the final part of the concentration–time curve when drug elimination is

the dominant process. Terminal half-life determines the time to eliminate a drug;

after 4–5 half-lives, a drug will effectively have been fully eliminated. Terminal

half-life may also determine the schedule of drug administration; to achieve

Practical Aspects of Pharmacokinetics and Pharmacodynamics 231

adequate exposure, a drug with a short terminal half-life may be best given over

successive days or by prolonged infusion. Conversely, if a drug is given frequently

in relation to its half-life, it will accumulate and concentrations rise over time.

Other PK parameters include the maximum plasma drug concentration

(C ) and V . C may correlate with drug effects, especially toxicity. The time

max

D

max

to reach C (known as T ) varies according to mode of administration, being

max

max

short after bolus i.v. injection and longer after infusion or with oral drugs. V is

D

less straightforward, as it does not represent a physiological volume. Rather, V D

relates plasma concentration to the total amount of drug in the body. A drug that

is retained in the vascular compartment will have a V of that compartment. In

D

contrast, a drug that distributed and was concentrated in the tissues, with very

low plasma concentrations, might have an apparent V much greater than the

D

total body volume of water. V can be used to determine loading doses if it is

D

important to rapidly achieve and then maintain drug concentrations above a cer-

tain threshold value. V depends on molecular weight, lipid solubility, and bind-

D

ing to tissues and plasma proteins.



10.2.2 Sample collection and processing



It is impossible to overstate the importance of sample handling and processing

for samples within PK studies. Any confusion at this early stage can lead to miss-

ing data; worse than missing data are misleading data. Incorrect recording of

when a sample was taken, or failing to process the sample in a timely manner, can

generate spurious estimates of drug concentrations.

It is advisable, well in advance of the study, to create a “laboratory manual,”

a set of clear instructions that can be distributed to all staff involved in sample

collection and even across hospital sites, if multiple hospitals are involved in

the study. It is also advisable to have input from all staff in the creation of these instructions or protocols to ensure each stage is feasible and that you are not

asking the impossible. Staff need to be identified and appropriately trained. The

usual model is to employ research nurses for this purpose. Relying on medical

staff with other clinical commitments increases the likelihood that samples will

not be taken in a timely manner or handled appropriately. It is very easy to leave

a sample in the centrifuge if another patient becomes unwell and needs atten-

tion. The protocol or manual should specify how and when samples are to be col-

lected, the volume to be sampled, how the sample should then be handled prior

to storage, and how it should be stored prior to shipping for analysis [3] .

The majority of samples collected for pharmacokinetic analysis will need to

be collected and processed under good clinical practice (GCP) guidelines. There

are several helpful and highly recommended documents and books available

2 3 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

to describe this process produced by the Medicines and Healthcare Products

Regulatory Agency (MHRA) [4,5] and the Experimental Cancer Medicine

Centre (ECMC) network [6] .

The procedure for sampling should be carefully described within the protocol.

Blood will usually be collected from an indwel ing cannula or catheter in a vein

of the arm contralateral to that through which the drug is administered if the i.v.

route is used. It is important to establish that the cannula, syringes, and tubes

in which the sample is collected, processed, and stored are compatible with the

investigational agent; highly reactive molecules may adhere to materials, invali-

dating assay results. If patency of the cannula is to be maintained with a heparin

flush, a volume representing the “dead space” of the cannula should be taken and

discarded before each PK sample is collected.

Sampling schedules will differ when PK are being studied in other tissues.

Estimation of urinary concentrations may be relevant for compounds that are

excreted by the kidneys. Although simple in theory, urine collection can be

difficult in practice. Specific containers are required, with the appropriate pre-

servatives. Calculating the total amount of drug or metabolite eliminated in

the urine requires voiding the bladder and discarding that urine at the start

( t = 0), and knowledge of the total volume of urine subsequently passed.

There is, however, always the risk that a patient will inadvertently fail to col-

lect all their urine. Alternatively, urine may be collected over blocks of time

collecting all urine passed, either over a series of 4-hour periods, or 0–4, then

4–8, and 8–24 hours following drug administration. Simply collecting “spot

samples”; i.e., a limited volume of urine at specific times, is easier but yields

less valuable information. Repeated sampling of ascites or cerebrospinal fluid

is impractical, but spot samples may be useful to establish whether a drug pen-

etrates a particular compartment. Measurement of drug levels in solid tissues

is addressed below.

The patient consent form or information sheet must describe the sampling

procedure, and any associated risks to, or additional demands on, the patient. It

may, however, be appropriate to describe the maximum number of samples and

total volume of blood to be taken, along with the period over which they may be

collected, rather than the exact timing and volume of each sample. This can allow

adjustment of sampling times, and the number of samples collected, within the

limits specified in the patient information sheet without the need for protocol

amendments as additional information becomes available from patients treated

early in the trial.



10.2.2.1 Timing of Samples

Early in the development of a new agent, a comprehensive PK profile will usually

be required, typically comprising 10–20 samples following drug administration

Practical Aspects of Pharmacokinetics and Pharmacodynamics 233

and the 24–72 hours thereafter. It is important that samples be collected at the

specified times, and even more important that the actual as well as planned sampling time be recorded. This is facilitated by a detailed work sheet, specifying the

planned sample times, and with spaces to record when the samples were actually

taken. Another important aid is a digital timer(s).

The sampling schedule is determined first by the route and mode of admin-

istration. After a bolus or short i.v. infusion, samples might be collected

pre-dose; at the end of infusion; 10, 20, 30, and 45 minutes after the end of

infusion; then at 1, 2, 4, 6, 8, 10, 24, 48, and perhaps 72 hours. Where a pro-

longed infusion is utilized, additional samples would usually be taken during

the infusion. Likewise, with oral drugs, fewer early samples may be collected,

but samples would be timed to identify the T and C following absorption

max

max

(often around two hours), as well as the subsequent periods of distribution and

elimination. Preliminary PK data from preclinical or earlier clinical studies may

assist in planning the sampling schedule. When a drug has an especially rapid

fall in initial plasma levels, greater emphasis may be placed on early time points.

By contrast, if the elimination half-life is long, accurate determination of the

later phase of the concentration–time curve through additional time points

would be appropriate. For drugs given with the aim of maintaining effective

plasma concentrations over a period of weeks or months, the priority is to

define steady-state or minimum drug concentrations. This can be done by col-

lecting samples prior to each treatment, in addition to defining the single-dose

PK described above.

Practical issues and attention to detail are important. The timing of early sam-

ples, within the first 15 minutes, can be especially difficult. A small error, of perhaps 30 seconds, can have a significant effect on the calculated PK parameters.

Indeed, collection of a sample from the cannula may take up to 60 seconds, and

it may not be clear whether the “start” or “stop” should be recorded. The specific

needs of sample processing (centrifugation, separation, freezing) may also deter-

mine how close together early samples can be collected or handled by a single

person. In studies of drug combinations, where the PK of more than one agent is

being studied, it is important that the timing of samples be matched, if this is pos-

sible. For example, previous studies of drug X may have utilized initial sampling

times of 5, 15, 30, and 45 minutes; whereas those for drug Y used 10, 20, 30, and

40 minutes. In a combination study, it is neither feasible nor sensible to collect

samples at all of these time points. Rather, the investigator should discuss with

the pharmacokineticist which combination of a limited number of samples pro-

vide the most information for both agents. With an increasing number of other

investigations (e.g., multiple electrocardiographs [ECGs]) being incorporated in

studies, care needs to be taken that it is possible to carry out all the required procedures at the specified times.

2 3 4

P H A S E I C A N C E R C L I N I C A L T R I A L S



10.2.2.2 Sample processing

The specific details of sample handling and storage will be determined by the

nature of the PK study and the investigational agent. For example, are drug lev-

els to be measured in serum or plasma, and is total or free drug to be assayed?

These questions will influence processing of the sample, so the procedures must

be clearly specified in the protocol and/or a separate working document that can

be kept by the research nurse and is available where the sample collection and

processing are being undertaken.

In general, blood samples are taken into prepared, labeled tubes; these are

often heparinized, but any additives must be specified. The samples are usu-

ally placed on ice, then centrifuged before separating the plasma, which is next

divided into aliquots to be frozen at −20°C or −80°C. The samples are subse-

quently transferred to the designated laboratory for analysis.

Again, practical issues are of paramount importance. Labeling of the tubes

at all times is vital; an unlabeled tube is at best useless, and a wrongly labeled

sample can generate incorrect and misleading data. It is important to use labels

that retain their adhesiveness when frozen at –80oC. Furthermore, the print or

ink used on these labels should not be water-soluble. Protocols may specify that

the sample is to be centrifuged immediately; this is difficult if a specialized cen-

trifuge must be used that is located in another department or building. The speed

and time of centrifugation should be specified, as should the need (or otherwise)

for a chilled centrifuge. In some cases, red blood cel s rather than plasma will

be needed; again, the investigator must be clear that they have the necessary

resources to separate the samples as directed. The sample is usually divided into

two or more aliquots in order that the analysis can be done on one aliquot, keep-

ing the other in reserve should there be problems with the assay and a need to

repeat the measurement. The investigator must have access to appropriate stor-

age conditions on site. Typically this will be in a –80°C freezer, but freezing may

damage some samples, so it is important to check the protocol. A careful record

should be kept of where and when samples were stored. Procedures should be in

place to monitor freezer temperatures, with alarms set to go off should the freezer

fail, and with personnel identified who can be contacted outside working hours

in that eventuality.

The final stage in sample handling will usually be ensuring the transfer of sam-

ples to an analytical laboratory. This may be done by a local col aborator or a com-

mercial courier. Either way, it is important to identify who will collect the samples, when this will happen, and how they are to be handled. Samples will often need to

be transferred frozen, so it must be clear at what temperature they are to be main-

tained, and who will provide the dry ice, flasks, and other equipment required. It

is equally important that the recipient laboratory have clearly defined procedures

to record receipt of the samples and their transfer to storage. It can be helpful to

Practical Aspects of Pharmacokinetics and Pharmacodynamics 235

alert the analytical laboratory that samples are due to be sent before they are dis-

patched, so that the necessary arrangements can be made for their receipt. At a

simple level, if samples are collected from the hospital on a Friday and arrive at

the laboratory the following day and no one is present to receive them, the data

are lost. Similarly, there must be procedures at both the hospital and the analytical laboratory to locate the person responsible for the samples, and arrangements in

place for someone else to act as replacement in the event of holidays or sickness.

Finally, with many trials now being international, when the study is being planned

it is important to be clear about cross-border transfer of biological samples, or personal patient information, and to acquire the appropriate documentation; dates

of national holidays will often differ between countries. Guidance documents are

now available from the United Kingdom (UK) ECMC network covering all of the

above, which are aimed at research nurses and junior clinical laboratory staff [6] .



10.2.3 Assay methods



The quality of PK data depends on the standard of the analysis. Detailed texts

describe the increasingly sophisticated bioanalytical methods that are now avail-

able. This section aims to provide the clinical investigator with sufficient insight

into bioanalysis to understand the basic terminology and procedures involved,

and to interpret the data.

At its simplest, there are three stages to bioanalysis. First, the sample must be

“cleaned up” and the drug(s) of interest extracted. The drug and its metabolites

then need to be separated from each other and any remaining contaminants.

Finally, the compounds of interest must be detected and quantified. Analytical

techniques are becoming more and more sensitive, and increasingly these pro-

cesses are becoming automated.

High-pressure liquid chromatography (HPLC) is the classical method for

sample separation. Other techniques may be used, such as gas chromatography for

volatile compounds. Historically, the separated peaks were detected and quantified

based on their fluorescence or absorption of ultraviolet or visible light, and these

techniques may still be used to analyze compounds that cannot be ionized effi-

ciently for mass spectroscopic (MS) detection. MS is, however, now the method

of choice for detection, being highly sensitive, rapid, and efficient, and capable of detecting drugs and metabolites at concentrations of 1 ng/mL or even less.



10.2.3.1 Sample Extraction and Separation

Both gas chromatography and HPLC linked to traditional ultraviolet or fluores-

cence detection techniques require quite complex sample preparation and extrac-

tion. Liquid–liquid extraction exploits differences in solubility to selectively

2 3 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

localize analytes in one solute (or liquid phase) while other material distributes

to the other liquid phase. Solid phase extraction utilizes carefully selected car-

tridges containing the stationary phase with specific physicochemical charac-

teristics through which the solvent bearing the analytes is passed; the analytes

retained in the solid phase are then washed off and collected.

HPLC separation is now generally linked to MS detection. Because MS itself

provides further selection beyond HPLC separation, requirements for sample

preparation are generally less rigorous. Protein precipitation, in which an organic

solvent such as acetronitrile is added to the sample to precipitate out the pro-

teins, is quick, simple, and broadly applicable for MS analysis.

Whatever the means of sample preparation, in most cases the next stage is

HPLC separation. This comprises a column or series of columns packed with

solid phase that has specific physico-chemical properties so it interacts with the

analyte. A “C-18 column” is widely used, and a solvent containing the analytes is

passed through the column under pressure. The solvent and contaminants pass

through, while the analytes are retained by the column, then eluted off under

pressure and collected. Differences in the interactions between several analytes

of interest and the solid phase lead them to eluted off the column more or less

rapidly. Hence, there is temporal separation of the peaks subsequently detected,

distinguishing each chemical entity.



10.2.3.2 Detection

After the analytes of interest have been separated out, they need to be identi-

fied and quantified. HPLC separation (abbreviated to liquid chromatography

or LC) followed by MS detection, commonly known as LC/MS/MS, is the

method of choice. Typically, the eluents from the HPLC column are intro-

duced into the ion source of a mass spectrometer, generating ions. A first mass

analyzer, set to the mass-to-charge ratio ( m/z) of the analytes of interest, filters the ions. The selected ions are sent as an ion beam into a chamber where they

collide with an inert gas in the collision cell and fragment. A second mass ana-

lyzer, set to the mass-to-charge ratio ( m/z) of the selected ion fragments, sends the ion fragments as a beam towards a detector. This LC/MS/MS system, comprising three key elements, is termed a “triple quadrupole.” It is more specific

than single-stage LC/MS, which utilizes a single MS and no collision chamber.

Other detection techniques such as ultraviolet and fluorescence are well estab-

lished, but now used less widely because LC/MS/MS offers substantial advan-

tages in terms of simpler sample preparation and greater speed, with enhanced

specificity and sensitivity.

Irrespective of the assay procedure, standard curves are prepared by analyz-

ing known concentrations of the compounds of interest and plotting the signal

strength; e.g., peak height, versus these known concentrations. The signal of each

Practical Aspects of Pharmacokinetics and Pharmacodynamics 237

of the compounds detected in the clinical sample is then compared with the stan-

dard curve to determine its concentration. Quality control samples are included

in each assay run.



10.2.3.3 Method Development and Validation

By definition, the initial doses of a new agent in first in human (FIH) phase I stud-

ies are low, with correspondingly low plasma drug levels. Assays, therefore, need

to be highly sensitive as well as specific and reproducible. The laboratory-based

requirements of GCP, often known as good clinical laboratory practice (GCLP), are also highly demanding, so it may take a great deal of time to establish an assay

of sufficient quality for use in an early clinical trial (see below). It is important that method development and validation begin many months in advance of

patient entry to the trial.

Guidelines have been published for method validation [7] , and acceptable

limits for assay performance defined. A detailed review of these guidelines is out-

side the scope of this text, but important assay parameters include: extraction

efficiency, accuracy, precision, specificity, sensitivity, and reproducibility. The

stability of the analyte, under different conditions (frozen, room temperature,

after thawing and refreezing) and for varying periods, is also evaluated. Once

all the validation parameters have been determined, a final report is required

describing the bioanalytical methods and a complete set of SOPs should be pre-

pared, detailing each step of the analysis.



10.2.3.4 Good Clinical Practice for Laboratories

GCP represents the international standard for the design, conduct, and report-

ing of clinical trials. The principles of GCP are incorporated as document E6 of

the internationally accepted International Conference of Harmonization (ICH)

guidelines [8] . Implementation of the European Union Clinical Trials directive

[9] further defined standards and requirements for the clinical conduct of trials

in the European Union member states. All these guidelines are, however, rather

vague with regard to the analysis of samples within those trials. Preclinical phar-

macology studies are covered by guidelines on good laboratory practice [10], but

they do not pertain to studies of clinical material in clinical trials. Nevertheless, in some countries the principles of good laboratory practice have been applied to

the analysis of clinical samples.

Phase I trials and associated PK analyses were previously often carried out at

academic centers without the infrastructure for good laboratory practice–like

quality control. Recognizing, however, the need to be seen to perform analytical

work to the appropriate standards, SOPs have now been introduced as a means

of demonstrating quality standards. More recently, rising levels of government

regulation, along with the desire of academic centers and groups to be integrated

2 3 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

into the drug-development process, have led to the concept of GCP for labo-

ratories (often known as GCLP) that seeks to provide a framework for sample

analyses within clinical trials. It applies the principles of good laboratory practice that are relevant in the setting of a clinical trial, while adhering to the principles of GCP.

GCP for laboratories defines standards and requirements across a broad range

of activities [4,11]:

• roles and responsibilities of laboratory staff

• facilities for the trial, waste disposal, and archiving

• SOPs for the work performed

• the analytical plan

• processing and tracking of trial materials

• conduct of the work, including requirements for computer systems

• reporting results

• quality control

• independent quality audit

• storage and retention of records

• confidentiality

In the United Kingdom, the charity Cancer Research UK and the ECMC

Network are supporting laboratories applying GCP (GCLP) principles. The

Research Quality Association (RQA) and the MHRA run courses and pro-

duces documents on GCP for laboratories [4,11], and the World Health

Organization has published a booklet on GCLP [12]. The United Kingdom

National Institute for Health Research (NIHR) also maintains a very useful

website of links to useful on-line GCP quality tools and resources [13], so

plenty of help is available.

A more detailed review of GCLP is not appropriate here, but investigators

need to be aware of the need to apply these principles to the analysis of samples

from early trials. Where laboratory studies are one of the primary aims of a study,

or may be included in a regulatory submission, GCLP will be increasingly impor-

tant. On the other hand, GCLP would not be a requirement where the assays are

considered secondary, tertiary or exploratory, not directly affecting the conduct

of the trial or its outcome, and not anticipated to be part of a regulatory submis-

sion. It is important, therefore, that the investigator be clear why assays are being performed so that the appropriate level of quality control can be applied.

These strict quality control issues will affect in which laboratories PK analysis

can be undertaken, the time to set up and validate the assay, how long it will take

to generate a laboratory report, and the overall cost of laboratory studies. From

a practical perspective, these developments are helpful insofar as they underpin

Practical Aspects of Pharmacokinetics and Pharmacodynamics 239

and validate laboratory data, provided the requirements do not become so strin-

gent as to obstruct the analysis of clinical samples.



10.2.4 Data analysis



Concentration–time (C × T) data are first plotted for each patient, using a linear

scale for time and logarithmic scale for drug and, where appropriate, metabo-

lite concentrations. Figure 10.1 is an example of how this might be shown

in a study report. In this figure, taken from a phase I report of 17-allylamino,

17-demethoxygeldanamycin (17-AAG), C × T data for the drug and its metabo-

lite are displayed for several patients treated at the highest dose level [14].



10.2.4.1 Compartmental and non-compartmental Analyses

There are two general approaches to PK data analysis—compartmental and

non-compartmental analysis. Non-compartmental analysis is the more straight-

forward. Such analyses generate the basic PK parameters described above, with-

out the need for devising a model or making extensive assumptions about the

data. Although these analyses can be done manually, by “curve stripping,” in prac-

tice, PK programs perform the same function more rapidly. The main limitation

of non-compartmental analyses is the restricted scope for modeling or simulat-

ing the data. In the context of early clinical trials, non-compartmental analyses

are, therefore, widely applicable when the initial requirement is to define basic

parameters.

In contrast, compartmental analysis is more complex, requires expertise in

the handling of PK data, but is potentially more informative. A series of com-

partments is defined between which the drug and metabolites pass. In a simple

model, a central compartment is defined, essentially the blood or plasma into

which drug first distributes. It then distributes into one or more peripheral com-

partments, representing extravascular tissues and organs. The compartments

are “virtual” rather than physiological, and the number of compartments can

be increased, depending on the complexity of the model. This more sophisti-

cated approach can help in understanding how a drug is handled. For example,

a non-compartmental analysis may identify the fact that a drug has non-linear

kinetics; e.g., there is a disproportionate rise in AUC in a phase I trial as dose is increased. Compartmental analysis can also identify how and where the drug is

distributed, explaining the cause of this non-linearity. Figure 10.2 provides an

example of the application of this approach to the analysis of the PK of paclitaxel

[15], illustrating the model developed to describe its non-linear disposition.

Several programs for PK models are available, including ADAPT 5 (Biomedical

Simulations Resource, University of Southern California, Los Angeles, CA), and

2 4 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

A

1,000,000

10,000

100

17-AAG Concentrations (ng/l)

1

0

10

20

30

40

50

Time (hours)

B

10,000

1,000

100

17-AG Concentrations (ng/l)

10

0

10

20

30

40

50

60

Time (hours)

Figure 10.1 (A) Plasma concentrations of 17-allylamino, 17-demethoxygeldanamycin

(17-AAG) in patients treated at 450 mg/m2/week. The dotted line represents the

mean IC of the National Cancer Institute 60 human tumor cell line panel. (B) Plasma

50

concentrations of the metabolite 17-AG (17-amino, 17-demethoxygeldanamycin).

From Banerji et al. (2005) J Clin Oncol 23:4152–4161. Reprinted with permission from the American Society of Clinical Oncology.

Phoenix® WinNonlin® (Pharsight Corp., Sunnyvale, CA). The website Boomer.

org is recommended as a source of freeware pharmacokinetic modeling software

and general pharmacokinetic and pharmacodynamic resources. The PK of E7070

provides a good illustration of the use of such models [16].

Practical Aspects of Pharmacokinetics and Pharmacodynamics 241

infusion

k31

Vm/ Km

3

1

2

k

k

21

13

oVm

oKm

Figure 10.2 Representation of a three-compartment model developed to describe

paclitaxel disposition.

Reprinted from Kearns et al. (2005) Semin Oncol 22 (3 Suppl. 6) 16–23, with permission from Elsevier.



10.2.4.2 Population Pharmacokinetics and

Limited Sampling Techniques

The terms “population pharmacokinetics” and “limited sampling techniques”

come up quite frequently when early clinical trials and drug development are

discussed. Both represent more advanced approaches to the use of PK data.

Whereas the approaches described earlier in this chapter use large numbers of

samples from a small group of patients to define the kinetics of a drug in each

individual, population PK and limited sampling strategies seek to gain more

information from fewer blood samples in a large population. They are often

based on preliminary data obtained in phase I trials and applied to later-phase

trials.

Population PK uses modeling to describe how a drug is handled across a

population rather than in a series of individuals [17]. NONMEM (non-linear

mixed effect modeling) is the best-known such software program, but it

requires highly specialized operators [18]. A NONMEM analysis uses fewer

samples, collected from a large number of patients at differing (but accurately

recorded) time points, and the data are analyzed for the population. Both the

inter-individual variability and the residual random variability can be esti-

mated, and the influence of factors such as age and organ impairment can be

investigated systematically. The use of population PK in drug development

has been reviewed [19]. One of the best illustrations of how population PK

can be used is the effect of liver dysfunction on docetaxel PK and toxicity.

A PK/PD study of 24 phase II trials with docetaxel monotherapy demon-

strated that the exposure was a strong predictor of grade 4 neutropenia and

febrile neutropenia. An update analysis found a threefold higher incidence of

neutropenia in patients with baseline abnormal hepatic enzymes compared

2 4 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

with patients with normal liver function. This was consistent with the PK/

PD model where patients with abnormal liver biochemistry tests had a 27%

decrease in docetaxel clearance. A 25% reduction should therefore, normalize

exposure to docetaxel so a starting dose of 75 mg/m2 was recommended [20].

This approach was also used with the novel topoisomerase inhibitor TP300 to

predict neutropenia from the total concentration of its metabolites TP3076

and TP3011 [21].

A limited sampling strategy is one that allows PK data to be calculated for an

individual based on only a few carefully timed samples. This makes PK studies possible in phase III trials where the collection of a full data set of 15–20 blood samples would usually not be feasible. Hence, although limited sampling strategies may be

based on data from phase I trials, they are usually implemented in later-phase tri-

als. The most straightforward approach to developing a limited sampling strategy

is to collect a conventional data set for a population and then define the PK param-

eter of interest, usually AUC. Stepwise linear regression is then undertaken on a

subpopulation, the “training set,” with AUC the dependent variable and each of

the individual time points independent variables [22]. Alternatively, a compart-

mental model can be fitted and the optimal sampling package of ADAPT II [23]

used, or a population approach using NONMEM may be implemented [24].



10.3 PHARMACODYNAMICS



PD endpoints assess the effects of a drug on the body. Although they are the focus of much recent interest due to the introduction of new targeted therapies, we

should remember that, traditionally, phase I trials of cytotoxics include PD

assessments in the form of monitoring blood counts that reflect anti-proliferative

effects on the bone marrow. Even with the increasing importance of more sophis-

ticated laboratory endpoints, clinical findings may still serve as PD endpoints,

as with the dose-related skin rash typical of epidermal growth factor receptor

(EGFR) inhibitors [25] and the hypertension associated with inhibitors of vas-

cular endothelial growth factor (VEGF) [26]. In both cases, however, the clinical

finding was validated by correlation with inhibition of the target or downstream

molecular measures in biopsy or imaging studies. The magnitude of a PD effect

may not, however, correlate with biological activity. In a phase III trial comparing

chemotherapy plus either bevacizumab or axitinib, the latter combination was

associated with more hypertension but less clinical efficacy [27].

With many targeted therapies, a clinical PD endpoint has not been identified.

Accordingly, there is increasing emphasis on molecular and functional changes,

measured either in tissue samples or by imaging techniques, that measure target

inhibition.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 243



10.3.1 Principles of pharmacodynamics

PD markers can be used in different ways within an early clinical trial, usually of a novel biological or targeted therapy. While planning the study, it is important to

establish why and how PD studies are to be incorporated:

• To define dose escalation. Here, the measurement of PD effects is incor-

porated into the trial as a primary endpoint so they can be used to assess

the magnitude of a biological effect and its relationship to the dose of

drug administered. Hence, it is necessary to study pharmacodynamics,

using a fully validated assay, on all patients at each dose level, with clear

implications for conduct of the trial. Indeed, where there is considerable

between-patient variability in the magnitude of that PD effect, it is likely

that more patients than usual will need to be treated at each dose level

to define differences in biological effects.

• To define the recommended dose. Again, the PD measurements are a pri-

mary endpoint. If there is no expectation or intention to escalate dose

to define a formal maximum tolerated dose (MTD), it may be neces-

sary to make detailed PD assessments at all dose levels to define the

recommended phase 2 dose (RP2D). Alternatively, the maximum dose

administered may be based on toxicity or by having achieved a specific

PK threshold. In that case, detailed PD studies may be carried out at

the RP2D and perhaps a second, lower dose at which there was either

evidence of activity or a potentially effective exposure was achieved.

This can establish whether or not maximal dosing is required to achieve

the biologically effective dose.

• To provide proof-of-concept. This is rather different, with PD studies

aiming simply to establish that the drug has its expected or designed

molecular effect. Although this can be done by conducting the PD stud-

ies in all patients as part of the phase I trial, this has disadvantages. PD

studies are often costly and time-consuming, and invasive procedures

such as tumor biopsies may delay trial recruitment. In this context,

PD studies may be a secondary rather than a primary endpoint, and

may only be required in a subset of patients such as those treated at the

RP2D, or patients treated at a center with access to specialized func-

tional imaging equipment. It is, however, important to clearly specify

which patients will be studied. If complex imaging or invasive biopsy

studies are optional, there is a likelihood that they will not be carried

out; so where they are important, PD studies should be mandatory.

• To explore novel markers. When a new drug enters the clinic, the tar-

get may not be fully defined, or a validated assay demonstrating target

2 4 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

inhibition may not yet have been developed. The phase I trial is a unique

opportunity to learn how a drug is acting over a range of doses, even

where this information will not directly influence the conduct of the trial.

Under these circumstances, “exploratory” or “experimental” PD studies,

carried out in a systematic manner, can be valuable in their own right.

The above aims may, however, overlap. A proof-of-concept study may confirm

that a dose is biologically effective, and the use of PD markers to guide dose esca-

lation and determine the recommended dose may provide de facto evidence of

proof-of-concept. Likewise, an exploratory study may identify markers that are

incorporated at a later stage of the trial or in a subsequent study. In some circum-

stances, a separate PD study may be conducted once the first-in-human (FIH)

study is complete. A proof-of-concept study may then be carried out at the rec-

ommended dose. Where the optimal biological dose has not been fully defined,

PD effects may be studied at two or more different doses (e.g., the RP2D and a

lower, better tolerated dose).

It is not clear to what extent a positive “signal” from PD studies can provide the

rationale for a larger, randomized trial. This is relevant because, whereas achiev-

ing a predefined response rate in a phase II trial traditionally provides that ratio-

nale for cytotoxics, objective responses may not be anticipated for at least some

biological agents, so an alternative signal is needed. Achieving a PD endpoint

may be a prerequisite for clinical efficacy, but it is not necessarily in itself sufficient to guarantee that efficacy. This distinction probably reflects, at least in part, whether the PD endpoint demonstrates interaction with the target or a downstream biological effect.

Issues specific to tissue biopsies and functional imaging are discussed in

more detail below. Several general points are, however, worth making. First, it

is important that preclinical studies (and any previous clinical studies of related

compounds) have defined the appropriate target, PD marker, and relevant bio-

logical outcome. This will often take the form of demonstrating dose-dependent

changes in a signaling pathway in tumors that respond to the drug in preclini-

cal models. However, despite the emphasis on rational development of targeted

therapies, drugs will often have more than one target or biological effect. It is

also possible that the antitumor activity that has been observed preclinically may

not be mediated by the inhibition of the putative target. This is illustrated by the

development of sorafenib, which was first thought to be a “specific” inhibitor

of raf-1 kinase [28] but was subsequently found to act on several other kinases

[29], inhibition of which may mediate its activity in some tumors. Under these

circumstances, using a PD marker, either to provide proof-of-concept or to

guide conduct of the study, may actually be positively misleading. By contrast,

PD proof-of-concept would probably have been useful in the development of

Practical Aspects of Pharmacokinetics and Pharmacodynamics 245

iniparib, a putative poly ADP ribose polymerase (PARP) inhibitor that failed in

phase III trials; subsequently, the lack of preclinical and PD data to support ini-

parib inhibiting PARP became apparent [30,31].

It is also important to define how the clinically relevant biological effect is best

measured. This will depend on the drug and its target, but whether this takes the

form of tissue biopsy or imaging, the PD assay must be validated and a clear pro-

tocol developed. Where the PD marker is a primary endpoint and fundamental

to the conduct and outcome of the trial, the same principles of GCLP apply as

described above. It is necessary to define not only what is measured and how, but

also the size of the biological effect that is considered “desirable” or to reflect adequate target inhibition, and in what proportion of patients. In the absence of clin-

ical data from related drugs, this will often mean extrapolating from good-quality

preclinical experiments.

A related question is that of how many patients are needed for adequate

evaluation of the PD marker. Intuitively, we might anticipate that incorporat-

ing a PD marker within an early trial would make the study more efficient and

reduce the number of patients required. In the longer term, such studies almost

certainly will streamline the development process, but in a phase I trial, more

patients may be required than when the primary endpoint is determined by

toxicity. For a trial to show a dose–response effect in target inhibition from

40% at one dose level to 90% inhibition at a higher dose, 17 evaluable patients

would need to be treated at each level [32]. Likewise, to demonstrate proof-of-

principle is likely to require PD studies in an expanded cohort of patients

treated at theRP2D.

The biopsy or assay procedures must be described adequately in the patient

information sheet (PIS) and/or informed consent document. It should be clear

whether or not consenting to the PD study is a prerequisite of trial participation.

A single PIS covering the clinical and PD aspects of the study will usually suffice

where opting out of the PD study is not an option. In some cases, one PIS may be

adequate, even if it is possible to participate only in the clinical study; this does, however, require that it be clear to the patient to what they are consenting. In

other cases, a separate PIS may be used for the PD studies. Investigators may be

guided by experience in their own institution or seek guidance from their local

ethics committee.

Finally, it is important to establish that each trial center has the resources

for PD studies. Close links between the clinic and the PD laboratory are vital;

laboratory scientists should be directly involved in writing the protocol and

acknowledged as authors and co-investigators. It is equally important that these

translational researchers be involved in a timely manner. Even more than with PK

studies, novel PD assays or imaging procedures may take many months to set up

and validate, especially if GCLP standards are required.

2 4 6

P H A S E I C A N C E R C L I N I C A L T R I A L S



10.3.2 Tissue biopsies



When developing molecularly targeted agents (MTAs), establishing whether

a drug is modulating the desired target is logical and desirable, but not always

straightforward. Even when preclinical experiments have defined the target and

an assay has been established, important questions remain: Which tissue should

be sampled and how much? When should samples be taken? How should they

be handled and processed? How are the data to be analyzed and interpreted? It is

important that clinicians, radiologists, pathologists, and research nurses, as well

as laboratory scientists, be involved at an early stage.



10.3.2.1 Sample Selection



Ideally, all patients should be included and target inhibition should be measured

in the tumor, comparing samples before and after treatment. In addition, more

than one baseline sample may be required to assess normal variability, and sev-

eral at different times during and after treatment to determine the onset of target

inhibition, the maximal effect, and recovery to baseline. Each sample should also

be sufficiently large that repeat measurements can be made and tissue stored for

future use. To do this across all dose levels in a phase I trial wil , however, usu-

ally be impractical, as it would limit the study to patients with multiple tumor

deposits accessible for repeat biopsy, and many would not consent to multiple

biopsies. It is, therefore, necessary to clearly establish the reasons for doing the

PD studies, to define the relevant patient group, and then develop a scheme that

is both scientifically sound and clinically feasible.

Tumor tissue will almost always yield the most relevant information, but is

also usually the most challenging to obtain; the exception has been hematologi-

cal malignancies, where tumor cel s are easily available. “Liquid biopsies” (see

below) offer a similar alternative in patients with solid tumors. Although tumor

biopsies are also relatively straightforward in patients with superficial melanoma,

head and neck cancer, cervical cancer, or women with soft-tissue metastases from

breast cancer, other sites are less accessible. Nevertheless, repeat liver biopsies

are feasible and generally safe [33,34]; other studies have investigated PK–PD

relationships, including drug metabolism [35].

There are many examples of phase I trials incorporating serial molecular tis-

sue measurements dating back several years [25,36–38]. The patient population

must be selected carefully, taking into account the key PD question(s), the study

drug, and the target under evaluation. It may be appropriate to mandate tumor

biopsies from patients with specific tumor types only in the expanded RP2D

cohort, after certain toxicities occur indicating that a potentially clinically rel-

evant dose is being administered, once a target PK exposure has been achieved,

or after a PD signal has been seen in other surrogate tissues.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 247

Because they are more easily accessible, normal tissues are attractive as “surro-

gates” to measure cellular changes in molecular effects. It is a prerequisite of using such tissues that the appropriateness of the tissue in question and validity of the

assay be confirmed first in preclinical models. The surrogate tissue should express

the target in pre-clinical models, and exhibit either a dose-related or pharmaco-

kinetically related inhibition of the target that parallels target inhibition seen in vivo in tumors. Ideally, the surrogate tissue should be easily accessible, such as

peripheral blood mononuclear cel s (PBMCs), skin, buccal mucosa, or hair fol-

licles (Table 10.1).

Until recently, the most convenient surrogate tissue has been PBMCs, but

recently other circulating material has been used such as soluble VEGF for anti-

angiogenic drugs), cytokines and immune biomarkers (for immunotherapies or

viral therapies), and in particular, blood-borne tumor material such as circulating

tumor cel s (CTCs), cell free circulating tumor DNA (ctDNA) or RNA; some

examples are shown in Table 10.1 [39–49, 57]. These are sometimes referred to

as “liquid biopsies” and are of particular interest as they are minimally invasive

but give information about changes in tumor cel s.



Circulating tumor cells (CTCs)

CTCs are released into the blood from primary and/or metastatic tumor; the

process of intravasation is, however, not well understood. CTCs have proved

clinically relevant in stratifying the risk of relapse in patients with early-stage

disease, establishing prognostic groups in those with advanced cancer, and the

molecular characterization tumors (e.g., HER2 amplification, ALK transloca-

tion, and EGFR over-expression). In phase I clinical trials, looking for molecular

changes in CTCs can be challenging due to the need to validate processes for

their collection, processing, and analysis [49,47] (Table 10.1).

Historically, fewer than ten CTCs/mL have been detected in most patients

with metastatic cancer, but newer techniques are more sensitive and can obtain

sufficient CTCs for multiple PD markers to be evaluated [49]. Different tech-

niques have been used to isolate CTCs, exploiting their physical properties, func-

tional characteristics, leukocyte depletion (after separation of red cel s, plasma,

and platelets), and antibody capture. The most widely accepted technology

involves antibody capture [50,51]. The commercial CellSearch platform uses

magnetically tagged antibodies against the epithelial cellular adhesion molecule

(EpCAM) to isolate CTCs [52,53]; an obvious limitation is that this can be

applied only to epithelial cancers. New techniques are attempting to overcome

these drawbacks. ApoStreamTM uses the distinct biophysical characteristics of

cancer and normal cel s applying dielectrophoretic technology in a microfluid

flow chamber and is independent of EpCAM expression. Another advantage is

that it allows isolation of viable cel s rather than using chemical and mechanical

Table 10.1. Examples of surrogate tissue samples

Drug

Surrogate Sample Analyses

Results

Reference

Cyclin-dependent

Tumor and skin

RNA extraction from skin and

7 of 19 patients from three distinct doses had skin and

Locatel i et al.

kinase inhibitor

biopsies

tumor biopsies.

tumor biopsies. There were significant transcriptional

(2010) [39]

PHA-793887

Analyses of a panel of 58

downregulation with a dose–response correlation

selected E2F-dependent genes

in skin biopsies: patients treated at low doses had

with quantitative real-time

less-modulated genes compared to patients treated at

PCR at baseline, during 2nd

the highest dose (p<0.05).

administration on cycle 1 and This dose–gene modulation correlation was not found

at day 8 of infusion.

in the RNA from the tumor biopsies, although there

was a higher modulation in RNA from patients that

had had ≥4 cycles (in all dose cohorts).

UCN-01

Normal

Phosphorylated ribosomal pro- pS6 was reduced in PBMC, normal rectal mucosa, and

Fracasso et al.

(multitarget protein rectal mucosa

tein S6 (pS6) Western blood.

tumor after UCN-01 administration. On 23 samples of

(2011) [40]

kinase inhibitor) + Tumor biopsy

Initially baseline and 24h

patients, pS6 expression in PBMC were significantly

irinotecan

PBMC

post-treatment colonos-

reduced at 24h after UCN-01 compared to baseline,

copy was required; this

and started to rise at day 6 post-treatment with no sig-

impaired recruitment. Use of

nificant difference when compared to baseline levels.

blood-based PD allowed 2nd

biopsy to be dropped.

Bexarotene

Buccal biopsies

Immunoblot analyses with

Buccal samples from 6 patients, and 5 were evalu-

Dragnev et al.

(cyclin

densitometry to deter-

able. Cyclin D1 protein expression was reduced in

(2012) [41]

D1 inhibitor) +

mine changes in cyclin D1

the 5 patients (4-fold decrease post-treatment vs.

Erlotinib

expression.

pre-treatment).

Oral pan-AKT

Hair fol icle

Phosphorylated Thr246

23 hair fol icles of 33 patients were analyzed. pThr246

Yap et al. (2011)

inhibitor

(pThr246) and total protein

PRAS40 was suppressed in hair fol icles at 6h and days

[42]

MK-2206

levels of protein-rich AKT sub-

7 and 15 compared to baseline (p = 0.025). This was

strate 40 (PRAS40) at baseline also observed in the 13 patients at the MTD dose.

and days 7 and 15.

TP300 (Topo1

PBMC

Single-strand breaks using

Full comet profile of 29 patients. DNA strand breaks

Anthoney et al.

inhibitor)

single-cell gel electrophoresis

increased x2 at 1h post-first dose compared to pre-dose (2012) [43]

(comet) assay pre-dose, 1, 3,

level in all dose levels.

and 24h post–cycle 1.

Imatinib +

CTC

Quantification of CTC by

15 out of 32 patients with ≥3 CTC. Number of CTC

Kelley et al.

bevacizumab

CEC

CellSearch and CEC by flow

during treatment changed from baseline levels, but no

(2013) [44]

+ metronomic

cytometry assay at baseline;

statistical significance correlation with time to treatment

cyclophosphamide

weeks 2, 6, and 8; and at the

failure (TTF), PFS, or best response. Absolute levels of

end of treatment.

CEC and changes from baseline did not correlate with

outcome or response. However, the ratio of CEC sub-

populations CD146+/CD31+ at cycle 1, day 15, had a

significant correlation with TTF, PFS, and best response.

HER2/CEA DNA

T cel s

Her2, CEA, and bacterial

None of the 11 patients achieved a measurable Her2

Diaz et al.

vaccine followed

Antibody

label toxine (LTB) specific

or CEA-specific T cell levels. LTB-specific T cell was

(2013) [45]

by adenoviral boost response

cel -mediated immunity were

increased at day 72 post-vaccination.

immunization

measured by IFN-γ ELISPOT Significant increase of antibody titre against the bacterial at baseline and different

heat labile toxin upon vaccination.

point times post-vaccination.

Staphylococcus aureus entero-

toxin B ELISPOT was used as

a positive control.

Antibody responses by ELISA.

( continued)

Table 10.1. (Continued)

Drug

Surrogate Sample Analyses

Results

Reference

Nivolumab plus

CD8+ T cel s

Leukapheresis at baseline,

37 patients had pre- and post-leukapheresis specimens, Weber et al.

ipilimumab

Tumor

weeks 12 and 24 in cohorts

and 48 patients had only pre-leukapheresis speci-

(2013) [46)

1 to 5. CD8+ T cel s were

mens. High pre-treatment-specific CD8+ T cel s were

selected by tetramer staining

associated with non-responders. Regulatory T cel s

for NY-ESO-I 157-165 and

decreased in responders and stable patients and rose in

MART-I 26-35

non-responders at 12 weeks. PDL1+ staining corre-

.

PDL1 tumor staining.

lated with tumor response.

Figitumumab

CTCs

Enumeration of CTCs using

CTCs> = 5 in 15 patients, including 10 patients with CRPC. Molife et al.

(insulin-growth

Soluble (s) IGF-IR Cel Tracks system.

Of these 10, 6 showed a fall from ≥5CTCs to <5CTCs.

(2010) [47]

factor-I) +

IGFR-IR-expressing CTCs by

23 patients with IGF-IR-positive CTCs; these increased De Bono et al.

docetaxel

Cel Tracks system.

towards the end of 21-day cycle and

(2007) [48]

sIGF-IR: enzyme immunoassay

fell again with retreatment.

that detects the extracellular

sIGF-IR: All patients had detectable levels of sIGF-IR.

domain of IGF-IR.

Dose-dependent decrease in sIGF-IR.

Etirinotecan pegol

CTCs

Enumeration of CTCs using

93% of the samples had detectable CTCs: median of

Hotch U et al.

(BEACON Study)

ApoCell/ApoStream

216 CTCs (range: 7.5–14816).

(2013) [49]

technology.

82%, 89%, 16%, 53%, 31%, and 52% of the samples were

Multiplex immunofluorescent

positive, respectively. Final report and analysis has not

assays of Top1, Top2, gHA2X,

published at the time of this chapter edition.

Rad51, ABCG2, and Ki67 pre

and post-treatment.

MK-2206 (AKT

ctDNA

PIK3CA (exon 20 and 9),

Biomarker study done in 68 patients. Only 7 were posi-

Molife et al.

inhibitor) +

KRAS (exon 2 and 3) and

tive for mutations: 4 patients with PIK3CA mutation

(2014) [57]

CBDCA/Paclitaxel,

BRAF mutations (exons 11

(exon 20); 3 pts. with KRAS (exon 12) mutation.

docetaxel or

and 15) were analyzed using

Stable disease according to mutational status:

erlotinib

real-time quantitative PCR.

– Non-mutated: range from 1 to 13 (median 7 months)

– PIK3CA mutated: range from 1.7 to 5.8 months

– KRAS mutated: range from 1.4 to 3 months

Practical Aspects of Pharmacokinetics and Pharmacodynamics 251

manipulation [54]. Interestingly, the ApoStreamTM method appears to isolate a

higher number of CTCs than CellSearch. In the BEACON phase III study in

metastatic breast cancer of 167 pre-dose blood samples found CTCs in 93% of

them and a median of 216 CTCs (range 7.5–14816); this should allow character-

ization of multiple PD markers [49] (Table 10.1).



Cell free circulating tumor DNA

Fragments of DNA are shed into the bloodstream from dying cel s. In patients

with cancer, the fraction of circulating free DNA from tumor cel s ranges from

<0.1% to >10% [55]. ctDNA is extracted from plasma using commercially avail-

able kits. Polymerase chain reaction (PCR) or gene-sequencing techniques can

detect mutations or other specific alterations in tumor DNA that are not present

in normal cel s [50,56]. This genetic material can be used in clinical trials as a

predictive or prognostic biomarker or to identify patients whose tumors express

a specific marker [57,58]. It may have the potential to identify changes resulting

from exposure to novel agents in trials of new agents.



Other circulating tumor material

Circulating free RNA has also recently been used on the same basis as ctDNA

[50,56]. Another possible future PD biomarker is tumor-derived RNA in plate-

lets. Tumor cel s transfer (mutant) RNA into platelets in vitro and in vivo, and

platelets isolated from patients with glioma and prostate cancers contain the

cancer-associated RNA biomarkers EGFRvIII and PCA3, respectively. In addi-

tion, gene-expression profiling revealed a distinct RNA signature in platelets

from glioma patients compared with control subjects. This is a promising PD

biomarker because of the easy availability of platelets and the ease of their isola-

tion in hematology laboratories [59].



10.3.2.2 Sample Collection and Processing

Preclinical data will guide the initial timing of samples; these may change as

early clinical data become available, but it is important that a degree of con-

sistency be maintained throughout the study so the data can be meaningfully

interpreted. Practical issues are also important; multiple time points are feasi-

ble for PBMCs or buccal smears, but less so for more-invasive procedures. The

question of how much tissue to sample is again determined by the needs of the

assay and the feasibility of the procedure. At one extreme, a large volume of tis-

sue may be available by surgical excision of a tumor; the opposite is true where

tissue is obtained by percutaneous biopsy or even fine-needle aspiration. The

smaller the biopsy, the greater the risk of sampling error; the tissue sampled

may not be representative of the tumor, may be necrotic, or may not even con-

tain malignant material. Whatever the circumstances, the amount of tissue

required should be clearly specified; “as much as you can get” is not acceptable!

2 5 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

All aspects of sample collection, processing, storage, and transport must be

described clearly in the study protocol. This will be along the lines described

above for PK sampling, but for PD samples, additional information may also

be important. For example, from which skin surface should a skin biopsy be

taken, and to what depth? How should the mouth be prepared before obtaining

a buccal smear?

It is unusual for a statistical power calculation to be used to determine the

number of patients to be sampled. This is understandable, given our limited

knowledge regarding target expression and its variability in different patients

or tumors, and the optimal level or duration of target inhibition. Such uncer-

tainty is, however, unsatisfactory if a PD marker is the primary endpoint.

Nevertheless, PD studies can define biological activity, as was the case with

a study of the aromatase inhibitor anastrozole, where six to eight patients

were enrolled per dose level and peripheral blood estradiol levels were the

endpoint [60].



10.3.2.3 Tissue-Based Pharmacodynamic Assays

The first question in these assays is what to measure and how. This may be fairly

straightforward when measuring cellular drug levels to demonstrate, for exam-

ple, that a delivery system does generate drug preferentially in tumor tissue.

More often, PD studies involve measuring inhibition of the specific target of a

new drug. Important questions include whether the level of protein expression,

its phosphorylation status, or downstream changes in cell signaling should be the

PD endpoint. Preclinical studies will guide the decision as to what is measured,

but practical aspects such as how robust or repeatable the assay is, how much tis-

sue is needed, and the condition or processing of that tissue are also important.

Where several assays are undertaken, the one that constitutes the “primary” end-

point should be defined upfront and a hierarchy established for the other assays

to be undertaken.

A range of assays is available to measure PD endpoints in plasma, normal tis-

sue, and tumor samples. These include enzyme-linked immunosorbent assay

(ELISA), immunohistochemistry (IHC), Northern and Western blotting,

gene-expression arrays, and real-time PCR (Table 10.1).

In the setting of drug development, most assays are refined and developed

for a specific target by the academic or pharmaceutical company that generated

the new molecule, and are not validated to GCLP. If the PD measurements

are a primary endpoint of the trial, however, the assay must be validated to

GCLP standards; this is time-consuming, expensive, and often quite challeng-

ing. The principles and implications of GCLP were described with respect to

PK assays and laboratories in Section 10.2.3.4; the same considerations apply

to PD assays. To enable some flexibility due to the challenging nature of some

Practical Aspects of Pharmacokinetics and Pharmacodynamics 253

of these assays, a fit-for-purpose approach is often adopted, as described by the

Bioanalysis and Quality Assurance Group of the ECMC network in the United

Kingdom [61,62]. Even where the PD endpoints are secondary or exploratory

endpoints, aspects such as test-to-test reproducibility should be assessed,

along with practical issues such as the effect of storage and extremes of heat. It

is also necessary to define who will interpret the data and according to which

criteria; i.e., what will constitute a “positive” result. These questions are clearly defined for clinical toxicities and radiological tumor response, but are much

more difficult for PD assays.

Development and validation of the assay should be completed and SOPs writ-

ten before the trial opens.



10.3.3 Functional/molecular imaging studies



Imaging has long been central to anticancer drug development as a means of

defining the extent of disease and monitoring response to treatment. In this

context, clear guidelines have been developed, the most widely used being the

Response Evaluation Criteria In Solid Tumors (RECIST) criteria for response

assessment [63]. More recently, functional or molecular imaging has been

developed as a relatively noninvasive means of assessing in vivo the effect of new

agents on both malignant and normal tissues [64]. In the USA, the National

Cancer Institute has established several In Vivo Cellular and Molecular Imaging

Centers; in the UK Cancer Research UK established the Pharmacodynamic/

Pharmacokinetic Technologies Advisory Committee, to review the use of these

approaches in hypothesis driven early clinical trials; Cancer Research UK also

supports a PET research group at the Wolfson Molecular Imaging Centre in

Manchester.

Functional imaging methods include dynamic contrast enhanced magnetic

resonance imaging (DCE-MRI), PET, functional (or dynamic) computerized

tomographic (CT) scanning, and ultrasound (US). Functional imaging has been

used to study drug distribution, changes in tumor metabolism, and alterations

in blood flow. Functional imaging is very attractive in certain situations, but

remains an evolving and often complex area of research. The feasibility of func-

tional imaging is clear, but there are major challenges around the standardization

of data acquisition and analysis between centers. In many cases it also remains

unclear to what extent changes detected by molecular imaging reflect altered

tumor biology and, ultimately, changes in clinical outcome.

As with other PK and PD studies, the first step in functional imaging stud-

ies is to define the appropriate endpoint. This will be determined by the mode

of action of the investigational agent and preclinical data. An endpoint that is

2 5 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

clinically relevant and linked to tumor response would be preferred, but this may

only be apparent in hindsight. It is also important to define ahead of the trial,

not only the key endpoints, but also the criteria defining an “effect” or biological

response. This threshold will vary with each drug and be determined in part by

what is adjudged significant from preclinical or earlier clinical studies. It is also determined, however, by the reproducibility (or otherwise) of the technique. As

described below, there are many sources of variability in functional imaging stud-

ies. It may, therefore, be necessary to study 10–15 patients at a single dose level

to be confident of identifying the effect of a drug using these studies. The need

to image significant numbers of patients mandates either that multiple institu-

tions be involved in the study, or that the data be acquired over a longer period

than would usually be necessary to explore an expanded cohort in a phase I trial.

Where multiple sites are used, maintaining consistency in data acquisition and

analysis between institutions is crucial.

Most functional imaging studies have focused on angiogenesis inhibitors and

vascular disrupting agents, assessing tumor blood flow and perfusion, but these

approaches could be applied more widely. The range of functional imaging tech-

niques, each with its own strengths and weaknesses, is described briefly below.

From a practical point of view, perhaps the most important action is for an inves-

tigator to seek out and talk to the functional imaging team as early as possible

when planning a clinical trial, to identify what should be imaged, how, and when.

It is also important to define local technical capabilities and man power for func-

tional imaging, which may limit is feasible. Before the trial opens, the protocol for data acquisition and processing will need to be defined, and agreed upon at other

sites in the case of multicenter studies (Table 10.2).



10.3.3.1 Magnetic Resonance (MR)

MR technology is best known as a means to image the size and structure of

tumors and define their relationship with adjacent tissues. It has been refined

to offer several new means to measure PD endpoints. An important advantage

of MR imaging and MR spectroscopy is that, because there is no ionizing radia-

tion involved, serial examinations do not raise the safety issues linked to PET

and CT.

It is beyond the scope of this chapter to describe in detail the techniques

involved or the clinical data that are emerging, so only limited examples will be

quoted.

• DCE-MRI uses changes in the site and intensity of signal after i.v. injec-

tion of the standard low molecular weight paramagnetic contrast agent

gadolinium-DTPA to generate information on tumor perfusion, vessel

density and permeability, and blood volume. DCE-MRI has been used

Practical Aspects of Pharmacokinetics and Pharmacodynamics 255

Table 10.2. Selected Pharmacokinetic-Imaging

Pharmacodynamic Relationships

Drug

Analyses

Results

Reference

Regorafenib

DCE-MRI

No apparent association of Strumberg

Area under contrast agent iAUC60 and PFS

et al. (2012)

concentration time

[66]

curve during the first

60’’ after contrast agent

arrived (iAUC60)

MEK inhibitor [18F]-FDG PET at base- [18F]-FDG PET responses Zimmer et al.

RO4987655

line, day 15 cycle 1, and on day 15 cycle 1 were

(2014) [70]

day 1 cycle 3

indicative of higher early

Changes in SUV

(but not later) RECIST

response rate

Patients without [18F]-FDG

PET responses on day 15

cycle 1 were not respond-

ing per RECIST (high

negative predictive value)

Anti-IGF1R

[18F]-FDG PET

One patient with meta-

Atzori et al.

Dalatozumab Pre and post-treatment

bolic response but stable

(2011) [71]

(MK-0646)

tumor samples

disease by RECIST had a

decrease in Ki67 expres-

sion in the tumor

Sorafenib plus Biopsies, [18F]-FDG

Vascular perfusion (K ) Azad et al.

trans

Bevacizumab PET (SUV) and

increased early in patients (2013) [72]

DCE-MRI (K for-

with an amplified VEGF

trans,

ward contrast transfer

staining in the tumor

rate; K reverse con-

Vascular permeability (K )

ep,

ep

trast transfer rate) at

increased in patients

baseline, 2, and 6 weeks who had a greater

CD31-positive microves-

sels post-treatment

successfully with anti-angiogenic agents such as PTK787/ZK222584

[65] and regorafenib [66]. Permeability to larger particles, and an esti-

mate of blood volume, can be obtained using larger-molecular weight

contrast agents such as ferric oxide, which are retained in the vascular

space to a greater extent.

• Diffusion-weighted MRI uses changes in the rate and diffusion of water

molecules to study alterations in the tumor micro-environment that

may predict subsequent response to anticancer treatment.

2 5 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

• Blood oxygenation level–dependent (BOLD) 1H MRI exploits the para-

magnetic properties of deoxyhemoglobin to demonstrate vessel density,

as well as the volume, flow, and oxygenation of blood in those vessels.

• Magnetic resonance spectroscopy (MRS) utilizes the same principles as

MRI, but a higher field strength (>1.5 tesla) magnet is required, as is addi-

tional hardware and software. Whereas MRI uses the 1H signal to produce

an image, with MRS the data are used to generate a biochemical spectrum

of specific metabolites. MRS is applicable only to atoms with particular

properties, such as 1H, 31P, and 19F, and has low sensitivity. Nevertheless,

31P-MRS can provide information about the pH, bioenergetics, and

membrane phospholipids in a selected region of interest that may again

be an early indication of response to therapy [67]. In addition, there is the

potential to study the tissue PK of drugs using MRS; again, this is limited

by the nuclei visible to MRS and its low sensitivity. 19F-MRS has, however,

been used to study the tissue PK of 5-fluorouracil [68].



10.3.3.2 Positron Emission Tomography (PET)

PET uses radio-labeled positron-emitting isotopes can show where a compound

is, how much is present, and what effect it has. It is sensitive and quantitative,

but spatial localization is less good than with MR or CT. A further issue is that

a cyclotron is needed to generate the labeled compound, and that isotopic label

then has a limited half-life over which PET data can be acquired. PET is quite

demanding for the patient—a perfusion scan taking about three hours in all, with

the need for arterial cannulation and exposure to ionizing radiation.

• [18F]-fluorodeoxyglucose (18F-FDG) PET is used diagnostically to

characterize potential tumor masses because of the avidity with which

they take up glucose, and for staging purposes. It has also been used to

demonstrate the rapid metabolic response of gastrointestinal stromal

tumors to imatinib that occurs long before any change in size [69].

These observations have raised hopes, as yet not entirely fulfilled, that

[18F]-FDG PET may identify patients benefiting from a cytostatic agent

without having an objective radiological response. Other examples are

shown in Table 10.2 [70–72].

• Other metabolic probes have also been used. Thymidine uptake relates

to DNA synthesis, and [11C]thymidine PET has been used to monitor

changes in tumor proliferation and inhibition of the enzyme thymi-

dylate synthase [73].

• Tumor perfusion can be studied by [15O]-H O PET and blood volume

2

by [15O]-CO PET. A potential limitation is the short half-life of 15O,

Practical Aspects of Pharmacokinetics and Pharmacodynamics 257

and the potential for contamination by signal from area adjacent to the

region of interest.

• Tissue drug PK can also be studied by injecting and imaging the

radio-labeled compound. In a study of the experimental cytotoxic

XR5000, conventional PK studies showed that potentially therapeu-

tic blood levels were achieved. PET studies showed drug distributed

into tumors, but there was also significant uptake into other tis-

sues, and at the MTD, saturation of tumor XR5000 uptake was not

achieved [74].



10.3.3.3 Dynamic Computed Tomography (CT) and Ultrasound

Dynamic CT is a more straightforward technique that can be incorporated

into standard CT examinations to measure tissue perfusion, blood volume,

capil ary permeability, and microvessel density. The attractions of dynamic CT

include the fact that it is widely available and quantification is less complex than

for DCE-MRI. Dynamic CT methodology is as yet less well developed than

DCE-MRI, and fewer clinical data are available. Recent developments in ultra-

sound, including microbubble contrast agents, make it possible to now study

much smaller vessels than was previously possible, although limited tissue pen-

etration may restrict its use to cutaneous studies.



10.3.4 Data analysis

The analysis of data from PD studies in tissue samples is complex, at least in part

because of the wide range of assays that are employed. The issues in relation to

functional imaging raise, however, still more challenges. A start has been made,

with specific recommendations for assessing anti-angiogenic and antivascular

therapeutic effects by MRI [75] and [18F]-fluorodeoxyglucose PET to measure

tumor responses [76]. Nevertheless, there remains a need to standardize further

the acquisition, analysis, and reporting of data, so that comparisons can be made

between centers and trials.

Reproducibility and quantification are major issues in functional imaging

studies. For example, if the day-to-day variability in a parameter is 25%, it wil

not be possible to say whether a drug causing a fall of 20% is biologically active.

Moreover, reproducibility will differ, not only depending on what imaging tech-

nique and parameter are being used, but also on which tissue is being studied.

The reproducibility of DCE-MRI is, for example, better in the brain than in the

thorax and upper abdomen, which are affected by motion artifacts induced by

respiration and the cardiac contraction. The importance of reproducibility was

illustrated when liver metastases were studied by DCE-MRI over an eight-hour

2 5 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

period, and the coefficient of variability was 11%; in these circumstances, a 15%

change in K would be required to show drug activity [77].

trans

The question of quantification is important, whether functional imaging is used

to provide proof-of-concept, or to determine dose or in an exploratory manner

[78]. Jayson et al. detected an impressive median decrease of 44% in first-pass per-

meability (K ) using DCE-MRI in patients receiving the anti-VEGF monoclonal

fp

antibody HuMV833. However, the heterogeneity of this response was such that,

using conventional cohorts of three patients, it was difficult to distinguish the PD

effects at different dose levels [79]. A more accurate assessment of the number

of patients to be treated can be made if the degree of change in an imaging end-

point that is deemed “significant” is defined a priori, and the reproducibility of the technique is understood. For PET, the standard deviation of the difference

between repeat measurements is reported to be about 10% for both the standard-

ized uptake value (SUV) and rate constant for uptake of FDG into tissue (K1).

With DCE-MRI, a coefficient of variation of 20% is quoted for measurements of

K , a measure of vascular permeability per unit volume. Using these figures, it

trans

is estimated that 10–15 patients would need to be imaged to measure a change in

15% with some statistical accuracy. In the context of a phase I trial, it is impractical to employ multiple cohorts of this size, all undergoing relatively complex imaging.

It is, therefore, likely that a more conventional trial design will often be used to

demonstrate tolerability and define a maximum dose level. One or more cohorts

can then be expanded, perhaps one at the R2PD and a second at the lowest dose

showing consistent but minor toxicity; an intermediate dose may also be evalu-

ated depending on results from the initial imaging studies (Table 10.2).

Tumor heterogeneity, both between and within patients, is also a major issue

for functional imaging studies in a hypothesis-driven early trial; this is in marked

contrast to the relative consistency of recording toxicity to normal tissues in a

conventional phase I study. With high-resolution techniques, a specific region

of interest is selected. The region of interest may be selected empirically, leading

to an area with a particularly “bright” but unrepresentative signal being selected.

Likewise, selecting a different image slice or region of interest for sequential studies will introduce further variability. Limiting the imaging studies to patients with a particular tumor type that is well suited to the imaging modality may also be

considered as a means of improving the consistency of data, but this can slow

down recruitment.

Where multiple study centers are involved, the question of uniformity

between sites is crucial. Imaging systems from different manufacturers may not

be compatible, and even where the same equipment is used, research groups

often devise their own data acquisition and analysis programs. More complex

algorithms may generate additional biological data, but they are also more dif-

ficult to standardize. A single patient preparation and imaging protocol, with a

Practical Aspects of Pharmacokinetics and Pharmacodynamics 259

single database analyzed in a uniform manner, is vital if the data are to be mean-

ingfully interpreted. The concept of GCP is now extended to functional imag-

ing, and the concepts discussed previously in relation to PK and PD laboratory

analyses are also relevant here.



10.4 PHARMACOKINETIC–PHARMACODYNAMIC

RELATIONSHIPS

Relationships may be sought between PK (i.e., drug exposure) and PD markers

of activity (be they clinical [usually toxicity] or novel [molecular or imaging]).

Interestingly, many publications do not present PK–PD correlations; rather, a

correlation is first shown between dose and PK (C , AUC, or steady-state con-

max

centrations), then relationships between dose and activity are explored. Although

less scientifically sound, this approach does reflect clinical practice where drug

exposure is determined by dose rather than PK.

Modeling of PK–PD relationships in relation to toxicity is applied in an

increasing proportion of phase I trials. A review of the place of such modeling

in phase I trials described situations where modeling was, or was not, likely to

be valuable and discussed issues of practical implementation [80]. One issue in

phase I trials is that often most patients are treated at relatively low dose levels

with a correspondingly low incidence of drug-related toxicity. Significant toxici-

ties tend, therefore, to be grouped together at the higher dose levels or exposures,

which may distort PK–PD analyses. Such approaches are widely used through all

stages of drug development; reviews specific to PK–PD modeling in the clinical

development of docetaxel [81] and capecitabine [82] have been published, and

other general reviews are also helpful [83,84].

The simplest analyses investigate the relationship between drug exposure and

adverse effects by, for example, plotting dose versus AUC or C , and highlight-

max

ing the patients with grade 3 or 4 or dose-limiting toxicity. Alternatively, mean

AUC or C may be compared in those patients with, and those without, sig-

max

nificant toxicity. More sophisticated mathematical models have been devised

to investigate in more detail the relationship between PK parameters, and PD

effects. These relationships have been best described in relation to antiprolifera-

tive cytotoxics and myelosuppression. The modified Hill equation, or E model,

max

describes a sigmoidal relationship between a PK parameter, in most cases overall

exposure as reflected by AUC, and “effect” expressed as a percentage change. For

example:

% change in endpoint = 100% Ch / Ch + EC h

×

) 

50





2 6 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

where C is the PK parameter, h is the Hill constant that describes the shape of

the sigmoid relationship, and EC is the value of C that achieves a 50% maxi-

50

mal effect. Applying the Hill model to the relationship between AUC and

myelosuppression:

% fall in neutrophils

100 % AUCh / AUCh EC h

=

×

+

0 ) 

5





Other PK parameters such as C or steady-state concentration (C ) can also

max

ss

be modeled in this way. Modeling relationships is, however, more difficult for

non-hematological toxicity where evaluation is more subjective and the catego-

ries represent non-continuous variables. In such cases, a logistic regression model

may be used to relate the PK parameter to toxicity expressed on the conventional

CTC grading system. Correlations between PK and tumor response have also

been difficult to establish, partly because anticancer drugs are often used in com-

bination, and also because response is usually only manifest after several cycles of

treatment, whereas in most cases PK are studied during cycle 1 only. Appropriate

statistical support is important to ensure that the analysis of data is conducted

appropriately.

The quantification of both tissue-based endpoints and functional imaging is

a continuing challenge. A distinction can be drawn between two of the settings

in which PD data are collected; i.e., to provide proof-of-concept or to identify

the recommended dose. In the first setting, PD markers have proved effective

in many studies in demonstrating proof-of-concept. This is valuable, and it cer-

tainly strengthens the case for further development of an agent. It is not, how-

ever, the same as proof of clinical efficacy, because the link between PD markers

and patient benefit is often unproven. This link can usually only be confirmed

retrospectively when phase III trials give clinical validation of the endpoint. The

second setting, using PD data to select dose, is a greater challenge. In the major-

ity of cases, both tissue-based and imaging studies more convincingly show a

threshold dose or concentration of study drug above which a target is seen to

be inhibited, than a clear dose–response curve that plateaus above a certain level

of drug exposure. With functional imaging studies, one of the difficulties is that

large numbers of patients may need to be studied at each dose level, and doing

this throughout dose escalation is unlikely to be feasible.

PK–clinical and PD correlations have been reviewed [85]; selected exam-

ples of such studies are shown in Table 10.3 [16,20,43,86–89]. Examples

of how tissue drug levels influence the development of a drug and some

PK–laboratory correlations are shown in Table 10.4 [86–96]. There are also

examples of dynamic imaging studies using both DCE-MR and [15O]H O

2

PET as PD biomarkers in early clinical trials [97–100]. A good example of

Table 10.3. Selected Pharmacokinetic-Clinical Pharmacodynamic Relationships Drug

Analyses

Results

Reference

Indisulam

NONMEM analysis of pharmacokinetic data Model predicted severity and duration of neutropenia and van Kesteren

from phase I trials

thrombocytopenia

et al. (2005)

Schedule-dependent differences in kinetics of hematological precursor

[16]

Irinotecan

Semi-physiological compartmental model

Biliary index (SN38/SN38 glucuronide) concentration ratio corre-

Gupta et al.

Patients studied in phase I SN38 glucuronida-

lated with diarrhea

(1994) [86]

tion rates studied

Clinical significance uncertain

Docetaxel

Limited sampling of patients from 24 phase

Docetaxel clearance predicted severe/febrile neutropenia

Bruno et al.

II studies

Cumulative dose predicted time onset of fluid retention

(1998) [20]

Bayesian population pharmacokinetic/ phar- Patients with elevated liver enzymes had reduced docetaxel clearance macodynamic analysis

Paclitaxel

Relationships to toxicity and efficacy sought

No significant correlation between AUC and toxicity

Huizing et al.

Patients received either 135 or 175 mg/m2 as a However, exposure above threshold paclitaxel concentration correlated (1993) [87]

1- or 3-h i.v. infusion in a phase III study

with changes in neutrophil count

Topo-1 inhibitor Relationship to myelotoxicity and PK

Strong correlations between TP3076 plus TP3011 AUC and fall in

Anthoney

TP300

myelosuppression

neutrophil count

et al. (2012)

5 patients with DLT were amongst the 9 whose total TP3076 plus

[43]

TP3011 AUC was 4.5 umol*h/L or more

Erlotinib plus

Relationship between skin rash and survival

Patients with ≥ grade 2 rash had better OS, PFS, response rate, and

Aranda et al.

Gemcitabine

from a phase II open-label study of erlotinib

disease control

(2012) [88]

plus gemcitabine in pancreatic cancer

In patients with grade ≥2 rash, cumulative dose of erlotinib to the maxi-

Cox regression analysis

mum grade of rash was significantly higher

Sunitinib

PK/PD metanalysis

Increased exposure to sunitinib was associated with better overall survival Houk et al.

Relationship between sunitinib efficacy and

Positive relationship between fatigue and diastolic blood pressure

(2010) [89]

tolerability endpoints

changes with drug exposure

Negative relationship between absolute neutrophil count and drug

exposure

NONMEM, non-linear mixed effect modeling.

Table 10.4. Selected Pharmacokinetic-laboratory Pharmacodynamic Relationships Drug

Analyses

Results

Reference

Capecitabine (oral 5-FU

Specific study after phase I completed and

Levels of 5-FU more than 20-fold higher in

Schuller et al.

prodrug)

recommended dose established

tumor compared with plasma

(2000) [90]

Patients received capecitabine before surgery

Levels of 5-FU more than 3-fold greater in

Tissue levels of 5-FU measured in plasma,

colorectal tumors than adjacent normal

tumor, and normal tissue

mucosa Development continued

MAG-CPT

Ten patients scheduled for colorectal cancer

No evidence of selective delivery to tumors

Sarapa et al.

(i.v. polymer-bound

surgery Received MAG-CPT 1, 3, or 7 days Polymer delivery program discontinued

(2003) [91]

camptothecin)

before surgery

Mag-bound and free CPT levels measured

Erlotinib

Within phase I study, patients had biopsy

28 patients studied using IHC phospho-EGFR Malik et al.

(oral EGFR-inhibitor)

of normal skin at baseline and at day 21 of

expression fell and p27 expression rose on

(2003) [92]

treatment

treatment, but not dose-related

Expression and activation of EGFR, and

downstream markers (ERK, p27)

Gefitinib

65 patients studied in phase I trials before

Thinning of stratum corneum and other histo-

Albanell et al.

(oral EGFR-inhibitor)

treatment and at day 28

logical changes in epidermis

(2002) [93]

Phosphorylation of EGFR lower, but p27KIP1

higher, on gefitinib

Biochemical effects not dose-related, but seen

at doses well below MTD

ABT-888 (PARP-inhibitor)

PAR levels in PBMC

PAR levels: >50% reduction in PBMC in all

Kummar et al.

plus topotecan

δH2AX quantification (DNA soluble strand

dose levels

(2011) [94]

break marker) in CTCs and PBMC

δH2AX: levels increased in PBMC and CTCs

cel s

AVE1642 (monoclonal anti- Enzyme immunoassay of IGF-I, IGF-II,

IGF-I: fourfold within 7 days of initiating treat- Macaulay et al.

body against IGF-1R)

IGF-BP3 at baseline and during cycle 1 (days ment with subsequent plateau in both cohorts (2013) [95]

1, 2, 7, 14)

IGF-II: elevation in cohort A and no differences

in cohort B

IGF-BP3:Twofold treatment-related elevation

in both cohorts

Pazopanib + ifosfamide

Plasma concentrations of PIGF, VEGF-A,

Dose-dependent increase in PIGF and VEGF-A Hamberg et al.

sVEGFR2 using ELISA

with concurrent decline in sVEGFR2

(2014) [96]

Quantification of CEC with

No consistent pattern by enumeration of CEC

flow-cyrometry-based method

Baseline and prior D1 C2

Abbreviations: EGFR, epidermal growth factor receptor; CPT, camptothecin; 5-FU, 5-fluorouracil; IHC, immunohistochemistry

2 6 4

P H A S E I C A N C E R C L I N I C A L T R I A L S

where pharmacokinetic and pharmacodynamic endpoints have been used to

determine the dose is with hypoxia-activated prodrug AQ4N (banoxantrone)

[35,101]. A range of tissue biomarkers were used, including the metabolism

of the drug, in seven different types of tumor and normal tissues to determine

whether the drug was being metabolized (and activated) in areas of low oxygen

tension. Studies with the VEGF-receptor tyrosine kinase inhibitor valatanib

(PTK787/ ZK222584) were especially interesting [65,102]. As shown in

Figure 10.3, the clear fall in Ki across the dose range shown using DCE-MRI

gave proof-of-concept. Even though the cohort sizes were too small to dis-

criminate clearly between PD effects at different dose levels, modeling of the

imaging data supported a dose of >1000 mg for further study. Interestingly,

the subsequent phase III trial in metastatic colorectal cancer did not, however,

achieve its primary endpoint [103]. One possible explanation for these disap-

pointing results is that the schedule of valatanib may not have been optimal

to achieve consistent drug exposure, a PK rather than PD issue. Of note, trials

with combretastatin A4 phosphate using both DCE-MRI [99,100] and PET

[104] gave comparable results, even though PET measures absolute blood flow

in tumor and normal tissue, whereas DCE-MRI measures a composite of blood

flow, vascular permeability, and surface area.

1000 mg/day (all cancer)

1000 mg/day (all cancer)

120

1000 mg/day (all liver metastases)

100

88.5 ± 8.0

76.3 ± 8.8

80

60.4 ± 8.1

53.8 ± 6.5

49.7 ± 6.7

60

49.7 ± 6.7

40

Baseline MRI Ki (%)

20

0

Day 2 ( n = 10, 18, 7)

Day 28 ( n = 6, 23, 16)

Day of assessment

Figure 10.3 Mean (± SE) percentage of baseline magnetic resonance imaging (MRI)

bidirectional transfer constant (Ki) for patients receiving < 1000 mg/day and >1000 mg/

day on days 2 and 28 of PTK787/ZK 222584 treatment. From Thomas et al. (2005)

J Clin Oncol 23:4162–71.

Reprinted with permission from the American Society of Clinical Oncology.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 265



10.5 SUMMARY

PK and PD measures play important roles in phase I trials of anticancer agents.

Both require clear protocol specifications regarding what, how, and when to col-

lect samples or to perform other special procedures on the patient. PK and PD

measures give information regarding how the drug is metabolized or cleared by the

patient and what impact the drug has on normal and/or tumor tissues. Results from

these studies may occasionally be the basis for recommending the dose at the con-

clusion of the phase I trial, but more often they reinforce dose recommendations.

Molecular and imaging PD studies are becoming more common in phase I studies

and can offer useful insights into whether the drug is in fact acting on the putative molecular target (i.e., proof-of-concept). Relationships between PK parameters

and PD effects can help shape the subsequent drug development plan for a novel

compound. All of these factors serve to highlight the importance of incorporat-

ing PK and PD measures in early phase studies and in investing in the necessary

assay-validation in preclinical models before phase I studies begin in patients.



REFERENCES

1. Col ins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I trials

based upon preclinical development. J Natl Cancer Inst. 1990;82:1321–1326.

2. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Decker; 1982.

3. Peng GW, Chiou WL. Analysis of drugs and other toxic substances in biological

samples for pharmacokinetic studies. J Chromatogr Biomed Appl. 1990;531:3–50.

4. Medicines and Healthcare Products Regulatory Agency (MHRA), Good Clinical

Practice—Guidance on the maintenance of regulatory compliance in laborato-

ries that perform the analysis or evaluation of clinical trial samples. Issue 1. July 2009. May be found at: (http://www.mhra.gov.uk/Howweregulate/Medicines/

Inspectionandstandards/GoodClinicalPracticeforClinicalLaboratories/) (last accessed Oct 2013).

5. Medicines and Healthcare Products Regulatory Agency (MHRA), Good Clinical

Practice Guide, TSO (The Stationery Office). Sep 2012. ISBN: 9780117081079.

6. Experimental Cancer Medicine Centre (ECMC) Early Phase and Translational

Research Nurse Network Group: Sample handling guidance document for

research nurses and junior clinical laboratory staff, version 1—March 2011.

May be found at: (http://www.ecmcnetwork.org.uk/news-events/news/

ecmc-sample-management-guidance (last accessed Oct 2013).

7. FDA Guidance for Industry, Bioanalytical method validation. May be found at:

http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (last accessed Oct 2013).

8. ICH Guideline on Good Clinical Practice (E6); may be found at the ICH web

site: www.ich.org (last accessed Oct 2013).

2 6 6

P H A S E I C A N C E R C L I N I C A L T R I A L S

9. European Union Clinical Trials Directive: may be found at http://ec.europa.eu/

health/human-use/clinical-trials/ (last accessed Oct 2013).

10. FDA: Good Laboratory Practice: may be found at http://www.accessdata.fda.gov/

scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=58 (last accessed Oct 2013).

11. Stiles T, Grant V. Research Quality Association (RQA) Good Clinical Laboratory

Practice (GCLP)—An international quality system for laboratories which under-

take the analysis of samples from clinical trials. Dec 2012. ISBN 978-1-904610-21-

2. May be found at: http://www.therqa.com/publications/booklets/gclp/ (last accessed Oct 2013).

12. World Health Organization, WHO Library. Good clinical laboratory practice

(GCLP). ISBN 9789241597852 (NLM classification: QY 25).

13. NIHR CRN GCP Resource—a compilation of links to useful on-line GCP quality

tools and resources. May be found at: http://www.crncc.nihr.ac.uk/workforce_devel-

opment/learning_and_development/gcp/gcp_resource (last accessed Oct 2013).

14. Banerji U, O’Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharma-

codynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with

advanced malignancies. J Clin Oncol. 2005;23:4152–4161.

15. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharma-co-

dynamics. Semin Oncol. 1995;22(3 Suppl 6):16–23.

16. Van Kesteren C, Zandvliet AS, Karlsson MO, et al. Semi-physiological model

describing the haematological toxicity of the anti-cancer agent indisulam. Invest New Drugs. 2005;23:225–234.

17. FDA. Guidance for Industry—Population pharmacokinetics. Food and Drug

Administration, Feb 1999. May be found at: http://www.fda.gov/downloads/

ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf (last accessed Oct 2013).

18. Beal SL, Sheiner LB. NONMEM Users Guide. Dublin, Ireland: Icon PLC; 1989.

19. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmokinet. 1996;30:81–93.

20. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacody-

namics of docetaxel in phase II studies in patients with cancer. J Clin Oncol.

1998;16:187–196.

21. Saito T, Iida S, Abe M, Kawanishi T, Twelves C. Population pharmacokinetic-

pharmacodynamic modelling and simulation of neutropenia induced by

TP300, a novel topoisomerase I inhibitor. J Pharm Pharmacol. Aug 2013;

65(8):1168–1178.

22. Ratain MJ, Vozelgang. Limited sampling model for vinbastine pharmacokinetics.

Cancer Treat Rep. 1987;71:935–939.

23. D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J

Pharmacokinet Biopharm. 1981;9:739–756.

24. Sallas WM. Development of limited sampling strategies for characteristics of a pharmacokinetic profile. J Pharmacokinet Biopharm. 1995;23:515–529.

25. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyro-

sine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol.

2002;20:4292–4302.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 267

26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,

fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335–2342.

27. Twelves C, Chmielowska E, Havel L, et al. Randomised phase II study of

axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line

therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. Jan 2014;25(1):132–138.

28. Lyons JF, Wilhelm S, Hibner B, Bol ag G. Discovery of a novel Raf kinase inhibitor.

Endocr Relat Cancer. 2001;8:219–225.

29. Wilhelm S, Carter C, Tang LY, et al. BAY 43–9006 exhibits broad spectrum

antitumour activity and targets Raf/MEK/ERK pathway and receptor tyro-

sine kinases involved in tumour progression and angiogenesis. Clin Cancer Res.

2003;9:A78.

30. Kopetz S, et al. First in human phase I study of BSI-201, a small molecule

inhibitor of poly ADP-advanced solid tumours [abstract]. J Clin Oncol. 2008;26

(Suppl):A3579.

31. Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the

PARP inhibitor that never was—what must we learn? Nat Rev Clin Oncol. Dec

2013;10(12):688–696.

32. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical

trial design for cytostatic agents: are new approaches needed? J Clin Oncol.

2001;19:265–272.

33. Dowlati A, Haaga J, Remick SC, et al. Sequential biopsies in early phase clini-

cal trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res.

2001;7:2971–2976.

34. Hidalgo A, Tabernero J, Rojo F, Marimon I, Andreu J, Baselga J. Feasibility of

CT-guided serial liver biopsies to evaluate pharmacodynamic endpoints in patients

with liver metastasis. Abdom Imaging. 2005;30(1):65–68.

35. Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and

pharmacodynamic end points to determine the dose of AQ4N, a novel 5 hypoxic

cell cytotoxin, given with fractionated radiotherapy in a phase I study. Ann Oncol.

2007;18:1098–1103.

36. Tabernero J, Rojo F, Marimon I, et al. Phase I pharmacokinetic and pharmaco-

dynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farne-

syl transferase inhibitor, in patients with advanced solid tumors. J Clin Oncol.

2005;23:2521–2531.

37. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res.

2000;60:1871–1877.

38. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and

pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 adminis-

tered twice weekly. Ann Oncol. 2003;14:766–774.

39. Locatel i G, Bosotti R, Ciomei M, et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor

PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer

Ther. 2010;9(5):1265–1273.

2 6 8

P H A S E I C A N C E R C L I N I C A L T R I A L S

40. Fracasso PM, Wil iams KJ, Chen RC, et al. A phase I study of UCN-01 in combi-

nation with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011;67(6):1225–1237.

41. Dragnev KH, Ma T, Cyrus J, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Cancer Prev Res. 2012;4(6):818–828.

42. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT

inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol.

2011;29(35):4688–4695.

43. Anthoney DA, Naik J, Macpherson IR, et al. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer. 2012;12(1):536.

44. Kelley RK, Hwang J, Magbanua MJ, et al. A phase I trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer.

2013;109(7):1725–1734.

45. Diaz CM, Chiappori A, Aurisicchio L, et al. Phase I studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral

boost immunization in patients with solid tumors. J Transl Med. 2013;11(1):62.

46. Weber JS, Kudchadkar RR, Yu B, et al. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naïve melanoma. J Clin Oncol.

2013;31(34):4311–4318.

47. Molife LR, Fong PC, Paccagnel a L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with

advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J

Cancer. 2010;103(3):332–339.

48. Molife LR, Fong PC, Paccagnel a L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with

advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Clin Cancer Res. 2007;13(12):3611–3616.

49. Hotch U, Fry DG, Chia YL, et al. Etirinotecan pegol (EP) target-specific pharma-

codynamic (PD) biomarkers measured in circulating tumour cel s (CTCs) from

patients in the phase III BEACON study in patients with metastatic breast cancer

(mBC). J Clin Oncol. 2013;31(Suppl; abstr 1087).

50. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cel s and circulating tumor DNA. Cancer Discov. 2014;4(6):650–661.

51. Attard G, de Bono JS. Utilizing circulating tumor cel s: challenges and pitfalls. Curr Opin Genet Dev. 2011;21(1):50–58.

52. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cel s in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–928.

53. Al ard WJ, Matera J, Miller MC, et al. Tumor cel s circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant

diseases. Clin Cancer Res. 2004;10:6897–6904.

54. Gupta V, Jafferji I, Garza M, et al. ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cel s from blood.

Biomicrofluidics. 2012;6(2):24133.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 269

55. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor

dynamics. Nat Med. 2008;14(9):985–990.

56. Schwarzenbach H, Hoon DS, Pantel K. Cel -free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437.

57. Molife LR, Yan L, Vitfel -Rasmussen J, et al. Phase I trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with

advanced solid tumors. J Hematol Oncol. 2014;7(1):1.

58. Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012;7(11):e47020.

59. Nilsson RJ, Balaj L, Hulleman E, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011;118(13):3680–3683.

60. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. ARIMIDEX™: a new

oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol. 1995;53:175–179.

61. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C. “Fit-for-purpose”

validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use.

J Immunol Meth. Mar 2009;342(1–2):106–114.

62. Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Review article. Drug Discov Today. Oct 2010;15(19–20): 816–825.

63. Therasse Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205–216.

64. Seddon BM, Workman P. The role of functional imaging in cancer drug discovery

and development. Br J Radiol. 2003;76:128–138.

65. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic reso-

nance imaging as a biomarker for the pharmacological response of PTK787/

ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine

kinases, in patients with advanced colorectal cancer and liver metastases: results

from two phase I studies. J Clin Oncol. 2003;21:3955–3964.

66. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in

advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722–1727.

67. Leach MO, Verrill M, Glaholm J, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998;11:314–340.

68. Wolf W, Presant CA, Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Res. 2000;41:55–74.

69. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib

(STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet.

2001;358:1421–1423.

70. Zimmer L, Barlesi F, Martinez-Garcia M, et al. (2014). Phase I expansion and

pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in

selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res.

2014;20(16):4251–4261.

71. Atzori F, Tabernero J, Cervantes A, et al. A phase I pharmacokinetic and pharma-

codynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1

receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17:6304–6312.

2 7 0

P H A S E I C A N C E R C L I N I C A L T R I A L S

72. Azad N, Yu M, Davidson B, et al. Translational predictive biomarker analysis of the phase Ib sorafenib and bevacizumab study expansion cohort. Mol Cell Proteomics.

2013;12(6):1621–1631.

73. Wel s P, Aboagye E, Gunn RN, et al. 2-[11C]thymidine positron emission tomog-

raphy as an indicator of thymidylate synthase inhibition in patients treated with

AG337. J Natl Cancer Inst. 2003;95:675–682.

74. Propper DJ, de Bono J, Saleem A, et al. Use of positron emission tomography in

pharmacokinetic studies to investigate therapeutic advantage in a phase I study of

120-hour intravenous infusion XR5000. J Clin Oncol. 2003;21:203–210.

75. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of antiangiogenic and anti-

vascular therapeutics with MRI: recommendations for appropriate methodology for

clinical trials. Br J Radiol. 2003;76(1):S87–S91.

76. Young H, Baum R, Cremarius U, et al. Measurement of clinical and sub-clinical

tumour response using [18F]-fluorodeoxyglucose and positron emission tomogra-

phy: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773–1782.

77. Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G. Breath-hold perfusion

and permeability mapping of hepatic malignancies using magnetic resonance imag-

ing and a first-pass leakage profile model. NMR Biomed. 2002;15:164–173.

78. Galbraith SM. Antivascular cancer treatments: imaging biomarkers in pharmaceuti-

cal drug development. Br J Radiol. 2003;76:83–86.

79. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of anti-angiogenic

antibodies. J Natl Cancer Inst. 2002;94:1484–1493.

80. Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer J-L, van Peer A. Role

of model ing and simulation in Phase I drug development. Eur J Pharm Sci.

2001;13:115–122.

81. van Kesteren Ch, Mathot RA, Beijnen JH, Schellens JHM. Pharmacokinetic–

pharmacodynamic guided trial design in oncology. Invest New Drugs.

2003;21:225–241.

82. Blesch KS, Gieschke, Tsukamoto Y, Reigner BG, Burger HU, Steimer J-L. Clinical

pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic

model ing in new drug development: the capecitabine experience. Invest New Drugs.

2003;21:195–223.

83. Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translat-

ing anticancer drug pharmacology to the clinic. Am Assoc Pharmaceut Sci. Mar

2011;13(1):111–120.

84. Jackson, RC. Pharmacodynamic model ing of biomarker data in oncology. ISRN

Pharmacol. Volume 2012 (2012):590626, doi: 10.5402/2012/590626.

85. Kobayashi K, Jodrell DI, Ratian MJ. Pharmacokinetic–pharmacodynamic relation-

ships and therapeutic drug monitoring. Cancer Surv. 1993;17:51–78.

86. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan (CPT-11) in humans; correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–3725.

87. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metab-

olites in a randomised comparative study in platinum-pretreated ovarian cancer

patients. J Clin Oncol. 1993;11:2127–2135.

Practical Aspects of Pharmacokinetics and Pharmacodynamics 271

88. Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/

or metastatic adenocarcinoma of the pancreas: relationship between skin rash and

survival (Pantar study). Ann Oncol. 2012;23:1919–1925.

89. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship

between exposure to sunitinib and efficacy and tolerability endpoints in patients

with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer

Chemother. 2010;66:357–371.

90. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–297.

91. Sarapa N, Britto MR, Speed W, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol.

2003;52:424–430.

92. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epider-

mal growth factor inhibitor OSI-774 in human epidermis of cancer patients. Clin

Cancer Res. 2003;9:2478–2486.

93. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of epider-

mal growth factor inhibitor ZD1839 in skin from cancer patients: histo-

pathologic and molecular consequences of receptor inhibition. J Clin Oncol.

2002;20:110–124.

94. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer

Res. 2011;71(17):5626–5634.

95. Macaulay VM, Middleton MR, Protheroe AS, et al. Phase I study of humanized

monoclonal antibody AVE1642 directed against the type 1 insulin-like growth fac-

tor receptor (IGF-1R), administered in combination with anticancer therapies to

patients with advanced solid tumors. Ann Oncol. 2013;24(3):784–791.

96. Hamberg P, Boers-Sonderen MJ, van der Graaf WT, et al. Pazopanib exposure

decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a

phase I study. Nature Publ Group. 2014;110(4):888–893.

97. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of

response and assessment of antiangiogenic activity in a clinical trial of recombinant human endostatin. J Clin Oncol. 2002;20:3804–3814.

98. Thomas JP, Arzoomaniam RZ, Alberti D, et al. Phase I pharmacokinetic and phar-

macodynamic study of recombinant human endostatin in patients with advanced

solid tumors. J Clin Oncol. 2003;21:223–231.

99. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and transla-

tional study of the novel vascular targeting agent Combretastatin A-4 phosphate on

the single-dose intravenous schedule in patients with advanced cancer. Cancer Res.

2002;62:3408–3416.

100. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has

tumor antivascular activity in rat and man as demonstrated by dynamic magnetic

resonance imaging. J Clin Oncol. 2003;21:2831–2842.

2 7 2

P H A S E I C A N C E R C L I N I C A L T R I A L S

101. Albertel a MR, Loadman PM, Jones PH, et al. Hypoxia-selective targeting by

the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase

I study. Clin Cancer Res. 2008;14:1096–1104.

102. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered

twice daily in patients with advanced cancer. J Clin Oncol. 2005;23:4162–4171.

103. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum

receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and

PTK787/ZK222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;23(16S[June

1 Suppl]):LBA3.

104. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price P. Assessment of pharmacodynamic vascular response in a phase I trial of Combretastatin A4 phosphate.

J Clin Oncol. 2003;21:2823–2830.





11

Process, Pitfalls, and

Logistics of Phase I Trials

E L I Z A B E T H A . E I S E N H A U E R , C H R I S T W E LV E S , H AY L E Y F A R M E R , A N D P H I L I P R O S S ■



11.1 INTRODUCTION

There are many administrative and organizational steps that must be undertaken

before a phase I trial may begin. An extremely important step for all investigators is to become familiar with the document “Good Clinical Practice” (GCP)

[1] developed by the International Conference on Harmonization (ICH) and

adopted by the regulatory authorities in the United States, European Union,

Japan, Canada, and many other international jurisdictions. This comprehensive

document details the responsibilities of investigators and sponsors in conducting

clinical trials; provides guidance on Ethics Review Board composition, responsi-

bilities, and function; and outlines templates for content of the protocol and con-

sent form, and the documents that must be on file before, during, and after the

trial. Although GCP was developed for use as an Industry Guidance document,

in fact it is being applied to academic studies more and more. In some countries,

all trials of drugs, whether investigational or marketed, whether sponsored by industry or academic investigator, must be conducted according to GCP standards if used in an investigational setting. Particular consideration should also

be given to specific types of trial, including those involving targeted therapies,

radiotherapy, combinations of investigational therapies, and immunomodula-

tory agents.

2 7 4

P H A S E I C A n C E R C l I n I C A l T R I A l S



11.2 ROLES AND RESPONSIBILITIES



A large team of individuals from multiple organizations will be involved in the

preparation for and conduct of a clinical trial, and it is critical that their respective roles and responsibilities be clearly defined. Of particular importance is setting

out clear responsibilities for decision-making: it may be worth capturing some

of these responsibilities either in the relevant agreement, or in a formal table of

responsibilities.



11.2.1 Investigator

The trial investigator (or “principal investigator” [PI] in the parlance of some

regions) has the ultimate responsibility for the correct conduct of the trial at the

local institutional level. This includes:

• shepherding the protocol through the required initial and annual review

committees at the institution

• preparation for study activation

• the identification of eligible patients, their recruitment, and the process

of gaining informed consent

• the arrangement of investigations and administration of trial treatment(s)

according to the protocol

• the medical care of patients in the trial

• appropriate storage and handling of investigational agents

• data collection, record keeping, preparation for any required audits, and

onsite monitoring.

The investigator must be appropriately qualified to manage the patients who are

to be enrolled, as well as appropriately educated with respect to the study plan

and the investigational agent to be used. Furthermore, the investigator must have

sufficient time to perform the required functions. He or she may delegate some of the tasks to qualified personnel, such as co-investigators (or sub-investigators),

nurses, data managers, and pharmacists, but those individuals must be adequately

schooled in the particulars of the trial. GCP indicates that the investigator should

maintain a written record of the individuals to whom significant trial-related

duties have been delegated. As noted earlier, all investigators should review and

abide by the GCP document as they perform their duties: it is not something that

is appended to a protocol to simply add weight! It contains important informa-

tion about investigator responsibilities (see the summary of duties of the investi-

gator in Table 11.1).

Table 11.1. Selected Investigator Responsibilities

Major area of

Selected subsections

Comments

responsibility

Investigator

Investigator must have appropriate

Delegation should

qualifications

education and training to conduct the

be documented in

and agreements

study and supply CV. Investigator must

writing on site. SOPs

be familiar with the appropriate use of

should indicate how

the investigational agent. Investigator

this is done and how

must comply with GCP. Investigator

those delegated to are

must maintain a list of qualified persons trained.

to whom trial-related activities must be

delegated.

Adequate

Investigator must show that he/she can

resources

recruit the required number of patients

and also show he/she has sufficient time

and appropriate facilities to conduct the

study.

Medical care

Investigator must provide adequate care It is important to

of trial subjects

during the study and for any adverse

ensure that refer-

events.

ring physicians and

hospitals are aware

the patient is on a

trial. Should adverse

events arise that

require admission to

hospital, this should

be done, if at all

possible, under the

investigator’s care.

Communication

Investigator must have written approval

with IRB/IEC

from the appropriate institutional

ethics committee before the trial begins.

Investigator must supply the

investigator’s brochure to the committee

and all required documents during

the trial.

Compliance

Investigator must follow the trial as

Deviations allowed for

with the protocol

written in the protocol, and obtain

immediate hazard.

approval of ethics committee before

implementing an amendment.

( continued)

Table 11.1 (Continued)

Major area of

Selected subsections

Comments

responsibility

Investigational

Investigator is responsible for appropri-

normally this responsi-

product

ate handling, storage, and dispensing of bility is delegated to a

investigational product.

qualified pharmacist.

Randomization

The investigator should follow the trial

For phase I trials,

procedures and

procedures in accordance with the

this means patient

unblinding

protocol.

registration before

treatment begins and

treatment at assigned

dose.

Informed consent Investigator must comply with relevant

Informed consent

regulations and adhere to ethical princi- includes not only

ples. Records identifying subjects will be written information

kept confidential. Consent form content but also a discussion

is described (see Chapter 5).

with the patient. The

discussion may be

shared with a desig-

nated person.

Records and reports Investigator is responsible for data collec- Again, this is usu-

tion and its accuracy in comparison with ally delegated to a

source documents. Case report form

qualified nurse or data

changes must be dated and

manager.

initialed (applies to both written and

electronic changes). Trial documents

should be maintained as required by

GCP section 8.

Progress reports

Investigator is responsible for reporting as

needed to institution/ethics committee,

and sponsor, especially on issues that

change trial conduct or risk to patients/

subjects.

Safety reporting

Investigator must report serious adverse

events immediately to the sponsor

(except those identified as not needing

immediate reporting).

Premature termina- Investigator must inform trial subjects and

tion or suspension required authorities/ethics committee.

Final report

Investigator is responsible for final report,

if required by regulatory authorities.

Adapted from ICH GCP (E6) Section 4. See Appendix I for web reference.

Process, Pitfalls, and logistics of Phase I Trials 277

On a practical note, the investigator should ensure that s/he, and their insti-

tution, have appropriate medical insurance that will cover untoward events that

might arise in the course of a phase I trial. Malpractice coverage varies: most

insurers cover activities associated with professional practice, including those of

an investigator on an approved (by regulatory authorities and ethical committee)

phase I trial. Finally, many pharmaceutical sponsors require the investigator to

sign a statement regarding his/her conflict of interest with respect to the com-

pany and the product under study.



11.2.2 Sponsor

The trial sponsor is the individual or organization that assumes legal responsibility for the conduct of the trial according to the regulations and guidelines in place

for that country or region. Thus, the sponsor must ensure that the trial is con-

ducted according to the principles of GCP where this is the accepted standard.

That includes ensuring that investigators are qualified to conduct the study, that

they are adequately informed about the trial procedures, and that they have the

time and resources to conduct it. The sponsor must also ensure that an ethical

review by appropriately constituted ethical committees takes place before the

study begins and patients receive investigational treatment. In addition, the spon-

sor must undertake measures to make certain that data quality is maintained as

the trial proceeds, by review of source documents and other processes, and must

ensure that serious, unexpected adverse drug reactions are reported appropri-

ately to all required individuals and bodies. It is important to note that the spon-

sor is not always a pharmaceutical firm; individual investigators, institutions, and

academic research groups may sponsor studies, but if doing so, they must under-

stand and undertake the relevant sponsor duties. Table 11.2 shows a selected list

of duties as described by ICH GCP. note in particular the need for appropriate

insurance coverage; if required by the relevant regulatory authority, the sponsor

should provide insurance for patients and should indemnify investigators and

institutions against claims arising from the trial by patients and others.



11.2.3 Communication

Running a phase I study, or in fact any type of clinical study, is the responsibility of a large team of individuals. In the institution, the investigator leads this group.

The sponsor of the trial will also have a team of individuals working on the study,

who will be responsible for the day-to-day management and oversight of the trial;

some of these responsibilities may be delegated to the investigator to a greater or

Table 11.2. Selected Sponsor Responsibilities

Item

Sponsor responsibility

Quality assurance

Written SOPs for QA and QC to assure conduct of trial and data

(QA) and Quality recorded are in compliance with protocol and are accurate and

Control (QC)

reliable.

Trial design

Sponsor must utilize qualified individuals (physicians, biostatisti-

cians, clinical pharmacologists, etc.) for design, data collection,

and analysis of the study.

Trial management

Sponsor should utilize appropriately qualified individuals to

supervise conduct of the trial, to handle and verify data, and to

analyze data. There are special rules for electronic data handling.

An independent data monitoring committee (IDMC) may

advise the sponsor, but should have written SOPs and maintain

records of meetings Each subject to be identified by an unam-

biguous subject identification code. Retain sponsor-specific

documents for time periods described in GCP.

Investigator

Sponsor is responsible for selecting the investigators/institutions

selection

qualified and with adequate resources and facilities to perform

the study. They must agree to conduct the trial in compliance

with GCP.

Compensation

If required by local regulatory authority, the sponsor should

to subjects and

provide insurance or should indemnify the investigators/institu-

investigators

tions against claims arising from the trial, except for claims that

arise from malpractice or negligence.

Financing

Financial aspects of the trial should be documented in an agree-

ment between the sponsor and the investigators/institutions.

Regulatory author- Before initiating the trial, the sponsor must seek and obtain the

ity submission/

required regulatory approval or permission (as required by the

notification

relevant authorities)

Confirmation of

The sponsor must obtain from the investigator/institutions a copy

review by ethics

of the initial and ongoing ethical approvals of the protocol, as

committee (IRB/

well as the name and address of the committee, and a statement

REB/IEC)

that it is organized and operates according to GCP and appli-

cable laws. Information must also be supplied on any conditions

associated with approval or withdrawals or suspensions of the

trial by the ethical committee.

Information on

Sponsor must assure sufficient efficacy and safety data are avail-

investigational

able to justify the proposed trial and must update the investiga-

products

tor’s brochure with any significant new information.

Manufacturing,

Sponsor must ensure the product is manufactured according to

labeling,

GMP, what the acceptable storage conditions are (and inform

packaging

those who must know), and that the packaging and labeling are

acceptable and comply with local regulations.

( continued)

Process, Pitfalls, and logistics of Phase I Trials 279

Table 11.2 (Continued)

Item

Sponsor responsibility

Supplying investi-

Sponsor is responsible for ensuring investigational drug supply

gational agent

to the institution(s) in the trial and for the procedures that the

investigator/institution should follow for receiving, tracking,

dispensing, and handling the drug.

Record access

Sponsor should ensure access to source documents for monitor-

ing, audits, and regulatory inspection.

Safety information Sponsor is responsible for ongoing safety evaluation of the investigational products and must notify the institution(s) and regula-

tory authorities of findings that could adversely affect safety or

impact conduct of the trial.

Adverse drug reac- Sponsor is responsible for expedited reporting to regulatory

tion reporting

authority(ies), investigators/institutions, and ethics committee(s),

of serious, unexpected, adverse drug reactions ( adverse drug reac-

tions are adverse events that are thought to be drug-related).

Monitoring

Sponsor should ensure the trial is adequately monitored to verify

that reported data are accurate and complete and that the trial

is being conducted in compliance with GCP and regulatory

requirements. The sponsor should determine the nature and

extent of monitoring necessary to accomplish this.

Audit

The sponsor is responsible for performing audits as part of QA to

evaluate compliance with the protocol, SOPs, GCP, and other

requirements.

Early termination

The sponsor must notify investigators/institutions, their ethics

committees, and regulatory authorities if the trial is stopped

early, and offer the reasons.

Clinical study

The sponsor must prepare final or ongoing reports as required.

reports

See ICH Good Clinical Practice for detailed description. See Appendix I for web reference.

lesser degree. It is important, therefore, to have clear lines of communication and

frequent contact within the institution and between the investigator and spon-

sor, should they not be the same individual. Frequent face-to-face meetings are

important, in addition to regular email and telephone contact; it is in these meet-

ings that issues about trial conduct, unusual observations, and patient recruitment

can be aired. The goal is to have a smoothly running study, which is completed in

a timely fashion, and from which the data generated are complete and accurate.



11.2.4 Funding

Developing a budget for the trial is part of the process of negotiating the contract; or, for academically funded studies, making the grant application. In general,

2 8 0

P H A S E I C A n C E R C l I n I C A l T R I A l S

funding is needed to support those costs over and above usual medical care, and

may include research nurse time, pharmacist time, data manager time, special

equipment, special laboratory assays, and special imaging studies. In particular, for a phase I trial, there may be a significant package of pharmacokinetic and pharmacodynamic work undertaken in an attempt to better understand the mechanism of

action of the investigational agent, and this wil almost certainly require additional funding. Institutions and countries vary as to whether extra funding for blood tests

done in the hospital laboratory, routine radiological studies, and physician’s visits required by the protocol are costed into the trial budget or are paid for through the usual healthcare insurance channels. Similarly, physician fees may not be charged

if patient care is covered by national or other insurance. If the institution conducting the trial is also responsible for data collection, cleaning, analysis, generating the clinical study report (see ICH Guideline for Structure and Content of Clinical

Study Reports), and is the sponsor of the trial, funding to cover the personnel costs associated with overall trial management and analysis is also required. Institutional rules regarding indirect costs or overhead payments must be factored into the budget. In general, direct physician-payment or incentives for recruitment other than reimbursement for medical visits or procedures should not be part of remuneration for clinical trials, as this creates a significant conflict of interest. To assure that trial funding is handled appropriately, all payments should be made to an institutional

or departmental account, not into a physician’s personal bank account.



11.3 CONTRACTS

It is almost always the case that phase I trials of new cancer drugs will be con-

ducted through partnerships: either between academic col aborators or between

academic investigators and pharmaceutical companies, both large and small.

Investigator/institution–industry partnerships are the most common. There

may be a series of contracts covering the conduct of the trial, and confidential-

ity agreements should be put in place between all interested parties before any

detailed discussions about the trial are initiated. Regardless of the nature of the

col aborations, they are usually (for academic partnerships) or always (for indus-

try partnerships) formalized by a letter of agreement or contract between the

party who owns the investigational agent and the party or parties involved in the

conduct of the trial. Investigators must ensure that their institution’s legal or contracts officer has an opportunity to review the agreement as it is being developed,

but the investigator cannot pass on all responsibility to her/his institution, as

much of the contract will be about what the investigator has agreed to deliver, and that is something only the s/he can attest to. Key elements to keep in mind when

reviewing a contract are summarized in Table 11.3. Freedom to publish, even if

Table 11.3. Important Contract Elements

Element

Comment

Trial

Ensure that the contract makes it clear who is responsible for which

respon sibilities aspects of the trial. This may be best accomplished by an appendix

to the contract that details which of company, investigator, and/or

institution is responsible for the various aspects of the trial such as

developing the protocol, case report forms, ethics review, regulatory

review, database development, trial report, and pharmacokinetic

analyses. Many such appendices also include expected timelines.

Sponsor

The contract must be clear on which party is the legal sponsor. The

sponsor must file any regulatory documents and will have respon-

sibility for overall trial conduct, SAE reporting, etc., as outlined in

Table 8.3.

Intellectual

The contract must specify who has rights to any discoveries or inven-

property (IP)

tions that arise as a result of the research. Clear language should

specify who has IP rights (it could be more than one party) and how

information about inventions made will be disclosed and if investi-

gators and/or institution have any negotiating rights or options.

Ownership

The contract must identify who “owns” the data that result from the

trial. If the institution or investigator(s) do not own the data, the

contract must indicate that they have access to the data for teach-

ing and publication. If the institution or investigator will hold the

database, the contract must specify if, when, and how the data will

be transferred to other parties. If tissue samples are collected for

research, the contract should indicate which party will store samples

and which has decision-making authority regarding their use.

Publications

The contract must specify who has the right to publish the data.

It should be clear that the trial data WILL be published.

Timelines should be included for review of draft publications or

presentations (usually 10 days for abstracts or presentations and

30 days for manuscripts). If the company wishes to publish part of

the report, the investigator(s) must be given reciprocal reviewing

rights. Delays beyond that should be allowed for confidentiality

or IP reasons only, and should be limited in length. The company

should not have the right to block submission if it disagrees with the

investigator’s interpretation of results. Generally, although not in the

contract, most such disagreements are easily dealt with by open and

honest communication between parties.

Confidentiality The contract will contain reference to what written or other materi-

als supplied by the sponsor to the investigator are to be regarded

as confidential, and with whom they may be shared. If there is a

separate confidentiality agreement that has been signed, care must

be taken to make sure that the contract and the confidentiality

agreement are concordant. Care should be taken to avoid listing the

research/study results as being “confidential.” If this is done, it may

serve to block the ability to publish results.

( continued)

2 8 2

P H A S E I C A n C E R C l I n I C A l T R I A l S

Table 11.3 (Continued)

Element

Comment

Indemnification The contract will specify how the parties will bear responsibilities for and insurance

each other in the case of legal action taken by patients or others. In

general, the investigator/institution must be responsible for their

own acts of negligence. The insurance and indemnification to be

held by the sponsor and manufacturer need to be clearly stated.

Which party will take responsibility for events that arise from proto-

col treatment-related outcomes (provided the protocol is followed

as written) and for events directly related to drug product should be

indicated: some countries require detailed information on this to be

submitted to the regulatory/competent authority when the clinical

trials authorization is requested. Care should be taken that investiga-

tors are not being asked to indemnify other parties for actions that

they cannot supervise or be responsible for. Finding appropriate

language in this section of the contract and obtaining the required

insurance coverage may be a source of prolonged negotiation.

Termination

The contract should specify who, and under what conditions, can stop

the study, and what the consequences of such termination wil be.

Most concern is raised when business decisions alone lead to trial

termination. The contract should be clear about what consultations

must take place before the trial is closed prematurely. Some institu-

tions will not sign contracts that allow the sponsor to prematurely

terminate the study for non-scientific or non-safety reasons.

Consistency

Make sure the protocol document and the contract/appendices are

consistent with respect to such things as SAE reporting responsibili-

ties, accrual expectations, roles and responsibilities.

Payments

The contract should specify amount and timing of any funding

arrangement.

Signatures

Investigators are not generally considered “legal entities.” The inves-

tigator’s institution must sign the contract as wel . The investigator’s

signature can attest to the fact that the investigator agrees with the

content of the contract, but it is the institutional signature that counts.

results are not as “positive” as expected, is key. It is reasonable to expect the company to have rights to review and co-author publications if they have contributed

to the data and content, but they should not be able to unduly delay or block

publication on the basis of a disagreement on the interpretation of results. If the

investigator or an academic group is not holding the trial database, the oppor-

tunity for trial investigators to access the database is also crucial and should be

accommodated in the contract under most circumstances. Recent major journals

have cited this latter issue as a critical one in developing a publication that is credible [2] , and many journals now require the first author to attest to the complete-

ness and accuracy of the reported data in a manuscript submission.

Process, Pitfalls, and logistics of Phase I Trials 283

In addition to the overarching agreement between the owner of the investiga-

tional agent and investigators or institutions involved in the conduct of the trial,

several other types of agreement may also be employed. There may, for example,

be a separate contract with departments within an institution, such as radiology.

If more than one trial site is to be involved in the trial, contracts will need to be put in place between the sponsor and each trial site, and care should be taken to

ensure that all such contracts are consistent as far as possible. If samples from trial patients are to be analyzed by a laboratory or laboratories separate from the trial

site(s) conducting the trial, agreements should put in place to cover this analysis.

In particular, details about the length of time samples should be stored before

analysis and the timing of data and/or report provision should be considered,

particularly if these data are to be used to inform decisions about the progression

of the trial in real time.



11.4 REGULATORY SUBMISSION



Each country or region has a process that must be undertaken before a trial

can begin, and regulatory requirements that must be met throughout the

course of, and at the end of the trial. In the United States, there are multiple

regulations governing the conduct of clinical trials; in the European Union,

the legislation covering clinical trials is the Clinical Trial Directive 2001/20/

EC, issued in 2001. For any individual study, compliance with these pro-

cesses is an absolute requirement. This book cannot supply an exhaustive list

of what is required; in general, documentation about the drug, its formula-

tion, toxicology, and non-clinical efficacy, along with the protocol itself and

other information, must be submitted by the study’s sponsor to the relevant

government authority for review and authorization (see section on Sponsor,

above). This submission is referred to as an Investigational new Drug applica-

tion (InD application) in the United States and is made to the Food and Drug

Administration (FDA). In Canada it is a Clinical Trials Application (CTA),

submitted to the appropriate department in Health Canada. In member states

of the European Union, the submission is called a request for a CTA, made to

the relevant national authorities. Studies operating in more than one mem-

ber state require approval from each member state in which the trial is being

conducted.

Certain types of clinical trial may be governed by specific guidelines and subject

to longer review timelines than is a “standard” study. Regulatory agencies may have

a specific review process, including reference to expert advice, for some classes of

agent. For example, phase I trials involving first-in-human (FIH) administration

of novel compounds meeting certain specific criteria are now subject to additional

2 8 4

P H A S E I C A n C E R C l I n I C A l T R I A l S

and rigorous review in light of the experiences with TGn1412 in the United

Kingdom in 2006.

Usually a minimum time must elapse for the review to take place, and there

may be questions about aspects of the submission that are sent back to the spon-

sor for clarification before the submission is cleared and the trial can proceed.

Some of the information required for the non-clinical aspects of the submission is described in Chapter 2, and the remainder of the content required for

US and EU submissions is summarized in Table 11.4. note, however, that regu-

lations regarding content are not static, so it is important to consult with local Table 11.4. Summary of Regulatory Submissions for

First-in-Human Phase I Trials

United States

European Union Member States

name of

Investigational new Drug

Clinical Trials Authorization (CTA)

submission

(InD) application*

Who may

Investigator

Individual, company, institution, or

sponsor?

(“sponsor-investigator”),

organization

individual, academic

institution or organization,

pharmaceutical company,

or other organization

Forms

FDA 1571 form†: cover

Sponsor must first register trial and obtain

sheet with sponsor details,

unique number from EudraCT, a data-

and other information

base of all interventional clinical trials of

about the application

medicinal products.‡ The CTA applica-

tion form must then be completed and

accompany the submission. In the UK,

submission is done online through the

Integrated Research Application System

(IRAS), which enables concurrent

review of the application by the MHRA,

Ethics Committee, and any other rel-

evant bodies.§

Table of

Required

Required (usually included in cover

contents

letter).

General

Introductory statement and Cover letter¶, which should introduce the

information general investigational plan submission, cite the EudraCT number,

/cover letter for the drug (generally 2–3

and should draw attention to the fact

pages)

that it is the first administration of a sub-

stance to humans. Other requirements

are detailed in the current guidance for

each member state.

( continued)

Table 11.4 (Continued)

United States

European Union Member States

Study

Protocol document(s)

Protocol document

information (may file more than one

trial protocol with initial

submission)

Investigator FDA 1572 form and CV

Required by some member states

information (to be submitted to the

sponsor, and incorporated

into InD application)

Drug

Investigator’s Brochure

Investigator’s Brochure

information Chemistry, manufacturing Investigational Medicinal Product Dossier

and control

(IMPD)—Full IMPD for first-in-man

Pharmacology and

trial (includes chemistry, manufacturing

toxicology

and control, pharmacology, toxicology,

Previous human experience

PK/PD, previous human experience and

risk/benefit assessment). If a marketed

agent is being used within its licensed

indication, reference may be made to

the Summary of Product Characteristics

(SmPC); if an IMPD and/or IB have

been approved as part of a different CTA

package, this can be cross-referenced.

Other

Additional information or

Copy of ethics committee opinion in the

other relevant information

member state concerned, when available.

is requested by FDA

Insurance and indemnification informa-

tion: member state–specific.

Other information may also be required;

check guidance for relevant member

state.

*For FDA InD application details, see http://www.accessdata.fda.gov/scripts/cdrh/

cfdocs/cfcfr/CFRSearch.cfm?fr=312.23 and see also: http://www.fda.gov/Drugs/

DevelopmentApprovalProcess/Forms SubmissionRequirements/default.htm

†For FDA forms, see: http://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/

HumanDrugForms/default.htm

‡To get a EudraCT number, see:

https://eudract.ema.europa.eu/

§To get information on CTA application form and process:

http://ec.europa.eu/health/documents/eudralex/vol-10/

Online application through IRAS:

https://www.myresearchproject.org.uk/

¶Specific information required by individual member states can be found on the websites of relevant competent authorities.

Website references were all last accessed in October of 2014.

2 8 6

P H A S E I C A n C E R C l I n I C A l T R I A l S

government authorities prior to beginning a submission process. There are a few

common terms and requirements that merit comment.



11.4.1 Protocol

The final protocol document, including all appendices, is a standard part of all regulatory submissions (see Chapter 9 for detailed information about the content of a protocol).



11.4.2 Investigator’s brochure

The investigator’s brochure (also called the “clinical brochure” or “investiga-

tor drug brochure”) is a summary document of the drug under study above and

beyond the information usually provided in the introduction to the protocol. It

includes summary information on the physical, chemical, and pharmaceutical

properties of the new drug; data on preclinical studies (pharmacology, including

efficacy, toxicology, and pharmacokinetics [PK]), and on any clinical studies that

have been conducted. There is also a reference guidance section for the investiga-

tor, which outlines expected events for safety and pharmaco-vigilance monitor-

ing. For phase I FIM trials, the section detailing previous clinical studies will be

limited, but as clinical data emerge, the investigator brochure is updated, often on

an annual basis. In some territories there is a legal requirement to regularly update the investigator brochure; local regulations should be consulted to determine

whether this applies. Tables 2.7 and 2.8 found in Chapter 2 describe the recom-

mended table of contents listing for an investigator’s brochure as outlined by ICH.



11.4.3 Chemistry, manufacturing, and

control (CMC) information

In the EU, regulations dictate that any investigational medical product (IMP) for

use in clinical trials be manufactured according to the principles of good manu-

facturing practice (GMP) (Eudralex Volume 4, Annex 13). This is to ensure the

safety of trial subjects, and that the results of clinical trials are unaffected by inadequately controlled manufacture. In the US, IMPs for use in Phase I trials are not

required to be manufactured according to GMP, although in many cases these

restrictions are applied nonetheless.

In addition to the information about the investigational agent provided in the

investigator’s brochure, further detailed information about the manufacture of

Process, Pitfalls, and logistics of Phase I Trials 287

Table 11.5. Investigational Review Board/Institutional Ethics

Committee (IRB/IEC) Composition/Function

IRB/IEC

At least five members:

composition

At least one member whose primary area of interest is in a

non-scientific area

At least one member independent of institution/trial site

Functions

Written operating procedures of functions, including definition of

a quorum for decision-making

Written records and minutes in compliance with GCP and regula-

tory requirements

Decisions

Decision of the IRB/IEC should be made at announced meetings

at which at least a quorum is present

Participants

The investigator may provide input, but should not participate in

deliberations or the vote/opinion of the IRB/IEC

Responsibilities

Major responsibility is to safeguard the rights, safety, and

wel -being of trial subjects

Trial: IRB/IEC must review protocol, amendments, informed

consent form(s), subject recruitment procedures, Investigator’s

Brochure, and other safety information, as well as information

about payment/compensation to subjects

Investigator(s) review: review investigator CV and other documents

to assess his/her qualifications for performing the trial

Trial review: initial review prior to trial activation, as well as ongo-

ing (continuing) review of each active trial at least once per year.

Further, ongoing safety review of serious unexpected adverse

drug reactions

Outcome of IRB/IEC decision may be categorized as:

• approval

• modifications required prior to approval

• disapproval

• termination/suspension of prior approval

This summary is condensed from ICH Guideline E6: Good Clinical Practice, Section 3.

Please note that there may be additional, or more stringent requirements, for composition and function within individual countries or regions. See Appendix I for web reference for GCP.

the agent wil be required. In the US this information should be included in the

InD documentation, and in the member states of the EU it is provided in the

form of an investigational medicinal product dossier (IMPD). The CMC infor-

mation should encompass both drug substance and drug product, and include

data to demonstrate the identity, purity, strength, and quality of the material, as

well as information about the analytical methods and acceptable limits used to

define these.

2 8 8

P H A S E I C A n C E R C l I n I C A l T R I A l S



11.4.4 Other documents

Each country or region has compiled lists of documents and forms that must

be completed to file the appropriate submission to local authorities for review.

Table 11.4 and Appendix I of this book provide some useful links to access this

information in various countries and regions.



11.5 ETHICS SUBMISSION

Every trial must receive ethical committee approval before opening for patient enrollment. The ethics committee, also called institutional review board (IRB),

independent ethics committee (IEC), research ethics board (REB), and other

monikers, has the responsibility of safeguarding the rights, safety, and wel -being

of trial subjects. To do so, it must conduct an independent review of trial docu-

ments and other information, including: the protocol, consent form, and any

other material to be used by or given to patients; investigator qualifications; subject recruitment procedures; as well as the investigator brochure (or similar

background information on the drug as appropriate), and information about any

payment that will be made to patients. The committee must also be responsible

for ongoing review of submitted serious adverse events and trial amendments,

and must ensure that the continued conduct of the trial is appropriate by an

annual approval process. Various regulations dictate the complement of ethics

committee members required for review at each step. The investigator may be

invited to attend the meeting, and this is an opportunity to explain aspects of

the study to the committee and give the investigator better insight into any ques-

tions raised by the ethics committee; in both cases, this can save time in gaining

ethics approval. All initial ethics reviews must be done by the “full” (as defined

in guidelines) committee, and other reviews may require the full committee or

be expedited, depending on the nature of the material and the local regulations.

Countries vary regarding how IRB/IEC membership and procedures are codi-

fied; in some, they are subject to governmental regulation, and in others, they are

subject to guidelines only. Table 11.5 outlines IRB/IEC composition and func-

tion as per ICH GCP guidelines. Essentially, all institutions at which phase I can-

cer trials are conducted will have an appropriately constituted ethical committee

and process already in place. The investigator’s responsibility with respect to this

process is to ensure that the committee has all the relevant documents and forms

submitted prior to the study start and throughout the trial, including submission

of safety reports and serious adverse events reports as required. It is also impor-

tant that the ethics committee review the final protocol submitted for approval

Process, Pitfalls, and logistics of Phase I Trials 289

by the regulatory authority. The investigator is also responsible for addressing the

committee’s questions or concerns in a timely way.

In addition to ethical committee review, other institutional or sponsor review

committees are now commonplace; examples include institutional scientific

review (by colleagues of the investigator, for example); and resource utilization,

pharmacy, and nursing reviews. In most institutions there is a standard sequence

through which a new trial protocol must pass: the institutions that are the most

efficient usually conduct such reviews in parallel. Some have observed that the

speed of passage through the various layers required to officially open a new trial for accrual is related to the energy and enthusiasm the investigator has for

the study; rapid responses to questions raised by various review bodies enable

the protocol to move quickly to approval. Institutions or investigators with very

poor track records in study activation timelines will lose opportunities for future

studies.



11.6 SETTING UP THE TRIAL



It may seem that once a protocol is finalized, all the various approvals required

are completed, and all the relevant clinicians have been made aware that the trial

is approved, it is ready to begin; this is not, however, the case, and there remain

a number of practical aspects to setting up a successful phase I project in the

institution(s) in which it is to be carried out.



11.6.1 Nursing

Many institutions have specialized cancer research nurses, and these individu-

als are in some respects the most important team members. Where appropriate,

wel -trained research nurses, research assistants, data managers, and technicians

may undertake a number of trial-related tasks under the investigator’s supervision

once formally delegated to do so; these include screening patients for eligibil-

ity and initial discussion of the trial with potential subjects, treatment admin-

istration, assessment of adverse effects, blood or tissue collection, preparation

and shipping samples for PK and special studies, and case report form (CRF)

completion (to name a few). Because of their vital role, it is recommended that

the primary study research nurse have the opportunity to review the protocol

while it is still in draft form: s/he may identify practical issues regarding patient treatment or monitoring that are best addressed by changes to the protocol document before it is finalized. Beyond this, it is essential that research nurses, data

2 9 0

P H A S E I C A n C E R C l I n I C A l T R I A l S

managers (if applicable), investigators, and other team members (see below)

meet before the trial is open in their institution to “walk through” the protocol, and educate personnel about the trial procedures and treatment plan, as well as

how to complete CRFs. These activities would usually form the agenda for the

site initiation visit (SIV), one of which should be undertaken at each clinical site

that will recruit patients for the trial.

If a pharmaceutical company, academic organization, or clinical research orga-

nization is sponsoring/managing the trial, they often organize such face-to-face

meetings themselves. Who will be responsible for drawing and processing blood

after hours? Who will make the laboratory and radiology bookings to comply

with the protocol calendar? And who will ensure that all results of those tests are

available and seen by the investigator as soon as possible? Experienced nurses

often develop trial activation checklists for such practical organizational matters

to use in their own institution.

Research nurses or, in some institutions, data managers, are also responsible

for maintaining all required trial files and organizing ethics committee and other

internal committee submissions; for example, some institutions have resource or

pharmacy committees that protocols must pass through before they can begin.

Whoever is responsible for this aspect of the trial coordination, ideally they

should have a set of written standard procedures to describe how trial organi-

zation is managed. GCP includes a section on essential trial documents, which

provides an overview of the files that the investigator and sponsor must maintain

to enable evaluation of the trial quality and conduct by external reviewers (see

Section 8.0 of GCP).

Standard operating procedures (SOPs) are detailed written instructions to

achieve uniformity in the performance of trial-related procedures. Institutions

participating in clinical trials need to have SOPs for key trial activities, such as

ethics committee processes, patient recruitment, registration (or randomization)

procedures, adverse event reporting, delegation of study responsibilities, and

CRF completion.



11.6.2 Data capture: case report forms and database



Al clinical trials require documentation of patient characteristics (including disease-history information) at study entry, other baseline information, study

treatment administration, adverse effects, various laboratory measurements (bio-

chemistry, hematology, etc.), and radiological or clinical measures of disease over

time, as appropriate. These data are entered into a database to enable the genera-

tion of study reports and summary tables. Data collection forms, or CRFs, are the

most common approach to data collection, either in paper or electronic format

Process, Pitfalls, and logistics of Phase I Trials 291

(“eCRF”). In a trial where information from more than one trial site is collected,

the central site (be it an academic site, cooperative group office, or pharmaceuti-

cal firm) enters, reviews, and queries the data. Electronic data capture (EDC)

systems permit data to be entered into the database at the site and interrogated

as a part of this process, improving the initial quality of data and reducing some

of the checks required afterwards. Typically, for single-center trials that do not

have a pharmaceutical partner, the trial personnel who collect the data may also

be responsible for entering the data into a local database.

nurses and/or data managers should also be trained in CRF or eCRF com-

pletion: if the data collection forms are not familiar, reviewing them prior to

usage is important. Training in and familiarity with EDC processes is essen-

tial for successful eCRF completion and should take place close to the initial

entry of patient data to maximize its effectiveness. Knowing whom to con-

tact if questions arise during data entry is also important. Furthermore, it is

important to understand that the eCRF content must be traced to “source”

documents in case of audit. That means that the medical records, flow sheets,

pharmacy records, prescription copies, and/or clinic notes must contain the

information recorded on the eCRF.



11.6.2.1 Case report Forms (CRFs)

Trials sponsored by industry will generally have eCRF development take place

within the company. It is useful for the phase I investigator and study nurses

to review the eCRFs while they are being developed in order to ensure that all

necessary trial information is being collected (and no extraneous information

is being sought) and to be confident that the format and content of eCRF are

unambiguous. eCRF development by an investigator or academic group should

happen in col aboration between the investigator, data management, and com-

puting/statistical staff. The eCRFs must collect data required by the protocol (not more), and should be designed in such a way that the data can be easily

entered. Finally, the data collected for the trial must take into account what all

those involved with the study can foresee will be needed in terms of reporting the

trial results. A useful strategy is to imagine at the outset of the trial what the tables in the final manuscript or report will look like. The content of the tables planned for the final report and the raw data required to populate them tel you what the

protocol must be written to collect, what goes on eCRFs, and what must be put

in the electronic trial database. Generally speaking, actual numbers and values

should be collected on the eCRFs, rather than calculated values by data managers

or nurses. For example: collect actual granulocyte values, computerize them, and

let a computer algorithm define the worst grade experienced, rather than have a

person figure out the grade and record only the grade on the eCRF.

2 9 2

P H A S E I C A n C E R C l I n I C A l T R I A l S



11.6.2.2 Database

The development of appropriate trial databases for cancer clinical trials is a topic

of considerable complexity. As noted above, if the phase I trial is being conducted

through pharmaceutical industry sponsorship, the database will be their respon-

sibility. However, access to database information, tables, and data listings is

important for the investigator to assist in the interpretation of trials results. If the trial is an academic one within a single center or within an academic trials group,

the database may be commercially purchased (e.g., Oracle Clinical) or designed

by personnel in the group or institution. Irrespective of who is building it, the

database must be ready for use in advance of the first patient’s being enrolled in

the study.

Thought must be given as to how the clinical data in the database will be

“merged” with special studies such as output from pharmacokinetic (PK) studies

or pharmacodynamic (PD) assays. Having all data from each patient in the same database facilitates analysis of the trial; however, it may not always be possible to capture PK and PD data within the clinical database. The format, content, and

frequency of analysis of PK and PD studies must be agreed upon in advance to

permit their review alongside the clinical data. Furthermore, regardless of the

structure of the database, it must be possible to transform data into the format

required. Examples include calculation of adverse event (AE) grades from raw

values, identification of worst toxicity by patient and by dose level, mean dura-

tion of certain toxic effects, and so on.



11.6.3 Pharmacy

Before beginning a phase I trial, the research pharmacist must review the drug

information in the protocol and investigator’s brochure. In addition, the phar-

macy must have adequate, secure facilities to store and prepare drug as per

protocol. All trials of investigational drugs require that a log of receipt and dis-

pensing be strictly maintained, and the pharmacy must employ appropriately

trained personnel for this quality-control aspect of the study. Details about

the disposal or destruction of empty vials or their return to the sponsor must

also be tracked.

Generally, the sponsor that is supplying drug will need to know the name

and address of the pharmacist who will be responsible for receiving ship-

ments. The drug shipment will not take place until all required approvals for

the protocol are completed. Shipments are accompanied by a trial-specific

drug log, an acknowledgement form to send back to indicate that the drug

arrived safely, and usually information on how to reorder the drug when sup-

plies are low (it is important for pharmacist to keep an eye on this, as drugs

Process, Pitfalls, and logistics of Phase I Trials 293

may take several days to arrive). Use of an investigational supply of drug for

non-trial patients is strictly prohibited.

As some protocols require extensive pre- and post-therapy administration of

fluids or supportive-care medications, some pharmacists prepare a pre-typed

order sheet or computer order-entry screen so that, not only the trial medication,

but all co-medications and fluids are prescribed correctly. The pharmacist must

pay special attention to drug reconstitution protocols and information on special

bags or tubing that may be required, to be sure that these are available when the

trial opens, as not all may be supplied.



11.6.4 Sample processing, packaging, and shipping

As almost all phase I trials involve sending blood or tissue specimens to special-

ized research facilities for PK or other assays, there must be clear instructions in

the protocol or appendices about how to procure the sample, into what type of

container or fixative it is to be taken, how it is to be processed (e.g., centrifugation within [how long] after sample is drawn, at what speed and at what temperature),

how the final sample is to be labeled and stored, and, finally, to whom it is to be

shipped. The use of a laboratory manual to describe these aspects of the study is a

useful means of providing this information in a dedicated format, with the added

benefit that it may be updated without the requirement for a protocol amend-

ment. A patient-specific log sheet to record when PK or pharmacodynamic

samples are taken is important to track what is due and when. In general, tubes

and labels are supplied by sponsoring pharmaceutical companies, but this may

not always be the case, particularly for sample shipping on academic trials where

the shipment is to a research laboratory. In these cases, the receiving laboratory

must provide detailed information on what, how, and when to send specimens.

Sample labels should be provided by the sponsor or receiving laboratory, and the

shipping conditions followed, to ensure sample integrity. Most laboratories ask

that the sending institution ship only on certain weekdays to ensure that samples

can be received during normal working hours. Furthermore, the receiving facility

must be notified before the sample is shipped so that they are aware it is on its way.

All of these aspects of the trial must be sorted out before the first patient is seen, and the pre-trial meeting serves as the best time to do this.



11.6.5 Treatment delivery

Some protocols require long-term infusions or frequent visits for treatment. The

investigator and their team must ensure there are outpatient or inpatient beds

2 9 4

P H A S E I C A n C E R C l I n I C A l T R I A l S

available to conduct the trial. Many clinics have a coordinator for bed space; this

individual is the one with whom these aspects of the trial setup are to be coordi-

nated. If patient samples are to be obtained “after hours” of operation, the logis-

tics of, not only delivering treatment, but also obtaining, preparing, and storing

samples must be addressed before the first patient is enrolled.



11.6.6 Trial registration

Recently, editors of major medical journals have made it a requirement that clini-

cal trials must be registered in an acceptable public registry prior to treatment

of the first patient, in order to be published once they are completed [3,4]. This

effort is to ensure that the public is aware of all trials that are being performed, not only those that are published because they have favorable outcomes. It is hoped

this endeavor will reduce publication bias. Although registration for phase I trials

may not always be mandatory, it is recommended that investigators involved in

phase I trials ensure that their trial is registered in such a database before enrol -

ing patients. Failure to do could result in difficulty publishing the results when

the trial is completed.



11.7 STUDY CONDUCT



The study protocol and investigator brochure are key to the safe and effective

delivery of a phase I trial. Both must be clearly version-controlled, with the cur-

rent versions readily available wherever they might be needed. Such documents

will be considered confidential, but in the event of there being a clinical prob-

lem, acute medical teams will need to have access to the protocol and investigator

brochure; broad, but controlled and auditable, access can be achieved by having

electronic copies available on the hospital intranet.



11.7.1 Identifying patients for a phase I trial

Institutions vary in their organizational structure. Many large cancer treatment

facilities have subspecialist oncologists treating only one type, or only a hand-

ful, of cancers. Because phase I trials, particularly FIH studies, may cross disease

boundaries by enrol ing patients with a variety of tumor types, there may be

logistical challenges in arranging for the investigator or her/his study nurse to

see or screen all potential patients for a study. There are three main approaches to

addressing this, as follows.

The first is to assign several co-investigators (also called sub-investigators) to

the trial team from a variety of oncology subspecialties. The disadvantage of this

Process, Pitfalls, and logistics of Phase I Trials 295

approach is that their practice locations and timing of outpatient clinics may not

make it easy for study personnel such as research nurses to organize trial-related

procedures. Furthermore, such an approach will dilute investigator experience

with the drug and its effects on patients. This may mean that some subtle but real

drug-related changes in patients may not be recognized as such, if every patient is

seen and followed by a different investigator.

The second, and preferred, approach is to organize a “phase I clinic,” or simi-

larly titled clinic, once a week. Colleagues can refer patients who have exhausted

standard curative therapeutic or palliative options to this clinic, where they will

be seen by the phase I investigator(s) to be screened for eligibility to any ongo-

ing phase I trials. This organizational approach will concentrate experienced

phase I personnel and resource into one place, but it wil require transfer of the

care of the patient from the original oncologist to the phase I investigator for

the period of time they are on the trial. Concurrent care arrangements may be

possible to avoid having to re-refer the patient to their original physician once

the study is completed. Where recruitment is limited to patients with a specific

tumor type(s) and/or patients have less-advanced disease than is usually the case

for FIM studies, close liaison may be needed between the phase I team and the

site-specific oncologists to identify patients and coordinate the management of

particular aspects of the patient’s cancer. For this to work wel , a menu of several

phase I trials, adequately resourced, is desirable so that referrals can be received

on an ongoing basis rather than being turned on and off when trials or dose levels

open and close.

The final, and least common, setting for phase I trials is in designated,

stand-alone commercial trials units that principally conduct healthy-volunteer

trials. By their nature, early-phase cancer trials in patients with advanced disease

and requiring specialist clinical care do not map naturally onto units designed to

accommodate healthy volunteers. This is unlikely to change to any great extent,

especially in the wake of the TGn1412 experience.



11.7.2 Discussing the trial with patients

Phase I oncology trials are unlike those in most other therapeutic areas in that

most are conducted in patients with incurable advanced cancer and a limited life

expectancy, rather than in healthy volunteers. Coupled with this is the fact that

the trial’s goals are not primarily concerned with efficacy. These factors create

special challenges for disclosure and discussion. Even though a consent form

may contain all the information believed to be relevant to an informed deci-

sion in a written document, the consent form itself is not a process: that must involve substantial discussion between the patient, members of the trial team,

and other caregivers if necessary. The consent process must be consistent with

2 9 6

P H A S E I C A n C E R C l I n I C A l T R I A l S

the principles articulated by the nuremberg Code, the Declaration of Helsinki,

and the precepts of GCP. Three fundamental ethical principles are invoked in

obtaining consent for research from human subjects: respect for persons (treat individuals as autonomous beings, capable of making informed choices), beneficence (maximize the possible benefits and minimize harms), and justice (treat research participants fairly and ensure there is a reasonable balance of risk and

benefit in any experimental undertaking). These principles are reflected in the

standard language required and the content of consent forms (see Chapter 5)

but also must be threaded through the discussions held with patients about the

options to enroll in a clinical trial. Investigators and staff must be aware in dis-

cussions with patients that varying cultural backgrounds can have an impact on

their, and families’, wil ingness to have frank discussions of their prognosis or of

experimental treatments. The framework for discussion of life-threatening illness

that a culture creates may not be well understood by caregivers (or well taught by

educators), so sensitivity to the cues presented in the conversation is extremely

important. See Chapter 5 for a more extensive discussion of this topic.



11.7.3 Other options for treatment

For a patient, entering a phase I trial may be one of several options at a particular time point in their illness. Therefore, the discussion regarding enrollment on a

trial must include a conversation of other possible options for management. In

combination phase I trials, it may be that the “standard” treatment with which the

new drug is combined is available to the patient of study and they do not need to

participate in the trial to receive it. Supportive/palliative care alone is an option that is difficult but important to discuss with patients who have exhausted all

forms of active therapy; otherwise, patients may feel that if they are not enrolled

on a trial, they will not have a chance to receive any care at all. It needs to be made clear to patients that they will continue to receive the best medical care possible if they choose not to enroll in a trial; if the patients believe that they will not receive such care, this may coerce them into enrol ing in a trial they do not really want

to join. likewise in some areas with limited access to palliative care, the provi-

sion of access to such care through participation in an early clinical trial may be

perceived as coercion.



11.7.4 What the trial involves

To make an informed choice, not only does the patient need to know what the

other options are for managing their disease, they also need to have a good under-

standing of what the trial itself involves: What is the goal of the study? What will

Process, Pitfalls, and logistics of Phase I Trials 297

treatment involve in terms of visits or tests? Are there special or genetic tests that are a mandatory part of the trial? Will there be personal costs that the patient

must bear? What are the expected side effects? Expected benefits? It is clear that,

despite the best process and consent forms, patients will not always understand

that the chances of antitumor benefit are extremely small in FIH phase I studies

(see discussion of this topic in Chapter 5). It is the investigator’s responsibility to ensure that the patient is sufficiently informed about the answers to these questions to make a truly informed decision.



11.7.5 Consent in two steps

Some studies have suggested that research subjects’ understanding of informed

consent is enhanced by more one-on-one interaction between the patients and

investigators [5] . To accomplish this, it is recommended that the process of con-

senting a patient be done in two steps. First, the investigator (alone or with the

research nurse) explains the study and determines if the patient is interested in

participating; this discussion can be supported by generic printed information

explaining in principle the rationale, design, and conduct of early-phase trials.

If the answer is “yes,” before final consent is given, the patient is asked to think

over the participation, then take home, read, and discuss the patient informa-

tion sheet (PIS) with his/her family, family physician, and/or another physician.

During this interlude, any additional routine testing to ensure eligibility may be

started—with the patient’s agreement. Some trials require full consent to the study before even routine investigations are undertaken, but others allow tests

such as imaging or basic hematology and biochemistry tests to be undertaken

before the consent form is signed. Al trials, however, require written consent

before any non-standard trial-related procedures such as a fresh tumor biopsy

can be done. Once the patient has had time to consider participation, a second

visit is scheduled in which the investigator can review once more the major ele-

ments of the trial, ask the patient what his/her understanding is of the study’s

purpose and procedures (to ensure that the patient is adequately informed), and

address any questions. If, after this is completed, the patient voluntarily agrees

to proceed, the consent form can be signed and the process of trial registration

and treatment begin. It is usual to give a copy of the consent form to the patient

to keep.



11.7.6 During the trial: continued feedback

It is important to engage in ongoing discussion with patients (or trial subjects)

during the study. As described in Chapter 5, investigators have a duty to inform

2 9 8

P H A S E I C A n C E R C l I n I C A l T R I A l S

patients of “significant new findings” that arise in other patients enrolled in the

same study, or in experience with the drug in other studies that might have an

impact on a patient’s continued wil ingness to remain on the study. Emerging

new toxicity information is an example: even before the consent form is altered

to update it (if that is deemed necessary), the patient should be verbally informed

about any significant new toxic effects of the investigational therapy and the con-

versation documented in the patient’s medical record. Patients may encounter

symptoms or have questions that they did not think to ask about at an appoint-

ment, and they must have reasonable access to study personnel, such as the

research nurse, to discuss these. Some research nurses make a point of telephon-

ing patients a few days or a week after the first phase I treatment is given to see

if there are any symptoms or questions; this is a good practice that should be

widely adopted. Patients may keep a diary of symptoms and questions to bring

to the attention of the trial team. The use of a diary is particularly important if the trial medication is to be self-administered; the patient should record when and

how much medication was taken and describe any adverse effects. The diary can

be returned to the study nurse when the next scheduled visit takes place. Finally,

it is good practice to provide the patient with a contact information card, which

states he/she is on a clinical trial and provides contact numbers for the investiga-

tor, nurses, and other trial personnel for the patient or other health professionals

to use between scheduled visits.



11.7.7 Data collection and management

It is vital for the credibility of results, as well as being essential for compliance with GCP principles, that the trial data be complete and accurate. As trial eCRFs

are not part of the “official” medical record, it is important that any information

recorded on eCRFs can be verified by examination of the official institutional

patient chart or medical record. As some required information, such as patient

symptoms, may not normally be recorded in the physician notes in the medical

record, study nurses or data managers can create trial-specific checklists or other

tools to ensure protocol compliance and facilitate complete and accurate data

collection. These can be appended to the patient chart to ensure that informa-

tion is obtained from patients at their visits and recorded in a manner that can be

transferred to the eCRFs.

In an individual center, it is important that such tools and the procedures to

use them be documented as part of the SOPs and that trials staff be educated in

their proper use. Undertaking this properly will not only ensure data accuracy,

but, if the institution undergoes an official audit, it will also be clear how data are managed and col ected.

Process, Pitfalls, and logistics of Phase I Trials 299

Examining the completeness and accuracy of trial data in the (e)CRF com-

pared to the medical records is a key function of a “monitoring visit,” conducted

by a representative of the sponsor (usually termed a “clinical research associate”

or “monitor”). The chief purposes of trial monitoring according to ICH GCP are

to verify that: the rights and wel -being of human subjects are being protected;

the reported trial data are accurate, complete, and verifiable from source docu-

ments; and the conduct of the trial is in compliance with the currently approved

protocol. The monitors’ responsibilities include checking that consent has been

taken appropriately; ensuring the completeness and accuracy of data in the eCRF

compared to source documentation; ensuring the investigator receives the cur-

rent IB, all documents, and supplies to conduct the trial properly; ensuring the

correct storage, accountability, and resupply of IMP, among others. Frequency of

visits will vary according to the rate of patient recruitment, and with the advent

of EDC, some monitoring activities can be performed remotely. A “risk-based”

approach to monitoring may also be adopted by some sponsors, whereby the

level of monitoring is adjusted up or down according to the level of risk assigned

to a trial. It is very important to ensure the ongoing interrogation of clinical

data: entry of data into the database should take place as soon as possible after

patient visits, and any discrepancies in the data should be identified and resolved

swiftly. This has particular resonance in early-phase studies where regular data

review is necessary to monitor patient safety and to inform decisions on changes

in dose level. It will also facilitate swift completion of the database when the trial recruitment period concludes.



11.7.8 Managing the dose-escalation scheme



11.7.8.1 Who is in Charge?

Each trial requires one “coordinator” who takes the overall responsibility for assembling the relevant data for each dose level as the observation period ends,

summarizing it, and conveying this information to colleagues for joint decisions

about what the next step will be regarding, for example, opening the next dose

level, expanding the current level, or reducing to the previous, lower dose. This

may be done by the trial investigator, the main data manager or statistician at

the study group, or the company coordinating center. This individual is respon-

sible for making sure all relevant clinical, laboratory, and PK data required for

decision-making are available. Conduct of a dose-review meeting should be the

subject of a sponsor SOP, describing the process of data review and the person-

nel required to be involved in these decisions. Final decision-making responsibil-

ity will lie with the sponsor, and the outcome of these meetings must be clearly

documented using a standardized approach. Core attendees of these meetings

3 0 0

P H A S E I C A n C E R C l I n I C A l T R I A l S

comprise the chief investigator and the sponsor’s medical and pharmaco-vigilance

representatives; the governance of these meetings is increasingly structured, with

many including an independent clinician. PK and PD scientists are frequent

attendees (this will vary, though, depending on the importance of such data

with regard to changes in dose level), as are the principal investigators from each

recruiting site. Data required to inform these decisions should be specified in the

protocol, and when documenting the decision, it is good practice to also specify

its status: namely, whether any clinical data have not been subject to monitoring

and first-pass data cleaning and whether PK and PD data have not been validated.

Ideally the opposite will always be the case; however, a balance must sometimes

be struck against impeding these decisions and hence trial progress.



11.7.8.2 Recruitment to Dose levels

The rules for opening and closing dose levels should be clearly described in

the design section of the protocol. This should include what data will be used

to make these decisions, including any PK and/or PD data (which should be

used to inform such decisions wherever possible). Generally for FIH trials for

a new drug, the first patient at the first dose level should be treated and observed for a cycle (or whatever the study-designed observation period is) before others

are entered on that first level (presuming that more than one patient per dose

level is planned) in order to be absolutely certain that the trial starting dose is, in fact, safe. Thereafter, most believe, it is acceptable to enter the required minimum number of patients per cohort at the same time, assuming that eligible patients

are available. It is also possible to continue to enroll only one patient (as for the initial dose level) and await the outcome in that individual before the remaining

patients for the minimum required per cohort are enrolled. Which approach is

followed can depend on the data from the previous level (e.g., was there a near

dose-limiting event?), or on the nature of the drug and trial (e.g., the first-ever

study of an agent of a new target or class may be a situation in which a more

conservative approach is warranted). numerous phase I dose-escalation designs

exist to account for these varying trial situations, and these are discussed in detail in Chapters 4, 6, 7 and 8.

Individual patient enrollment should take place only after the consent form is signed for that patient and when a dose level is open for enrollment. Registration

is usually done by calling or faxing the central “trial office” responsible for trial coordination, or using a web-based registration system. Effective communication and coordination are key to completing recruitment to dose levels with

minimal delay. Advance warning of the opening of new dose levels must be given

by the trial coordinator to all participating sites, along with notification if any

particular site is already nominated to fill the slot. A system of guaranteeing slots

Process, Pitfalls, and logistics of Phase I Trials 301

to individual sites on a rotating basis ensures fairness and allows sites to approach patients in the knowledge that there is an opening available, but that can slow

down recruitment; accordingly, a contingency must exist to replace patients who

“fail” the screening assessments or do not complete the required observation period once on a study. Having “back-up” patients in place for these situations

will ensure efficiency in fil ing dose levels.



11.7.8.3 When the Dose Level Has Completed

Minimum Recruitment

When the dose level has completed the first stage of recruitment, enrollment to

the trial is put on hold and patients observed for the protocol-specified period.

At the end of that period, all data needed to make the end-of-dose-level decisions must be submitted without delay (e.g., by fax or electronically). Usually clinical data are reported in a timely fashion, but there may be problems receiving PK or PD

information expeditiously. If these latter data are critical to dose-escalation deci-

sions, then it must be clear to those concerned that “real-time” completion of

assays and analysis is essential. Once the material is received, a decision can be

made by the study’s coordinating office/investigator, in consultation with trial

colleagues, regarding opening a new level, expanding the current one, or reduc-

ing the dose level according to the criteria set by the protocol.



11.7.8.4 When the Escalation-Switching Event is Seen

As noted in Chapters 4 and 8, many protocols are designed to change the size of

the dose-escalation interval and/or the number of patients per dose level when a

specific event is seen or criterion is met. Examples of “switching events” include

the observation of grade 2 drug-related toxicity (many protocols in which dose

levels are being doubled and only one patient per level is being entered will

increase the number of patients per cohort and switch to a more conservative

dose-escalation scheme at this point); PK results indicating a target area under

the curve of drug exposure has been achieved; or laboratory data showing that

target inhibition has been accomplished. The observation of the switching event

will trigger a communication from the trial coordinator to all concerned that

from that point forward, according to protocol design, the changes in cohort size

or escalation step size are in effect.



11.7.8.5 When a Dose-Limiting Event is Seen

If it is anticipated that toxicity will be dose-limiting, the observation of the first dose-limiting toxic effect (DlT) means the study may be nearing the final dose

level. If, at the time the first DlT is reported, only one patient has been entered

on that dose level (i.e., one of one has DlT), it is wise to enroll only one (not two) more patients until the outcome of the second patient is known. If the second

3 0 2

P H A S E I C A n C E R C l I n I C A l T R I A l S

patient experiences DlT (that is, two of two patients), then adding a third is not

necessary if the definition of maximum tolerated dose (MTD) is two out of three

(or six) patients with DlT. If three patients are already entered when the first

DlT is seen, and only one of the three has a DlT, expansion to six is allowed.

However, the same cautionary approach may apply: if patient 4 has a DlT as

wel , then, depending on the protocol “rules,” the MTD may have been reached

without needing a total of six patients treated. Real-time interaction between

investigators and the trial coordinator is essential to ensure that no more patients

than are absolutely necessary to define MTD are enrolled. If, after expansion to

the maximum number of patients, no more dose-limiting events are seen, further

escalation according to the scheme in the protocol can occur.

If measures other than toxicity are planned to limit dose escalation (e.g., mea-

surement of a minimum target-related change in tumor tissue samples), then the

observation of a single dose-“limiting” event need not necessarily lead to such a

cautious approach to fil ing the dose level; the level may be filled to the maximum

number planned and should then be analyzed to determine if escalation can

cease using the protocol-defined rules. Please note that, even when something

other than toxicity is planned to define the upper limit of dosing in a protocol, a definition of those toxic events must be included that, if seen, will limit further

escalation regardless of whether the “other” dose-limiting events are documented

(sometimes toxicities that are unexpected at the dose levels planned will occur).



11.8 EXPECTING THE UNEXPECTED



Despite explicit and detailed design plans, not everything will go as planned in

most phase I trials, particularly FIM studies. Table 11.6 lists some of the common

problems seen during the setup and conduct of these studies and offers some

practical solutions. By and large, this list comprises unexpected observations.

Provided the protocol design section is written to allow reasonable judgement

based on safety, some of the solutions proposed can be implemented without the

need for a protocol amendment, which would, of course, take time to process.



11.8.1 Conflict of trial protocol versus medical judgement

As in one of the examples in Table 11.6, sometimes what the protocol says should

be done and what the investigator believes is in the best interest of the patient

are in conflict. As outlined in the table, toxic effects were seen that the investigator believed needed a response, yet the protocol did not deal with this eventual-

ity. Another circumstance where this might arise is when the protocol requires

Process, Pitfalls, and logistics of Phase I Trials 303

imaging studies to be done every other cycle, yet the patient’s symptoms suggest

they are needed sooner. In all cases such as this, the investigator must act in the best interests of that patient, even if the protocol does not require or recommend it. The investigator’s most important responsibility is to act in the best interests

of the patient when matters of safety or important disease-management decisions are in question. It is important, however, not to let this principle slide into areas where it is not intended; if the patient prefers, because of personal convenience,

to have protocol-specified blood tests drawn on Tuesday and Thursday rather

than Monday, Wednesday, and Friday, then the investigator must reinforce with

the patient the importance of following the protocol correctly.

Another source of conflict may arise in the interpretation of the causality of

an AE. Investigator and sponsor may disagree over whether a particular AE is

likely to be treatment-related. It is important that investigators not feel coerced

into calling an event “unrelated” if their medical judgement suggests otherwise.

Sometimes in the rush to move to the next dose level, it is tempting to ascribe

events that might otherwise be considered dose-limiting to disease or other fac-

tors. Caution should be exercised in this; it is always better to expand a dose level to be certain that the MTD has not been reached, rather than to escalate to the

next level and have serious or fatal outcomes in patients enrolled at a dose that, in retrospect, exceeded the MTD.



11.8.2 How to build in flexibility

It is useful to build into the design section of the protocol options to use emerging data from the trial to guide intel igent protocol decisions. Table 11.6 includes a few examples: introduction of intermediate dose levels; cautious expansion of

what appears to be the MTD if inter-patient variability in toxicity has been seen.

Other examples include:

1. allowing one “extra” patient to be entered into a cohort to protect against

lost time if a patient cannot complete a long cycle,

2. allowing split dosing of oral medication if PK suggests saturable

absorption,

3. stipulating the minimum percentage of total doses a patient must have

received to be evaluable for dose-escalation decisions, and

4. including in the definition of “DlT” missing a significant proportion of

planned drug due to (even moderate) toxicity.

All of these variations in the plan are permissible without protocol amendment,

provided the protocol design section includes these options. The US Federal

Table 11.6. When the Unexpected Happens

If this happens . . .

Consider doing this:

Although the patient has a grade 3 Expand the dose level.

toxicity (fatigue), it is not clear if

this is due to drug or disease.

Two of six patients have a grade

Investigate if there are other causes for either of the

3 event, which qualifies as DLT,

events. Consider expanding the dose level further,

but they are not the same event,

with appropriate premedication, if applicable, if

(e.g., one is myelosuppression,

none was administered before, to see if this level is

the other is nausea).

truly the MTD.

Alternatively, you may declare that the MTD has

been reached and decrease a dose level.

Preclinical toxicology suggested

All protocol definitions of DlT should include

that myelosuppression will be

a non-specific inclusion of “any other ≥grade 3

dose-limiting, and the DlT defi-

organ toxicity” to cover this eventuality. If your

nition is based on this. However, protocol did not, this type of event should still

another grade 3 organ toxicity

be treated as DlT in terms of decision-making.

has been seen.

Depending on the nature of the unexpected toxic

effect, special monitoring procedures might also

be advised and may need a protocol amendment

(including consent form amendment to advise of

new toxicity and procedures). For example, grade

3 chest pain of uncertain significance might lead

to more frequent follow-up, troponin levels, and

ECGs in new patients.

In a weekly intravenous phase

Patient safety concerns should take precedence over

I study, the protocol calls for

protocol direction: particularly if, as in this case,

holding the dose if DlT criteria

the way the protocol was written did not seem to

are met (grade 4 neutropenia for take this type of problem into account. In weekly

7 days). A patient has grade 3

schedules of myelosuppressive agents, it is often the

neutropenia on day 15: although case that the treatment-day dose has to be reduced

the protocol does not require

or held for degrees of toxicity that are less that

holding the dose, the investiga-

what would be called a DlT. In fact, some would

tor is uncomfortable giving

advise including as one of the definitions of DlT

treatment.

the need to hold or reduce more than 1 or 2 weekly

treatments per cycle because of toxic effects. In any

event, the investigator should hold treatment in

this case, and parties to this protocol should discuss

how to amend the dose-reduction section.

A dose level is found to meet

Treat a new cohort of patients at a dose level

criteria for MTD: two of

intermediate to the two dose levels described.

three patients had DlT.

Protocol design section should be written so as to

The next-lower dose level is

allow this: otherwise an amendment will need to

expanded, and no toxicity more

be made.

than grade 1 is seen.

( continued)

Process, Pitfalls, and logistics of Phase I Trials 305

Table 11.6 (Continued)

A dose level is found to produce

It may be that your drug is affecting different

DlT in two of six patients,

patient risk groups differently. look at the entire

making it the MTD: BUT the

trial database to see if there is an obvious differ-

other four patients at that dose

ence in those that get toxicity versus those that

experienced no more than grade

do not: e.g., prior treatment, performance status,

2 toxicity.

renal or hepatic function. If there is an obvious

cause, consider amending the protocol to continue

escalation in the low-risk group. If no obvious

patient risk group is found, choices are to proceed

to lower dose as per protocol or to cautiously add

one to two more patients to the current dose level

to further assess it, provided protocol language is

permissive enough to allow this.

Regulations, as part of information supplied on InD applications, states that: “In

general, protocols for Phase 1 studies may be less detailed and more flexible than

protocols for Phase 2 and 3 studies” [6] . Although this document is probably

intended for phase I trials of non-cancer medications for healthy-volunteer stud-

ies, it also makes the point that phase I trial design may require language that

permits an appropriate response to unexpected emerging data.



11.8.3 When to stop a study



It is not a problem to stop a study when the primary study endpoint(s) is/are

reached as per protocol design. More problematic is to stop a study for other rea-

sons, unless these are clear and well thought-through. The most common reasons

for stopping a trial prematurely are the following.



11.8.3.1 Encountering Irreversible and Significant Toxicity

Seeing a serious irreversible AE (e.g., cardiomyopathy) in one patient may raise

the question of whether this is truly due to drug effect or unrelated. If the event

was predicted by animal toxicology, then observation of such an event in one

patient should be enough to pause the trial and rethink what to do. If this was

not foreseen from toxicology studies, and if there is another possible explana-

tion for the effect (e.g., serious viral infection), then cautious enrollment of new

patient(s) may be warranted. However, if a second patient experiences the same

adverse effect, the trial must be stopped and the underlying mechanism inves-

tigated. Often this means additional animal testing to see if there is a model for

the toxic effect and, if so, can modifications in how the drug is administered (for

example, slow infusion rather than bolus) modify the effect. If the decision is

3 0 6

P H A S E I C A n C E R C l I n I C A l T R I A l S

made to go back into human trials, a new protocol will need to be written, incor-

porating the relevant toxicology and other information that supports the new

study plan.



11.8.3.2 Failing to Achieve any Biological Effect

and/or Unable to Achieve Minimum Blood Levels

Sometimes doses are escalated past what was thought to be the maximum and

nothing at all is seen in patients, either in terms of toxic effects or in translational laboratory studies. If, in addition, PK data do not show that the drug is achieving

levels that are effective in animal models, there comes a point when continued

study of the drug in that schedule is no longer warranted. Inadequate drug sup-

ply or the physical inability to administer the amount needed for dose escalation

can also play a part in this decision. For some drugs (particularly oral agents),

this situation is sometimes encountered when there is saturable absorption (or

another pharmacological problem) in the drug’s behavior. Although, if written

appropriately, the protocol may allow some changes in drug delivery (e.g., split

dosing) to get around this, strategies like this may not solve the problem, and a

point of futility is reached. If, at the maximal deliverable dose, there are no signs the drug is having a biological effect and it is not achieving critical minimum

blood levels, then the trial should stop. Once again, further preclinical investiga-

tions may be required to see if there is something else that could be done in terms

of formulation, for example, to address this.



11.9 SUMMARY

The background work required to get a completed protocol activated is substan-

tial. Although the setting of this chapter is phase I studies, most of what has been

written applies to all clinical trial protocols. An efficient and wel -oiled “machine”

for trial start-up, along with adequate numbers of wel -qualified personnel, add

substantial quality to the trial conduct and make the entire process much more

efficient.



REFERENCES

1. International Conference on Harmonization Guideline (E6) on Good Clinical

Practice may be found at: http://www.ich.org/products/guidelines/efficacy/arti-

cle/efficacy-guidelines.html (last accessed October 2014).

2. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and account-

ability. N Engl J Med. 2001;345:825–826.

3. De Angelis CD, Drazen JM, Frizelle FA, et al., & International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International

Committee of Medical Journal Editors. CMAJ. 2004;171:606–607.

Process, Pitfalls, and logistics of Phase I Trials 307

4. De Angelis CD, Drazen JM, Frizelle FA, et al., & International Committee

of Medical Journal Editors. Is this clinical trial fully registered? A state-

ment from the International Committee of Medical Journal Editors. CMAJ.

2005;172:1700–1702.

5. Flory J, Emanuel E. Interventions to improve research participants’ under-

standing in informed consent for research: a systematic review. JAMA.

2004;292:1593–1601.

6. US Code of Federal Regulations, Title 21, Vol. 5, Parts 300–299: Part 312: Investigat ional new Drug Application, Subpart B: Section 312.23 (a)(6). Available at: http://

www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.23

(last accessed October 2014).





12

Reporting and Interpreting Results

L E S L E I G H S . A B B O T T , E L I Z A B E T H A . E I S E N H A U E R , A N D L E S L E Y K . S E Y M O U R ■



12.1 BACKGROUND

Phase I trials are the cornerstone of the development of any new cancer thera-

peutic. While is it imperative that design, conduct, and analysis of phase trials

be conducted with appropriate methodology, a critical and sometimes underval-

ued step is the complete and transparent reporting of the results. Although most

of the literature regarding inadequate reporting of clinical trials has focused on

later-stage trials, with the creation of registries and mandatory reporting, phase

I trials may also either not be reported at all (if development stops), or not be

adequately reported [1–4]. Failure to adequately report the key design, conduct,

and results of the phase I trial in a timely manner may negatively affect the further development of that new therapeutic, or other agents in the same class, and result

in failure of the agent and increased risk to patients [5–9].

Almost all early clinical trials conducted or planned in the last decade have

included at least one molecularly targeted agent, used either as a single agent,

or more commonly, in combination with standard therapies, usually cytotoxic

chemotherapy [10]. Increasingly, immunotherapies are entering the clinic in tri-

als that incorporate novel designs and endpoints [11]. Therefore, the need to

adequately report the results is now even more critical as, not only are the designs

more complex, with multiple arms, adaptive model-based designs, randomiza-

tion, dose-expansion cohorts, incorporation of multiple correlative studies and

biomarkers, but also the recommended dose may be based on feasibility, cost, or

a decision that is not toxicity-based (Figure 12.1).

Reporting and Interpreting Results 309

A

B

Phase I: Two novel

agents in combination

and each alone

Phase I: Novel

Eligibility

cytotoxic agent +

conventional

chemotherapy

Randomization

Eligibility

Arm C

Arm B

Non-randomized

Arm A

Novel Agent 1 +

Novel Agent 2

Novel agent given on

Novel Agent 1

Novel Agent 2

No dose escalation

Days 1 and 8, every

Dose escalation

Dose escalation

planned

three weeks

planned

Evaluations on

Evaluations During Protocol (images, bloodwork)

Therapy

Translational Research Samples

Physical exam,

clinical

measurements,

ECG, biochemistry,

hematology, PK, PD

For Dose escalation:

Minimum of 3 patients at the first dose level, until MTD is

reached

Escalation to next dose level: only if none of the first three

patients at the current dose level do not exhibit DLT

Phase II Expansion:

After full review of phase I results

Figure 12.1 Comparison of two possible phase I clinical trials to demonstrate the growth in complexity of trial regimens evolved. DlT: dose-limiting toxicity; MTD: maximum

tolerated dose; PK: pharmacokinetics; PD: pharmacodynamics.

Because targeted agents act by different mechanisms and may lead to distinc-

tive toxicities, and are often administered in a chronic oral-dosing schedule, phase

I designs, endpoints, and conduct have often been modified. Increasingly, doses

for further study (recommended dose [RD]) are not defined based only on tra-

ditional dose-limiting toxicity (DlT) and maximal tolerated doses (MTD). It is

also important to demonstrate that a novel compound has the target effect for

which it was designed [12].

new targeted agents are now being combined with each other, in the hopes

of maximizing anticancer effect by using two or more drugs active on the same

target or on different targets within an aberrant pathway. The selection of agents

3 1 0

P H A S E I C A n C E R C l I n I C A l T R I A l S

to combine, and the design and conduct of early clinical trials of combinations of

molecularly targeted agents, has been largely empirical and based on experience

with cytotoxic agents leading to difficulties with trial design, endpoint selection,

and combination effects of the agents themselves being novel [13].

not only are phase I trials now more complex and more likely to combine

two or more agents, novel designs are being used. Phase 0 or exploratory trials,

are exploratory first-in-human trials, where sub-therapeutic doses of an agent

are administered to a small number of participants to obtain preliminary data

on drug pharmacokinetics (PK) and pharmacodynamics (PD). Phase 0 stud-

ies are conducted prior to traditional phase I dose-escalation safety and toler-

ance studies and involve very limited human exposure, with no therapeutic or

diagnostic intent. The purpose of the phase 0 study is to assist in the go/no-go

decision-making process of a drug’s fate earlier in the development process, using

relevant human models instead of relying on sometimes inconsistent animal data

to confirm endpoints such as mechanism of action, pharmacology, bioavailabil-

ity, PD, and metabolic microdose assessments. A small number of patients are

exposed (10 or fewer, usually) to a limited duration (generally seven days or less)

and dose of a novel agent. Such studies can be conducted early in the develop-

ment process to be more of a discovery tool to assist in efficient development and

understanding. Information from sub-therapeutic dosing has helped us move

more quickly into combination studies, and should be considered [7] .

Most modern reports now include such key elements as the rationale for the

trial, justification for starting doses and escalation schemes, what occurred during

the course of the study, including key safety information, PK, signs of antitumor

activity, and, hopefully, recommendations regarding future trials of the agent or

drug combination. As described in other chapters and by published recommen-

dations, prior to the implementation of a phase I trial, preclinical data should

ideally establish the molecular target of the novel drug, the effect of the drug on

malignant (and normal) cel s, and the relationship between dose/schedule of the

drug and antitumor effects, target effects, PK measures, and toxicology [12].

Unfortunately, even when the results of phase I trials are published, many stil

do not report fully on preclinical data that may be pertinent; complete adverse

event data, including, if any, those from later cycles; dose intensity; and dosing

information, as well as results of planned correlative studies and biomarkers.

Frequently studies did not report the recommended dose (RD) or the planned

dose-escalation scheme, putting the design of the study into question [14–18].

Parulekar and Eisenhauer also reported that most publications did not indi-

cate how the starting dose was justified or describe the planned dose-escalation

scheme [19].

This chapter is intended to outline how phase I results should be represented,

and incorporates published recommendations, including the Consolidated

Reporting and Interpreting Results 311

Standards of Reporting Trials (COnSORT) statement, which applies to

randomized trials but may also be applicable in early-phase trials [20]. The

Standards for Reporting of Diagnostic Accuracy (STARD) are particularly rel-

evant to biomarker discovery research [21]. The REporting recommendations

for tumour MARKer prognostic studies (REMARK) guidelines, which were

a major recommendation of the national Cancer Institute and the European

Organization for Research and Treatment of Cancer (nCI-EORTC) presented

at the First International Meeting on Cancer Diagnostic (From Discovery to

Clinical Practice: Diagnostic Innovation, Implementation and Evaluation) con-

ducted in nyborg Denmark, July 2000 [22]. REMARK presents recommenda-

tions for reporting studies on tumor markers. The goal of all these guidelines is to

encourage transparent and complete reporting so that the relevant information

will be available to others to help them to judge the usefulness of the data and

understand the context in which the conclusion apply. In the phase I context, the

data may also inform future studies.



12.2 CONTENTS OF PHASE I TRIAL REPORTS



The following discussion outlines the common sections, including content rec-

ommendations, for authors to use when creating a report or manuscript describ-

ing the results of a phase I trial. Other guidelines for reporting include: Food

and Drug Administration (FDA) mandated reporting: participant flow, baseline

characteristics, outcome measures and statistical analysis, and adverse events;

and requirements for reporting to clinical trial registries such as clinicaltrials.

gov. Further details can be found under “How to Submit Your Results, Scientific

Information” (https://clinicaltrials.gov/ct2/manage-recs/how-report). An example flow diagram representing the enrollment of patients and their loss to a

study based on the COnSORT guidelines is shown in Figure 12.2.



12.2.1 Introduction; disease and drug information

The introductory section of a report should provide a succinct summary describ-

ing the background of the drug and disease, as well as the hypothesis to be tested.

An important focus should be the justification of why the target is relevant, and

why the agent was selected for testing in humans, and it should include relevant

supporting preclinical data as well as references. A description of the hypoth-

esized target, describing what steps were taken to confirm proof-of-target and

proof-of-principle, should be summarized. In addition, biomarkers that have been

tested and undergone preliminary validation and are to be included in the clinical

3 1 2

P H A S E I C A n C E R C l I n I C A l T R I A l S

CONSORT 2010 Flow Diagram

Enrollment

Assessed for eligibility (n= )

Excluded (n= )

Not meeting inclusion criteria (n= )

Declined to participate (n= )

Others reasons (n= )

Randomized (n= )

Allocation

Allocated to intervention (n= )

Allocated to intervention (n= )

Received allocated intervention (n= )

Received allocated intervention (n= )

Did not receive allocated intervention (give

Did not receive allocated intervention (give

reasons) (n= )

reasons) (n= )

Follow-Up

Lost to follow-up (give reasons) (n= )

Lost to follow-up (give reasons) (n= )

Discontinued intervention (give reasons) (n= )

Discontinued intervention (give reasons) (n= )

Analysis

Analysed (n= )

Analysed (n= )

Excluded from analysis (give reasons) (n= )

Excluded from analysis (give reasons) (n= )

Figure 12.2 COnSORT Statement 2010: Diagram for patient tracking in early-phase

clinical trials.

Reprinted with permission from COnSORT: Flow Diagram 2010. Available at http://www.

consort-statement.org/consort-statement/flow-diagram0/. Published 2010. Accessibility verified October 30, 2013.

trial should be briefly described and their inclusion justified. The patient popula-

tion must be justified, including a brief description of standard treatments and

what setting is to be tested. If the patient selection is planned (e.g., based on a biomarker), then a brief summary and justification should be provided. The structure

of the agent must be included or referenced. Safety data pertinent to expected tox-

icities and the dose should be summarized, as well as preclinical efficacy data that

support the design of the study. Reference should be made to any available data

on the schedule and route of administration, along with details of the planned

schedule in the trial. Comparative data available for other agents of similar struc-

ture or target already in clinical use or development should also be included.

For phase I trials of combination agents, begin with describing the disease(s)

for which the combination is intended and the justification for improving on

Reporting and Interpreting Results 313

currently available therapy. Each drug used in the combination should be sum-

marized, including the safety and activity of each drug alone in the disease being

tested. The hypothesis for using the combination should be clearly described,

with available preclinical data provided or referenced. A robust justifiable

hypothesis is required, one that is tested and proven in validated non-clinical

models that demonstrate clear synergy or synthetic lethality and also demon-

strate effects in multiple different models. Ideally, clear pharmacodynamic mark-

ers should be present and tested on clinical models and be benchmarked to

“active” and “inactive” levels to help with go/no-go decision-making in the clinic

[13]. A summary of combination toxicology should be included, or if not avail-

able, an estimation of what additive or synergistic toxicities might be expected.

For combination studies, future plans for the combination should be described

to ensure that there is a clear development plan and resources are used wisely [7] .

Finally, a brief justification of the design should be included, and whether it is to be rule- or model-based.

The introduction should conclude with a statement to indicate the primary

and secondary goals of the study and to justify those objectives. There should

be clear objectives that will prove or disprove the hypothesis being tested. The

goals of a typical phase I clinical trial of single agent and combination agents are

to determine the RD for further testing. For cytotoxic agents, this optimal dose is

typically based upon the highest dose level that can be achieved without encoun-

tering unacceptable toxicity in a prescribed number of patients. For molecularly

targeted agents, the dose that results in a relevant level of target modulation and

clinical activity may differ greatly from the MTD, complicating the design of

studies with regard to determination of the optimal dose for future clinical trials

[7,24]. The go/no-go criteria in these objectives must be met before researchers

test the agents or combinations in later phase studies [13].



12.2.2 Methods



The methods section is usually divided into subsections for clarity.



12.2.2.1 Patient Entry Criteria

This section should include relevant requirements for ethical review (e.g., by the research ethics board/committee) as well as for informed consent. Relevant

inclusion and exclusion criteria should be clearly summarized so that the

reader clearly understands the patient population that was tested. If patients

were selected based on the presence of a biomarker, then that should be clearly

described, including the method used to test the biomarker, and the cutoff used

for entry. For phase I studies, it is generally recommended that patients not be

3 1 4

P H A S E I C A n C E R C l I n I C A l T R I A l S

selected based on biomarkers unless there is a reasonable hypothesis that would

suggest that only a subset of patients would benefit [13]. If an expansion cohort

is planned in patients with specific biomarkers or tumor types, these must be

described here.



12.2.2.2 Starting Dose and Schedule

Detail the starting dose and justify why this dose was chosen, using preclinical

animal toxicology data for first-in-human studies or clinical data for later phase

I trials or combination studies. The schedule should always be justified (e.g., daily or weekly dosing), as well as any planned changes in the event of toxicity, or lack

thereof; or unexpected pharmacokinetics.

For combination-agent trials, the optimal dose for each drug in a combination

may not always be the same for all tumor types, patients, or molecular pheno-

types [13,25]. The schedule of the agents used in combination should be justi-

fied, including sequences used for ease of PK assays.



12.2.2.3 Design

The method of dose escalation, the number of patients per dose level, and the

planned dose-escalation steps/levels should all be included in this section. It is

important that the original plans be described, rather than what was actually done

during the trial, as that will be reported in the Results section. A description of

the rules for expansion, escalation, or reduction of dose levels and the basis of the decision (toxic effects or other observations) are also part of this section. Indicate the rules for terminating escalation and declaring the RD, along with definitions

of terms used such as MTD, maximum administered dose (MAD), and DlT.

The Task Force for the Methodology for the Development of Innovative Cancer

Therapies (MDICT) noted that MTD generally refers to “recommended dose”

in the United States, while in Europe and other jurisdictions it often refers to the

dose level above the RD; thus, it is imperative to be clear about this definition in the report [12]. It is critical that the DlT criteria are clearly described, including any exceptions (such as alopecia, or inadequately managed nausea), and what

period of time was used to assess them (e.g., cycle one only? Were DlTs in cycle

2 onwards further used to inform decisions or evaluate RD?). Any intra-patient

dose escalation must be clearly defined, if planned, and it must also be defined

whether or not data from patients undergoing intra-patient escalation will be

used to guide decisions about further dose-level escalation or the selection of a

recommended phase II dose [7] .

For combinations of agents, an early clinical study is an appropriate setting to

explore dose and schedule by including a randomized component in the study

or by considering a Bayesian adaptive design, which allows learning from emerg-

ing data so that toxic or ineffective doses or schedules can be closed to further

Reporting and Interpreting Results 315

accrual. If the trial design is flexible rather than being based on a strict progres-

sion from phase I to II to III, then this should be described in this section [13].

If an expansion at the RD, or phase II component, is planned, this should be

described in this section, justifying the number of patients, as well as describ-

ing any additional selection criteria that might be considered, such as selecting

patients with tumor types where clinical activity was seen in earlier patients. If

all patients treated at the RD are to be included in that expansion (rather than

only patients included after the decision has been taken), that should also be

described.

If there is a change in the design, dose levels, or escalation approach at any time

in the study, this should be briefly detailed here along with the new design. Plans

for replacing patients who were not evaluable should be prospectively included

in the protocol and described in this section of the report.



12.2.2.4 Treatment

The drug administration plan is described in this section. This includes the rec-

ommended or required pre-medication and supportive post-medication, drug

route, and schedule of administration, as well as the dose-adjustment criteria for

adverse effects. Also include the planned maximum treatment duration and indi-

cations for therapy discontinuation, which should include: intercurrent illness of

the patient affecting clinical status to a significant degree, unacceptable toxicity

(specific to agents/combinations involved), objective tumor progression or dis-

ease recurrence, or a request by the patient.



12.2.2.5 Follow-up and Investigations

The timing/intervals and type of standard investigations to be done before,

during, and after therapy completion should be outlined in this section. This

typically includes laboratory and imaging investigations as well as correlative

studies. Efforts should be made to maintain the investigation schedule and con-

tinue follow-up, even if patients discontinue protocol treatment prematurely

and/or are no longer attend the participating institution, and this should be

documented here.



12.2.2.6 Criteria for Assessing the Study Endpoint

Description of and reference to the criteria used for assessment of toxic effects,

objective tumor response, and any other study endpoints should be included

here. Laboratory, imaging, or PD studies are described in subsequent sections.

Traditional phase I trial design assumes toxicity and clinical benefit will

increase as the dose of an agent increases, so toxicity has long been the usual

primary endpoint, used to inform RD, of phase I trials. For cytotoxic therapeutic

3 1 6

P H A S E I C A n C E R C l I n I C A l T R I A l S

agents, this assumption usually holds true, and it may hold true even with tar-

geted agents. However, if toxicity is not mechanism-based, it may not be as use-

ful to guide dose selection to find the most biologically active dose level [12],

although toxicity is often used, together with PK, to establish the dosing range.

Targeted agents may show a plateau on the dose-efficacy curve, meaning higher

doses will not improve clinical benefit. Because of this, alternate endpoints have

been used in many phase I trials, including measuring inhibition of a target;

plasma drug levels that are estimated to be likely to be biologically relevant (PK);

surrogate markers of biological activity in non-tumoral tissues [26]; and novel

or functional imaging. If PD and PK are used as the primary means of selecting

the RD, then ideally there should be a clear relationship with antitumor efficacy.

Whatever the primary endpoint selected, PKs and toxicity evaluation are stan-

dard and/or mandatory endpoints for first-in-human studies [7] .

Whatever endpoints are selected and justified, this section should define

clearly what reference criteria were planned and used for the assessment of toxic

effects, objective tumor response, and all other study endpoints.

The national Cancer Institute (nCI) Common Toxicity Criteria for Adverse

Events (CTCAE) [27] were initially developed for use in adverse drug experi-

ence reporting, study adverse event summaries, and investigational new drug

(InD) reports to the FDA and publications. The CTCAE (now in version 4.0)

has been used for collecting treatment-related adverse event data when study-

ing new cancer therapies, treatment modalities, and supportive measures.

The CTCAE can be mapped back to the Medical Dictionary for Regulatory

Activities (MedDRA) [28], which is a dictionary of highly standardized

medical terminology that facilitates sharing of regulatory information inter-

nationally for medical products used by humans. It can also be appropriate to

develop trial-specific criteria for agents with unusual toxicity, such as BKM120,

a small-molecule inhibitor of PI3 kinase, which results in mood alterations,

including depression [29].

All serious adverse events (SAE) reported in the trial should also be briefly

summarized. The total number of patients with such events should be reported,

along with description of their disease, where they were in the treatment cycle of

the agent, and a description of the event itself. This should include the grade of

the event as per the reporting guidelines being used (e.g., CTCAE), the believed

relationship to the agent (possible, unlikely, probable, related, unrelated), out-

come of this event for the patient, and outcome for the therapy of the event: dis-

continuation, continuation, or alterations to the therapeutic regimen for the

patient.

Although efficacy has usually been an exploratory endpoint of phase I trial,

for targeted agents and highly selected patient populations, it may be critical

to establish proof-of-principle and inform development decisions. For solid

Reporting and Interpreting Results 317

tumors, the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria

are typically used to describing response to treatment [30], although in the phase

I setting other criteria may be incorporated. RECIST 1.1 may underestimate evi-

dence of clinical activity that may be of interest in an early-phase study, as it is

categorical—as tumor shrinkage is actually a continuous variable [31]. Further

tumor necrosis may also occur without a marked decrease in tumor size: the

receptor tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, sorafenib,

and axitinib are known to cause early and extensive necrosis [31]. Functional

imaging, while exploratory and not yet validated, may provide additional useful

information that may guide decisions regarding selection of dose and schedule.

In gastrointestinal stromal cell tumors (GISTs) [32], investigators have devel-

oped new response criteria to evaluate imatinib treatment in patients with GIST.

These criteria include change in tumor attenuation on computed tomography

(CT), which reflects tumor density. The Choi criteria appear to correlate bet-

ter with disease-specific survival in imatinib-treated GIST patients than RECIST

does [32].

When evaluating the response of immune therapy activity in solid tumors,

recent guidelines published by Wolchok et al. describe the immune-related

response criteria (irHC) [11]. Because immunotherapeutic agents produce

antitumor effects through the induction of cancer-specific immune responses

or through modification of native immune processes, the outcomes are beyond

those of cytotoxic agents, leading to the need for specific encompassing

assessment criteria. The irHC was developed through phase II data with ipi-

limumab, an antibody that blocks cytotoxic T-lymphocyte-associated (CTl)

antigen-4, and was evaluated in the treatment of advanced melanoma. These

response definitions are listed in Table 12.1. Similarly, assessment of response

for leukemia and lymphomas or so-called liquid tumors also differs from

RECIST 1.1 criteria. The International Workshop on Chronic lymphocytic

leukemia (Cll) of the nCI—Working Group, updated their guidelines for

the diagnosis and treatment of Cll in 2008. Specific responses to treatment

guidelines were included in this meeting discussion and have been published

[33] and include multiple criteria that are needed for response definitions

(Table 12.2).

For malignant pleural mesothelioma, the growth pattern makes use of RECIST

response criteria difficult. RECIST specifies that partial response (PR) is defined

as a 30% decrease in the sum of the longest diameter for all target lesions; how-

ever, it is difficult to select measurement sites in mesothelioma with potential

for inter-investigator variation. Bryne and nowak reported on the development

and validation of modified RECIST [34] criteria adapted to the growth pattern

of malignant pleural mesotheliomas where tumor thickness perpendicular to

the chest wall or mediastinum was measured in two positions at three separate

3 1 8

P H A S E I C A n C E R C l I n I C A l T R I A l S

Table 12.1. Immune-related Response Criteria: Response Categories

By irRC

Description of response

Confirmation by

irCR

Complete disappearance of all Repeat, consecutive assess-

lesions (whether measurable

ment no less than 4

or not), and no new lesions

weeks from the date first

documented

irPR

Decrease in tumor burden

Consecutive assessment

> 50% relative to baseline

at least 4 weeks after first

documentation

irSD

not meeting criteria for irCR

or irPR, in absence of irPD

irPD

Increase in tumor burden

Confirmation by a repeat,

> 25% relative to nadir (mini-

consecutive assessment no

mum recorded tumor burden)

less than 4 weeks from the

date first documented

new measureable

Incorporated into tumor

lesions (i.e., > 5 ×

burden

5 mm)

new, non-measurable Do not define progression

lesions (i.e.,

(but preclude irCR)

<5 × 5 mm)

non-index lesions

Contribute to defining irCR

abbreviations: irCR: immune-related complete remission; irPR: immune-related

partial remission; irSD: immune-related stable disease; irPD: immune-related progres-

sive disease.

Reprinted from Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of

immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420, with permission from AACR Publications.

levels on thoracic CT scans. The sum of the six measurements defined a pleu-

ral unidimensional measure. “Partial response” was defined as a reduction of at

least 30% on two occasions four weeks apart; progressive disease was an increase

of 20% over the nadir measurement. Response according to these criteria pre-

dicted a superior survival (15.1 versus 8.9 months; P = 0.03), and these modified RECIST criteria are now used in subsequent clinical trials [34].

The Prostate-Specific Antigen (PSA) Working Group has proposed a

hybrid-type model for measurement of response to therapy in patients with

prostate cancer. RECIST 1.1 works for the solid lesions identified on imaging,

but PSA levels are not taken into account with RECIST [35]. Thus, in the latest

nCIC-CTG trials for prostate cancer for example, response sections are used

to define objective response as well as PSA response criteria. It is important to

clearly define the response criteria chosen in this section.

Table 12.2. Response Definition After Treatment for Patients with Chronic lymphocytic leukemia

Parameter

CR*

PR*

PD*

Group A

lymphadenopathy†

none > 1.5 cm

Decrease > 50%

Increase > 50%

Hepatomegaly

none

Decrease > 50%

Increase > 50%

Splenomegaly

none

Decrease > 50%

Increase > 50%

Blood lymphocytes

< 4000/µl

Decrease > 50% from Increase > 50%

baseline

over baseline

Marrow

normocellular, <30% 50% reduction in

lymphocytes, no

marrow infiltrate, or

B-lymphoid nodules. B-lymphoid nodules

Hypocellular marrow

defines Cri (5.1.6)

Group B

Platelet count

>100 000/µl

> 100 000/µl or

Decrease > 50%

increase > 50% over from baseline

baseline

secondary to

Cll

Hemoglobin

>11.0 g/dl

> 11g/dl or increase Decrease of >2

> 50% over baseline g/dl from

baseline sec-

ondary to Cll

neutrophils‡

>1500/µl

> 1500/µl or >50%

improvement over

baseline

abbreviations: CR: complete remission; PR: partial remission; PD: progressive dis-

ease, SD: stable disease, Cll: chronic lymphocytic leukemia.

Group A criteria define the tumor load, group B criteria define the function of the hematopoietic system (or marrow).

*CR (complete remission): all of the criteria have to be met, and patients have to lack disease-related constitutional symptoms; PR: at least two of the criteria of group A plus one of the criteria of group B have to be met; SD is absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the above criteria of group A or group G has to be met.

†Sum of products of multiple lymph nodes (as evaluated by CT scans in clinical trials, or by physical examination in general practice).

‡These parameters are irrelevant for some response categories.

Reprinted from Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop

on Chronic lymphocytic leukemia updating the national Cancer Institute—Working

Group 1996 Guidelines. Blood. 2008;111(12):5446–5456, with permission from the American Society of Hematology.

3 2 0

P H A S E I C A n C E R C l I n I C A l T R I A l S



12.2.2.7 Pharmacokinetics

This section should include the blood sampling plan, as well as justification for

the timing of the sampling, methods for measurement, and analysis for PK.

Often an appendix is useful in this section to detail analytic methods, if there are

no previously published references.

Although PK evaluation is mandatory for early phase I studies, it is not always

required for combination studies. In combination studies, PK evaluation should

always be performed when interactions are anticipated or where overlapping tox-

icity is likely to guide the optimal dose of the two agents. In other situations, limited or no PK evaluations may be appropriate. The FDA published “Guidance for

Industry, Population Pharmacokinetics” [36] in 1999 to aid with reporting PK,

and the European Medicines Agency published its “Guidelines on Reporting the

Results of Population Pharmacokinetic Analyses” [37] in 2007.



12.2.2.8 Biomarkers

The three main types of biomarkers are type 0 biomarkers, which correlate with

the emergence or development of a disease; type 1 biomarkers, which reflect the

action of a therapeutic intervention; and type 2 biomarkers, which may be used

as surrogate clinical endpoints. The last aims to predict the outcome (e.g., com-

plications and clinical response) of a patient exhibiting disease symptoms [21].

PD biomarkers are of particular interest, as these markers have the potential to

give proof of drug-target inhibition and support further studies of the agent with

the goal of providing evidence that the agent reaches or modulates the putative

target [21]. While PD evaluation to confirm the hypothesis should always be for-

mally considered, researchers might consider performing these only in a subset

of patients closest to the RD, rather than during dose escalation [13].

Biomarkers include qualitative and semi-quantitative assays of tumors (indi-

rect assays such as apoptosis or reduction in blood flow) or surrogate tissues

such as peripheral-blood mononuclear cel s (PBMCs). Assays may be based on

various methods, including imaging, immunohistochemistry or fluorescence in

situ hybridization (FISH), circulating tumor cel s (CTC), or circulating DnA

(cDnA) [38,39].

The development of an appropriate, accurate, and standardized assays is

critical [40]. Predictive biomarkers/classifiers should preferably be explored in

phase I studies, rather than used to select patients [13], unless there is a strong

hypothesis.

The degree of scientific and analytical validation of a biomarker and assay

depends on whether the biomarkers are exploratory or are to be used to make

decisions within the trial. If a biomarker has an integral role to guide the

dose-escalation decisions for subsequent patients in a phase I trial, key challenges

are determining the magnitude of biomarker effect related to drug; detecting

Reporting and Interpreting Results 321

the effect within patients or samples independently of the variability due to

specimen or assay performance; and establishing the methodology for complet-

ing the assay within a short turnaround time. In addition, Clinical laboratory

Improvement Amendment (ClIA) [41] regulations imply that if the test results

are used for medical decisions for the patient who has the test, the test should be

done in a ClIA facility. The rule for deciding whether to dose escalate, expand,

or de-escalate the trial design will reflect the specifics of the agent tested, the biomarker characteristics, and whether toxicity or other parameters will also be used

to guide the decisions. When the biomarker levels are approximately normally

distributed, the number of patients will determine the precision with which the

true standard deviation can be estimated [42].

Biomarkers have the potential to benefit clinical development assisting both

in dose determination as well as identification of patients likely to benefit or be at greater risk of toxicity. However, practically speaking, their success remains limited in early clinical drug development. In 2010, the Biomarker Task Force of the

nCI Investigational Drug Steering Committee (IDSC) published guidelines for

the development and incorporation of biomarker studies in early clinical trials of

novel agents [42]. These recommendations provide a useful checklist, not only for

the trial designs, but also for the reporting of biomarkers included in phase I trials.

Recommendations to the investigator include ensuring a hypothesis and rationale

for the biomarker are clearly stated as well as a description of the impact of the

biomarker on the therapeutic agent development. In addition, a description of

the assay’s method of validation, the investigators’ experience with the proposed

assays, and data supporting the fit of a biomarker for the particular study should be included, along with justification for the number of patients and specimens, with

references to studies that show feasibility and interpretable, meaningful results.

Given that biomarker studies often require fresh sampling from the patient, with

varying degrees of risk to the patient, consideration of feasibility, patient eligibility in the population in question, the amount of specimen needed, central and laboratory processing, and confidentiality for patients must also be described [42].

Good reporting practice should provide enough information to allow the

reproduction of experimental findings and the reconstruction of quantitative

prediction models [21].



12.2.2.9 Statistical Analysis

Because phase I trials are non-randomized, generally no direct comparisons

between cohorts are performed. In certain instances, more formal compari-

sons of measurements at different dose levels may be required. These compari-

sons and the tests used for them are often best summarized in a subsection of the

Methods section. All tests should be described upfront in the protocol. It is not

recommended to perform post-hoc statistical testing. Clearly, if a model-based

3 2 2

P H A S E I C A n C E R C l I n I C A l T R I A l S

design has been used [43,44] or the trial is randomized, then complete details are

required, including the statistical methodology.

All patients should be accounted for in the report, and if certain patients are to

be excluded (e.g., patients who did not receive a pre-specified number of doses

of drug for reasons other than toxicity), this should be appropriately justified and

prospectively described.



12.2.2.10 Quality Assurance

The key monitoring and auditing plans should be briefly described, as well as

whether any external review was planned, such as an external imaging review.



12.2.3 Results



Key trial results are described, using text, tables, figures, and diagrams to display data. All tables, figures, and diagrams should be clearly described. The following

are standard Results subsections.



12.2.3.1 Patient Entry

Patient characteristics can be easily represented in a table: see example Table 12.3.

Descriptions should include the dates when the trial opened and closed, the

number of centers that participated, and the total number of patients enrolled.

All patients should be accounted for. Patients who were ineligible should also

be indicated, along with their reasons for ineligibility and whether they received

any study therapy. The number of patients who were evaluable for toxicity and

response or other secondary endpoints should also be included. In general, at a

minimum, all treated patients should be included in the reporting of phase I tri-

als, especially for safety reports.



12.2.3.2 Drug Administration and Dose Levels

Drug administration by dose level is best described by a table that details the

total number of patients treated, the total number of cycles given for each dose

level, and the number of incomplete cycles (Table 12.4). Also in this section, a

brief description of what happened in dose escalation should be included; e.g.,

if DlT was seen, at which dose level, and details on the creation of intermediate

dose levels.

Dose holds, reductions, and delays, and permanent discontinuation of drug

should be summarized, with reasons for each. In addition, some estimation of

dose intensity should be summarized; for example, how many patients were able

to receive the planned dose intensity (Table 12.5).

Reporting and Interpreting Results 323

Table 12.3. Patient Characteristics: Sample

No. Patients

number of Patients

Entered

Eligible

Evaluable for toxicity

Evaluable for response

Evaluable for PD

Endpoint

Etc.

Median age (range)

(years)

Performance status (ECOG)

012

Prior chemotherapy regimens

0123Etc.

Prior therapy

(specific agent as

appropriate)

Prior radiation

Primary tumor site

lung

Colon

Etc.

Sites of disease

liver

lung

Etc.

Measurable disease

Yes

no

abbreviation: ECOG, Eastern Cooperative Oncology Group.

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.



12.2.3.3 Adverse Effects

The estimation of whether adverse events (AEs) are causally related to a drug

is often difficult to ascertain, especially for symptoms such as fatigue, and also

because the toxicity profile of a drug is not known for an agent entering clini-

cal testing. While some toxicities are easy to assign causality to (such as rash or

diarrhea that resolve on de-challenge or dose reduction), others may be unusual,

such as thromboembolism or psychiatric disorders. Because of this, all AEs are

usually reported rather than only those considered potentially drug-related. It is

also important to present the AE data in two ways—including the data/cycles

upon which decisions were made, so that the decisions are easily understood and

justified, but also including all available AE data [24].

3 2 4

P H A S E I C A n C E R C l I n I C A l T R I A l S

Table 12.4. Dose levels and Drug Administration: Sample

Dose

Actual dose No. patients

No.

No. cycles No. patients No. cycles

Level

(mg/m2)

started at

cycles

completed escalated to at esca-

Days 1, 8, 15

that dose

started

that dose lated dose

1

100

1

3

2

–

–

2

200

3

8

8

1

2

3

300

8

18

15

1

1

4

400

6

15

13

2

2

Total

18

44

38

4

5

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.

Table 12.5. nCIC-CTG InD.181: Phase I study of AT9283 Given as a

Weekly 24-hour Infusion in Advanced Malignancies. Dose levels and

Dose-limiting Toxicities in Cycle 1.

Dose level

No. of

No. of patients with

DLT

(mg/m2/day) cycles

DLT/Total no. of patients

1.5

5

0/3

–

3.0

8

0/3

–

4.5

7

0/3

–

9.0

5

0/3

–

18

5

0/3

–

24

9

0/4

–

36

22

0/3

–

40

14

0/7

–

47

14

2/6

1 (febrile neutropenia), 1

(grade 3 wound infection)

Abbreviations: no.: number; DlT: dose-limiting toxicity; nCIC-CTG InD.181,

nCIC Clinical Trials Group InD.181.

Reprinted from Dent SF, Glemon KA, Chi Kn, et al. nCIC-CTG InD.181: Phase

I study of AT9283 given as a weekly 24-hour infusion in advanced malignancies [pub-

lished on-line ahead of print]. Invest New Drugs. 2013, with permission from Springer.

Simple tables of AEs display the worst grade by dose level, which allows the

reader to understand whether a dose relationship was seen. Some variations in

the table include columns for each grade, while some only include a column

for “any grade” and separate columns for grades 3 and 4. Most often, hema-

tological and non-hematological effects are reported in separate tables (see

Tables 12.6–12.9 for examples). Tables may also report effects by cycle, which

may aid interpretation if intra-patient dose escalation was common. To explore

evidence of cumulative toxicity, the worst cycle toxicity may be compared with

the first cycle. In some instances, figures may be useful to demonstrate specific

Table 12.6. non-hematological Adverse Effects: Worst by Patient by Assigned Dose level.* Sample Dose level

100

200

300

400

No. Patients

1

3

8

6

Category

Adverse event term

Any Grade 3 Grade 4 Any Grade 3 Grade 4 Any Grade 3 Grade 4 Any Grade 3 Grade 4

Gastrointestinal

nausea

1

2

5

5

2

Vomiting

1

3

1

4

1

1

Diarrhea

1

1

3

1

5

2

Constitutional

Fatigue

1

2

5

6

2

neurology

neuropathy—sensory

2

Etc.

*Indicate here if any of the grade 3/4 events were seen in patient when they were receiving an escalated dose: i.e., at one level higher than assigned and found in the table. As a way of avoiding this confusion, sometimes patients at escalated levels do not have the events “counted” if seen at the escalated level.

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.

Table 12.7. non-hematological Adverse Effects: Worst by Cycle. Sample Dose level

100

200

300

400

No. Cycles*

3

10

19

17

Category

Adverse event term

Any Grade 3 Grade 4 Any Grade 3 Grade 4 Any Grade 3 Grade 4 Any Grade 3 Grade 4

Gastrointestinal nausea

1

5

12

14

4

Vomiting

2

4

1

7

1

1

Diarrhea

1

1

4

1

8

2

Constitutional

Fatigue

2

4

9

10

3

neurology

neuropathy—sensory

2

Etc.

*This includes cycles for patients escalated to this level.

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.

Table 12.8. Hematological Adverse Effects: Worst by Patient by Dose level (Described by Grade) Sample

Dose

No. Patients Grade

0

1

2

3

4

Level

Evaluable*

100

Granulocytes

1

1

Platelets

1

1

Hemoglobin

1

1

200

Granulocytes

3

1

2

Platelets

3

3

Hemoglobin

3

1

1

1

300

Granulocytes

8

1

2

3

3

Platelets

8

4

2

2

Hemoglobin

8

1

2

3

1

400

Granulocytes

6

1

1

3

1

Platelets

6

1

2

3

Hemoglobin

6

1

4

1

*To be counted as “evaluable,” a patient must have had a baseline value and at least one follow-up determination while on study.

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.

Table 12.9. Hematological Adverse Effects: Worst by Cycle by

Dose level (Described by Grade). Sample

Dose Level

No. Cycles Grade

0

1

2

3 4

Evaluable*

100

Granulocytes

3

1

2

Platelets

3

3

Hemoglobin

3

1

2

200

Granulocytes

9

6

3

Platelets

9

9

Hemoglobin

9

4

4

1

300

Granulocytes

18

6

4

5

3

Platelets

18

8

6

4

Hemoglobin

18

2

6

8

2

400

Granulocytes

17

2

2

5

7 1

Platelets

17

5

8

4

Hemoglobin

17

2

5

8

2

*To be counted as “evaluable,” a cycle must have had at least one follow-up deter-

mination between days 8 and 22.

Reprinted from Eisenhauer EA. Reporting and interpreting results. In: Phase

I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275, with permission from Oxford University Press.

3 2 8

P H A S E I C A n C E R C l I n I C A l T R I A l S

12

Vomiting

10

Headache

Diarrhea

8

Absolute

number of

patients with

6

Adverse Event

4

2

0

1

2

3

4

CTCAE4 Adverse Event Reaction Grade

Figure 12.3 Example of bar-style graph to represent AEs in one cycle of therapy.

information (Figure 12.3). In the text, this section should describe the main

findings shown in the tables, including the most common and the most serious

effects, especially DlTs. If toxicity-modifying therapies were used, they should

be discussed here with a description of their impact. Serious and severe events

that are life-threatening deserve special attention.

The full reporting of all adverse event data is critical for the interpretation of

the results and informing the design of later studies with the same, or similar,

agents. Traditional DlT classification is not always appropriate for non-cytotoxic

chemotherapy because of prolonged administration with more chronic toxicities,

which do not wax and wane. The DlT and Toxicity Assessment Recommendation

Group for Early Trials of Targeted therapies (DlT-TARGETT) presented

data from 27 centrally reviewed phase I trials evaluating non-cytotoxic agents

as monotherapy in 1,126 patients. The overall conclusions recommend that

selected lower-grade toxicities need to be taken into account to lead to a signifi-

cant decrease in recommended dose intensity (RDI). Also, the RD for further

studies should take into account toxicities observed after the first cycle and pref-

erably be based on achieving >75% RDI [24].



12.2.3.4 Pharmacokinetics

Tables that show mean (+/– standard deviation [SD]) PK parameters by dose

level and overall are ideal for facilitating the reader’s understanding. General

trends can be demonstrated with a representative patient plasma × time curve. If

the PK observations have high variability between patients who were treated at the

same dose level, a plot of several patients can be helpful. Figure 12.4 demonstrates

Reporting and Interpreting Results 329

1500

→

→

→

→

1000

→

(ng/ml)

maxC 500

→

0

0.45 .9

1.8

3.6

4.5

5.4

6.3

Dose per cycle (mg/m2)

Figure 12.4 Phase I trial of OSI-211. C vs dose (dose 1 from cycle 1). ⧠, heavily

max

pretreated; *, minimally pretreated; → patient with DlT.

Reprinted from Gelmon K, Hirte H, Fisher B, et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 2004;22(3):263–275.

substantial inter-patient variability in C and the area under the curve (AUC)

max

from a liposomal encapsulated topoisomerase 1 inhibitor. This figure also indi-

cates the patients who had dose-limiting effects, thus demonstrating no obvious

predictable level for this. Other elements to include are information on whether

the PK follows a linear or non-linear pattern related to dose and factors that seem

to impact on PK observations (e.g., patients with low creatinine having lower

AUC). These observations are not conclusive, but they help with directing future

studies and should be further elaborated upon in the discussion section.

All correlations between PK measures and PD effects, including adverse events

or other correlative studies, are best mentioned in this section, and are often

best represented by a figure. This includes more examples of the relationship

between C , AUC, or steady-state levels in individual patients, and the occur-

max

rence of DlT, grades 3 or 4 events, changes in surrogate markers, or tumor tissue

effects. Figure 12.5 demonstrates how both dose-PD and PK-PD effects can be

effectively represented in a phase I study report of farnesyltransferase inhibitor

BMS-214662 [48]. The relationship between farnesyltransferase expression over

time to dose in PBMCs in two schedules (panels A and B) and the relationship

in each of those schedules between plasma levels in selected patients (Panels C

and D) is demonstrated.

Other considerations with PK reporting include indicating whether the trial

showed that the drug achieved minimum blood levels or some other critical

3 3 0

P H A S E I C A n C E R C l I n I C A l T R I A l S

Figure 12.5 (A) Mean inhibition of PBMCs farnesyltransferase (FT) activity in the

1-hour infusion schedule; (B) mean inhibition of PBMCs FT activity in the 24-hour

infusion schedule; (C) correlation between BMS-214662 PKs and PBMCs FT inhibition

(FTI) in two patients at 245 mg/m2 1-hour infusion schedule dose level; (D) correlation between BMS-214662 PKs and PBMCs FTI in patients at 84 mg/m2 24-hour infusion

schedule dose level.

Reprinted with permission from Tabernero J, Rojo F, Marimon I, et al. Phase I pharmacokinetic and pharmaco- dynamic study of weekly 1-hour and 24-hour infusion BMS-214662,

a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol.

2005;23(11):2521–2533.

measure derived from preclinical data, and at what dose level did this occur.

Protein-binding information should also be included to explain any important

variance between species. Also include the presence and degree of any inter- or

intra-patient variability seen in PK.



12.2.3.5 Biomarkers

Key results of biomarker assays by dose level are easier to follow when you

include the number of evaluable patients per dose level, any meaningful changes

in dose level, and the relationship between dose levels, toxicity, PK measures, or

Reporting and Interpreting Results 331

type of tissue. Figures can clearly illustrate these points, especially for immuno-

histochemical or other semi-quantitative measures, if used. Most figures com-

pare PD measure with dose, rather than with PK parameters. Figures 12.5 and

12.6 demonstrate options from phase I trials of how to report such data. Figure

12.6 is from a report of a phase I trial of the small molecular angiogenesis inhibi-

tor PTK87, which targets vascular endothelial growth factor (VEGF) recep-

tor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/

Flt-4, the platelet-derived growth factor receptor tyrosine kinase, and the c-kit

protein tyrosine kinase. In the phase I study, dynamic-contrast enhanced mag-

netic resonance imaging (MRI) was used as a technique for studying the effect

of the drug on permeability and vascularity of tumor masses measured by the

bidirectional transfer constant (Ki). The results were presented in several differ-

ent ways: Figure 12.6a shows the mean change from baseline in Ki, expressed

as a percentage of baseline values, in two dose groups. The results suggest that

there was a greater reduction in Ki at higher doses (1000 mg/day) compared

with lower doses (<1000 mg/day). Figure 12.6b shows the relationship between

the effect of Ki and the plasma AUC of PTK787 in patients with liver metasta-

ses. Again, results suggest that greater effects on Ki were seen at higher levels of

exposure [49].



12.2.3.6 Antitumor effects

There is often a subset of patients who can be evaluated for antitumor effects

using standard criteria in phase I trials. In some trials where activity is expected

to be high, the protocol may require all patients to have response-evaluable dis-

ease. This section should outline the number of patients who are evaluable for

antitumor assessment. Radiological images can be used to demonstrate effects

in selected patients. It may be appropriate to summarize evidence of antican-

cer effects that did not meet the protocol definition of response, such as other

biological effects. This may help with determining in which tumor types the

agent or regimen should be evaluated in subsequent trials. Figure 12.7 shows a

waterfall-style plot, which can be used to demonstrate the change in tumor size

of each patient.

In interpreting the results of phase I trials, there should be a clear distinction

between the observation of the desired molecular effect of a drug (i.e., proof of

concept) and the impact of the drug treatment on clinical measures such as tumor

shrinkage or delay in progression (i.e., clinical benefit). Although tumor response

is not normally a primary endpoint in phase I trials, evidence of molecular target

effects in subsets of phase I patients may assist in defining which predictive bio-

markers and assays are worth investigating further in phase II studies [12]. For

vismodegib, for example, a first-in-class, small-molecule inhibitor of smoothened

homologue, a phase II study was performed to more fully evaluate its efficacy

1000 mg/day (all cancer)

A

1000 mg/day (all cancer)

120

1000 mg/day (all liver metastases)

100

88.5 ± 8.0

76.3 ± 8.8

80

60.4 ± 8.1

53.8 ± 6.5

49.7 ± 6.7

60

49.7 ± 6.7

40

Baseline MRI KI (%)

20

0

Day 2 ( n = 10, 18, 7)

Day 28 ( n = 6, 23, 16)

Day of assessment

B

160

140

non-progressors (day 2)

progressors (day 2)

120

non-progressors (day 28)

progressors (day 28)

100

×

× not evaluable (day 2)

+ not evaluable (day 28)

+

80

regression

60

Baseline MRI KI (%)

40

×

20

0

50 000

100 000

150 000

200 000

AUC (h·ng/ml)

Figure 12.6 (A) Mean (=/– SE) percentage of baseline MRI bidirectional transfer

constant (Ki) for patients receiving <1000 mg/day and >1000 mg/day on days 2 and 28

of PTK787/ZK 222584 treatment. (B) Inhibitory maximum effect (E ) model fitting

max

for percentage of baseline MRI bidirectional transfer constant (Ki) versus area under the plasma concentration curve (AUC) for patients with liver metastases.

Reprinted with permission from Thomas Al, Morgan B, Horsfield MA, et al. Phase

I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/

ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol.

2005;23(18):4162–4171.

Reporting and Interpreting Results 333

150

100

50

inkage from baseline

0

Tumour Shr

–50

Best %

–100

–150

Figure 12.7 Simulated examples of a waterfall plot to represent tumor response with a particular agent.

and safety in patients with locally advanced or metastatic basal-cell carcinoma

(BCC). RECIST 1.1 was used for evaluation of metastatic BCC; however, a stan-

dard endpoint for locally advanced basal-cell carcinoma did not exist at the time

of the study design. Response was then defined as a decrease of 30% or more in

the externally visible or radiographic dimension (if applicable), or complete res-

olution of ulceration (if present at baseline). Progressive disease was defined as

an increase of 20% or more in the externally visible or radiographic dimension, a

new ulceration, or a new lesion. These endpoints were assessed by both indepen-

dent reviewers (with photographs and radiological images) and the investigators

themselves [50]. It is always important to provide a full and accurate description.



12.2.3.7 Recommended phase II dose

Arguably, this is the most critical section of the report. Establishing a clinical dose range with the upper limit defined by toxic effects is the key goal in this section

(if feasible), as it is generally agreed that toxicity remains a useful measurement

to establish dose range where feasible. This is particularly true if toxic effects are mechanism-based. In the absence of a clear biological rationale to suggest otherwise, it should generally be concluded that the RD will be the highest safe dose.

3 3 4

P H A S E I C A n C E R C l I n I C A l T R I A l S

However, before a final decision on the RD is made, it is necessary to review all

data from the trial. The PK data should be reviewed to ensure that the minimum

or target concentrations are achieved in plasma and/or tissue (taking account of

protein-binding). Evidence of antitumor activity and its relationship to the dose

should be considered. Evidence of proof-of-concept data of the drug’s having the

intended molecular effect, in the relevant and expected tissue(s), relationship to

dose, and whether the minimum target effect level was achieved must also be

factored into the decision.

This section must indicate whether a dose is recommended for further study

(and if not, why not) and the basis for the recommended phase II dose. It is useful

to outline the number of patients actually treated at this dose level and their toxicities, as well as the dose intensity delivered. This will inform later trials, including combination trials, since it may affect future consent forms, safety information,

and estimating starting doses in combination studies. If multiple phase I studies

have been performed testing different doses and schedules, but only one feasible

schedule and dose will be taken forward, that should also be stated.

If the RD decision is not made based on the pre-specified criteria in the pro-

tocol for the degree of toxicity permissible, level of target or clinical activity, PD

effect or PK, then a robust justification should be provided.



12.2.4 Discussion

The discussion section brings all the observations of the trial together. Details

here should include what was observed, any interpretations that have been made,

and the investigator’s opinion on the significance of the results. Information on

data that became available during the conduct or analysis of the study on the

agent or regimen should also be added. The final dose recommendation and evi-

dence for its selection, along with any caveats about the agent’s use in subpopu-

lations, should be reiterated. In conclusion, the author should give suggestions

for subsequent plans for the agent, such as planned phase II trials, or whether

subsequent trials wil define the dose–effect relationships in phase Ib trials, or in randomized or combination phase I trials.



12.3 AFTER PHASE I

Increasingly, more importance is given to the results of phase I studies, and the

need to make development decisions as early as possible, including a decision

not to proceed further, for reasons such as safety concerns, poor PK, inadequate

evidence of target effect, or inability to deliver a dose likely to be active. Decisions

Reporting and Interpreting Results 335

on further development of an agent may require the evaluation of more than one

phase I trial, or may require the conduct of additional studies, either pharmaco-

dynamic studies, or in specific patient or molecular subsets. In other instances,

reformulation of a drug or the selection of another candidate with a superior PK

profile may be appropriate, and require additional phase I studies. Drug devel-

opment continues to move toward a more tumor- and/or target-specific focus,

and it is increasingly recognized that the incorporation of endpoints relative to

patient selection and eligibility in the design of phase I trials is needed to more

effectively and efficiently develop therapies [7] . Although there may be a reluc-

tance to delay further development to optimize the dose, schedule, or patient

population, phase III studies are not cost-effective ways to demonstrate inade-

quacies in dose or design. Adequate phase I and II testing is critical. The Clinical

Trial Design Task Force (CTD-TF) of the nCI IDSC has published a series of

discussion papers on phase II trial design in Clinical Cancer Research [50] which discuss these topics in greater detail.

Critical evaluation of drug-development methodology is critical. Complete

reporting of clinical trials assists in the review and evaluation of methodology, but is limited. The collection of individual patient data, such as is done for RECIST

and DlT-TARGETT initiatives is important to further inform future clinical tri-

als. Col aborations wil allow the acquisition of data that wil better inform future development of effective combination therapy for cancer [13].



REFERENCES

1. Hunig T. The storm has cleared: lessons from the CD28 superagonist TGn1412.

Nat Rev Immunol. 2012;12(5):317–318.

2. Prayle AP, Hurley Mn, Smyth AR. Compliance with mandatory reporting of clinical

trial results on ClinicalTrials.gov: cross-sectional study. Br J Cancer. 2011;344:d7373.

doi:10.1136/bmj.d7373

3. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGn1412. N Engl J Med. 2006;355(10):1018–1028.

4. World Health Organization: International Clinical Trials Registry Platform, reporting of findings of clinical trials. http://www.who.int/ictrp/results/en/. Published 2013. Accessed October 30, 2013.

5. Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published. BMJ. 2013;346:f105.

6. Dickersin K, Chalmers I. Recognizing, investigating and dealing with incomplete

and biased reporting of clinical research: from Francis Bacon to the World Health

Organization. JLL Bulletin: Commentaries on the history of treatment evaluation

(www.jameslindlibrary.org). [Brief history]. http://www.jameslindlibrary.org/illus-

trating/articles/recognising-investigating-and-dealing-with-incomplete-and-biase.

Published 2010. Accessed October 30, 2013.

3 3 6

P H A S E I C A n C E R C l I n I C A l T R I A l S

7. loRusso PM, Boerner SA, Seymour l. An overview of the optimal planning,

design, and conduct of phase I studies of new therapeutics. Clin Cancer Res.

2010;16(6):1710–1718.

8. Ross JS, Tse T, Zarin DA, Xu H, Zhou l, Krumholtz HM. Publication of nIH funded

trials registered in ClinialTrials.gov: cross-sectional analysis. BMJ. 2012;344:d7292.

doi:10.1136/bmj.d7292

9. Song F, Parekh S, Hooper l, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):i i, ix–xi, 1–193.

10. Huang J, Zhang W, Bowden D, Tam J, Wu H, Fung M. Emerging trends in US onco-

logical approvals: a 13-year review (1999–2001). Drug Inf J. 2012;46:344–357.

11. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune

therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res.

2009;15(23):7412–7420.

12. Booth CM, Calvert AH, Giaccone G, lobbezoo MW, Seymour lK, Eisenhauer EA.

Endpoints and other considerations in phase I studies of targeted anticancer ther-

apy: recommendations from the Task Force on Methodology for the Development

of Innovative Cancer Therapies (MDICT). Eur J Cancer. 2008;44(1):19–24.

13. Seymour lK, Calvert AH, lobbezoo MW, Eisenhauer EA, Giaccone G. Design and

conduct of early clinical studies of two or more targeted anticancer therapies: rec-

ommendations from the Task Force on Methodology for the Development of

Innovative Cancer Therapies. Eur J Cancer. 2013;49(8):1808–1814.

14. Ezzalfani M, Zohar S, Mandrekar SJ, Vassal G, le Deley MC. novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA). Presented at

the American Society of Clinical Oncology; May 31–June 4, 2013; Chicago, Illinois.

J Clin Oncol. 2013;(Suppl):abstr 2577.

15. Freeman GA, Kimmelman J, Dancey J, Monzon JG. Reporting practices of phar-

macodynamics studies involving invasive research procedures in cancer trials. Br J

Cancer. 2013;109(4):897–908.

16. Freeman GA, Kimmelman J. Publication and reporting conduct for pharma-

codynamic analyses of tumor tissue in early oncology trials. Clin Cancer Res.

2012;18(23):6478–6484.

17. Ivy SP, Siu l, Garrett-Mayer E, Rubinstein l. Approaches to phase I clinical trial design focused on safety, efficiency, and selected patient populations: a report from the Clinical Trials Design Task Force of the national Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010;16(6):1725–1736.

18. le Tourneau C, lee JJ, Siu ll. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–720.

19. Parulekar WR, Eisenhauer EA. Phase I trials designs for solid tumor stud-

ies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst.

2004;96(13):990–997.

20. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The COnSORT statement. JAMA. 1996;276(8):637–639.

21. Azuaje F, Devaux Y, Wagner D. Challenges and standards in reporting diagnostic and prognostic biomarker studies. Clin Transl Sci. 2009;2(2):156–161.

Reporting and Interpreting Results 337

22. McShane lM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM.

Reporting recommendations for tumor marker prognostic studies. J Clin Oncol.

2005;23(36):9076–9072.

23. COnSORT: Flow diagram 2010. Available at http://www.consort-statement.org/

consort-statement/flow-diagram0/. Published 2010. Accessibility verified October 30, 2013.

24. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer. 2010;100(9):1373–1378.

25. lee JJ, Chen n, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res. 2012;18(17):4498–4507.

26. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel lecture, held at the 10th MCI-EORTC

Conference on new Drugs in cancer Therapy, Amsterdam, June 16–19, 1998. Ann

Oncol. 1998;9(10):1047–1052.

27. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse

Events (CTCAE) version 4.0. Available at http://ctep.cancer.gov/protocolDevelop-

ment/electronic_applications/ctc.htm. Published 2009. Accessed October 30, 2013.

28. Medical Dictionary for Regulatory Activities (MedDRA) version 16.1. http://

www.meddra.org/how-to-use/support-documentation/english. Published 2013.

Accessed October 30, 2013.

29. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol.

2012;30(3):282–290.

30. Eisenhauer EA, Therasse P, Bogaerts J, et al. new response evaluation crite-

ria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer.

2009;45(2):228–247.

31. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi

response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010;102(5):803–809.

32. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal

tumor treated at a single institution with imatinib mesylate: proposal of new com-

puted tomography response criteria. J Clin Oncol. 2007;25(13):1753–1759.

33. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on

Chronic lymphocytic leukemia updating the national Cancer Institute—Working

Group 1996 Guidelines. Blood. 2008;111(12):5446–5456.

34. Byrne MJ, nowak AK. Modified RECIST criteria for assessment of response in

malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257–260.

35. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Groups. J Clin Oncol.

2008;26(21):1148–1159.

36. United States Department of Health and Human Services, Food and Drug

Administration. Guidance for Industry, Population Pharmacokinetics. http://

3 3 8

P H A S E I C A n C E R C l I n I C A l T R I A l S

www.fda.gov/downloads/Drugs/.../Guidances/UCM072137.pdf. Published 1999.

Accessed October 30, 2013.

37. European Medicines Agency, Committee for Medicinal Products for Human

Use: Guideline on Reporting the Results of Population Pharmacokinetic Analyses.

http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide-

line/2009/09/WC500003067.pdf. Published 2007. Accessed October 30, 2013.

38. Parkinson DR, Dracopoli n, Petty BG, et al. Considerations in the development

of circulating tumor cell technology for clinical use. J Transl Med. 2012;10:138.

doi:10.1186/1479-5876-10-138

39. Punnoose EA, Atwal S, liu W, et al. Evaluation of circulating tumor cel s and circulating DnA in non–small cell lung cancer: association with clinical endpoint in a phase

II clinical trial of pertuzumab and erlotinib. Clin Can Res. 2012;18(8):2391–2401.

40. Booth CM, Calvert AH, Giaccone G, lobbezoo MW, Eisenhauer EA, Seymour lK.

Design and conduct of phase II studies of targeted anticancer therapy: recommen-

dations from the Task Force on Methodology for the Development of Innovative

Cancer Therapies (MDICT). Eur J Cancer. 2008;44(1):25–29.

41. Centers for Medicare and Medicaid Services, Clinical laboratory Improvement

Amendments (ClIA). http://www.cms.gov/Regulations-and-Guidance/

legislation/ClIA/index.html?redirect=/clia/. Published 2013. Accessed October 30, 2013.

42. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res.

2010;16(6):1745–1755.

43. lalonde Rl, Kowalski KG, Hutmacher MM, et al. Model-based drug development.

Clin Pharmacol Ther. 2007;82(1):21–32.

44. Mil igan PA, Brown MJ, Marchant B, et al. Model-based drug development: a

rational approach to efficiently accelerate drug development. Clin Pharmacol Ther.

2013;93(6):502–514.

45. Eisenhauer EA. Reporting and interpreting results. In: Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford, England: Oxford University Press; 2006:261–275.

46. Dent SF, Glemon KA, Chi Kn, et al. nCIC CTG InD.181: Phase I study of AT9283

given as a weekly 24-hour infusion in advanced malignancies [published on-line

ahead of print]. Invest New Drugs. 2013. doi:10.1007/s10637-013-0018-9

47. Gelmon K, Hirte H, Fisher B, et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 2004;22(3):263–275.

48. Tabernero J, Rojo F, Marimon I, et al. Phase I pharmacokinetic and pharmaco-

dynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farne-

syltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol.

2005;23(11):2521–2533.

49. Thomas Al, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered

twice daily in patients with advanced cancer. J Clin Oncol. 2005;23(18):4162–4171.

50. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.





APPENDIX

Useful Web Resources



The following websites provide access directly to information and documents of

use in clinical trial design and development.



SUBMISSIONS TO REGULATORY AUTHORITIES



United States

• Chapter I—Food and Drug Administration, Department of Health and

Human Services, Part 312—Investigational New Drug Application: http://

www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevel

opedandapproved/approvalapplications/investigationalnewdrugindap

plication/default.htm

• Guidance for Industry: Content and Format of IND Applications for

Phase I Studies of Drugs (etc.): http://www.fda.gov/downloads/drugs/

guidancecomplianceregulatoryinformation/guidances/ucm074980.pdf



Europe

• European Clinical Trials database:

https://eudract.ema.europa.eu/

• National Competent Authorities Clinical Trial contacts: https://eudract.

ema.europa.eu/docs/msca/MSCA_Contact_List.pdf



Canada

• Drug products information, including application material:

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/

guide-ld/clini/index-eng.php

3 4 0

A P P E N D I x



PROTOCOL TEMPLATES

• US National Cancer Institute, Cancer Therapy Evaluation Program:

http://ctep.cancer.gov/protocolDevelopment/templates_applications.htm

• University of California, San Francisco (UCSF) Phase I protocol template:

http://hub.ucsf.edu/protocol-development



INFORMED CONSENT TEMPLATE AND CHECKLIST

• US National Cancer Institute, Cancer Therapy Evaluation Program:

http://ctep.cancer.gov/protocolDevelopment/informed_consent.htm

• US Department of Health and Human Services, Office of Human

Research Protections (OHRP):

http://www.hhs.gov/ohrp/policy/consentckls.html



STATISTICAL RESOURCES

• Windows implementations of Continual Reassessment Method (CRM):

http://cshspccweb.csmc.edu/biostats/

https://biostatistics.mdanderson.org/SoftwareDownload/

SingleSoftware.aspx?Software_Id=13

• Windows implementation of Escalation With Overdose Control EWOC:

http://biostatistics.csmc.edu

• R-package: implementation of CRM, likelihood-based CRM, and

time-to-event CRM with additional model-design tools:

http://cran.r-project.org/web/packages/dfcrm/index.html

• STATA module to implement the CRM: http://ideas.repec.org/c/boc/

bocode/s457625a.html

• Excel macro to produce a table of Toxicity Probability Intervals: https://

biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware.

aspx?Software_Id=72



GOOD CLINICAL PRACTICE

• E6: International Conference on Harmonization (ICH) Guideline on

Good Clinical Practice: http://www.ich.org/fileadmin/Public_Web_

Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf



GENERAL RESOURCES

• International Conference on Harmonization: ICH home page: http://

www.ich.org/products/guidelines.html

A P P E N D I x

3 4 1

• United States Code of Federal Regulations Title 21: Food and Drugs

(searchable database): http://www.accessdata.fda.gov/scripts/cdrh/

cfdocs/cfcfr/cfrsearch.cfm

• ICH General Considerations for Clinical Trials (E8): http://www.

ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/

Efficacy/E8/Step4/E8_Guideline.pdf

• European Union Directive on Clinical Trials: http://ec.europa.eu/

health/human-use/clinical-trials/index_en.htm#rlctd

• European Medicines Evaluation Agency: Committee for Proprietary

Medicinal Products (CPMP): Note for guidance on the preclinical evalu-

ation of anticancer medicinal products: http://www.iss.it/binary/scf1/

cont/CPMP_SWP_997_96.pdf

• Association of the British Pharmaceutical Industry: http://www.abpi.

org.uk/our-work/library/guidelines/Documents/guidelines_phase1_

clinical_trials.pdf#search=clinical%20trials



ENDPOINTS CRITERIA



Response criteria

• Response Evaluation Criteria in Solid Tumors (RECIST) crite-

ria: https://www.eortc.be/Recist/documents/RECISTGuidelines.pdf



Toxicity criteria

• Common Terminology Criteria for Adverse Events (CTCAE) version

4.03: http://evs.nci.nih.gov/ftp1/CTCAE/About.html

• Medical Dictionary for Regulatory Activities (MedRA): http://www.

meddra.org/

• ICH E2A: Clinical Safety Data Management: Definitions and Standards

for Expedited Reporting: http://www.ich.org/fileadmin/Public_

Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_

Guideline.pdf



ETHICAL GUIDELINES

• Canadian Tri-Council Policy: http://pre.ethics.gc.ca/eng/index/

• United States: Title 45 Code of Federal Regulations, Part 46: Protection

of Human Subjects: http://www.hhs.gov/ohrp/humansubjects/

guidance/45cfr46.html

• United Kingdom: Human Tissue Act: http://www.hta.gov.uk/legisla-

tionpoliciesandcodesofpractice/legislation/humantissueact.cfm

3 4 2

A P P E N D I x

• Australia: National Statement on Ethical Conduct in Research Involving

Humans:

https://www.nhmrc.gov.au/guidelines/publications/e35

• Europe: Ethical Aspect of Human Tissue Banking (paper): http://

ec.europa.eu/bepa/european-group-ethics/docs/avis11_en.pdf

• Council of Europe: Convention for the Protection of Human Rights and

Dignity of the Human Being with Regard to the Application of Biology

and Medicine: Convention on Human Rights and Biomedicine: http://

conventions.coe.int/Treaty/en/Treaties/Html/164.htm



SPECIAL POPULATIONS

• FDA guidance for the conduct of renal impairment studies: http://www.

fda.gov/downloads/Drugs/Guidances/UCM204959.pdf

• FDA guidance for the conduct of hepatic impairment studies: http://

www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory

Information/Guidances/ucm072123.pdf

• EMA guidance for the conduct of renal impairment studies: http://

www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide

line/2009/09/WC500003123.pdf

• EMA Guidance for the conduct of hepatic impairment studies: http://

www.ema.europa.eu/docs/en_GB/document_library/Scientific_

guideline/2009/09/WC500003122.pdf

• NCI Organ Dysfunction Group template for renal and hepatic dysfunc-

tion studies: http://ctep.cancer.gov/protocolDevelopment/templates_

applications.htm

• FDA Guideline for Industry: Studies in support of special popula-

tions:

http://www.fda.gov/downloads/Drugs/GuidanceCompliance

RegulatoryInformation/Guidances/UCM189544.pdf

• Note for guidance on studies in support of special popula-

tions: Geriatrics: http://www.ema.europa.eu/docs/en_GB/document_

library/Scientific_guideline/2009/09/WC500002875.pdf

• FDA: Pediatric product development: http://www.fda.gov/drugs/

developmentapprovalprocess/developmentresources/ucm049867.htm

• EMA: Submitting pediatric studies: http://www.ema.europa.eu/ema/

index.jsp?curl=pages/regulation/general/general_content_000038.jsp

• FDA guidance for drug-interaction studies:

http://www.fda.gov/downloads/Drugs/GuidanceCompliance

RegulatoryInformation/Guidances/UCM292362.pdf

• FDA guidance: Food effect bioavailability and fed bioequivalence studies:

http://www.fda.gov/downloads/regulatoryinformation/guidances/

ucm126833.pdf





INDEX

Page numbers in bold indicate major discussions. Boxes are indicated by b, figures by f, and tables by t following the page number.

accelerated titration, 174–175

pharmacokinetics, 29–30

ADAPT 5 (pharmacokinetics

starting-dose calculations for phase

model), 239

I trials, 60–61

adolescents. See pediatric patients

antiproliferative assays, 16

adverse events

antitumor effects

assessing toxic effects, 68–69

in vitro assays, 16

chronic toxicities, 72–73

preclinical efficacy data, 11–13, 12t

grading of, 171

reporting trial results, 331, 333, 333f

protocol, 212–213

area under the curve (AUC), 230

reporting trial results, 323–324,

assay methods

325t–327t, 328, 328f

detection techniques, 236–237

risk/benefit ratio in phase I trials, 93

development and validation, 237

serious, reporting of, 218, 219t, 316

drug sample extraction and separation,

terminology, 69, 69t, 171

235–236

age factors

pharmacodynamic, tissue-based,

elderly patients, 104, 118–119,

252–253

123–124

pharmacokinetics, 235–239

pediatric patients, 119–123

availability for follow-up, 65, 315

animal testing. See also in vivo

studies

Belmont Report (U.S.), 91

preclinical data and

Bioanalysis and Quality Assurance

requirements, 16–25

Group, Experimental Cancer

choice of design and

Medicine Centre, 253

endpoints, 19–20

bioavailability studies, 127, 128

effects on target and in vivo

biological agents. See molecularly targeted

activity, 21

agents (MTAs)

immune therapies, 24–25

biological product characterization,

in vivo efficacy models, 17–19,

156–157

18t, 19t

biomarkers. See also immunotherapeutics

3 4 4 I n D E x

biomarkers ( cont. )

circulating tumor cel s (CTCs), 75–76,

biomarker-guided studies

247–251, 248t–250t

design of, 84–85

circulating tumor DnA (ctDnA), 251

reporting trial results, 320–321,

clinical brochure. See

330–331, 330f, 332f

investigator’s brochure

statistical designs for first-in-human

Clinical Laboratory Improvement

trials, 192–195

Amendment (CLIA), 321

genomic profiles and patient

clinical pharmacology, 227–229

selection, 62–63

Clinical Trial Directive 2001/20/EC

guiding dose escalation, 193–195, 195f

(European Union), 283

patient population enrichment, 193

Clinical Trials Application, Canada,

predictive, 162, 192–193

283, 339

types of, 320

Code of Federal Regulations, U.S., 11–12,

biopsies. See tissue biopsies

156, 341

blood oxygenation level-dependent

cohort size

(BOLD) 1H MRI, 256

expansion at recommended dose,

Boomer.org (website), 240

175–176

brain tumors, 125–126

expansion cohorts, phase I and II trials,

breastfeeding, 64

188–191, 190t, 191t–192t

immunotherapeutic trials, 158–159

Canada

organ impairment studies, 111

drug products information

study design and, 82

(website), 339

combination phase I trials, 135,

ethical guidelines, 99, 341

137–141

regulatory submissions, 283

aims of, 138

Cancer Research UK, 27, 238, 253

background, 137

cancer therapeutics

dose escalation designs,

cytotoxic vs. non-cytotoxic agents, 58

186–188, 188f

differences from other therapeutic

drug combinations with radiotherapy,

areas, 5

140–141

need for new therapeutic options,

first-in-human phase I trials vs., 137

149–150

immunotherapeutics in, 165

Cancer Therapy Evaluation Program, 214

phase 0 trials and sequencing of

cardiac arrhythmias, QTc studies for,

agents, 48

113, 118

preclinical data and requirements, 29

case report forms (CRFs), 291–292, 298

protocol, 203–204

cell lines, preclinical models, 20

study design, 82, 138–140

cel -based therapies, 153–154

Commission on Human Medicines

chemistry of agent, 11, 30–31, 286–287

(United Kingdom), 60

Child-Pugh classification of hepatic

Committee for Medicinal Products for

dysfunction, 108–110

Human Use (CHMP)

children. See pediatric patients

on preclinical testing of anticancer

chimeric antigen receptors (CARs), 153

agents, 11, 12t

CHMPO. See Committee for

preclinical toxicology guidelines, 25

Medicinal Products for Human

repeat-dose toxicity studies

Use (CHMP)

guidelines, 27

I n D E x 3 4 5

Common Terminology Criteria for

cytokines, 154–155

Adverse Events (CTCAE), 69,

cytotoxic agents

69t, 171, 213, 316, 341

development, 1, 3

Common Toxicity Criteria (CTC), 69

dose-response relationship, 68, 68f

communication between trial members,

goals of first-in-human studies, 58

277, 279

immunological effects, 150

compartmental analysis, 239–242, 241f

toxicity as primary endpoint, 67

computed tomography (CT),

traditional development paradigm, 52

dynamic, 257

conducting phase I trials. See

data analysis, 239–242, 240f, 257–259

study process and logistics

data collection and management,

consent

290–292, 298–299

disclosure of information and, 94–95

databases, 292

immunotherapeutics trials, 159

DCE-MRI (dynamic contrast enhanced

informed consent

MRI), 254–255, 257–258

checklist, 221t–222t, 340

Declaration of Helsinki, 91, 92, 96, 296

discussing trial with patients,

design of study. See study design

295–298

development of drugs. See

protocol form, 220–221

drug development

template (website), 340

diffusion-weighted MRI, 255

as two-step process, 297

discussion section, trial results report, 334

as ongoing processes, 99–100,

disease characteristics, patient entry

297–298

criteria, 62–64

pediatric studies, 120

DLT. See dose-limiting toxicity (DLT)

phase 0 trials, 49

DLT-TARGETT, 73, 171, 328

phase I trials, 65, 295–298

DnA, tumor (ctDnA), 251

tissue procurement and invasive

dose establishment and escalation.

procedures, 97–99

See also dose-limiting toxicity

Consolidated Standards of Reporting

(DLT); starting dose

Trials (COnSORT), 310–311

combination phase I trials,

continual reassessment method (CRM),

138–139, 138f

178–181

dose-escalation management

variations in, 181–184, 182f

decision-making responsibility,

contracts and contracting, 280–283,

299–300

281t–282t

dose-limiting events, 301–302

correlative assays, preclinical, 30

escalation-switching events, 301

creatinine clearance, 108

patient recruitment to dose levels,

CRFs (case report forms), 291–292, 298

300–301

CTCAE. See Common Terminology

expert advisory group

Criteria for Adverse Events

recommendations, 60–61

(CTCAE)

first-in-human phase I trials, 3–5, 58.

CTCs (circulating tumor cel s), 75–76,

See also statistical designs for

247–251, 248t–250t

first-in-human trials

ctDnA (circulating tumor DnA), 251

immunotherapeutics, 158

CYP P450 isoenzymes, 133–134, 133t

intra-patient dose escalation, 83–84

cytokine release syndrome, 59

organ impairment studies, 111

3 4 6 I n D E x

dose establishment and escalation ( cont. )

timing of pediatric studies,

pediatric studies, 122

120–121, 121t

pharmacodynamics, 243

drug interactions. See also

phase 0 trials, 36

combination phase I trials

radiotherapy in combination trials,

background, 130, 133

140–141

examples of studies, 135, 136t

reporting trial results, 322, 324t, 328

immunotherapeutics trials, 161

single-dose toxicity studies, 25, 26t–27t

study types and design, 133–135

trial design and, 71, 171–172, 172t,

dynamic contrast enhanced MRI

314–315

(DCE-MRI), 254–255, 257–258

dose-limiting toxicity (DLT)

children vs. adults, 120

Eastern Cooperative Oncology Group

combination phase I trials, 139

(ECOG) scale, 121–122

definitions, 6, 70, 70t, 171, 196

efficacy data

dose-escalation management, 301–302

combination data, 22

radiotherapy combination trials, 141

combination phase I trials, 140

severity and timing of event, 71

first-in-human phase I trials, 170

trial design and dose escalation,

preclinical, 11–25

71, 171–172, 172t, 314. See

elderly patients, 104, 118–119, 123–124

also statistical designs for

electrocardiography (ECG), 118

first-in-human trials

ELISA (enzyme-linked immunosorbent

Dose-Limiting Toxicity and Toxicity

assay), 252

Assessment Recommendation

endpoints, 67–79

Group for Early Trials of Targeted

alternative, 78

Therapies (DLT-TARGETT), 73,

criteria (websites), 341

171, 328

drug development, 2t, 80f

dose-response relationship

first-in-human phase I trials, 171–172

cytotoxic agents, 67–68, 68f

imaging and immune response

drug efficacy and toxicity, 67–68

evaluation, 163–165, 164t

endpoints and, 171–172, 172f

immunotherapeutics trials, 161–165,

molecularly targeted agents, 68, 194

164t, 317

drug combinations. See

measurement criteria, 67t, 315–319

combination phase I trials

molecularly targeted agents, 73, 74t,

drug development

75f, 78, 316

average time for process, 44

non-toxicity measures, 73–78, 79t

cancer trial goals, designs, and

pharmacodynamics, 45–46, 75–77,

endpoints, 2t

112–113, 242, 243–244

chemistry, manufacturing, and control

pharmacokinetics, 77–78

information, 286–288

phase 0 trials, 36, 45–46

cytotoxic agents vs. molecularly

preclinical in vivo efficacy

targeted agents, 52

studies, 20, 77

first-in-human phase I trials, 3–5

protocol, 224–226

introduction, 1–3

toxicity, 67–73. See also

non-toxic endpoints, 78–79, 80f

toxicity and toxicology

pediatric trials, 119–120

enzyme-linked immunosorbent assay

phase 0 trials in, 54–55

(ELISA), 252

I n D E x 3 4 7

escalation with overdose control, 184

(ECMC), Bioanalysis and Quality

ethical issues, 91–101

Assurance Group, 253

cancer therapeutics, 5

consent for tissue procurement and

first-in-human phase I trials. See also

invasive procedures, 97–99

study design; study process and

disclosure of information, 94–95

logistics

ethical review and informed consent as

combination phase I trials vs., 137

ongoing processes, 99–100

endpoints, 67–74

exclusion criteria, 49–50, 96, 120,

goals, 58, 58t

122–123

patient population, 62–67

first-in-human trials in oncology, 92–96

protocol, 200, 202–203, 204t

human subjects research principles, 91,

regulatory submissions and

100, 296

documentation, 284t–285t

institutional review boards and

special role in drug development, 3–5

committees, 287t, 288–289

Food and Drug Administration (FDA)

international codes and standards,

food–effect studies

91–92, 296

recommendations, 129

patient vulnerability and

geriatric population guidelines, 124

consent, 95–96

investigational new drug guidance and

phase 0 trials, 37, 49–50

applications, 44, 51–52

phase I trials in children, 120

pediatric studies guidance, 120

risk/benefit ratio, 92–93

pharmacokinetics reporting

websites, 341–342

guidance, 320

European Medicines Agency (EMA),

preclinical efficacy regulations, 11–12

11. See also Committee for

preclinical toxicology guidance, 25, 80

Medicinal Products for Human

repeat-dose toxicity studies

Use (CHMP)

guidance, 27–28

geriatric population guidelines, 124

food–effect studies, 126–130

oncolytic viruses guidance, 157

background, 127

pediatric studies guidance, 120

eligibility criteria, 128–129

pharmacokinetics reporting

examples, 130, 131t–132t

guidance, 320

study design, 128–129

preclinical toxicology

types of, 127–128

assessment, 80, 81

functional imaging

European Organization for Research and

endpoints, 73, 78, 211, 215, 317

Treatment of Cancer (EORTC),

pharmacodynamics, 229, 253–257

171–172, 172t, 311

protocol, 254, 255t

exclusion criteria

reproducibility and quantification,

ethical issues, 96

257–258

immunotherapeutic trials, 159–161

tumor heterogeneity, 258

older adults, 123

funding of trials, 279–280

pediatric patients, 120, 122–123

phase 0 trials, 49–50

gas chromatography, 235, 236

expansion cohorts, phase I and II trials,

gastrointestinal stromal cell tumors

188–191, 190t, 191t–192t

(GISTs), 317

Experimental Cancer Medicine Centre

gene expression arrays, 252

3 4 8 I n D E x

genotype, 62–63. See also biomarkers

immunotherapeutics, 149–165. See also

glomerular filtration rate, 108–109

biomarkers

go/no-go clinical development decisions

assessment criteria, 317

as first-in-humans study goal, 58

background data for cancer treatment,

phase 0 trials, 50–51, 51f

150–151

Good Clinical Practice (GCP)

combination studies, 165

ethical issues, 91–92

imaging and immune response

for laboratories (GCLP), 25,

evaluation, 163–165, 164t

237–239, 252

in vivo evaluation, 24–25

phase I trials guidance, 273

practicalities of phase I trials,

sample collection and processing,

156–165

231–232

biological product characterization,

website, 340

156–157

good manufacturing practice,

cohort size, 158–159

30–31, 286

endpoints, 161–165

Guidance for Industry, Population

escalation plan, 158

Pharmacokinetics (FDA), 320

patient population, 159–161

Guidelines on Reporting the Results of

pharmacokinetics, 161

Population Pharmacokinetic

starting dose, 157–158

Analyses (EMA), 320

safety issues, 151–152, 162–163

treatment modalities, 152–156

hematological malignancies, 124–125

cel -based therapies, 153–154

hepatic impairment. See liver function

cytokines, 154–155

higher risk agents

monoclonal antibodies, 152–153

animal models vs. effects in humans, 61

radio-immunotherapy, 154

expert advisory groups recommended

vaccines, 155

for, 60

viruses, 155–156

first-in-human trials, 59

in vitro studies, 16, 24–25

high-pressure liquid chromatography

In Vivo Cellular and Molecular Imaging

(HPLC), 235

Centers (nCI), 253

hollow-fiber assay, 17, 19

in vivo studies, 16–25

agent’s effects on target and in vivo

IC50 (inhibitory concentration of

activity, 21

50%), 77

combination efficacy data, 22

ICH. See International Conference on

comparative data with other

Harmonization (ICH)

agents, 21–22

imaging studies

efficacy measures, 20

immunotherapeutics response

immune therapies evaluation, 24–25

evaluation, 163–165, 164t

model systems, 17–19, 18t, 19t

pharmacodynamics, 253–257

single-agent efficacy studies,

phase 0 trials, 48–49

16–22, 23–24

protocol, 216, 218

study design and endpoints, 19–20

immune assays, 161–162

InD (Investigational new Drug)

immune-related response criteria (irHC),

applications, 44, 51–52, 156

317, 318t

independent ethics committees, 287t,

immunohistochemistry (IHC), 252

288–289

I n D E x 3 4 9

informed consent. See consent

laboratories, good clinical practice for,

institutional review boards and

237–239

committees, 287t, 288–289

Lansky scale, 121

interaction studies, 126–141

leukemia, acute myeloid, 123

about, 126

“liquid biopsies,” 247

combination phase I trials, 135,

liver function

137–141

classification of dysfunction,

drug–drug interactions, 130, 133–135

108–110, 109t

food–effect studies, 126–130

immunotherapeutics trials, 159

International Conference on

organ impairment studies, 105–107,

Harmonization (ICH). See also

107b, 110–111, 116t–117t

Good Clinical Practice (GCP)

pharmacokinetics, 112

General Considerations for Clinical

logistics of phase I trials. See

Trials, 11

study process and logistics

preclinical data and requirements, 25,

lymphocytes, tumor-infiltrating (TIL),

27, 28, 28t

153, 162

website, 31, 340

International Workshop on Chronic

MABEL (minimal anticipated biological

Lymphocytic Leukemia,

effect level), 81

317, 319t

magnetic resonance imaging (MRI),

intracerebral tumors, 125–126

254–256

intra-patient dose escalation, 83–84

magnetic resonance spectroscopy

invasive procedures, consent for, 97

(MRS), 256

Investigational Drug Steering

mass spectroscopy, 235, 236

Committee Biomarker Task

maximum administered dose (MAD)

Force, 321

determination of, 71

Investigational new Drug (InD)

statistical designs for

applications, 44, 51–52, 156

first-in-human trials

investigators

classical design, 173–174, 173f

acting in best interests of patients, 303

continual reassessment method,

informed consent and communication

178–184, 182f

with patients, 295–298

escalation with overdose

responsibilities, 274, 275t–276t, 277

control, 184

investigator’s brochure, 31, 32t–33t,

isotonic regression, 184

286, 287t

modified toxicity probability interval

isotonic regression, 184

(mTPI), 185

optimal-method approach, 185

Karnofsky scale, 121–122

rol ing six, 175

kidney function

terminology, 6–7, 71, 72t

classification of dysfunction,

maximum tolerated dose (MTD). See

107–108

also maximum administered

immunotherapeutics trials, 159

dose (MAD)

measures of impairment, 108t

children vs. adults, 120

organ impairment studies, 105–108,

definitions, 6, 71, 314

107b, 110–111, 114t–115t

optimal biologic dose vs., 52

pharmacokinetics, 112

preclinical toxicology, 25

3 5 0 I n D E x

Medical Dictionary for Regulatory

Common Terminology Criteria for

Activities (MedDRA), 316, 341

Adverse Events, 69, 69t, 171

Medicines and Healthcare Products

In Vivo Cellular and Molecular Imaging

Regulatory Agency

Centers, 253

(MHRA), 232

International Workshop on Chronic

mesothelioma, malignant pleural,

Lymphocytic Leukemia,

317–318

317, 319t

metastatic cancer, alternative

Investigational Drug Steering

treatments, 149

Committee, 321

Methodology for the Development of

Organ Dysfunction Working Group,

Innovative Cancer Therapies, 22

108, 109

methods section of trial results report,

support for REMARK guidelines, 311

313–322

no observed adverse effect level

minimal anticipated biological effect level

(nOAEL), 25, 81

(MABEL), 81

non-compartmental analysis, 239

minimum biologically active dose

non-cytotoxic agents. See molecularly

(MBAD), 194, 195f

targeted agents (MTAs)

modified toxicity probability interval

nuremberg Code (1947), 91, 92,

(mTPI), 185

96, 296

molecular aberrations, 62–63

nursing role in trials, 289–290

molecular imaging, 228, 253–257

molecularly targeted agents (MTAs). See

older patients, 104, 118–119, 123–124

also immunotherapeutics

optimum biologically active dose

development, 3

(OBAD), 52, 194

dose-response relationships, 68

organ impairment, 105–118

endpoints, 67, 73, 74t, 75f, 78

cardiac arrhythmias, QTc studies for,

genotype and patient selection, 62–63

113, 118

goals of first-in-human studies, 58

patient selection and, 64, 105

on-target effects in normal tissues, 78

renal and hepatic impairment,

optimal biologic dose, 52

105–113. See also

tissue biopsies, 246

kidney function; liver function

monitoring of trials, 299

orthoptic models, in preclinical testing,

monoclonal antibodies, 152–153

17, 19t

MRI (magnetic resonance imaging),

254–256

PARP (poly (ADP-ribose) polymerase)

MRS (magnetic resonance

inhibitors, 13, 37, 46, 245, 263t

spectroscopy), 256

patient population

MTD. See

characteristics, 64, 333t

maximum tolerated dose (MTD)

cohorts. See cohort size

multi-institutional trials, patient

combination phase I trial

enrollment, 65, 67

eligibility, 139

murine model variables, 17, 18t

consent and availability, 65

disease characteristics, 62–64, 159–160

national Cancer Institute (nCI)

drug interaction studies, 130

Cancer Therapy Evaluation

first-in-human trials, 62–67

Program, 214

food–effect studies, 128–129

I n D E x 3 5 1

healthy volunteers vs. previously

pharmacodynamics (PD), 242–259

treated, 61

about, 227–229

identifying patients for phase I trial,

data analysis, 257–259

294–295

endpoints, 45–46, 75–77, 112–113,

immunotherapeutics trials, 159–161

242, 243–244

multi-institutional trials, 65, 67

functional and molecular imaging

predictive tools for phase I enrollment,

studies, 253–257

65, 66t

older adults, 123

protocol description, 205–206,

preclinical data and requirements, 36,

207t–208t

45–47, 244–245

radiotherapy combination trials, 141

principles, 243–245

recruitment to dose levels, 300–301

relationship with pharmacokinetics,

reporting trial results, 312f, 313–314,

259–265, 261t–263t, 264f

332, 333t

target effect measures, 75–77

patients, discussing trial with, 295–298.

tissue biopsies, 246–251

See also consent

pharmacokinetic–pharmacodynamic

PBMCs (peripheral blood mononuclear

relationships, 259–265,

cel s), 161–162, 247

261t–263t, 264f

peak plasma concentration (Cmax),

pharmacokinetics (PK), 229–242

230, 231

about, 227–229

pediatric patients

assay methods, 235–239

classification, 121

assessment in combination trials,

complications of clinical trials,

139–140

119–120

data analysis, 239–242, 240f

design of phase I studies, 121, 175

drug interactions, 133–135

ethical issues, 120

endpoints, 77–78

features of studies, 121–122

immunotherapeutics, 161

physiology and drug response, 119

phase 0 trials, 36, 46–47

teenagers and young adults, 122–123

preclinical data and requirements,

timing of drug studies, 120–121, 121t

25, 29–30

performance status

principles, 229–231

immunotherapy trials, 159

protocol, 216

measurement scales, 64

relationship with pharmacodynamics,

patient eligibility and, 96, 139

259–265, 261t–263t, 264f

pediatric trials, 122

reporting trial results, 320, 328–230,

phase I trials, 64, 85

329f, 330f

peripheral blood mononuclear cel s

sample collection and processing,

(PBMCs), 161–162, 247

231–235

PET (positron emission tomography), 48,

special populations and conditions

256–257, 258

older adults, 123–124

PFS (progression-free survival), 163

organ impairment, 105–112

pharmaceutical manufacture, 30–31, 286

pediatric trials, 122

Pharmacodynamic/ Pharmacokinetic

terminology, 229–231

Technologies Advisory

pharmacological audit trail, 10

Committee (Cancer Research

pharmacology, clinical, 227–229

UK), 253

pharmacy role in trials, 292–293

3 5 2 I n D E x

phase 0 trials, 44–53

chemistry, formulation, and

about, 44–45

manufacturing quality, 30–31

assay development, 50

correlative assays, 30

ethical considerations, 5, 37, 49–50

efficacy data, 11–25

as first-in-human studies, 44

investigator’s brochure, 31, 32t–33t

go/no-go clinical development

pharmacokinetics, animal, 29–30

decisions, 50–51, 51f

phase 0 trials, 31, 33–38

imaging modalities and trials, 48–49

protocol, 211

investigational new drugs guidance and

regulatory agency

applications, 44, 51–52

recommendations, 11–12

5-iodo-2-pyrimidinone-2′-deoxyribose

toxicology, 25–29

(IPdR) evaluation, 47

pregnancy, 64, 159

molecule and efficacy data, 33

prior treatment, 61, 63–64

objectives, 45

progression-free survival (PFS), 163

pharmacodynamics and

proof-of-concept studies

pharmacokinetics, 36, 46–47, 51

pharmacodynamics, 77, 243–244, 245

preclinical data and requirements,

protocol, 205

31, 33–38

prostate cancer, assessment criteria,

radiopharmaceuticals, 48–49

317–318

role of, 37

Prostate-Specific Antigen (PSA) Working

selection of lead agents from

Group, 317–318

analogs, 48

protocol, 200–226

sequencing of agents in drug

administrative issues, 218–219

combinations, 48

appendices, 223

single-agent trials, 46–47

background information, 200, 202–204

standard operating procedures

consent form, 220–221

development, 33, 36, 50

checklist, 221t–222t

toxicology and drug-manufacturing

correlative or translational studies,

considerations, 51–52

216–218

trial design, differences from phase I,

data collection, 218

53t–54t

endpoints, 211–215

types of, 46–49

adverse events, 212–213

when to conduct, 45–46, 47f

response criteria, 213–215,

phase I clinics, 295

214t, 215t

plasma clearance, total, 230

standard toxicity criteria, 213

poly (ADP-ribose) polymerase (PARP)

imaging studies, 216, 218

inhibitors, 13, 37, 46, 245, 263t

outline, 200, 201t–202t

polymerase chain reaction (PCR),

pharmacokinetics, 216

251, 252

serious adverse events and expedited

population pharmacokinetics, 241–242

reporting, 218, 219t

positron emission tomography (PET), 48,

statistical considerations, 215–216

256–257, 258

study design, 206, 209b

preclinical data and requirements, 9–39

example, 224–226

about, 9–10

study objectives, 204–205

agent’s target and chemistry, 10–11,

study population, 205–206, 207t–208t

34t–35t

templates for (websites), 340

I n D E x 3 5 3

treatment, 208–211, 210t

reporting trial results, 308–335

trial procedures, 211, 212t

background, 308–311, 312f

publication of results

discussion, 334

authorship, 220

disease and drug information

contracts and freedom to publish,

(introduction), 311–313, 312f

279–282

expedited reporting of serious adverse

patient confidentiality, 222t

events, 218, 219t

trial registration and, 294

methods, 313–322

outcome of reports, 334–335

QT interval, 113, 118

recommendations and standards,

quality assurance

310–311

chemistry, formulation, and

results, 322–334

manufacturing quality, 30–31

resistance-modulating agents, 22

pharmacokinetics, 229

resources, generally (websites), 341

protocol, 220

Response Evaluation Criteria in Solid

reporting trial results, 322

Tumors (RECIST)

quality of life measures, 93

basal-cell carcinoma, 333

comparison with immune-response

radio-immunotherapy, 154

related criteria, 163, 164t

radiopharmaceuticals, 48–49

malignant pleural mesothelioma,

radiotherapy combination trials, 140–141

317–318

randomized statistical design, 197

response definitions, 213–214, 214t

RECIST. See Response Evaluation

use of, 125, 189, 253

Criteria in Solid Tumors

website, 341

(RECIST)

risk/benefit ratio, 92–93, 97

recommended dose intensity (RDI), 328

RnA, circulating free, 251

recommended phase II dose (RP2D)

rol ing six trial design, 175

chronic toxicities, 72–73

RP2D. See recommended phase II

combination phase I trials, 139

dose (RP2D)

definition, 7

running phase I trials. See

dose-related toxicity, 71

study process and logistics

organ impairment studies, 111

reporting trial results, 333–334

safety pharmacology studies

registration of trials, 294

first-in-human trials, 170

regulatory submissions and

immunotherapeutics, 151–152, 162–163

documentation, 283–288, 287t

preclinical data and requirements, 28

chemistry, manufacturing, and control

sample collection and processing. See also

information, 286–287

tissue biopsies

first-in-human trials, 284t–285t

acquisition measures, 75–76

investigator’s brochures, 286

consent, 97–99, 232

protocol, 286

limited sampling techniques,

websites, 339

241, 242

REMARK (REporting recommendations

pharmacodynamics, 251–252

for tumour MARKer prognostic

pharmacokinetics, 231–235

studies), 311

processing procedures, 234–235

repeat-dose toxicity studies, 27–28, 28t

protocol, 231–232, 293

3 5 4 I n D E x

sample collection and processing ( cont. )

organ impairment studies, 111

sample size and pharmacodynamic

phase 0 trials, 36

endpoints, 77

phase I trial report, 314

timing of samples, 232–233

preclinical toxicology, 29, 80–81

serious adverse events (SAEs)

statistical analysis

protocol, 218, 219t

protocol, 215–216

reporting of, 316

reporting trial results, 321–323

setting up trial, 289–294

statistical designs for first-in-human trials,

data capture, 290–292

170–196

nursing, 289–290

basic requirements, 170–171

pharmacy, 292–293

biological measures in phase I designs,

sample processing, packaging, and

192–195, 195f

shipping, 293

classical design (3+3), 173–176, 173f

treatment delivery, 293–294

accelerated titration, 174–175

trial registration, 294

expanded cohort at recommended

single-photon-emission computed

dose, 175–176

tomography (SPECT)., 48

operating characteristics,

site initiation visit, 290

176–178, 177f

SOPs. See standard operating

rol ing six, 175

procedures (SOPs)

continual reassessment method,

special populations or circumstances,

178–181

104–141

variations in, 181–184, 182f

about, 104–105

dose escalation for combination

age and early clinical trials, 118–124

treatments, 186–188, 188f

hematological malignancies, 124–125

endpoint and dose-response

interaction studies, 126–141

relationship, 171–172, 172f

intracerebral tumors, 125–126

escalation with overdose control, 184

minority underrepresentation in

expansion cohorts, 188–191, 190t,

studies, 124

191t–192t

organ impairment, 105–118

isotonic regression, 184

websites, 342

modified toxicity probability

SPECT (single-photon-emission

interval, 185

computed tomography)., 48

optimal-method approach,

sponsors, role in phase I trials, 277,

185–186, 186t

278t–279t

randomization and stratification, 195

standard operating procedures (SOPs)

stratification, 197

phase 0 trials, 33, 36, 50

website resources, 340

phase I trials, 290

stromal cell tumors, gastrointestinal

protocol, 211

(GISTs), 317

Standards for Reporting of Diagnostic

study design, 57–85

Accuracy, 311

biomarker-driven studies, 84–85

starting dose

cohort size, 82

animal models and calculation

combination phase I trial, 138–140

of, 60–61

endpoints. See endpoints

combination phase I trials, 138

escalation plan, 81–82. See also

immunotherapeutics, 157–158

dose establishment and escalation

I n D E x 3 5 5

food–effect studies, 128–129

efficacy, 11

in vivo studies, 18t, 19–20

evidence of target effect, 13,

intra-patient dose escalation, 83–84

14t–15t, 16, 21

organ impairment studies, 106–113

pharmacodynamic measures, 75–77

patient selection. See

Task Force for the Methodology for

patient population

the Development of Innovative

pediatric studies, 121

Cancer Therapies (MDICT), 314

phase 0 vs. phase I trials, 53t–54t

teenagers. See pediatric patients

protocol, 206, 209b, 224–226

terminal half-life (t ), 230

1/2

starting dose. See starting dose

therapeutic misconception, 94–95

statistics. See statistical designs for first- time to reach C (T ), 231

max

max

in-human trials

tissue biopsies, 246–253

trial design, 79–85, 110–111, 314–315

immunotherapeutic trials, 160

study process and logistics, 273–306. See

“liquid biopsies,” 247

also reporting trial results

sample collection and processing,

conducting study, 294–302

251–252

data collection and management,

sample selection, 246–247

298–299

sequential, 76, 76t, 246

identifying patients for trial,

surrogate tissue samples, 247,

294–295

248t–250t

informed consent and

tissue-based assays, 252–253

communication with patients,

tissue sampling/procurement. See

295–298

sample collection and processing

managing dose-escalation scheme,

titration, accelerated, 174–175

229–302

TKIs (tyrosine kinase inhibitors),

contracts, 280–283, 281t–282t

149, 317

ethics review boards and process, 287t,

toxic dose low (tdl), 81

288–289

toxicity and toxicology. See also statistical

expecting the unexpected, 302–306,

designs for first-in-human trials

304t–305t

chronic toxicities, 72–73

building in flexibility, 303, 305

combination phase I trial toxicities, 139

stopping trial prematurely, 305–306

phase 0 trials, 36

trial protocol vs. medical judgment,

preclinical data and

302–303

requirements, 25–29

funding, 279–280

drug combinations, 29

monitoring of trials, 299

repeat-dose and chronic toxicity

regulatory submissions and

studies, 27–28, 28t

documentation, 283–288

safety pharmacology studies, 28

roles and responsibilities, 274–280,

single-dose toxicity studies, 25,

289–290, 292–293

26t–27t

setting up trial, 289–294

starting dose selection, 29, 80–81

surrogate tissue samples, 247, 248t–250t

protocol, standard toxicity

criteria, 213

target, molecular. See also molecularly

toxicity as primary endpoint, 67–73,

targeted agents (MTAs)

171–172. See also adverse events;

chemistry and plausibility for

dose-limiting toxicity (DLT)

3 5 6 I n D E x

toxicity and toxicology ( cont. )

tyrosine kinase inhibitors (TKIs),

assessing toxic effects, 68–69, 188–189

149, 317

chronic toxicities, 72–73

dose-response relationships, 67–68

ultrasound, 257

websites, 341

United Kingdom, Commission on

transgenic models, in preclinical testing,

Human Medicines, 60

17, 19t

treatment

vaccines, 155

delivery during trial, 293–294

vesicular stomatitis virus,

description in trial reporting, 315

recombinant, 156

prior, and trial patient criteria,

viability assays, 16

61, 63–64

viruses, in immunotherapeutics,

protocol description of,

155–156

208–211, 210t

volume of distribution (V ), 230, 231

D

tumor biopsy. See tissue biopsies

tumor heterogeneity, 258

websites, 240, 339–342

tumor type, patient entry criteria, 62

writing protocol. See protocol

tumor-infiltrating lymphocytes (TIL),

153, 162

xenograft models, 17–19, 18t, 19t





Document Outline


Cover

Phase I Cancer Clinical Trials

Copyright

Contents

Preface

Contributors

1 Introduction

2 Preclinical Data and Requirements

3 Phase 0 Clinical Trials

4 Basics of Phase I Design: First-in-Human Studies

5 Ethical Issues in First-in-Human Phase I Cancer Trials

6 Phase I Trials in Special Populations and Circumstances

7 Phase I Trials of Immunotherapeutics

8 Statistical Designs for First-in-Man Phase I Cancer Trials

9 Writing the Protocol

10 Practical Aspects of Pharmacokinetics and Pharmacodynamics

11 Process, Pitfalls, and Logistics of Phase I Trials

12 Reporting and Interpreting Results

Appendix

Index





